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ABSTRACT 
Proteolysis is a component of protein turnover, controlled by multiple proteolytic 
systems. Alterations in system components within skeletal muscle has been 
associated with hypertrophy, remodelling, atrophy, apoptosis and metabolic 
dysregulation. Key components may have novel regulatory roles, e. g. calpain-3 and 
cathepsin-L. Experiments described within this thesis investigated the hypothesis that 
the gene expression of specific proteolytic system components within skeletal muscle 
may be co-ordinately regulated and altered during nutritional and pharmacological 
states known to modify protein turnover and induce muscle growth. 
Gene expression for multiple components of the calpain system was analysed in calf 
LD (Longissmus Dorsi) by Quantitative Real-Time PCR in a plane of nutrition trial. 
There were three groups: low (LOW), high (HIGH) plane of nutrition and LOW to 
HIGH (REFED). Half of each group were slaughtered 48 hrs after refeeding, whilst 
the remainder were slaughtered 13 days later. Total RNA yield/g LD increased (P < 
0.05) across all groups between slaughter dates. Calpain-3 expression increased in 
LOW and REFED and calpastatin in all groups between slaughter dates, with a trend 
towards significance (P = 0.073, P=0.085, respectively). In the 1St slaughter, 
calpain-3 expression had a trend to be lower in the LOW group and values for 
REFED were similar to HIGH value level. 
cDNA probes for unique and novel proteolytic system components were generated 
by RT-PCR and used to investigate the effects of acute and chronic Q-adrenergic 
stimulation, on the gene expression of those specific components in pig LD, by 
northern blotting. 
The ß2-adrenergic agonist clenbuterol (5 ppm) decreased glycogen levels (mg/g LD) 
(P < 0.001), increased cathepsin-L expression (P < 0.001) and increased E2G 1 
values numerically within 24 hrs of treatment. Cathepsin-L was unchanged by 
adrenaline administration. Calpain-3 was unchanged with either clenbuterol or 
adrenaline treatment. 
The significance and implications of the data are discussed. 
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CHAPTER 1 INTRODUCTION 
This thesis examines the effects of nutritional and pharmacological treatments- 
known to alter protein turnover and muscle growth, on the mRNA expression of 
various proteolytic system components within skeletal muscle. In addition it explores 
the development of experimental techniques to quantify the mRNA expression of a 
range of specific proteolytic system components within bovine and porcine skeletal 
muscle. 
Skeletal muscle is a large functional metabolic tissue with a continuous flow and 
turnover of substrates and amino acids. The constituent cellular proteins exist in a 
dynamic state and are subject to characteristic turnover rates (Garrow, James and 
Ralph, 2000 c). Their `steady-state' levels are thus maintained by a delicate balance 
of both protein synthesis and degradation (Doherty and Mayer, 1992 a). Intracellular 
protein degradation is a tightly controlled and highly regulated process, with multiple 
protease systems and their endogenous inhibitors working in concert to bring about 
the net process of cellular protein degradation. 
Intracellular proteases involved in protein degradation, and thereby turnover have 
been identified within skeletal muscle and shown to play a role in the processes of 
muscle growth, wasting, remodelling and balance between life and death of the cell. 
The four intracellular protease systems to be discussed within this thesis include the 
lysosomal-cathepsin, calpain, ubiquitin-proteasome and caspase systems. Each sys- 
tem has specific roles within the cell selectively degrading proteins of intracellular, 
membrane and extracellular origin. 
The lysosomal cathepsin system is predominantly involved in the bulk degradation of 
sarcoplasmic proteins whole to amino acids. Within the acidic environment of the 
lysosome there are a number of cathepsin endo-proteases that act on proteins in co- 
ordination with exopeptidases and di-and tri-peptidases (Doherty and Mayer, 1992 
c). Under catabolic conditions the system may play a role in the degradation of 
cleaved myofibrillar proteins within skeletal muscle, leading ultimately to atrophy. 
The calpain system comprises of non-lysosomal, calcium-dependent, neutral, cys- 
teine proteases in skeletal muscle. The calpains are involved in specific cleavage 
events as opposed to bulk degradation of proteins whole to amino acids (Goll et al, 
2003). Proteins of interest (within the scope of this thesis) degraded include cy- 
toskeletal and myofibrillar proteins along with regulatory proteins. It has been sug- 
gested that the calpains may act as the rate-limiting step in myofibrillar breakdown 
(Goll et al, 2003). This process is altered during hypertrophy, remodelling and cata- 
bolic-atrophic conditions, in co-ordination with changes in the calpain system 
(Thompson and Palmer, 1998, Goll et al, 1998, Goll et al, 2003). 
The ubiquitin-proteasome system degrades a large number of proteins whole to 
amino acids. Specific proteins targeted for degradation are `tagged' with ubiquitin 
and transported to the proteasome (a multi-protease complex), with the aid of spe- 
cific ubiquitin conjugation and ligase enzymes (Ciechanover et al, 2000, Glickman 
and Ciechanover, 2002). Within muscle, cleaved myofibrillar units are degraded by 
the system, with various system components up-regulated during catabolic, atrophic 
and remodelling conditions (Lecker et al, 1999, Jagoe and Goldberg, 2001). 
The caspase system is composed of a number of highly specific cysteine proteases 
that are involved in the process of controlled cell death, apoptosis (Grimm, 2003d). 
The caspases cleave a number of regulatory and cytoskeletal proteins. They are con- 
stitutively expressed as inactive precursors and activated by caspase-mediated cleav- 
age or autocleavage. Caspases are activated by diverse signals including: extracellu- 
lar mediators (e. g. TNFa), mitochondrial and sarcoplasmic reticulum stress. This 
leads to the activation of the downstream caspases, that initiate the apoptotic path- 
way. Within skeletal muscle, the system may be activated under catabolic, atrophic 
and pathophysiological conditions, including myopathies and muscular dystrophies 
(Sandri and Carraro, 1999). 
Experiments carried out within this thesis examined different methods to quantita- 
tively measure mRNA gene expression changes within skeletal muscle of different 
species including: Real-Time Quantitative RT-PCR and the development of cDNA 
probes with the aim of utilising them in northern blot hybridisation's and/or a global 
approach like cDNA macroarrays. 
2 
Altered levels of dietary feeding and hence ` plane of nutrition' can have a significant 
effect on protein deposition in rapidly growing farm animals (Lee, 2001, Kristensen 
et al, 2002, Kristensen et al, 2004) During rapid growth phases where there is a high 
level of muscle remodelling and hypertrophy taking place, nutrition can have a sensi- 
tive effect on these processes. Of interest within the scope of this thesis is how an 
altered plane of nutrition alters proteolytic systems, which in turn may contribute to a 
net effect on protein 
-turnover and -deposition. Initial experiments carried out in this 
thesis were concerned specifically with the effects of altered plane of nutrition in 
growing calves on the mRNA gene expression of components of the calpain system 
within skeletal muscle. 
The beta-adrenergic agonist class of compounds are known to act as nutrient reparti- 
tioning agents, inducing skeletal muscle hypertrophy and fat loss in adipose tissue 
when administered in chronic high doses in farm animals (Mersmann, 1998). It is 
believed that beta-adrenergic agonists such as clenbuterol achieve increases in mus- 
cle protein accretion through primarily decreasing cellular protein degradation. Al- 
terations in the calpain-calpastatin system have been observed with beta-agonist 
treatment (Mersmann, 1998, Navegantes et al, 2002). There is limited information 
whether other proteolytic system components are altered with treatment and in turn 
how this may alter protein turnover and the hypertrophy process. Later experiments 
carried out in this thesis examined whether beta-adrenergic agonist administration 
would specifically alter the mRNA expression of key components of specific prote- 
olytic systems within porcine skeletal muscle. 
3 
CHAPTER 2 LITERATURE REVIEW 
2.1 INTRODUCTION 
The area investigated within this thesis is that proteolytic systems within skeletal 
muscle are to some degree co-ordinately regulated in response to stimuli which alter 
muscle growth. Therefore, this review of the literature will firstly consider the struc- 
ture, function and metabolic role of skeletal muscle. This leads to a description of the 
signals which alter muscle protein metabolism, with particular reference to those 
which affect muscle-protein catabolism. There is then an examination of the prote- 
olytic systems which are likely to play a key role in skeletal muscle proteolysis. 
2.2 SKELETAL MUSCLE STRUCTURE, FUNCTION AND PROTEIN 
METABOLISM 
2.2.1 The Dual Function of Skeletal Muscle Tissue 
Skeletal muscle may be viewed as possessing two separate functional roles con- 
trolled ultimately by the process of protein turnover; the balance between protein 
synthetic and protein degradative processes (Rooyackers and Nair, 1997, Liu and 
Barrett, 2002). 
The first and most obvious function of skeletal muscle is that of its critical role in 
allowing biomechanical joint movement, force production and protection of or- 
gans/tissues (Voet and Voet, 1995a, Garrow, James and Ralph, 2000 a). Skeletal 
muscle is the largest tissue of the human body comprising 
-40-45% of total body 
weight, 
-50% of total body protein and -70-80% of the cell mass (Rooyackers and 
Nair, 1997). It is made unique amongst other cell types by the presence of a network 
of structural proteins arranged in a fibrillar, `lattice-like' structure. These proteins 
and the overall complex cell architecture act in concert to allow contractile activity 
and force production in response to neural stimuli from the neuro-muscular junction. 
The second function is that skeletal muscle can be viewed in parallel as a large, dy- 
namic, functional, metabolic pool/temporary store of amino acids that can be utilised 
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and partitioned into various pathways during daily functioning, stress and immune 
responses/reactions, cell damage and various pathophysiological conditions. 
2.2.2 Cell Architecture 
Many of the proteins that form the complex muscle cell architecture and are essential 
for contractile and regulatory functions are substrates for intracellular protease sys- 
tems; and are possible substrates for subsequent amino acid repartitioning pathways. 
Skeletal muscle consists of long cylindrical multinucleate cells called muscle fi- 
bers/myofibers, arranged in parallel. A single myofiber is composed of a number of 
parallel contractile myofibrillar subunits which in turn consist of sarcomere units, 
repeated longitudinally (see Figure 2.2.2-1). This `myofibrillar lattice' consists of 
numerous structural proteins but there is three main fractions: 1) actin associated 
with tropomyosin and troponin (thin filament), 2) myosin (thick filament), and 3) 
titin and nebulin making up the cytoskeletal structure mainly (Voet and Voet, 
1995a). Each sarcomere unit is bound at either end by aZ disk/Z line composed of a- 
actinin. The actin myofilaments are anchored and extend out from the Z line in both 
directions. The thick myosin filaments interdigitate with thin filaments, are able to 
slide over each other and have a point of contact via myosin head cross bridges. My- 
osin filaments are anchored centrally within the sarcomere to the M disk, composed 
of myosin, C-protein, and M-protein. Titin, (-3600-kD), extends from the thick fila- 
ment, and M-disk, to the Z-line and may act as a `spring' to keep thick filaments cen- 
tered, and `mechanical sensor'. Nebulin (-800-kD), is thought to `wind' along the 
whole length of the thin filament, join to the Z line and may function as a thin fila- 
ment `length controller' (Voet and Voet, 1995a). 
The contractile apparatus is linked to the extracellular matrix (ECM) and periphery 
by a number of cytoskeletal proteins and the dystrophin-associated protein complex 
(DAPC) (see figure 2.2.2-1). The cytoskeletal costameres consist of focal adhesion 
proteins including vinculin, talin, a-actinin, and ßl integrins (Ervasti, 2003). Muscle 
costameres contain y-actin, spectrin, desmin, vimentin, clathrin, ankyrin, and techni- 
cally dystrophin (Taylor et al, 1995). They are subsarcolemmal protein assemblies 
that physically couple peripheral myofibrils to the sarcolemma via interacting with 
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the Z line. It is suggested that they may be responsible for transducing contractile 
forces laterally from sarcomeres, across the sarcolemma to the ECM and neighbour- 
ing myofibers (Taylor et al, 1995, Ervasti, 2003). They may play a role in sarcolem- 
mal stabilisation and have greater functions in linking mechanotransduction signal- 
ling to the regulation of gene expression (Sadoshima and Izumo, 1997, Carson and 
Wei, 2000, Rennie and Tipton, 2000, Kääriäinen et al, 2001, Ervasti, 2003, Katsumi 
et al, 2004). 
The DAPC plays a key structural link between the ECM and F-actin thin filaments 
(see figure 2.2.2-1); and may stabilise the sarcolemma (Ervasti, 2003), transduce 
force from sarcomeres to ECM and be involved in cell signalling (Brown et al, 1997, 
Ono et al, 1999, Tkatchenko et al, 2001, Ehmsen et al, 2002, Kumar et al, 2004). 
Dystrophin binds to actin at its N-terminus, associating with dystrobrevin at its C- 
terminus, in turn, interacting with a- and ß-syntrophins. a- and ß-dystroglycans make 
the link between laminin connecting to the ECM and subsarcolemmal dystrophin. 
There are five transmembrane sarcoglycans, a, ß, y, S and c., and a transmembrane 
protein called sarcospan. Other proteins known to be associated with the DAPC in- 
clude syncoilin, laminin-2, caveolin-3, nNOS (neuronal nitric oxide synthase) and 
sodium channels (Ehmsen et al, 2002). The absenceldownregulation of one or more 
of many of these structural proteins may initiate muscular dysfunction, disorders, and 
proteolytic system activation. 
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Figure 2.2.2-1. Diagrammatic representation of the dystrophin-associated com- 
plex (DAPC) connecting the myofibrillar apparatus to the extracellular matrix 
(ECM). 
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2.2.3 Skeletal Muscle Fiber Types 
The relevance muscle fiber type has to this thesis subject is that there are fiber type 
dependent variations in function and metabolism which influence the processes of 
muscle atrophy and hypertrophy; which may relate to variability in proteolytic sys- 
tems contained within these differing fiber types. 
Mammalian skeletal muscle consists of a mosaic of different fiber types that are ver- 
satile and adapt in response to different functional and mechanical demands (Maltin 
et al, 2001, Spangenburg and Booth, 2003). They accomplish this by adjusting their 
phenotypic properties (Spangenburg and Booth, 2003). Fiber types may be character- 
ised by physiological, metabolic and molecular markers. In general, studies based on 
myosin heavy chain (MHC) isoform profiles, show there to be at least four types of 
fibers. More types have been suggested and `hybrid-fibers' detected, which co- 
express two or more MHC isoforms within the same fiber (Pette and Staron, 2000, 
Spangenburg and Booth, 2003). 
Type I, red, or slow-oxidative fibers have been characterised as being slow-twitch, 
fatigue-resistant, containing slow isoform contractile proteins, high volume-density 
of mitochondria, high levels of myoglobin, high oxidative enzyme capacity, high 
capillary density and small fiber CSA (Cross Sectional Area). 
Type IIA, red, fast-oxidative fibers are fast-contracting, relatively fatigue resistant 
with high oxidative capacity and medium fiber CSA. 
Type IIX and JIB are white, fast-glycolytic fibers with increased contraction rate, 
low fatigue-resistance, containing increased expression of fast contractile protein iso- 
forms, high myosin ATPase activity, low mitochondrial volume-density, high glyco- 
lytic enzyme capacity and large CSA. 
Literature suggests that muscle fiber type expression is regulated by multiple signal- 
ling pathways and transcription factors as opposed to a single controlling pathway 
(Swoap et al, 2000, Pette and Staron, 2000, Maltin et al, 2001, Spangenburg and 
Booth, 2003). Certain physiological and pathological stimuli are known to influence 
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fiber type gene expression, transformation and myosin heavy chain transitions (Pette 
and Staron, 2000, Maltin et al, 2001, Spangenburg and Booth, 2003). These include 
hormonal administration, mechanical loading, innervation, aging, atrophy, muscle 
disease and cachexia (Sultan et al, 2001, Maltin et al, 2001, Diffee et al, 2002, Ste- 
venson et al, 2003). Intracellular Ca2+ concentration ( [Ca2+]i ) homeostasis may have 
a prominent role in fiber type regulation (Pette and Staron, 2000, Allen and Lein- 
wand, 2002, Spangenburg and Booth, 2003). 
There are vast variations in the phenotypic expression of proteins within type I and 
type II fibers (Cambell et al, 2001). Some authors have suggested from animal 
growth promoter studies, medical cachexia and sarcopenia studies that type II fibers 
have greater `plasticity', adaptive potential and are more susceptible to atrophy and 
hypertrophy (Pette and Staron, 2000, Maltin et al, 2001, Spangenburg and Booth, 
2003). 
2.2.4 Subcellular Protein Compartments and Myofibrillar Turnover 
Roughly 30-35% of all proteins within the muscle cell comprise of cytoplasmic, 
short-lived, moderate-to-rapidly turning over proteins (see figure 2.2.4-1) (Goll et al, 
2003). This subfraction of `sarcoplasmic' non-myofibrillar proteins consists of meta- 
bolic enzymes and regulatory proteins. Slowly turning over myofibrillar proteins 
within skeletal muscle constitute 55-65% of the total protein content (Goll et al, 1998 
Goll et al, 2003). Individual myofibrillar units may have different turnover rates. For 
skeletal muscles to function properly as contractile tissue, the myofibrils must remain 
intact. It has been suggested contractile proteins are able to move between myofila- 
ments, move to the periphery of the myofibril, interact with degrading system(s) and 
be exchanged for newly synthesised myofilaments. Research suggests the presence 
of a separate identified protein fraction of myofibrillar origin, with a higher turnover 
rate, accounting for -5-10% of total protein in cell (Goll et al, 1998, Thompson and 
Palmer, 1998). This small fraction of `easily releasable myofilaments' (ERMs), that 
exist on the periphery of the myofibril, would contain newly synthesised, and par- 
tially degraded myofilaments (Goll et al, 1998, Thompson and Palmer, 1998). 
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Figure 2.2.4-1. A schematic diagram of the proposed flow of amino acids within 
skeletal muscle. Amino acids flow from the free intracellular pool to other dynamic 
protein compartments, with different turnover rates. 
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Myofibrillar turnover is dependent on the proteolysis of specific myofibrillar protein 
substrates. It has been suggested that this is primarily through a calcium-dependent, 
calpain-protease mediated mechanism (Goll et al, 2003) (discussed in later calpain 
Section 2.6.3) (see Figure 2.2.4-2). Nebulin and Titin, which stretches across fila- 
ments to the Z-line, is degraded by calpain-protease action on the surface of the myo- 
fibril at the point where they enter the the Z-line. This severs attachment of the Z-line 
proteins to the remainder of the myofibril, releasing the Z-line proteins like a-actinin 
and releasing myosin (thick) and actin (thin) filaments from the surface of the myofi- 
bril (see 1. of Figure 2.2.4-2). After the release of a single `layer' of filaments, the 
remaining myofibril is narrowed by one thick filament and two thin filaments but is 
otherwise unchanged and functionally able to contract. The released filaments can 
reassemble back onto the surface of the myofibril, or additional degradation of tro- 
ponin and tropomyosin (Tm) (on thin filament) and C-protein (on thick filament), 
results in disassociation of thick and thin filaments to myosin and actin molecules, 
respectively (see 2. of Figure 2.2.4-2). The myosin and actin molecules and polypep- 
tide fragments of other calpain-degradaded proteins (i. e. titin, nebulin, desmin, tro- 
ponin, tropomyosin and C-protein) are degraded to amino acids by the proteasome, 
cellular peptidases and possibly lysosomal-cathepsin proteolysis (Goll et al 2003) 
(see 3. of Figure 2.2.4-2). The relevant protease systems are introduced and de- 
scribed in great detail in later sections. 
A final point of discussion with the model presented for myofibrillar turnover, is that 
only surface myofibrillar proteins appear able to turnover. The myofibrillar proteins 
within a myofibril would not be turned over as they are not accessible, according to 
this model. The only way to initiate turnover would involve `opening' the myofibril 
up to allow the release of myofibrillar proteins. This leaves the question as to 
whether this model is valid and whether only surface myofibrillar proteins on a myo- 
fibril turnover. 
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Figure 2.2.4-2. A schematic diagram of a proposed model of myofibrillar turn- 
over/degradation. Adapted from Goll et al, 2003. See Figure. 2.2.2-1 for identifica- 
Lion of specific proteins. 
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2.2.5 Amino Acid Repartitioning 
As already indicated skeletal muscle acts as a large metabolic pool/ temporary dy- 
namic store of amino acids that can be repartitioned into a number of essential path- 
ways and processes that require specific amino acids (Rooyackers and Nair, 1997, 
Rennie and Tipton, 2000) The source of amino acids required for various pathways 
may come from the breakdown of proteins of myofibrillar and non-myofibrillar ori- 
gin; a coordinated process controlled by multiple protease systems. Essential meta- 
bolic pathways that require amino acids include: 
BCAA (Branched Chain Amino Acid) synthesis and oxidation. 
Glutamine synthesis with subsequent uptake and utilisation by the gut, immune sys- 
tem, liver and kidneys. 
Glutamine and Alanine release with subsequent partitioning towards gluconeogenic 
pathways. 
Partitioning of amino acids towards hepatic synthesis of acute phase reactants. 
Sulphur containing amino acids, eg. Cysteine is required for glutathione synthesis. 
The processes and pathways listed above are up-regulated differentially during fast- 
ing, stress, illness and infection (discussed in Section 2.4), leading to an increased 
demand for amino acids. Hence, raised net skeletal muscle protein degradation sat- 
isfy's much of the raised demand (see Figure. 2.2.5-1). 
Figure 2.2.5-1 The balance of supply and demand on the plasma amino acid 
pool during stress and infection. 
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2.2.6 Protein Metabolism Studies 
Skeletal muscle protein metabolism has been studied in animals, humans, incubated 
muscle and cell cultures. The majority of the research effects have focused on the 
process of protein synthesis (Thompson and Palmer, 1998, Liu and Barrett, 2002). 
The process of proteolysis/protein degradation has yet to be as well understood. Pre- 
viously proteolysis has been viewed as a bulk process with no definite, specific 
pathway of degradation. This is in part a reflection of the complexity of this process. 
Clinical methods proven to be useful in evaluating protein metabolism and proteoly- 
sis include: Amino acid kinetics studies which allow estimations of protein turnover 
at a whole-body level and within individual tissues/organs (Liu and Barrett, 2002). 
Muscle tissue release of tyrosine, phenylalanine and leucine has been used as a 
measure of cell proteolysis. Phenylalanine and tyrosine are neither catabolised nor 
synthesised within skeletal muscle, therefore the rate of appearance (Ra) of these 
amino acids is a good estimate of protein degradation and amino acid release (Liu 
and Barrett, 2002). Researchers have also focused on other markers including, mus- 
cle glutamine and alanine release, BCAA release and uptake (Ohara et al, 1995) and 
plasma glutamine. During illness and metabolic stress there is a raised requirement 
for glutamine which correlates with increased plasma glutamine, leucine Ra and 
muscle degradation (Yarasheki et al, 1998, Claeyssens et al, 2000). Although 70% of 
overall glutamine comes from muscle tissue, it is not an estimate of muscle proteoly- 
sis however, as much of glutamine tissue release (-'87%) is believed to be satisfied 
by de novo synthesis (Kuhn et al, 1999, Claeyssens et al, 2000). Level of 3- 
methylhistidine (3-MH) release from muscle cells enables the determination of the 
specific rate of myofibrillar breakdown (Liu and Barrett, 2002, Rooyackers and Nair, 
1997). 3MH is a post-translationally modified amino acid derived from myofibrillar 
proteins (actin and myosin), is not reincorporated into other protein pools but re- 
leased from the cell and excreted (although the estimation of smooth muscle contri- 
bution to 3-MH is not accurately known). 
There are many types of proteolytic events taking place over multiple time courses 
and subcellular compartments. For example, there may be an increase in overall in- 
tracellular proteolytic cleavage events, but no complete degradation of the proteins, 
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subsequent conversion to free amino acids and release from the cell. This is a likely 
occurrence during growth and remodelling events. Therefore researchers have fo- 
cused attention towards non-tracer methods, measuring mRNA, protein levels and 
activities of components of specific identified proteolytic systems within skeletal 
muscle (Thompson and Palmer, 1998). Specific substrate cleavage by proteases has 
also been focused on, e. g. those that are regulatory or cytoskeletal proteins. 
2.2.7 Summary 
Skeletal muscle makes up a large proportion of total body weight (-40-45%) and to- 
tal body protein (-50%). The overall intracellular architecture within skeletal muscle 
is highly complex, with subcellular protein compartments with different turnover 
rates and functional activities. The myofibrillar proteins that make up to 55-60% of 
the proteins within skeletal muscle are required to be functionally intact to allow con- 
tractile activity. Therefore, myofibrillar turnover is a highly regulated process that 
has been suggested to involve calpain proteases. Both the sarcoplasmic and myofi- 
brillar proteins can be degraded completely to amino acids by protease systems, to 
satisfy increased demands for amino acids for different pathways and processes; 
many of which are up-regulated during stress, illness and infection. 
2.3 REGULATION OF PROTEIN TURNOVER 
2.3.1 Introduction 
Protein turnover within skeletal muscle is regulated by a number of diverse signals 
including nutrients, hormones, autocrine/paracrine factors and stretch- /mechanical 
loading- induced pathways (Rooyackers and Nair, 1997, Thompson and Palmer, 
1998, Rennie and Tipton, 2000). This thesis is predominantly concerned with the ef- 
fects of specific dietary and a pharmacological treatment (ß-adrenergic agonists) 
known to alter muscle growth/hypertrophy and how specific proteolytic systems may 
be involved in these processes. Therefore, within the scope of this literature review 
the topics to be covered in this section include muscle growth so as to describe the 
general cellular growth process and importance of remodelling and proteolysis. A 
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description of the GH-IGF-1 endocrine axis then follows as the GH-IGF axis is the 
major controller of cell growth, known to alter in many states including during al- 
tered planes of nutrition. An in depth description of the ß-adrenergic agonists and 
their effects on muscle growth is included to provide an understanding of how these 
growth-promoting agents may alter specific signalling pathways and induce changes 
in proteolytic systems. The effects of nutrition/feeding and various hormones on pro- 
tein turnover, hypertrophy and proteolysis then follows. This was important so as to 
indicate that during feeding and altered planes of nutrition a myriad of endocrine and 
cellular signalling pathways are altered, which leads to various global effects on pro- 
teolysis. A description of the importance of proteolytic systems with regards to se- 
vere catabolic, stress, infection and atrophy states follows in Section 2.4. 
2.3.2 Muscle Growth 
Cellular growth requires the organism to sustain a phase of net gain of cellular com- 
ponents, i. e. a net positive protein-energy anabolic state. For an increase in protein 
constituents at a cellular level there must be a net increase in protein synthesis to lead 
to protein accretion. This may be accomplished by increasing protein synthesis 
and/or decreasing protein breakdown (Rooyackers and Nair, 1997). Skeletal myocel- 
lular hypertrophy (defined as an increase in size of myofibers with an increase in 
protein content, cytoplasm, nuclei and myofibrils) and at specific times hyperplasia 
(increase in cell number) collectively leads to whole muscle increases in protein con- 
tent, cross sectional area (CSA) and mass (Paul and Rosenthal, 2002). 
Presumably for skeletal muscle cell and tissue growth to occur there must be a huge 
co-ordination of processed effort to allow growth to occur (Maltin et al, 2001, Paul 
and Rosenthal, 2002). This is accomplished by remodelling and modifying the inter- 
nal cell environment/architecture and extracellular components (Maltin et al, 2001, 
Paul and Rosenthal, 2002, Kristensen et al, 2002, Feasson et al, 2002). Remodelling 
has been suggested to be important during `catch-up' growth after a nutrient-feed 
restiction (Kristensen et al, 2002, Kristensen et al, 2004), muscle recovery during 
reloading after unloading-induced atrophy (Taillandier et al, 2003) and eccentric- 
contraction exercise (Fasson et al, 2002). Remodelling may involve an increase in 
myofibrillar and cytoskeletal re-arrangement and net protein synthesis; and increase 
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in sarcoplasmic protein pool turnover (Kristensen et al, 2002, Feasson et al, 2002, 
Taillandier et al, 2003, Kristensen et al, 2004). These processes are likely to require 
an increase in specific proteolytic cleavage events, but not bulk degradation of pro- 
teins to amino acids and concomitant release of amino acids into the bloodstream. It 
has been confirmed that protease activity and protein degradation is heightened dur- 
ing periods of `catch-up' growth, muscle recovery and remodelling (Kristensen et al, 
2002, Hasson et al, 2002, Taillandier et al, 2003, Kristensen et al, 2004). 
2.3.3 Growth Hormone (GH) 
The GH-IGF (Growth Hormone-Insulin-Like Growth Factor) hypothalamic- 
pituitary-axis (also involving hepatic and local tissues) acts as a major controller of 
cell and tissue growth. GH-IGF axis activity is greatest during early life cycle growth 
phases in animals and humans, rises during puberty and decreases in adults. The axis 
has complex coordinated, regulatory feed-back relationships with the hypothalamic- 
pituitary-testicular axis (HPTA), androgens, estradiol, thyroid hormones, insulin, 
glucocorticoids, noradrenaline and neurotransmitters (Lackey et al, 1999). 
Circulating GH, secreted by the pituitary gland is known to directly bind to GH re- 
ceptors (GHR) on skeletal muscle and stimulate protein synthesis, but studies regard- 
ing muscle protein breakdown are unclear (Rooyackers and Nair, 1997, Garlick et al, 
1998, Breier, 1999, Vann et al, 2000). The main anabolic effects of GH are through 
the stimulation of hepatic-systemic and local tissue production of IGF-1 (Rooyackers 
and Nair, 1997, Garlick et al, 1998, Lackey et al, 1999, Breier, 1999). IGF-1 in- 
creases protein synthesis and decreases protein degradation, in addition to stimulat- 
ing satellite cell proliferation and differentiation (Bass et al, 1999, Liu and Barrett, 
2002). The biological effects of IGF-1 are modulated by specific IGFBP's (Insulin- 
like Growth Factor Binding Proteins), which are known to alter during dietary and 
pharmacological treatments (Vestergaard et al, 2003). A specific skeletal muscle 
specific isoform of IGF-1 (termed mechano-growth factor) has recently been found 
which only appears to be produced by damaged or loaded muscle (Adams, 2002, 
Spangenburg, 2003). 
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Figure 2.3.3-1 illustrates a simplified model of how the GH-IGF axis interacts with 
skeletal muscle and alters protein turnover and hypertrophy. GH may directly bind to 
GH receptors (GHR) on skeletal muscle cells, stimulating protein synthesis and the 
local production of IGF-1. GH also stimulates hepatic IGF-1 secretion and modulates 
hepatic IGFBP production. Hepatic-systemic IGF-1 travels to skeletal muscle in the 
circulation bound to specific IGFBPs. In reality there a number of IGFBPs known to 
have positive and negative effects on IGF-1 activity, relationships too complex to go 
into detail within this literature review however. The IGF-I-IGFBP complex may be 
disassociated by protease actions on IGFBPs, thus releasing IGF-1. Released IGF-1 
may subsequently bind to IGF-1 receptors on skeletal muscle cells, stimulate protein 
synthesis and decrease protein degradation. Mechanical damage may stimulate the 
local production of a muscle-specifc isoform of IGF-1. Systemic, locally produced 
and muscle-specifc IGF-1 may stimulate satellite cell proliferation and differentia- 
tion. The net effect of these stimuli is an increase in protein accretion, increase in 
myonuclei and increase in hypertrophy. 
Nutritional and metabolic-endocrine status has important complex regulatory effects 
on the GH-IGF axis (Breier, 1999). Increased protein intake in steers has been shown 
to increase GH pulse frequency and level of nutrition positively correlate with he- 
patic GHR (Breier, 1999). Thyroid hormones, dependent on nutritional-micronutrient 
status, protein and carbohydrate intake, affect GH-IGF axis activity and 'anabolic- 
effectiveness' of GH (Lackey et al, 1999). For example, normal/normal-high range 
of T3, thyroid hormones are known to increase the mRNA levels of GHR and IGF-1 
in fetal sheep skeletal muscle (Forhead et al, 2002). Insulin, also dependent on 
macronutrient-calorie intake is known to have a permissive regulatory role in IGF-1 
secretion. Insulin increases IGF-1 levels and regulates the expression of the IGF-1 
receptor (IGF-1R) (Lackey et al, 1999). Androgens increase GH concentrations by 
modulating pulse amplitude and frequency of GH secretions from the pituitary gland. 
This is thought to be directly linked to the aromatisation of androgens to estrogens 
(Lackey et al, 1999). Androgens may also up-regulate the expression of IGF-1 and 
down-regulate the expression of IGFBP-4 in muscle (Bhasin et al, 2001). Glucocor- 
ticoids have negative effects on the GH-IGF- I axis. In excess they can decrease GH 
and IGF-l levels and thought to also modulate IGF-R and IGFBP (Lackey et al, 
1999). 
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Figure 2.3.3-1. A simplified proposed model of the actions of the GH-IGF axis 
on skeletal muscle protein turnover and hypertrophy. 
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High GH levels in the `fed state' acts as a protein-anabolic hormone, as all the regu- 
latory hormones described above that affect GHR, IGF-1, IGF-IR and IGFBP's are 
all affected and up-regulated (note that the IGFBPs are differentialy regulated); and 
glucocorticoids decreased (see Section 2.3.5.3 for information about hormonal re- 
sponse to feeding). In the `fasted state', GH secretion increases and acts to increase 
fat mobilisation and metabolism and may have a protein sparring effect aiding in 
preventing muscle protein catabolism. However, during fasting a degree of hepatic 
GH resistance takes place and systemic IGF-1 secretion is dramatically reduced 
(Henricks et al, 1994, Breier, 1999, Vestergaard et al, 2003). 
GH administration has been well researched and widely used as a growth-promoting 
agent in livestock production (Bell et al, 1998, Breier, 1999, Vann et al, 2000, 
Vestergaard et al, 2003), treatment for catabolic wasting conditions (Garlick, 1998, 
Mann, 1999, Kotler, 2000) and in performance enhancement as a protein-anabolic 
and lipolytic agent (Sonksen, 2001). Chronic high dose administration of GH in fed, 
growing animals is known to act as a nutrient repartitioning agent, increasing lean 
body mass and decreasing fat mass (Bell et al, 1998, Breier, 1999, Vann et a! 2000). 
Studies in humans are less conclusive and suggest that tissues other than skeletal 
muscle may be more sensitive to the protein-anabolic effect of GH (Rooyackers and 
Nair, 1997). Zhang et al, 1999 showed evidence that GH administration does not 
stimulate muscle protein anabolism directly in rabbit muscle. The lack of conclusive 
evidence in humans of GH acting as a potent anabolic agent may also be due to dose 
treatment patterns, time length of treatment and dose concentrations, along with spe- 
cies variability. In catabolic patients, GH has had a positive effect in myotonic dys- 
trophy but some negative effects in the critically ill (Rooyackers and Nair, 1997, 
Herrington and Su, 2001). It has been suggested that GH administration during an 
acute-phase response to infection/illness may disturb the hepatic synthesis of acute- 
phase proteins and may increase mortality rates (Kotler, 2000). 
In summary, GH acts as a protein-anabolic agent in the fed state, when other hormo- 
nal factors are in place (i. e. insulin, thyroid hormones and sex steroids in particular). 
Much of its positive effects are through the stimulation of hepatic and local produc- 
tion of IGF-1. In this state there is a potent suppression of proteolysis, rise in protein 
synthesis and protein accretion, which may lead to myofiber hypertrophy. 
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2.3.4 Beta-Adrenergic Agonists 
2.3.4.1 Introduction 
A major part of this thesis work involves the effects of beta-adrenergic stimulation 
on proteolytic systems, therefore this section contains a more detailed examination of 
these growth promoting effects. 
The beta-adrenergic agonist (8AA) class of compounds are chemically and physio- 
logically based on the endogenous catecholamines, adrenaline, secreted systemically 
by the adrenal medulla and noradrenaline, secreted by the sympathetic nervous sys- 
tem (SNS) through adrenergic terminals (Frayn, 1997b, Frayn, 1997g, Mersmann, 
1998). They are classically thought of as counter-regulatory stress hormones 
(Rooyackers and Nair, 1997, Frayn, 1997b, Frayn, 1997g). They have actions on al- 
pha (a) and beta (ß) adreno-receptors (AR) throughout the body (Frayn, 1997b, 
Mersmann, 1998). A number of synthetic phenethanolamine derivative compounds 
have been developed with varying drug half-lives and specificities/affinities for dif- 
ferent beta receptor types. Examples, include the ß2-specific-agonists clenbuterol, 
salbutamol (albuterol), ractopamine (`Paylean'®), fenoterol and the non-specific ago- 
nist ephedrine (Mersmann, 1998). ßAAs have been used clinically in medicine at low 
doses as bronchodilators, alleviating asthma symptoms. (Mersmann, 1998, Pellegrino 
et al, 2003) 
2.3.4.2.8AA Effects on Muscle Metabolism 
The QAAs, including the endogenous catecholamines noradrenaline and adrenaline, 
are known to have a general catabolic effect on lipid and glucose metabolism pro- 
moting degradation, mobilisation and oxidation, but an anabolic effect on protein 
metabolism in skeletal muscle (Rooyackers and Nair, 1997, Mersman et al, 1998, 
Navegantes et al, 2002). The beta-adrenergic system has been characterised and 
shown to have a positive effect on lean-muscle tissue deposition in a number of spe- 
cies, including humans (Kissel et al, 2001, Fowler et al, 2004), mice (Pellegrino et 
al, 2003), rats (Cardoso et al, 1998), horses (Kearns et al, 2001) and recently fish 
(Lortie et al, 2003), but effects are most prominent in farm-meat animals (Mersmann, 
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1998, Bell et al, 1998). 8AAs have been studied extensively for use as growth- 
promoting/modifying agents in livestock (Mersmann, 1998, Bell et al, 1998). QAAs 
improve feed conversion, increase the rate and efficiency of protein deposition in 
lean tissues and decrease fat deposition (Mersmann, 1998, Bell et al, 1998). They 
induce increases in protein accretion, CSA and glycolytic capacity/fast-twitch charc- 
teristics. There effects are to increase the proportion of type 2B and fast-twitch fi- 
bers, in a `time- and dose-dependent' manner, through altering the myosin heavy 
chain isoform content, increasing glycolytic (e. g. PFK and LDH) and decreasing mi- 
tochondrial oxidative enzyme activities (e. g. CS and COX) (Rajab et al, 2000, De- 
preux et al, 2002, Pellegrino et al, 2003). 
ßAAs have also been shown to decrease muscle protein loss during protein-catabolic 
conditions including denervation-induced atrophy (Sneddon et al, 2000), food re- 
striction (Cardoso et al, 1998), glucoccorticoid-induced atrophy (Pellegrino et al, 
2003), aging (Ryall et al, 2003), injury (Beitzel et al, 2004) and muscular dystrophy 
(Lynch et al, 2001). ßAA like clenbuterol potentially could be utilised in clinical set- 
tings as a possible means of reducing skeletal muscle protein loss/depletion in condi- 
tions such as cancer cachexia, AIDS wasting and age-related sarcopenia (Kotler 
2000, Ryall et al, 2003). A trial using albuterol in child patients with Duchenne and 
Becker muscular dystrophies showed that there was an increase in strength and mus- 
cle function over a3 month treatment period (Fowler et al, 2004). 
The ßAAs have come to be regarded as `nutrient repartitioning' agents (Bell et al, 
1998, Kearns et al, 2001). ßAAs have in turn been used/abused by athletes and 
bodybuilders for a number of years to enhance muscle growth, muscle function and 
fat loss (Grundig and Bachmann, 1995, Duchaine, 1996, Dawson, 2001). Elite power 
athletes and sprinters have relied on it not only due to its repartitioning effects, but 
due to its potential fiber type switching properties (slow to fast), which are particu- 
larly suited to higher intensities of exercise (based on power output). 
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2.3.4.3 Potential Mechanisms for /AA Induced Hypertrophy 
The effects of QAAs on overall animal performance and nutrient repartitioning are 
well documented, but the exact underlying mechanism of their action within skeletal 
muscle has yet to be clarified. 
In terms of specific actions on protein turnover, studies suggest ßAA are able to 
stimulate skeletal muscle protein synthesis (Bell et al, 1998, Mersmann et al, 1998, 
McDonagh et al, 1999, Sneddon et al, 2001) and increase the abundance of mRNA 
for muscle specific proteins, although increased synthesis hasn't been consistently 
proven (Bell et al, 1998, Mersmann et al, 1998, Navegantes et al, 2002). Other stud- 
ies strongly suggest that they are able to decrease proteolysis (Bell et al, 1998, Nave- 
gantes et al, 1999, Navegantes et a12001, Navegantes et al, 2002). McDonagh et al, 
1999, showed an increase in synthesis, but no decrease in degradation, despite a de- 
crease in calpain protease system activity. McDonagh suggested that there was no 
decrease in net cell degradation as myofibrillar degradation may be independently 
regulated to sarcoplasmic proteins degradation. 
It is thought that ßAAs exert most of their effects in skeletal muscle via the ß2- 
receptor (ß2-AR). Although ßi and 83 have been detected, ß2 is the predominant re- 
ceptor type in muscle tissue (Mersmann, 1998). 
Activation of the G-protein linked/coupled ß2-ARs increases cAMP (cyclic adeno- 
sine monophosphate) production from ATP (adenosine triphosphate) through ade- 
nylate cyclase (AC) activation (see Figure. 2.3.4.3-1) (Mersmann, 1998, Navegantes 
et al, 2002). Protein kinase A (PKA) then becomes activated by cAMP. PKA is the 
main effector of fl-AR activation responses/functions. PKA is then able to. phos- 
phorylate a number of intracellular proteins to activate/deactivate them accordingly. 
In terms of gene transcription, PKA once activated can activate the cAMP response 
element binding protein (CREB), which subsequently binds to a cAMP response 
element (CRE) in the regulatory part of a specific gene (Navegantes et al, 2002). 
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Figure 2.3.4.3-1. A proposed scheme of the mechanism of action of fAAs in 
skeletal muscle. Adapted from Na>>egantes et al, 2002. 
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One mechanism by which ßAAs decrease protein degradation is through the inhibi- 
tion of calpain-dependent proteolysis by increasing the mRNA and activity of calpas- 
tatin (Parr et al, 1992, Bardsley et al, 1992, Speck et al, 1993, Sensky et al, 1996, Mc 
Donagh et al, 1999), an endogenous inhibitor of the calpains, through a cAMP- 
dependent mechanism. Phosphorylation of calpastatin and calpains by PKA has also 
been suggested to act as a controller of activity (Navegantes et al, 2002). This topic 
is also covered in detail in the calpain system, Section 2.8. The ßAAs may also affect 
sarcoplasmic reticulum (SR) calcium sequesteration which may in turn affect prote- 
olysis (Navegantes et al, 2002). Figure 2.3.4.3-1 illustrates the proposed scheme of 
ßAA action. 
The adrenoceptors vary in number and type amongst tissues, species and muscle fi- 
ber types (Mersmann, 1998). Slow twitch fibers have been reported to contain more 
ß-receptors than fast twitch fibers (Ryall et al, 2002, Ryall et al, 2003). 
The regulation of functional membrane ß-AR number/density, down-regulation and 
internalisation is determined principally by key metabolic hormones and mediators. 
Thyroid hormones, GH, sex steroids, glucocorticoids, insulin, and QAA may affect 
receptor sensitivity and/or regulation. In human epidermoid carcinoma cells, insulin 
and ßAAs have been shown to internalise the ß2-G-protein-coupled receptor through 
distinct and separate cytoskeletal pathways (Shumay et al. 2004). 
Glucocorticoids are able to induce muscle atrophy and fast to slow fiber type trans- 
formations, whereas ßAAs have the opposite effects and can antagonize glucocorti- 
coid-induced atrophy and fiber type transformation (Pellegrino et al, 2003). How- 
ever, glucocorticoids may also potentiate the effects of ßAAs by possibly preventing 
desensitisation and down regulation, through a reduction in ß-AR phosphorylation 
(reduction in desensitisation) and acting on GRE (Glucocorticoid Response Element) 
sequence in ß2-AR gene (oppose downregulation). 
Some researchers have suggested that as growth occurs predominantly in fast fibers 
and fast fibers have a lower receptor density than slow twitch fibers, this indicates 
that there is little relationship between receptor density/distribution and muscle hy- 
pertrophy, suggesting other pathways of action (Ryall et al, 2002, Ryall et al, 2003). 
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However, studies show that optimal repartitioning occurs within the first 2 weeks of 
administration, leveling off thereafter in a number of species (Bell et al, 1998, 
Mersmann, 1998, Kearns et al, 2001). This is thought to be directly related to the 
rapid downregulation and desensitisation of the ß-AR in response to chronic agonist 
stimulation, suggesting repartitioning is ß-AR dependent. In terms of proteolysis, 
Navegantes et al, 2002, makes convincing arguments that the decrease in proteolysis 
is ß-AR, cAMP, and Cat+-dependent. Also, rather than a fast twitch specific protein- 
anabolic response, it may be that ßAA increase muscle growth by modifying fiber 
type composition, i. e. they stimulate to a greater degree slower fibers with higher #- 
AR densities and induce fast-twitch fiber modifications. In turn this increases the 
proportion of fast fibers, protein content and CSA. However, the connection between 
CSA, hypertrophy and fiber type can only be taken as a hypothetical view, as many 
studies suggest that slow to fast transformations take place during atrophy in rats 
(Stevenson et al, 2003, Casse et al, 2003), spaceflight in rats (Fitts et al, 2000), 
cachexia in mice (Diffee et al, 2002) and mechanical unloading (Pette et al, 2000). 
Fiber typing of muscle fibers varies immensely across species as discussed earlier in 
Section 2.2.3 (Pette et al, 2000, Spangenburg and Booth, 2003), so we cannot make 
any true judgements relating to human muscle tissue. It is unknown in humans 
whether a slow to fast transformation is indicative of a catabolic, pathological state 
or an anabolic state. 
Other suggested mechanisms of action of QAA and/or ß-AR activation are that they 
may modulate other anabolic hormone pathways/receptor sensitivities. There maybe 
a potential role played by PKC and specific isoforms. PKC-a and PKC-0 have been 
suggested to play potential roles in the action of clenbuterol on amelioration of den- 
ervation-induced atrophy in rats (Sneddon et al, 2000). It has also been reported that 
the Gß/y proteins (of the G-protein-coupled ß-AR) activate the PI(3)K/Akt (PKB) 
pathway (Glass, 2003); the same pathway utilised by IGF-1. Other studies suggest a 
possible interaction between the IGF system and clenbuterol administration. Cardoso 
et al, in 1998 showed that serum IGF-1 increased (110%) in food-restricted, clen- 
buterol-treated rats. More recently, Sneddon et al, in 2001 showed an elevation in the 
neurotrophic agents IGF-II and H19 transcripts and phosphorylation of 4E-BPI and 
p70s6k in rat plantaris muscle undergoing clenbuterol-induced anabolism. Awede et 
al, in 2002, measured a fivefold increase in local IGF-1 mRNA, eightfold increase in 
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IGFBP-4, fivefold increase in IGFBP-5 mRNA and increase in IGF-1 content in rat 
soleus muscle after clenbuterol administration. 
Additional effects on calcium homeostasis and activation of other pathways has been 
suggested. ßAA may decrease cytosolic Ca2+ by possibly affecting sarcoplasmic re- 
ticulum Ca2+ sequesteration and in turn decrease calcium-dependent proteolytic ac- 
tivity (Navegantes et al, 2002) (see Figure 2.3.4.3-1). However, Kearns et al, 2001 
commented that clenbuterol is highly lipophylic, can enter muscle tissue and increase 
passive Ca2+ release from the SR of single fibers. If true this may explain why there 
is reports of an increase in m-calpain (m-calpain is a calcium-dependent protease dis- 
cussed in Section 2.8, activated at higher calcium concentrations) protease activity 
with ßAA administration (Parr eta! 1992). 
A Cat+-mediated pathway may very well be implicated in clenbuterol and ßAA- 
induced hypertrophy considering the possible effects of clenbuterol and ßAA on pro- 
tein kinase activation (PK's can affect Ca2+ homeostasis and some are dependent on 
Ca2), IGF pathways, calcium-dependent protease pathways and fiber type transfor- 
mations. The Cat+/calmodulin 
-dependent protein phosphatase calcineurin has been 
linked to IGF-mediated hypertrophy and fiber-type transformations (Semsarian et al, 
1999, Olson and Williams, 2000, Swoap et al, 2000, Mitchell et al, 2002). If ßAA 
initiate hypertrophy along with fiber type transformations which are known to be 
calcium-dependent/regulated events controlled by a host of signalling pathways in- 
cluding, calcineurin and calpains, then it points the way to a more complex control of 
hypertrophy. 
2.3.4.4 Summary 
ßAA have potent nutrient repartioning effects, inducing muscle hypertrophy and fat 
mobilisation and oxidation, when administered in chronic and relatively high doses. 
The positive effects of ßAAs on muscle protein turnover and hypertrophy makes 
them important potential agents for the meat and livestock industry, but also for 
clinical applications in treating catabolic wasting disorders. 
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The mechanism by which they induce hypertrophy and protein accretion in skeletal 
muscle is not completely resolved but is thought to primarily involve a decrease in 
protein degradation. The decrease in protein degradation has been linked to increases 
in #AR binding to receptor followed by their activation and subsequent cAMP for- 
mation, and PKA activation. A component of this response are alterations in the 
mRNA and activity of components of the calpain-calpastatin system. The net effect 
is thought to be a decrease in calcium/calpain-dependent proteolysis (to be described 
in detail in Section 2.8). 
2.3.5 Dietary Feeding and Plane of Nutrition 
2.3.5.1 Introduction 
Feeding and alterations in the level of daily dietary nutritional, calorie and protein 
intake, relative to daily total energy expenditure (TEE), can have a profound effect 
on metabolism and lean and fat tissue deposition / loss in many organisms; including 
humans and farm animals (Henricks et al, 1994, Frayn, 1997f, Garrow, James and 
Ralph, 2000b, Costa et al, 2004, Kristensen et al, 2004). Nutritional intake of macro- 
and micro-nutrients affects levels of metabolic hormones, mediators, degradatory 
products (metabolites) and metabolic processes, systemically and within skeletal 
muscle tissue (Frayn, 1997a, Frayn, 1997c, Rooyackers and Nair, 1997, Rennie and 
Tipton, 2000, Garrow, James and Ralph, 2000b). This leads to alterations in whole- 
body and skeletal muscle protein turnover and regulation of protease-system path- 
ways. 
2.3.5.2 Plane of Nutrition 
The level of dietary-nutritional calorie and protein intake relative to the total energy 
expenditure (TEE), or `plane of nutrition', will dictate whether an organism is in net 
gain or loss of lean body/fat tissue mass (Frayn, 1997f). 
A high plane of nutrition above the daily TEE, i. e. a nutrient-calorie excess, in hu- 
mans/farm animals leads to specific adaptations to switch to a mode of metabolic in- 
efficiency (upregulated thermo-genic/-regulatory pathways) and nutrient deposition 
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(as lean and fat tissues) (Frayn, 1997f). The level of lean tissue gain, skeletal muscle 
protein accretion and ratio of lean gain : fat gain, may depend on a number of com- 
plex factors known to alter endocrine pathways and protein turnover. These may in- 
clude the age, sex, pre-set genetic factors, health (exposure to stress, infections, 
trauma etc. ), physical activity and pre-existing bodyfat level of the subject; along 
with macro/micro-nutrient composition of high-plane diet and how long the dietary 
intervention takes place (Henricks et al, 1994, Frayn, 1997f, Rooyackers and Nair, 
1997, Roubenoff, 1997, Biolo et al, 1997, Raina and Jeejeebhoy, 1998, Bistrian, 
1999, Rennie and Tipton, 2000, Garrow, James and Ralph, 2000e, Kotler, 2000, Pi- 
Sunyer, 2000, Lee, 2001, Maltin et al, 2001). 
A low plane of nutrition relative to daily TEE would be in negative energy balance. 
This would initiate nutrient depletion and up-regulation in metabolic efficiency. This 
is characterised by losses of fat and lean body mass and down-regulation of thermo- 
regulatory pathways (Frayn, 1997d, Frayn, 1997f, Lee, 2001, Costa et al, 2004). The 
ratio of lean tissue loss : fat loss may depend on the same factors as listed above. 
2.3.5.3 Feeding and Protein Turnover 
There are profound differences between the `fasting' and `fed state', with regards to 
skeletal muscle protein metabolism and turnover. In brief, the `fed-state' is thought 
to be a protein-anabolic state where net protein synthesis may be stimulated and net 
protein degradation reduced. The `fasting' state is known as a protein-catabolic state 
where net protein synthesis is reduced, net protein degradation is increased and 
amino acids are readily re-partitioned into pathways and processes mentioned in Sec- 
tion 2.2.5 (Rooyackers and Nair, 1997, Rennie and Tipton, 2000). Obviously this 
process is exacerbated greatly during prolonged fasting, leading to starvation. The 
metabolic hormone mediators of the protein-anabolic response to feeding (increase in 
protein synthesis and/or decrease in protein degradation) and protein-catabolic re- 
sponse to fasting (decrease in protein synthesis and/or increase protein degradation) 
is summarised in Table 2.3.5.3-1 (Symonds et al, 1989, Henricks et al, 1994, Frayn, 
1997a, Frayn, 1997b, Frayn, 1997c, DeFeo, 1998, Lackey et al, 1999, Liu and Bar- 
rett, 2002, Vestergaard et al, 2003, Kiyma et al, 2004). The endocrine mediators in 
Table 2.3.5.3-1, respond at different time frames. For example, thyroid hormones, 
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androgens and IGF-1 form part of a long-term response to feeding on muscle protein 
turnover, where as insulin is a classical short term response. Feeding and fasting may 
also affect endocrine mediator receptor levels and/or binding proteins. An example 
discussed in Section 2.3.3 includes the increase in GH that has been observed with 
both feeding (although some studies show a decrease in GH) and fasting. During the 
fasting state, hepatic GHR and heptic IGF-1 activity is down-regulated so GH acts 
predominantly as a fat mobilising hormone. 
Nutrients may also have direct effects on protein turnover within skeletal muscle. 
Amino acids have been shown to directly stimulate protein synthesis (Rennie and 
Tipton, 2000, Greiwe et al, 2001, Balage et al, 2001), possibly lower degradation 
(Balage et al, 2001) and may also down-regulate lysosomal proteolysis (Busquets et 
al, 2000). 
Table 2.3.5.3-1. A summary of the main protein 
-anabolic and -catabolic endo- 
crine responses to feeding and fasting, that alter skeletal muscle protein turn- 
over. 
Protein-anabolic response to feeding Protein-catabolic response to fasting 
T insulin J, insulin 
T/JGH TGH 
I T3-thyroid hormone j T3-thyroid hormone 
t IGF-1 J, IGF-1 
T androgens J. androgens 
J, glucocorticoids T glucocorticoids 
Excess nutrients stored within myofibers include fats stored as intracellular triglyc- 
erides, glucose as glycogen and a raised free amino acid pool (post-prandial). The 
subsequent increased water drawn into the cell due to nutrient excess leads to an in- 
creased cell hydration state. Increased hydration state alone may decrease proteolysis 
(Vomdahl and Haussinger, 1996). 
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2.3.5.4 Endocrine Mediators and Proteolysis Influenced by Fed/Fasted State 
Specifically with regards to skeletal muscle protein breakdown, insulin and IGF-1 
are known to decrease net cellular protein degradation and have strong anti- 
proteolytic effects, possibly inhibiting lysosomal-cathepsin proteolysis and ubiquitin- 
proteasome system activity (Liu and Barrett, 2002) (systems discussed in detail in 
Sections 2.7 and 2.9, respectively). Insulin is known to rapidly and potently decrease 
protein breakdown post-meal, although the protein pools affected are thought to be of 
non-myofibrillar origin, i. e. sarcoplasmic proteins (Rooyackers and Nair, 1997). A 
dramatic and rapid decrease in proteolysis would obviously affect fast-turnover pro- 
teins of sarcoplasmic origin, a process thought to predominantly involve lysosomal- 
cathepsin proteolysis (described in Section 2.7). Fasting increases mRNA and/or ac- 
tivity of components of both the lysosomal-cathepsin system (Doherty and Mayer, 
1992c, Thompson and Palmer, 1998, Mosoni et al, 1999, Jagoe et al, 2002, Lecker et 
al, 2004) and the ubiquitin-proteasome system (Mosoni et al, 1999, Jagoe et al, 
2002, Lecker et al, 2004). It is thought that this response is attributed mainly to low 
insulin, IGF-1 and raised glucocorticoids. 
GH is described in detail in Section 2.3.3. Its effects on proteolysis are unclear. Ex- 
cess T3, for example during hyperthyroidism, increases degradation (Rooyackers and 
Nair, 1997). Androgens are known to increase protein synthesis but effects on bulk 
degradation are unclear (Bhasin et al, 2001). Many of the long-term effects of andro- 
gens on muscle protein turnover and proteolysis may involve alterations in the GH- 
IGF axis (Bhasin et al, 2001). Catecholamines are increased in response to fasting 
(Frayn, 1997g). As described in Section 2.3.4, the endogenous catecholamines (nora- 
drenaline and adrenaline) are known to decrease protein degradation, believed to be 
mediated in part through down-regulating calcium-calpain dependent proteolysis 
(Rooyackers and Nair, 1997, Navegantes et al, 2002). 
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2.4 SEVERE CATABOLIC STATES AND THE STRESS REACTION 
2.4.1 Introduction 
During catabolic states including; prolonged fasting and malnutrition, illness, infec- 
tion, trauma, pathophysiological disorders and severe stress the mammalian organism 
responds to the stimuli by mounting a stress response (Biolo et al, 1997, Ingenbleek 
and Bernstein, 1999). This may generate a whole body catabolic response, with in- 
creased amino acid and energy requirements (hypermetabolism) and upregulation of 
the previously mentioned amino acid partitioning processes (see Section 2.2.5) (Bi- 
olo et al, 1997, Ingenbleek and Bernstein, 1999, Jackson et al, 1999). There is a 
characteristic fall in nitrogen balance and loss of lean body mass (LBM) / body cell 
mass (BCM). This is a purposeful response to promote survival. The level of the 
stress response and its protein-catabolic effects ultimately depends on the intensity 
and duration of the insult/stimuli (Biolo et al, 1997, Ingenbleek and Bernstein, 1999). 
In the long term the greater the loss and rate of loss of LBM/BCM, the higher the 
levels of morbidity and mortality, which is a considerable clinical problem in states 
such as sepsis, cancer cachexia and HIV/AIDS wasting (Kotler, 2000). The intracel- 
lular proteolytic systems may act in co-ordination to control amino acid production 
and mobilisation from myofibrillar and sarcoplasmic protein pools (Hasselgren and 
Fischer, 2001). Therefore, it is appropriate for the purposes of this literature review 
to discuss this area of research. 
2.4.2 Relevant Clinical Catabolic Conditions 
There are three known classifications of protein-catabolic states that exhibit skeletal 
muscle depletion and loss. They tend to follow different patterns and pathways of 
loss and have different effects on skeletal muscle proteolysis. 
1) Wasting: Involuntary weight loss, generally driven by inadequate dietary intake 
(Roubenhoff, 1997). In general, although protein degradation is increased, inade- 
quate dietary intake doesn't evoke an intense stress reaction and massive rise in 
skeletal muscle proteolysis (Bistrian, 1999). 
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2) Cachexia: A state of intense protein loss (depending on the severity of the insult) 
during chronic or end stage diseases, due to the impact of an immune/acute-phase 
response/stress reaction and its encompassing hormonal and peptide mediators on 
protein turnover (Biolo et al, 1997, Roubenhoff, 1997, Kotler, 2000). Examples of 
conditions include: Bums, trauma, post-operative stress, cancer, infections/sepsis, 
AIDS/HIV, heart failure, rheumatoid arthritis, tuberculosis, chronic obstructive pul- 
monary disease (COPD), and other inflammatory and autoimmune disorders (Biolo 
et al, 1997, Yarasheki et al, 1998, Kotler and Heymsfield, 1998, Macallan, 1999, 
Libera, 1999, Tisdale, 1999, Vescovo, et al, 2000, Baracos, 2000, Tisdale, 2000, 
Kotler, 2000). 
3) Sarcopenia: An involuntary loss of muscle mass that may be an intrinsic part of 
aging (Roubenoff, 1999). Thought to be due to primarily alterations in hormonal 
output and balance. Studies have linked sarcopenia and aging to decreased levels of 
GH, sex steroids (testosterone etc. ), IGF-1, possibly T3 and possibly decreased a- 
motorneuron activity, along with a simultaneous rise in catecholamines, glucocorti- 
coids and cytokines (Proctor et al, 1998, Roubenoff, 1999, Yeh and Schuster, 1999). 
Conditions classified under sarcopenic states, but not intrinsic with ageing include, 
disuse atrophy and weightlessness (Fitts et al, 2000, Adams et al, 2003). 
Other examples, that fall outside the main classifications include: 
A) Direct local damage/trauma, including eccentric contraction induced damage to 
musculoskeletal tissues activates proteolysis directly and indirectly via the systemic 
stress response initiated in hypothalamic-pituitary glands and immune system (Man- 
soor et al 1996, Biolo et al, 1997, Sandri and Carraro, 1999, Farges et al, 2002, 
Stupka et al, 2001, Fasson et al, 2002). There will be varying effects on total cell 
damage and proteolysis depending on the type and intensity of trauma. 
B) Muscular dystrophy (MD) and limb girdle muscular dystrophies (LGMDs) are 
debilitating conditions, causing decreased muscle function, pain and disability, due to 
genetic defects in expression of skeletal muscle specific proteins (Brown, 1997, 
Bushby, 1999). Absence of proteins involved in sarcolemma stabilisation, force 
transduction/transmission and possible regulatory roles (e. g. sarcoglycans and dys- 
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trophin) gives rise to duchenne and LGMDs. This causes impaired contractile activ- 
ity/force production, increased susceptibility to muscle injury, sarcolemmal destabili- 
sation and dysregulation in cytoplasmic calcium homeostasis (Tidball and Spencer, 
2000, Lynch et al, 2001, Spencer and Meligren, 2002). Clinical features can include 
increased proteolysis, muscle atrophy, apoptosis, and necrosis (Baghdiguian et al, 
1999, Engvall and Wewer, 2003). As will be discussed in later sections, protease sys- 
tems play a key role in the pathogenesis of these conditions. 
C) A rise in proteolysis and possibly muscle atrophy may occur in other diverse set- 
tings including: Kidney dysfunction and uremic states (Mitch, 1997), Type I and 
Type II diabetes (Rooyackers and Nair, 1997, De Feo, 1998), Cushings syn- 
drome/glucocorticoid treatment (Rooyackers and Nair, 1997, Claeyssens et al, 2000), 
obesity (Argiles et al, 1999), hyperthyroidism-denervation (Authier et al, 1997, 
Llovera et al, 1999). 
In summary, diverse signals may induce similar end results, i. e. muscle atrophy 
through activation of the stress reaction and/or similar degradatory pathways. 
2.4.3 The Stress Reaction and Other Stress-Related Factors on Muscle 
Proteolysis 
The stress reaction encompasses a large spectrum of metabolic, endocrine and im- 
mune alterations developed by the injured body in response to varying causal agents 
(Biolo et al, 1997, Ingenbleek and Bernstein, 1999). The reaction to stress and acute 
injury is primarily characterised by the release of cytokines by activated macro- 
phages/monocytes or other reacting cells. They are regarded as major autocrine, 
paracrine and endocrine orchestrators of the stress response (Biolo et al, 1997, In- 
genbleek and Bernstein, 1999). Interleukin-1, 
-6 (IL-1 and 11-6) and Tumour necrosis 
factor-a (TNF-a) reveal prominent activities, notably enhanced production of coun- 
terregulatory hormones (cortisol, catecholamines and glucagon). GH and thyroid 
hormones adapt to these metabolic adjustments along complex regulatory mecha- 
nisms, too complex to be discussed in detail in this review. A brief indication of the 
factors and resulting effects of `the stress reaction' on skeletal muscle are described 
below. 
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In skeletal muscle during a stress reaction/immune response there is a characteristic 
depression of anabolic processes and responsiveness (Biolo et al, 1997, Ingenbleek 
and Bernstein, 1999). For example, a development of insulin and GH resistance, and 
probably IGF-1 resistance. The effects of hyper-cortisolaemia, 
-glucagonemia, and - 
catecholemia, along with cytokine overproduction enforces this state of anabolic de- 
pression/refraction/resistance, general catabolism, fuel mobilisation, protein catabo- 
lism and amino acid mobilisation. This is compounded by an increased demand for 
specific limiting amino acids to synthesise acute-phase reactants (APRs) during an 
acute phase response. These APRs tend to have unusual amino acid compositions. 
For example, elevated fibrinogen synthesis in cancer patients with an acute phase 
response has been reported (Preston, 1998). It was suggested that to synthesise 1g of 
fibrinogen it may require 2.6g of muscle protein (12g skeletal muscle tissue), due to 
requirement for limiting aromatic amino acids. 
Proteolytic systems within skeletal muscle become upregulated by the effects of 
hormones and cytokine interactions with receptors, activation of intracellular path- 
ways and concomitant rise in gene transcription and post-translational modifying ac- 
tivation of systems (Hasselgren and Fischer, 2001). The key activating cytokines in- 
clude IL-1, IL-6, TNF-a and interferon-y (IFN-y) (Roubenoff, 1997, Kotler, 2000, 
Baracos, 2000). Prostaglandin E2 (PGE2) may also be implicated as a key factor 
(Thompson and Palmer, 1998, Tisdale, 2000). 
Evidence points towards induction of proteases and pro-apoptotic responses (i. e. 
promotion of cell death, a topic discussed in Section 2.10) during diverse catabolic, 
stress and immuno-inflammatory responses. Overproduction of proinflammatory cy- 
tokines, in particular TNFa is suggested to be a key stimulus. The generation of reac- 
tive oxygen species (ROS) and activation of the NF-icB (Nuclear-Factor kappa B) 
transcription factor pathway is reported to be involved and affect proteolysis. Kumar 
and Boriek, reported an increase in NFKB activation in mechanically stretched dia- 
phragm muscle from normal and mdx (dystrophic) mice (Kumar and Boriek, 2003). 
The basal level of NFxB activity was higher in mdx mice and mechanical stress fur- 
ther upregulated activity. They found that activity is dependent on free radical pro- 
duction and is Cat+-independent. The increase in activity concided with increased 
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expression of IL-10 and TNF-a, which preceeded muscular dystrophy in the mdx 
mice. 
The function of increased NF-KB activity is to promote cell survival initially and in- 
hibit apoptosis (Grimm, 2003e). Insulin, known for its metabolic and anti-proteolytic 
effects in muscle, has been observed to have an anti-apoptotic function in cells, pos- 
sibly through activation of NF-xB and NF-KB-dependent survival genes, like TRAF2 
(Tumour Necrosis Factor Receptor-associated Factor 2) and Mn-SOD (Manganese- 
superoxide Dismutase) (Bertrand et al, 1998, Bertrand et al, 1999). In support of this 
role it should be noted that a total loss of NF-icB activity in human skeletal muscle 
promotes myoapoptosis (see LGMD2A in calpain Section 2.8.4). Proinflammatory 
cytokines up-regulated in the NF-xB `survival' response may have important effects 
on proliferation and differentiation of satellite cells (Alvarez et al, 2002), which in 
turn, allows muscle fiber regeneration after injury (Mitchell and Pavlath, 2001, 
Grounds et al, 2002), which is important during MDs. Ladner et al, 2003, reported a 
biphasic activation of NF-KB in skeletal muscle cells in response to prolonged expo- 
sure to TNFa. The first phase was "potent but transient", but the second was sug- 
gested to be a `persistent' signal (lasting additional 24-36 hours), due to a long-term 
exposure to TNFa, which lead to loss of muscle gene products. In basal situations the 
effects of TNFa is to induce an apoptotic (via. Death receptor) and anti-apoptotic 
(via. NF-KB) effect through its receptors, leading to an eventual cancelling out of re- 
sponses (possibly occuring in initial cachexia). However, during high chronic levels 
of TNFa (and other inflammatory mediators), muscle fibers may be more sensitive to 
the pro-apoptotic effects and protease activation. 
During cellular dysfunction (e. g. during MDs) and excessive and prolonged inflam- 
matory stimulation, a positive feedback mechanism may function. Increased cell 
damage and free radical production increases NFKB activity, in turn, increasing pro- 
inflammatory cytokine production, inflammatory mediators and ROS production. 
This increases further inflammation, cell damage and intracellular protease and 
NFxB activation (Ladner et al, 2003). Increased oxidation of membrane lipids (per- 
oxidation), proteins and DNA (Macdonald et al, 2003) can lead to ubiquitin- 
proteasome system activation (Merker et al, 2001) and further trigger cell death 
pathways. It is interesting to note that a number of genes that have NF-xB binding 
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sites in their promoter regions include cytokines, calpain proteases, ubiquitin- 
proteasome system components and a number of inflammatory mediators (Hassel- 
gren and Fischer, 2001, Penner et al, 2002, Macdonald et al, 2003). 
The transcription factors AP-1, C/EBP-ß and 
-8 are also associated with inflamma- 
tory responses, have binding sites in the promoter regions of members of the calpain 
and ubiquitin-proteasome systems and are up-regulated in muscle during sepsis 
(Thompson and Palmer, 1998, Hasselgren and Fischer, 2001, Penner et al, 2002, 
Macdonald et al, 2003). Penner et al, 2002, reported that the up-regulation in C/EBP- 
ß and 8 was partly glucocorticoid-dependent. Previously Penner et al, 2001, sug- 
gested NF-uB and AP-1 are differentially regulated during sepsis. He found that us- 
ing the glucocorticoid receptor antagonist RU38486, sepsis-induced AP-1 activity 
dropped but increased NF-KB activity. This is an important finding as glucocorti- 
coids are thought to have an anti-inflammatory effect (decreasing NF-uB activity) 
and have been implicated in the atrophy response to many stimuli but never fully 
proven (Thompson and Palmer, 1998, Railliere et al, 1997). Partly, because re- 
searchers have focused on genes containing the GRE (Glucocorticoid Response Ele- 
ment) previously, with no success (Thompson and Palmer, 1998). Interestingly also, 
GH which is generally elevated during stress responses and plays a key metabolic 
role during many of the conditions discussed, is thought to regulate the transcription 
factors, C/EBP-ß and 4 and glucocorticoid receptor (Herrington and Su, 2001). 
In summary, muscle protein loss is a serious concern affecting morbidity and mortal- 
ity in many clinical situations and states that involve stress/immuno-inflammatory 
responses, e. g. cachexia. Much is known about the stress reaction and its mediators, 
yet the precise effects on intracellular protease systems within skeletal muscle is un- 
clear and may involve complex mechanisms. The pro-inflamatory cytokines, gluco- 
corticoid receptor and transcription factors NF-KB, AP-1 C/EBP-ß and 
-S, altered 
during stress/immuno-inflammatory responses may play key roles in the induction of 
protease systems. 
Clinical research has recently been driven towards investigating the use of anti- 
inflammatory and anti-cytokine compounds, and nutrients, including: protein and 
amino acids, anti-oxidants and n-3 fatty acids (Mayer et al, 1998, Bistrian, 1999, Yeh 
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and Schuster, 1999, Tisdale, 1999, Kotler, 2000, Baud et al, 2001, Grimble, 2003, 
Grounds and Torrisi, 2004); in many stress reaction/immuno-inflammatory condi- 
tions. The aim being to reduce inflammation, oxidant stress, tissue damage and in 
turn reduce lean body mass loss. 
2.5 SUMMARY OF THE RELEVANCE OF SKELETAL MUSCLE 
PROTEOLYSIS 
Skeletal muscle tissue has a dual role. Firstly, it is required for muscle contractile 
activity and secondly, due to its mass, composition and energy expenditure it is im- 
portant for amino acid repartitioning, glucose and lipid clearance (Rennie and Tipton, 
2000). It is therefore important to maintain muscle tissue for optimal physical health. 
Conditions that induce muscle wasting/atrophy are associated with decreased muscle 
function, increased disability, debilitation, morbidity and mortality (Roubenoff, 
1999, Tisdale, 1999, Tisdale, 2000, Kotler, 2000). Proteolytic systems within skeletal 
muscle are activated during many catabolic states and may act as the primary mecha- 
nism in myofibrillar degradation (Hasselgren and Fischer, 2001, Goll et al, 2003). 
The medical application of growth-promoting/nutrient-repartitioning agents like tes- 
tosterone analogues, GH, IGF-1, insulin, insulin-sensitisers and ß-adrenergic agonists 
has been to attempt to drive anabolism and/or prevent/reduce catabolism; and thereby 
combat muscle wasting/atrophy in a number of animal models and clinical settings 
(Rooyackers and Nair, 1997, Garlick et al, 1998, Mann, 1999, Yeh and Schuster, 
1999, Bistrian, 1999, Kotler, 2000, Fowler et al, 2004). Many have been utilised and 
studied extensively in farm animals and shown to increase lean body mass and effi- 
ciency of growth (Grant and Gerrard, 1998, Bell et al, 1998, McDonagh et al, 1999). 
The different pharmacological agents are known to have variable suppressing effects 
on proteolysis. Proteolytic system inhibitors have been suggested by both the live- 
stock industry (Goll, et al, 1998) and in clinical medicine to potentially have a bene- 
ficial effect on muscle growth and protein accretion in a number of catabolic states 
indicated in Section 2.4.2. 
Proteolysis and specific intracellular protease systems are also involved in the meat 
tenderisation process and meat quality (Taylor et al, 1995, McDonagh et al, 1999, 
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Hopkins and Thompson, 2001a, Hopkins and Thompson, 2001b, Hopkins and 
Thompson, 2001c). This has important commercial implications for the livestock in- 
dustry. Meat tenderness post-slaughter is dependent on the rate of proteolysis of 
myofibrillar and cytoskeletal proteins within skeletal muscle (process described in 
Section 2.2.4). Studies suggest that for an increase in muscle growth, a decrease in 
proteolysis is favourable, whereas for meat tenderisation, an increase in proteolysis 
pre-slaughter is favourable. This contradiction makes the use of pharmacological 
growth-promoting agents difficult in the livestock industry. Therefore, a greater un- 
derstanding of the significance of the individual proteolytic systems in muscle may 
allow manipulation which will enhance muscle growth, but not have a negative effect 
on the proteolytic dependent process of tenderisation. 
2.6 INTRODUCTION TO THE PROTEOLYTIC PATHWAYS 
Proteolysis in skeletal muscle serves 3 major functions: 
- 
1) Protein turnover at steady state conditions. 
2) Muscle wasting/compartmental depletion under catabolic conditions. 
3) Sarcomeric remodelling, related to adaptive responses. e. g. during growth. 
Research suggests that these functions are achieved within skeletal muscle through 
coordinate interactions between four major intracellular proteolytic systems, other 
intracellular (local, independent, mitochondrial and sarcoplasmic reticulum proteases 
may function) and extracellular proteases and endogenous, intracellular protease in- 
hibitors (Doherty and Mayer, 1992c, Thompson and Palmer, 1998, Jagoe et al, 2002, 
Stevenson et al, 2003, Lecker et al, 2004). It has been suggested that the vast major- 
ity, if not all proteolysis is ATP-dependent. Although peptide hydrolysis by many 
proteases does not require energy, ATP is required for various activation steps, ion 
pump functioning and possible catalysis and protein transport mechanisms (Doherty 
and Mayer, 1992c). An important source of proteases during inflammatory/immune 
responses and local trauma is white mononuclear cells, which may invaginate muscle 
cells and subsequently release proteases, including cathepsins (Farges et al, 2002). 
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The four major intracellular proteolytic systems operating within skeletal muscle tis- 
sue include: 
Lysosomal-Cathepsin protease system, 
ATP-dependent Ubiquitin-Proteasome system, 
Calpain system, 
Caspase pathway. 
All four systems have individual importance in regulating specific proteolytic events 
within skeletal muscle, under different nutritional, metabolic, endo-, para- and auto- 
crine influences, and pharmacological and pathological conditions. 
Protease systems have been implicated not only in intracellular protein turnover but 
also highly specific `recycling' functions, sarcoplasmic and myofibrillar remodelling 
and repartitioning (Glickman and Ciechanover, 2002, Goll et al, 2003). Whole cell 
protein turnover in basal cell turnover conditions, cancer growth, excessive cell 
loss/death during apoptotic and apoptotic-like and necrotic states are all dependent 
on regulation of protease system activation (Sandri and Carraro, 1999, Tidball and 
Spencer, 2000, Grimm, 2003a). More recently, as will be described, various prote- 
ases have been linked to myocellular glucose and fat metabolism, or the dysregula- 
tion of, and pathological states such as diabetes (Baier et al, 2000, Walder et al, 
2002, Huang et al, 2003). This is an unexpected role for enzymes which were tradi- 
tionally associated with gross protein turnover. 
2.7 THE LYSOSOMAL CATHEPSIN PROTEASE SYSTEM 
2.7.1 Structure and Function 
Lysosomes are located in the interior of irregular, single-membrane bound, vesicular 
structures found ubiquitously in the cytoplasm of mammalian cells. Lysosomes are 
more acidic than the cytoplasm and contain a variety of enzymes that are responsible 
for `digesting' various cell materials (Doherty and Mayer, 1992c, Voet and Voet, 
1995b). The lysosome is responsible for degrading extracellular proteins (e. g. plasma 
lipoproteins and hormones) and phagocytosed bacteria after undergoing endocytosis. 
The endosome-lysosome pathway is also responsible for peptide generation to the 
immune system and turnover of cell membrane proteins. Some cytosolic proteins are 
40 
also degraded through a process involving engulfing in autophagic vacuoles and 
eventual fusion with the lysosome (Doherty and Mayer, 1992c, Voet and Voet, 
1995b). The numerous functions of the system are limited however to individual cell 
types, such that for example, mature myofibers would be incapable of phagocytosing 
bacteria. 
Lysosomes are capable of the rapid breakdown of intact cytoplasmic and extracellu- 
lar proteins completely to amino acids, through a combined action of cathepsin 
endoproteases (which cleave internal peptide bonds of proteins), exopeptidases (car- 
boxypeptidases A and B and aminopeptidases) and di- and tripeptidases (Doherty 
and Mayer, 1992c). The acid proteases of the lysosomal compartment are most active 
at a low pH and thus a low pH is maintained by an ATP-dependent H+ pump. 
Cathepsins are classified on the basis of the important amino acid at the active site. 
Cathepsins B, H and L have cysteine, D, aspartate and G, serine (see Table 2.7.1-1). 
They are thought to be activated by auto-proteolysis in acidic pH or by proteolysis by 
other proteases (Grimm, 2003a). For example, cathepsin D can activate B and L. Ce- 
ramide is also reported to bind and promote proteolytic activation of cathepsin D 
(Grimm, 2003a). A number of endogenous inhibitors for the cathepsins have been 
identified termed the `cystatin superfamily', although little is known about their 
function within skeletal muscle (Auerswald et al, 1996, Grimm, 2003a, Stevenson et 
al, 2003). 
Table 2.7.1-1. Lysosomal-cathepsin proteases. Cathepsins B, D, L and Hare main 
enzymes identified in skeletal muscle. 
Enzyme Essential active site residue Presence in 
skeletal muscle 
Cathepsin B Cysteine Yes 
Cathepsin D Aspartate Yes 
Cathepsin G Serine ? 
Cathepsin H Cysteine Yes 
Cathepsin L Cysteine Yes 
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Due to the nature of autophagy, lysosomal proteolysis was originally viewed as a 
`bulk' non-specific protein degrading system, incapable of degrading short-lived, un- 
stable regulatory proteins. Several mechanisms operate with regards to sequestera- 
tion of cytoplasmic proteins which can impart (Doherty and Mayer, 1992c, Voet and 
Voet, 1995b). Bulk non-selective autophagy is accomplished by macroautophagy 
(known to be able to sequester whole organelles). Microautophagy is thought to be a 
more selective process involving multivesicular body (containing protein aggregates) 
invagination. Heterophagy (internalisation of extracellular materials into the ly- 
sosome-related system) is important for cellular homeostasis, nutrition, hormone and 
growth factor action. Secretion-coupled degradation involves the lysosomal system 
in regulation of the rate of secretion of various secretory proteins. Examples are that 
of casein secretion from mammary glands (Doherty and Mayer, 1992c). It would be 
interesting to know whether the lysosomal system plays a role in regulation of auto- 
crine and paracrine secretion of growth factors, including IGF-1, FGF and TGF-ß, 
from skeletal muscle cells. Another point of interest is that older studies suggested 
ubiquitin has a minor role in lysosomal proteolysis during nutrient deprivation and 
heat stress (Doherty and Mayer, 1992c). This may suggest another pathway for 
specificity control or `cross-over' of system pathways. However, the primary mecha- 
nism of selective sequesteration of certain proteins (including possibly some that are 
unstable and short-lived) is through recognition of proteins containing a certain pen- 
tapeptide motif, Lys-phe-Glu-Arg-Gln (KFERQ) or a closely related sequence. The 
KFERQ motif (or similar) containing protein is recognised and bound in the cytosol 
by prp73 (73-kDa peptide recognition protein), a member of the 70-kD heat shock 
protein (hsp70) family; and subsequently targeted to the lysosome (Doherty and 
Mayer, 1992c, Doherty and Mayer, 1992d, Voet and Voet, 1995b). 
2.7.2 Metabolic Role in Skeletal Muscle 
Lysosomes and lysosomal cathepsin proteases are detected in skeletal muscle (see 
Table 2.7.1-1) (Thompson and Palmer, 1998). It is known that lysosomes degrade 
many intact cellular proteins (e. g. membrane and soluble proteins) completely to 
amino acids, but thought to only play a minor role in myofibrillar degradation under 
basal and catabolic conditions (roles thought to be attributed to calpain and ubiquitin- 
proteasome systems) (Farges et al, 2002). The lysosomal-cathepsin system is unable 
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to directly degrade intact myofibrillar proteins, only cleaved myofilament units. This 
is thought to be due to their cellular location, i. e. outside the periphery of the myofi- 
brillar apparatus (Doherty and Mayer, 1992e). 
The lysosomal system is thought to be regulated by specific nutrients, hormones and 
nutritional feeding and fasting (Doherty and Mayer, 1992c, Doherty and Mayer, 
1992d, Voet and Voet, 1995b). BCAAs may decrease activity of lysosomal proteases 
(Busquets et al, 2000) and insulin may inhibit lysosomal proteolysis possibly due to 
a reduction in autophagic vacuole formation and/or decrease in lysosomal fragility 
(Thompson and Palmer, 1998). As described in Section 2.3.5.4, the rapid and potent 
decrease in protein breakdown post-meal is thought to be attributed to a rise in insu- 
lin (and probably amino acids) and affect proteins of non-myofibrillar origin 
(Rooyackers and Nair, 1997). Therefore, it is likely that any rapid and potent de- 
crease in protein breakdown and rise in lysosomal proteolysis indicates that the ly- 
sosomal-cathepsin system may play a major role in `bulk' sarcoplasmic proteolysis 
(note: in co-ordination with the ubiquitin-proteasome system). 
Serum and nutrient deprivation of cells leads to a rapid rise in non-selective macro- 
autophagy. During prolonged nutrient deprivation (e. g. starvation) a rise in selective 
uptake of proteins takes place via the KFERQ-motif recognition-prp73 mechanism, 
which may function to spare essential and recycle non-essential proteins (Doherty 
and Mayer, 1992d, Voet and Voet, 1995b). 
The lysosomal-cathepsin system has been suggested to play a role in the induction of 
the proteolytic response in muscle during a number of diverse catabolic-atrophic 
states (Tsujinaka et al, 1996, Tsujinaka et al, 1997, Farges et al, 2002, Deval et al, 
2001, Stevenson et al, 2003), the pathogenesis of degenerative myopathies (Wein- 
stein et al, 1997) and involved in cell death, apoptosis and necrosis (Grimm, 2003a). 
Table 2.7.2-1 indicates the various conditions and states that have been reported to 
affect the lysosomal enzymes in skeletal muscle. In nearly all catabolic states listed 
there is a loss of muscle weight (of studied organism), increase in protein degrada- 
tion and common increase in cathepsin-L mRNA and/or activity. Many of the states 
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affect whole body proteolysis and involve stress-immune responses as described in 
Section 2.4. For example, Mansoor et al, 1996 (see Table 2.7.2-1) observed increases 
in whole-body and myofibrillar breakdown, cortisol excretion, IL-10, IL-6 and pro- 
teolytic system activities in human head trauma patients; in addition to an increase in 
cathepsin-D mRNA. An important observation to note with many of the studies is 
that there is an associated rise in pro-inflammatory cytokines. Interestingly, the in- 
crease in cathepsin-B and -L mRNA and activities observed in IL-6 transgenic mice 
and during abcess formation in mice, was inhibited using an IL-6 receptor antibody 
(Tsujinaka et al, 1996 and Tsujinaka et al, 1997). 
Therefore, under catabolic-atrophic conditions lysosomal proteolysis may play a 
greater role in muscle and myofibrillar protein breakdown (Weinstein et al, 1997). It 
is possible that specific cathepsins up-regulated during these states, in particular ca- 
thepsin-L, may play a role in this response (Deval et al, 2001, Stevenson et al, 2003). 
In Table 2.7.2-1, Fasson et al, 2002 observed an increase in activities of cathepsins 
B and L after a bout of eccentric exercise in humans. This is obviously interesting as 
it may implicate the cathepsins in a possible coordinated remodelling response to ex- 
ercise-induced muscle damage. 
In Table 2.7.2-1, Huang et al, 2003 found that cathepsin-L mRNA may play a role in 
glucose metabolism in skeletal muscle in humans. An impairment in an insulin- 
mediated rise in cathepsin-L mRNA was associated with a diabetic state. This is the 
first study to suggest that lysosomal-cathepsin proteolysis, in particular, cathepsin-L 
activity is involved in myocellular glucose metabolism and/or insulin signalling. 
From Table 2.7.2-1 it can be seen that much is known about conditions that alter 
mRNA levels of cathepsins during various catabolic-atrophic stimuli, yet little is 
known about their transcriptional control. Similar regulators may be involved as de- 
scribed in Section 2.4.3, i. e. the glucocorticoid receptor, NF-xB, AP-1, C/EBP-ß and 
-S, which are known to alter during stress/immuno-inflammatory responses. Further 
studies would need to confirm these theories. 
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Table 2.7.2-1. Reported effects of various conditions and states on cathepsins in 
skeletal muscle. 
Condition or state Effect on Lysosomal Cathepsin system Reference 
Fasting j/- mRNA for Cathepsins. Thompson and Palmer, 1998, 
t mRNA Cathepsin L is consistant finding. Mosoni et al, 1999, Jagoe et 
al, 2002, Lecker et al, 2004. 
Dis- j/- mRNA for Cathepsins. T mRNA Ca- Ikemoto et al, 2001, 
use/unloading/mic thepsin L is consistant finding. T mRNA Stevenson et al, 2003. 
rogravity Cystatin C. 
Head trauma. T Cathepsin D mRNA. Mansoor et al, 1996. 
Local blunt j Cathepsin B activity and mRNA for Farges et al, 2002 
trauma. Cathepsins B, L, H and C. Cathepsin B Lo- 
cated to mononuclear cells. 
Distal and proxi- j protein degradation and DECLINE in ly- Weinstein et al, 1997. 
mal denervation. sosomal latency (indication of increased 
lysosomal response). 
Diabetes mellitus j Cathepsin L (2-3 fold) mRNA, no change Lecker et al, 2004. 
and in other Cathepsins. 
Uremia. 
Sepsis T Cathepsin-L mRNA and protein. Others Deval et al, 2001. 
components INCREASE up to 4-fold. 
Dexamethasone 'j Cathepsin-L mRNA. 
treatment 
Cancer cachexia j Cathepsin-L mRNA and activity. Deval et al, 2001, Lecker et 
al, 2004. 
11-6 transgenic j Cathepsin-B and 
-L mRNA and activities, Tsujinaka, 1996. 
mice. inhibited by MR 16-1 (IL-6 receptor anti- 
body) treatment. 
Inflammation and T Cathepsin-B and -L mRNA and activities, Tsujinaka, 1997. 
abcess formation. inhibited by MR 16-1 (IL-6 receptor anti- 
body) treatment. 
Eccentric exercise t apoptotic markers and loss of dystrophin. Birai et al, 2000, Fdasson et 
bout. j in Cathepsins B and L activities al, 2002 
Diabetes and con- t Cathepsin L mRNA correlated with insu- Huang et al, 2003 
trol subjects. tin-mediated glucose uptake, glucose oxida- 
tion, and fasting glucose concentrations. 
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L- I Impaired in diabetic subjects. 
2.7.3 SUMMARY 
A number of specific cathepsin proteases function in co-ordination with exopepti- 
dases and di- and tri- peptidases, within the acidic lysosomal compartment, to com- 
pletely degrade in an ATP-driven process, proteins of intracellular and extracellular 
origin within skeletal muscle. Under basal conditions the system may play a key role 
in `relatively non-selective' bulk sarcoplasmic protein degradaton (in co-ordination 
with the ubiquitin-proteasome system), but a limited role in the degradation of 
cleaved-myofibrillar units. 
Evidence suggests the lysosomal-cathepsin system has a role in fasting-, denervation- 
, 
disuse/microgravity-, trauma-, sepsis-, cancer- and cytokine-induced rises in muscle 
proteolysis and atrophy. Other diverse conditions like age-related sarcopenia, uremia, 
type I and II diabetes and glucose intolerance may also be affected. Studies indicate 
that cathepsin L is the key functioning lysosomal protease in nearly all of the studied 
states. This suggests that during such states the system may play a more selective 
role in proteolysis. 
Evidence suggests a strong regulatory role played by various mediators of the stress 
and immune response, with regards to cathepsin regulation. Cytokines and glucocor- 
ticoids are potentially implicated, in particular the proinflammatory cytokines, IL-6 
and TNF-a. Regulation of cathepsin gene transcription is under regulatory control, 
but it is unknown which factors are involved. It may involve a number of factors as- 
sociated in immuno-inflammatory/stress responses. 
2.8 THE CALPAIN SYSTEM 
2.8.1 Structure and Activity 
The calpains are calcium-dependent, neutral, cysteine, intracellular, non-lysosomal. 
proteases. The first characterised vertebrate calpains were the ubiquitous µ- (micro) 
and m- (milli) calpains, with repsective requirements for p- and m- concentrations of 
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calcium ions for activation (Sazontova et al, 1999, Goll et al, 2003). The calpains 
have been found to be a complex family with at least 11 different calpain genes now 
identified (Huang and Wang, 2001). In skeletal muscle, the calpains of importance 
include p- and m-calpain, a skeletal muscle specific calpain known as calpain 3 or 
p94 and more recently identified, calpain 10 (Goll et al, 1998, Sazontova et al, 1999, 
Tidball and Spencer, 2000, Huang and Wang, 2001, Ma et al, 2001, Goll et al, 2003) 
In terms of structure 4u-(Aoki et al, 1986)- and m-(Imajoh et al, 1998)- calpain (or 
calpains 1 and 2), were found to consist of a different large 80kDa and small 28 kDa 
subunit that associate non-covalently. The large subunit contains four different dis- 
tinct domains. Domain 1 may be a regulatory domain cleaved during calpain activa- 
tion (autolytic activation). Domain 2 acts as the proteolytic domain, similar to other 
cysteine proteases (cysteine catalytic site). Domain 3 may be involved in binding 
phospholipids and regulating calpain activity by electrostatic interactions (Goll et al, 
2003). Domain 4 is the calcium binding domain similar to calmodulin, with five EF- 
hand structures. The small subunit, contains domains 5 and 6. Domain 5 being im- 
portant in enabling calpain association with membrane phospholipids. Domain 6 con- 
tains four calcium binding domains homologous to domain 4. Figure 2.8.1-1, illus- 
trates the domain structures of the ubiquitous 1u- and m-calpains. Calpain 3/p94 (94 
kDa protein) contains four distinct domains and has 50% sequence homology with 
the ubiquitous u- and m-calpains. It is different in structure in that it has no small 
subunit and presence of three additional insertion sequence regions (NS, IS I and 
IS2), with expected functional importance (Sorimachi et al, 1989). IS1 has three 
autolytic sites, Si, S2, and S3. The IS2 sequence is capable of associating with titin. 
In immunostained myofibrils it is located along the N2 and Z-line in vivo. Within the 
IS2 region there is a potential nuclear translocation signal (NTS) (Goll et al, 2003). 
Figure 2.8.1-1, illustrates the domain structures of calpain-3, in relation to the ubiqui- 
tous p- and m-calpains. 
Calpain 3 has an unknown function and activation mechanism due to its instability in 
muscle extracts. It has been suggested that Calpain 3 is produced as an inactive zy- 
mogen, similar to the Caspase family and has a proteolytic activity that is activated 
on autolytic cleavage in the IS1 region (Taveau et al, 2003). 
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Figure 2.8.1-1. Schematic structures of A) ubiquitous p-and m-calpain and B) 
muscle-specific calpain-3. The large catalytic subunit and small regulatory subunits 
are indicated for the ubiquitous calpains and muscle-specific calpain-3. The four 
domains (I, 11, III and IV) are indicated with three specific regions of muscle-specific 
calpain-3 (NS, ISI and IS2). The Nuclear Localisation Signal (NLS) is indicated 
within IS2. The size scale in number of amino acids is indicated at either end of the 
sequence. p- Calpain is 714 amino acids long and m-calpain, 699. Calpain-3 is as 
described 821 amino acids long and 94 kDa in mass. 
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Calpain 10 has recently been characterised, found to be ubiquitously expressed and 
linked to insulin dependent glucose metabolism (Ma et al, 2001). It is thought to be a 
novel calpain, found in many cell types in human, mouse and rat. It is devoid of a 
calmodulin domain and exhibits a nuclear localisation capability (Ma et al, 2001). 
The calpains are regulated in activities by a complex number of interactions and re- 
quirements (Sazontova et al, 1999, Perrin and Huttenlocher, 2002). These include, 
whole cell and near-membrane intracellular Ca2+ ion concentrations. The calpains 
interact with the endogenous inhibitor calpastatin (see below). Regulation of calpain 
gene transcription has not been fully characterised at present, but may involve a 
number of factors involved in inflammatory/stress responses. Binding sites for the 
transcription factors NF-iB, AP-1, C/EBP-ß and 
-6 in the promoter region for mem- 
bers of the calpain system have been found. (Sorimachi et al, 1996, Penner et al, 
2002). 
Calpains are also known to be regulated in activation by translocation to the plasma 
membrane, subsequent binding with specific phospholipids and activation (Perrin 
and Huttenlocher, 2002). Calpains may be regulated by phosphorylation state. Acti- 
vator proteins for the calpains have also been identified and are thought to function 
attached to the plasma membrane (Sazontova et al, 1999). It has been speculated that 
µ- and m- calpains are in their active state prior to autolysis, where as calpain 3 has 
been suggested to be activated on autolysis. In vivo [Ca21 and the presence of cal- 
pastatin suggests that true in vivo basal activity for p- and m- calpain is low. 
Calpastatin is the specific endogenous inhibitor of p- and m- calpains which does not 
modulate the activity of any other proteases. It is thought to be regulated by phos- 
phorylation state and Ca2+ ions, and may be inactivated by calpain- or caspase- 
mediated cleavage (Sazontova et al, 1999, Goll et al, 2003). Calpastatin protein is 
heterogenous in size across species and tissue and this heterogeneity is thought to be 
due to alternative splicing and post-translational processing. Different isoforms are 
expressed in cardiac and skeletal muscle and may have differential effects on calpain 
activity (Goll et al, 1998, Parr et al, 2000, Parr et al, 2001). Gene expression may be 
regulated in part through actions on a cAMP-responsive element (confirmed in bo- 
vine) (Cong et al, 1998) by CREB. Activity may be regulated by PKA-mediated 
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phosphorylation, as PKA phosphorylation sites have been identified in the XL do- 
main (see Figure 2.8.1-2. ) (Goll et al, 2003). 
Figure 2.8.1-2. Schematic structure of calpastatin. Calpastatin consists of a non- 
inhibitory N-terminal XL and leader domain (L),. followed by four inhibitory domains 
(1, II, III and IV). Bovine cardiac calpastatin is 786 amino acids long and has all 
domains present. Other species have different size sequences. 
Calpastatin 
Inhibitory Domains 
786 
2.8.2 Calpain Function 
The precise physiological function of the calpains is not known. They are believed to 
be involved in processes such as exocytosis, cell fusion, differentiation, apoptosis, 
proliferation, metabolism, myofibrillar, cytoskeletal and sarcoplasmic protein pool 
turnover (Sazontova et a!, 1999, Goll et al, 2003). 
The calpains do not degrade intact proteins into amino acids like the lysosomal and 
ATP-dependent ubiquitin proteasome system, but instead cleave specific proteins. 
The list of proteins that undergo proteolytic cleavage includes: cytoskeletal and myo- 
fibrillar proteins, transcription factors and their inhibitors, e. g. IKBa, ion channels, 
protein kinases, glycolytic and other metabolic enzymes and membrane bound pro- 
teins, like Ca'+-ATPases (Verret et a!, 1999, Krebs and Graves, 2000, Chen et a!, 
2000, Baghdiguian et al, 2001, Shen et al, 2001). 
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The calpain system is thought to have a prominent role in muscle protein turnover, 
through its involvement in basal protein degradation and cytoskeletal and myofibril- 
lar cleavage (Huang and Forsberg, 1998, Goll et al, 2003). They may act as the rate- 
limiting factor in myofibrillar degradation and disassembly. They are thought to be 
unable to directly degrade actin and myosin but able to cleave troponin T, desmin, 
vinculin, talin, spectrin, nebulin and titin; and cleave at a slower rate, troponin I, 
filamin, C-protein, dystrophin, tropomyosin, a-actinin, and M protein (Taylor et al, 
1995, Huang and Forsberg, 1998, Goll et al, 2003). Integrins (Pfaff et al, 1999), 
other costameric proteins and transmembrane plaques may also be cleaved by cal- 
pains (Taylor et al, 1995, Perrin and Huttenlocher, 2002). They may also associate 
with some of these target proteins in their resting state. For example, u-calpain has 
been reported to interact with a-actinin in a resting state (Raynaud et al, 2003). These 
potential substrates are involved in myofibrillar structure and stability, Z-disk integ- 
rity, costameric function and cytoskeletal integrity. Their cleavage inevitably leads to 
a loss of muscle cell structure, integrity and function. This may lead to a lack of abil- 
ity for cellular mechano-transduction and myofibrillar contraction. 
p- and m- calpains and calpastatin are thought to be involved in myoblast fusion 
(Barnoy et al, 1997, Barnoy et al, 1998). Integrin BI subunit, talin, and B- 
tropomyosin (specific proteins responsible for stability of the membrane-cytoskeletal 
organisation, and interaction of the cell with the extracellular matrix) are degraded 
specifically in a process thought to involve u- and m- calpains (Barnoy et al, 1997, 
Barnoy et al, 1998). These specific cleavage events allows destabilisation of the 
membrane and the creation of membrane fusion-potent regions. 
Calpain 3 is believed to have different functional activities in skeletal muscle com- 
pared to q- and M. calpains. Calpain-3 mRNA is expressed at levels -10 times 
greater than 4u- and m- calpains, although `free' p94 protein is rapidly degraded 
within the cell (Ono et al, 1999, Goll et al, 2003). Its precise functional role is un- 
known, but it has been observed to exhibit various regulatory functions. It is unlike 
other calpains in that it doesn't appear to participate in whole-cell cytoskele- 
tal/myofibrillar cleavage and degradation (Ono et al, 1999, Goll et al, 2003). Al- 
though a recent study reported that cells expressing active autolysed p94 were able to 
cleave talin, filamin A, vinexin, ezrin, along with possibly titin and filamin C 
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(Taveau et al, 2003). The proteolytic cleavage lead to disruption of the actin cy- 
toskeleton and disorganisation of focal adhesions. p94 is known to have a specific 
binding affinity to titin and is located along the N2 and Z-line in vivo, in immu- 
nostained myofibrils. A proposed function for p94 binding to titin may be that titin 
acts as a negative regulator preventing rapid autolytic cleavage of other p94 mole- 
cules, and/or to prevent other calpains (i. e. p- and m-) from binding and initiating 
cleavage of myofibrillar proteins (Ono et al, 1999). p94 may also be involved in 
regulation of turnover or activity of transcription factors as it posesses a nuclear 
translocation sequence (NTS) (Ono et al, 1999, Goll et al, 2003). 
2.8.3 Metabolic Role in Skeletal Muscle 
Calpains are thought to play a role in hypertrophy, remodelling and atrophy under 
catabolic conditions, incl. muscular dystrophy states (Goll et al, 1998, Hasselgren 
and Fischer, 2001, Goll et al, 2003). Recent work has indicated that they are also 
play a role in insulin-mediated glucose disposal, fat and carbohydrate metabolism 
(Baier et al, 2000, Walder et al, 2002, Otani et al, 2004). 
Remodelling of the cytoskeletal and myofibrillar apparatus is necessary during peri- 
ods of rapid myofiber growth, fiber type transitions in response to various stimuli 
and possibly in regenerating cells. The calpain protease system may function as a 
rate-limiting step in many of these ` cleavage-dependent' processes. This ties in with 
the principle that proteolytic cleavage is a valuable means of controlling cellular pro- 
cesses, that doesn't have to be reversible. 
Mechanical stimulation/loading and resistance `training' are thought to affect the 
calpain-calpastatin system. Chronic low frequency stimulation (CFLS) studies in rat 
skeletal muscle (Sultan et al, 2000) and rabbit (Sultan et al, 2001) have showed an 
exchange of myofibrillar protein isoforms from fast-to-slow, MHCIIb-to MHCIId(x) 
and MHCIIa. The `chronic' nature of CLFS cannot be compared to resistance train- 
ing bouts in humans however as CLFS leads to formation of necrotic fibers and pos- 
sible mononuclear infiltration. CLFS upregulates [Ca2+]i and free calpain activity, 
with no change in calpastatin activity. m-Calpain is prominent in mainly necrotic fi- 
bers and p-calpain is elevated in intact fibers. In addition p-calpain and to a lesser 
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extent m-calpain were shown to translocate from the cytosol to the myofibrillar and 
microsomal structures. CLFS caused a temporary reduction in the expression levels 
of calpain 3 in rabbit muscle possibly suggesting that it has a regulatory role in fiber 
type transformations. Fdasson et al, 2002, showed that an eccentric exercise (muscle 
lengthening contractions) bout in humans decreased the mRNA levels of u-calpain 
and calpain-3 by 25% and 40%, respectively, on day 1 post exercise, whereas m- 
calpain was dramatically increased (220%). Jones et al, 2002 found that calpastatin 
gene expression was increased by 300% following 8 weeks of resistance training in 
healthy female subjects; and remained increased 4 weeks after the cessation of train- 
ing (P < 0.05). m-Calpain was also increased following training (154%, P<0.01) 
and remained elevated after cessation (P < 0.01). 
Calpain activity is important for remodelling, but overactivity has been associated 
with muscle atrophy (Thompson and Palmer, 1998, Williams et al, 1999, Busquets et 
al, 2000). Calpain inhibition has been suggested as a strategy for inducing hypertro- 
phy in a number of settings. ß-adrenergic stimulation (discussed at length in Section 
2.3.4) increases lean muscle mass (Goll et al, 1998, Grant et al, 1998), induces a fast- 
twitch fiber transition (Rajab et al, 2000, Depreux et al, 2002, Pellegrino et al, 2003); 
and is known to increase calpastatin mRNA and activity, and down-regulate calpain 
activity (Parr et al, 1992, Bardsley et al, 1992, Speck et al, 1993, Sensky et al, 1996, 
Goll et al, 1998, Mc Donagh et al, 1999, Navegantes et al, 2002). Callipyge lambs 
with 30-40% greater muscle mass (than in half-siblings), deposited in the pelvic 
limbs and back, have associated 68-126% higher calpastatin activities. Muscle 
groups with no increase in mass in callipyge lambs had no change in calpastatin ac- 
tivities (Goll et al, 1998). Transgenic mice overexpressing calpastatin have been re- 
ported to have higher muscle weight (Otani et al, 2004). 
Calpain 
-3 and -10 have been suggested to have a relationship with fat-carbohydrate 
metabolism/oxidation, insulin signalling, diabetes and obesity progression (Baier et 
al, 2000, Walder et al, 2002). There was reduced calpain 3 gene expression in human 
skeletal muscle from a group of 27 non-diabetic subjects and in psammomys obesus 
(a polygenic animal model of obesity and diabetes) (Walder et al, 2002). This corre- 
lated with reduced carbohydrate oxidation, elevated blood glucose, insulin, increased 
body fat and abdominal fat. Genetic variation in the gene encoding calpain 10 has 
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been linked to reduced skeletal muscle calpain 10 mRNA and insulin resistance 
(Baier et al, 2000), type 2 diabetes (Horikawa et al, 2000, Permutt et al, 2000) and 
increased serum cholesterol (Daimon et al, 2002) in different sub-populations. Cal- 
pain 10 gene polymorphism has also been associated with reduced ß3-adrenoceptor 
function in human fat cells (Hoffstedt et al, 2002), which may reduce fat cell lipoly- 
sis and regulate thermogenesis. Otani et al, in 2004, using transgenic mice that over- 
expressed calpastatin found that GLUT4 was increased 3-fold at protein level, whilst 
decreased at mRNA level (relative to wild type controls). They also showed m- 
calpain can degrade GLUT4 and suggest that the ubiquitously expressed calpain sys- 
tem is involved in the regulation of insulin-stimulated glucose disposal. 
The calpain system may play a role in accelerated proteolysis and pathogenesis in 
skeletal muscle during catabolic conditions including cachexia (Hasselgren and 
Fischer, 2001). A summary of various studies looking at the effects of different con- 
ditions/states on changes in the calpain system is presented in Table, 2.8.3-1. One 
point of interest not noted in Table 2.8.3-1 is that Mosoni et al, 1999 found that in a 
fasting study, older rats had higher baseline m-calpain mRNA. 
Table 2.8.3-1. Reported effects of conditions and states on calpains in skeletal 
muscle. 
Condition or state Effect on Calpain-Calpastatin system Reference 
Fasting 1 mRNA for Calpains. Mosoni et al, 1999, 
. 
Calpain-3 mRNA. Jagoe et al, 2002 
Hindlimb unloading mRNA for Calpain-3, NO CHANGE for m- Stevenson et a12003. 
Calpain, T in Calpastatin. 
Hindlimb unloading in j muscle atrophy by 30% in transgenic mice, Tidball and Spencer, 
transgenic mice over- compared to normal non-transgene mice. 2002 
expressing Calpastatin. 
Head trauma t mRNA for m-Calpains-2. Mansoor et al 1996. 
Sepsis T mRNA fort-and m-Calpains and Calpain 3 Williams et al, 1999. 
Cancer cachexia J Calpain-3 mRNA with j m-Calpain mRNA. Busquets et al, 2000. 
IL-6 transgenic mice. I mRNA for Calpain-3, inhibited by MR 16-1 Tsujinaka et al, 1996. 
(IL-6 receptor antibody) treatment. 
Denervation. J. mRNA for Calpain-3. Stockholm et al, 2001. 
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2.8.4 Muscular Dystrophies 
The calpain system has a key role in the progression and pathogenesis of muscular 
dystrophies (MDs). As this is a complex area under investigation by many research 
groups it requires a greater description. In duchenne (DMD) and some variations of 
Limb Girdle Muscular Dystrophies (LGMDs) there is a loss of various specific pro- 
teins involved in sarcolemmal stability/integrity, force transduction and transmission, 
e. g. loss of dystrophin or sarcoglycans (Brown et al, 1997, Bushby, 1999, Ehmsen et 
al, 2002). This causes the skeletal muscle cells to become more susceptible to dam- 
age and loss of sarcolemmal integrity, which in turn increases the amount of Ca2+ 
entering the cell and cytosolic [Ca2+] (Tidball and Spencer, 2000). Research suggests 
that the increase in Ca2+ may be also due to increased activation of leak or stretch 
regulated Ca2+ channels (Mallouk et al, 2000) and growth factor-regulated channels 
(GRC) (Iwata et al, 2003). This may set up Ca2+ gradients within the cell, increasing 
the near-membrane concentration instead of a `whole-cell' rise in concentration 
(Mallouk et al, 2000). This rise in [Ca2+] may cause an up-regulation in calpain ac- 
tivity (Tidball et al, 2000). Calpains specifically bound to phospholipids at the mem- 
brane, or near membrane activator proteins may also be preferentially activated 
(Mallouk et al, 2000, Tidball and Spencer, 2000). 
Muscular dystrophies tend to cause the development of degenerative, necrotic muscle 
tissue (Chae et al, 2001). The suggested model of the sequence of events that may 
lead to this pathological state, may involve a chain reaction of positive feedback, in- 
volving cytosolic Ca2+ ion dysregulation and the calpain system (Ono et al, 1999). 
Intitially, as [Ca2+] near-membrane increases calpain activity may also increase. Cal- 
pain-mediated Ca2+ leak channel activity may increase (Mallouk et al, 2000) along 
with a calpain-mediated decrease in Ca2+ ATPases activity (Mallouk et al, 2000). 
This may further increase cytoplasmic [Ca2+], calpain activity and cell damage. Fur- 
ther cell damage, Ca2+ dysregulation and calpain activity will initiate caspase de- 
pendent/independent cell death pathways (discussed in Section 2.10). 
Further evidence that the calpain system is involved in the pathology of dystrophies 
has been shown by the specific inhibition of calpastatin. Overexpression of a calpas- 
tatin transgene in mdx dystrophic mice muscle reduced 1c- and m-calpain activities, 
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muscle necrosis and hence dystrophic pathology (Spencer and Mellgren, 2002). 
`Booster' gene therapy for calpastatin has been suggested to be used clinically in the 
future as one target of many, to slow/prevent MD pathogenesis (Engvall and Wewer, 
2003). 
A more specific association of a particular calpain isoform with muscular dystrophy 
is the role of calpain-3. Two non-sarcoglycan forms of LGMD, types 2A and 2B are 
thought to involve calpain 3 (Bushby, 1999, Anderson et al, 2000). Secondary reduc- 
tion in calpain 3 expression has been observed in patients with LGMD2B and also 
miyoshi myopathy (MM), known as primary dysferlinopathies (Anderson et al, 
2000). Defects in the human calpain 3 gene are responsible for LGMD2A (Ono et al, 
1999, Baghdiguian et al, 1999, Tidball and Spencer, 2000, Chae et al, 2001, Richard 
et al, 2000). There is a characteristic atrophy and weakness of the proximal muscle 
of the limbs (Bushby, 1999, Chae et al, 2001). It is unclear how p94 ab- 
sence/deficiency causes the dystrophic condition characterised by apoptosis. How- 
ever, there is a very strong correlation between deficiency of p94, myoapoptosis and 
a perturbation in the hcBa/NF-xB pathway (Baghdiguian et al, 1999, Tidball and 
Spencer, 2000, Richard et al, 2000, Baghdiguian et al, 2001). One hypothesis is that 
low/non-existant levels of p94 prevents proteolytic cleavage of the endogenous in- 
hibitor of NF-KB, IxBa. Other studies confirm a relationship between the whole cal- 
pain-calpastatin system and regulation of the IxBa-NFO pathway (Chen et al, 2000, 
Shen et al, 2001). NFKB activation is dependent on IKK (Inducible Kinase)- 
phosphorylation of IicB (inhibitory protein) (Macdonald et al, 2003) and degradation. 
It has been suggested that IiBa (IuB3 IiBE also exist) proteolysis by calpains is the 
rate-determining step in NFKB activation (Lin et al, 1995). A reduction in calpain- 
dependent proteolysis would mean less NF-KB would be able to translocate to the 
nucleus and drive transcription of a number of survival genes (Baghdiguian et al, 
2001). 
Figure 2.8.4-1 illustrates a model adapted from Tidball and Spencer, 2000 and Bagh- 
diguian et al, 2001, of the possible function of p94 in relation to myoapoptosis ob- 
served in LGMD2A. p94 associates with titin along the N2-line and M-line of the 
sarcomere. Activation of cell death pathways may lead to apoptosis in skeletal mus- 
cle (see Section 2.10). During normal cell function, cell death can be averted through 
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the actions of cell survival proteins, including anti-apoptotic proteins within skeletal 
muscle. The up-regulation of these proteins is dependent on NF-icB-dependent gene 
transcription. For NF-KB to successfully translocate to the nucleus and increase tran- 
scription of cell-survival genes, the NF-icB inhibitor IKBa must be cleaved and de- 
graded. Cleavage may be dependent on p94 and possibly p- and m- calpains. It is also 
proposed that as p94 has a nuclear translocation sequence, may be able to translocate 
to the nucleus and cleave the nuclear located form of the NF-uB-IxBa complex. Ab- 
sence or mutation of p94 may lead to a perturbation in this pathway and increase 
apoptosis in skeletal muscle. 
Figure 2.8.4-1. A proposed model of the action of p94 in skeletal muscle, in rela- 
tion to the origin of apototic myonuclei in LGVID2A. 
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Another hypothesis is that p94 may have an important role in myofibrillar integrity, 
through its association with titin. Kramerova et al, 2004 observed abnormal sar- 
comere formation in calpain-3 knockout mice. Whether p94 association protects titin 
from degradation is unknown, but titin which plays a key role in myofibrillar integ- 
rity is known to be downregulated in standard DMD (Tkatchenko et al, 2001) and 
may have other unknown regulatory functions; possibly associating with myostatin 
(Nicholas et al, 2002). 
2.8.5 Summary 
Calpain proteases are calcium-dependent cysteine proteases with many effects glob- 
ally within cells and tissues. They are involved in the specific cleavage and hence 
partial degradation of a number of cytoskeletal, myofibrillar and regulatory proteins 
within skeletal muscle. 
A reduction in calpain-mediated proteolysis, mediated by an up-regulation in calpas- 
tatin, has been found to coincide with an increase in muscle hypertrophy, during ß- 
adrenergic stimulation, in callipyge lambs and in transgenic mice overexpressing cal- 
pastatin. 
Calpain-3 and in particular calpain-10 have been linked to alterations in insulin resis- 
tance, glucose and fat metabolism. Preliminary studies suggest calpastatin and m- 
calpain may also affect metabolism. 
Contraction-induced muscle damage has been shown to increase m-calpain and de- 
crease calpain-3 mRNA, possibly indicating part of a remodelling response to allow 
cytoskeletal and myofibrillar alterations and adaptations. 
Components of the calpain system have been found to be differentially altered during 
a number of catabolic-atrophic states, including fasting, cancer-cachexia, sepsis, 
hindlimb unloading, denervation, IL-6 transgenic mice and muscular dystrophies. In 
particular, a rise in m-calpain and decrease in calpain-3 activity/mRNA is a common 
theme. Absence and genetic abnormalities in calpain-3/p94 has been linked to 
myoapoptosis and a perturbation of the NF-xB pathway during LGMD2A. 
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Therefore, two distinct roles have now been identified for calpains. Cytoskeletal and 
myofibrillar proteolysis linked to turnover and remodelling; and proteolysis associ- 
ated with specific alterations in cellular carbohydrate-fat metabolism and transcrip- 
tion factor regulation. 
2.9 THE UBIQUITIN-PROTEASOME SYSTEM 
2.9.1 Structure of the Ubiquitin-Proteasome System 
The ATP-dependent ubiquitin-proteasome (Ub. Prot. ) system is thought to play a ma- 
jor role in basal skeletal muscle protein degradation and myofibrillar degradation un- 
der basal and catabolic conditions (Lecker et al, 1999, Attaix et al, 2001, Jagoe and 
Goldberg, 2001). The proteins within muscle may undergo complete proteolysis to 
amino acids through a non-lysosomal, Cat+-independent, ATP-requiring process. 
The Ub. Prot. pathway consists of several components acting in concert. This in- 
volves two main processes: the covalent attachment of multiple ubiquitin molecules 
to the protein substrate and degradation of the targeted protein by the 26S protea- 
some complex. A number of review articles have been written describing the struc- 
tural and functional properties of the system (Schwartz and Ciechanover, 1999, Wil- 
kinson, 1999, DeMartino and Slaughter, 1999, Ciechanover et al, 2000, Glickman 
and Ciechanover, 2002, Attaix et al, 2001, Attaix et al, 2002). 
The basic steps are illustrated in Figure 2.9.1-1: Ubiquitin is converted to a high- 
energy thiolester, by the ubiquitin-activating enzyme, El. Once activated by El, one 
of the several E2 class enzymes (including, ubiquitin-carrier proteins, ubiquitin- 
conjugating enzymes (UBCs)), transfers ubiquitin from El to a member of the E3 
ubiquitin-protein ligase family, to which the substrate protein is specifically bound. 
The E3 enzyme catalyses the conjugation (covalent attachment) of ubiquitin, to the 
protein substrate. A polyubiquitin chain is synthesised in successive reactions and 
serves as a recognition `tag', or `marker', for the 26S proteasome. The ubiquitin- 
conjugated protein substrate is then degraded completely by the 26S proteasome 
complex, with free and reutilisable ubiquitin released. 
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Figure 2.9.1-1. The ubiquitin-proteasome system pathway. Ilustrates the basic 
steps associated with the ubiquitination and subsequent degradation of proteins. 
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The structure of the proteasome complex is such that it comprises of two `cap' com- 
plexes, PA700 (19S cap) and proteasome activator, PA28 (11 S regulator) that act as 
regulatory subunits, imparting specificity and control (Figure 2.9.1-2). These are as- 
sociated with a 20S cylindrical `core catalytic' structure, which contains 28 subunits 
forming four rings of seven subunits each. The outer rings (a-subunits) regulate sub- 
strate entry, whereas the inner rings (0-subunits) encode the catalytic centers. Asso- 
ciation of the 19S and 11 S structures generates a `dumbell-shaped' protein complex 
(26S proteasome, 
- 
2000kDa). The 26S proteasome is an intricate, structured protease 
complex with over 30 subunits, ubiquitin and ATP-dependence. It possesses trypsin- 
like, chymotrypisn-like and post-glutamylpeptidyhydrolytic activities, able to de- 
grade muscle structural proteins (Matsuishi and Okitani, 1997). Of possible signifi- 
cance, a proline-rich endogenous inhibitor of the 20S proteasome, P131 (Proteasome 
Inhibitor of 31,000 daltons) was identified, cloned and sequenced from bovine tissue 
(McCutchen-Maloney et al, 2000). It is thought to directly inhibit the 20S and inhibit 
activation of the proteasome by each of the regulatory proteins, PA700 and PA28. 
Associated isopeptidases also play a major role in acting as `de-ubiquitinating' en- 
zymes. These may have specific regulatory functional roles in stabilising proteins 
that would be other-wise targeted for degradation, for example. 
Although peptide hydrolysis by many proteases does not require energy, the whole 
protein degradation process is ATP-dependent. ATP hydrolysis is required for ubiq- 
uitin activation by El. ATP is required for assembly of the 26S complex from its 
components along with ATP probably needed for catalysis of protein un-folding, fa- 
cilitate entry into the 20S core and proteolytic activities. 
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Figure 2.9.1-2. Diagram to show representation of A) the proteasome-activator 
complex and B) the proteasome-inhibitor complex. 
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2.9.2 System Function 
The Ub. Prot. proteolytic pathway plays a crucial role in the degradation of short- 
lived and regulatory proteins important in a multitude of cellular processes. Among 
these are the cell cycle, the cellular response to stress and to extracellular modulators, 
morphogenesis of neuronal networks, modulation of cell surface receptors, ion chan- 
nels, the secretory pathway, DNA repair and biogenesis of organelles (Glickman and 
Ciechanover, 2001). The system plays a critical role in degrading damaged, unfolded 
and abnormal proteins, including those damaged by free radicals (Merker et al, 
2001). 
The activity of the Ub. Prot. pathway can be regulated and modulated in a number of 
ways (Thompson and Palmer, 1998, Schwartz and Ciechanover, 1999, Wilkinson, 
1999, DeMartino and Slaughter, 1999, Ciechanover et al, 2000, Attaix et al, 2001, 
Glickman and Ciechanover, 2002, Attaix et al, 2002). Overall activity has been stud- 
ied by measuring component mRNA, protein levels, proteasome activity, ubiquitin 
conjugation rates and short-term phosphorylation events. Regulation of system- 
component gene transcription is unknown at present but may involve a number of 
factors involved in immuno-inflammatory/stress responses, including glucorti- 
coids/glucocorticoid receptor and cytokines (Thompson and Palmer, 1998, Hassel- 
gren and Fischer, 2001, Penner et at, 2002). Binding sites for the transcription factors 
NF-KB, AP-1, C/EBP-ß and 
-S in the promoter region of genes for members ubiq- 
uitin-proteasome systems have been found (Thompson and Palmer, 1998, Hasselgren 
and Fischer, 2001, Penner et al, 2002). 
With regards to proteasome activity, it is recognised that IFN-y stimulation drasti- 
cally up-regulates activity (DeMartino and Slaughter, 1999, Glickman and Ciech- 
anover, 2002). Whether this occurs in skeletal muscle and what function it has is un- 
known. Studies suggest it is activated during antigen processing (DeMartino and 
Slaughter, 1999, Glickman and Ciechanover, 2002). The proteasome is regulated by 
at least one endogenous inhibitor as described previously (DeMartino and Slaughter, 
1999). Some proteasome subunits have been shown to be subject to phosphorylation 
and be cGMP-dependent. Poly-ADP-ribose polymerase (PARP) is also thought to 
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activate the proteasome and may be important in integrating protease and cell death 
pathways (Thompson and Palmer, 1998, Glickman and Ciechanover, 2002). 
2.9.3 Metabolic Role in Skeletal Muscle 
The Ub. Prot. pathway within skeletal muscle is thought to play a major role in the 
complete proteolysis of specific sarcoplasmic and myofibrillar proteins (Lecker et al, 
1999). Although, there is no evidence to suggest that the pathway can degrade myo- 
fibrillar proteins in their intact functional state (i. e. non-cleaved myofilaments linked 
together by other proteins, in a myofibrillar lattice structure). This system is thought 
to only degrade myofilaments cleaved and released by the actions of other protease 
systems (principally the calpains) (Thompson and Palmer, 1998). 
Evidence suggests that key components of the system are up-regulated in skeletal 
muscle in a number of catabolic and stress reaction conditions like cachexia, as re- 
viewed in a number of articles (Mitch and Goldberg, 1996, Lecker et al, 1999, Tis- 
dale, 2000, Kotler, 2000, Baracos, 2000, Hasselgren and Fischer, 2001, Jagoe and 
Goldberg, 2001). Conditions including denervation atrophy, fasting, glucocorticoid 
treatment, kidney disease, metabolic acidosis, trauma, infection/sepsis, cancer ca- 
chexia, MDs, possibly myopathies, burns, hyperthyroidism, diabetes, resistance 
training and aging exhibit increased system up-regulation/activity (Mitch, 1997, Tis- 
dale, 1999, Llovera et al, 1999, Baracos, 2000, Merker et al, 2001, Stupka et al, 
2001, Hasson et al, 2002, Lecker et al, 2004). 
Table 2.9.3-1 summarises observations from various studies relating to the effects of 
different states and conditions on the Ub. 
-Prot. system. Most are catabolic states 
known to induce whole-body and skeletal muscle protein loss due to increased deg- 
radation and decreased synthesis. The system may play a key role in the regulation of 
muscle proteolysis in response to feeding and fasting. This response is probably me- 
diated by glucocorticoids, insulin and amino acids (Thompson and Palmer, 1998, 
Busquets et al, 2000). Interestingly, an increase in Ub. Prot. pathway activity has 
been observed after eccentric-exercise induced muscle damage (Stupka et al, 2001, 
Fasson et al, 2002). This may indicate an up-regulation of the system as part of a 
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remodelling response to contraction-induced muscle damage, to increase degradation 
of damaged muscle proteins. 
Recent studies have revealed muscle-specific E2 and E3 enzymes that are up- 
regulated during catabolic, atrophic states (as seen in Table 2.9.3-1). Examples in- 
clude the E214k, UBC, which functions with E3a (also suggested to be up-regulated 
in some catabolic conditions) to ubiquitinate muscle proteins in the N-end rule path- 
way, although recent studies suggest no significant changes in gene expression 
(Jagoe et al, 2002, Lecker et al, 2004). Two E3 enzymes have been found to be mas- 
sively up-regulated during skeletal muscle atrophy under a variety of conditions. 
They are known as Muscle RING Finger I (MuRF1) and Muscle Atrophy F-box 
(MAFbx)/Atrogin-1, a member of the SCF family of E3s (Bodine et al, 2001, Gomes 
et al, 2001). Interestingly, MuRF 1 was identified by its interactions with a domain of 
titin, similar to p94, in a yeast two-hybrid system. MuRFI and Atrogin-1 have been 
reported to be up-regulated in rat muscle during immobilisation, denervation, un- 
weighting, treatment with IL-1, treatment with dexamethasone glucocorticoid 
(Bodine et al, 2001). Bodine et al, 2001, overexpressed Atrogin-1 in myotubes caus- 
ing atrophy and mice deficient in either Atrogin-1 or MuRF1 were resistant to atro- 
phy. Gomes et al, 2001, reported massive up-regulation in Atrogin-1 gene expression 
in muscle during fasting (2 days in mice), diabetes (3 day streptozotocin-treated rats), 
tumor-bearing (yoshida ascites hepatoma for 6 days in rats) and renal failiure 
(nephrectomised rats). 
Another point of interest is that Mosoni et al, 1999 found that older rats had higher 
baseline levels of mRNA for ubiquitin, C2 (proteasome subunit) and E214k (see Table 
2.9.3-1). m-Calpain was also found to be increased in the study (listed previously in 
Table 2.8.3-1). Whether this links to sarcopenia is unknown. 
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Table 2.9.3-1. Reported effects of conditions and states on Ubiquitin-Proteasome 
system in skeletal muscle. 
Condition or state Effect on Ubiquitin-Proteasome System Reference 
Fasting j' mRNA for Ubiquitin, E214k, subunits of the Mosoni et al, 1999. 
20S proteasome and 19S cap including C8 Jagoe et al, 2002. 
(proteasome unit), Atrogin-1 and MuRF- 1. Lecker et al, 2004 
Diabetes with metabolic T mRNA for E214k, Ubiquitin and C3 (protea- Mitch et al 1999. 
acidosis and increased some subunit), Ubiquitin-fusion proteins, At- Lecker et al, 2004 
glucocorticoid levels. rogin-1 and MuRF 1 
Obesity. I mRNA of Ubiquitin. Argil6s et al, 1999. 
Microgravity-induced j mRNA for RC2 and RC9 (proteasome com- Ikemoto et al, 2001, 
atrophy, unloading and ponents), polyubiquitin and ubiquitin- St-Amand et at, 
immobilised muscle. conjugating enzyme. T mRNA for E3 en- 2001, Stevenson et 
zymes, Atrogin-1, MuRFI al, 2003. 
Trauma T mRNA of Polyubiquitin and E214k and pro- Mansoor et al, 1996, 
teasome subunits Biolo et at, 2000 
Sepsis Proteasome inhibitors J total and myofibrillar Hobler et al, 1998, 
breakdown in vitro and in vivo. T activity of Williams et al, 
20S proteasome, inhibited by proteasome in- 1998,. Hobler et al, 
hibitors. T mRNA of subunits RC3, RC9 and 1999a, Hobler et al, 
RC7,1 mRNA for E214k 1999b, 
. 
Fischer et al, 
T mRNA for Ubiquitin in IL-6 knockout mice. 2000 
-Separate groups of rats Torbafyline (xanthine derivative) inhibited Lydie et al, 2002. 
with induced sepsis and TNF-a production, muscle wasting and 
cancer ubiqutin-dependent proteolysis. 
Administration of TNF- j mRNA Ubiquitin with TNF-a, IFN-y and Llovera et al 1998. 
a, IFN-y, IL-1, IL-6 and IL-1. NO CHANGE with IL-6 and LIF. 
LIF. 
Cancer cachexia T Ubiquitin conjugation. T mRNA Ubiquitin Lazarus et al, 1999, 
and C8 proteasome subunit, subunits of 20S Busquets et al, 2000, 
and 19S cap. Atrogin-1 and MuRF-1. Lecker et al, 2004. 
Muscular dystrophy, I expression of proteasomes and staining for Kumamoto et al, 
neuromuscular disor- ubiquitin. 2000. 
ders. 
Muscle denervation j mRNA Ubiquitin. Llovera et al, 1999. 
Eccentric-exercise in- I in proteasome activity. T in Ubiqutin- Stupka et al, 2001, 
duced muscle damage. conjugated proteins F6asson et al, 2002. 
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2.9.4 Summary 
The ubiquitin-proteasome system is an ATP-dependent system involved in the spe- 
cific degradation of a wide range of proteins completely to amino acids, including 
sarcoplasmic and myofibrillar proteins. Specific E2 ubiquitin-carrier, conjugating 
and E3 ligase enzymes provide substrate targetting specificity to the system. 
A number of conditions involve activation of the ubiquitin-proteasome system and 
many of these result in muscle atrophy. Certain signalling molecules coincide with 
pathway activity. Alterations in insulin, glucocorticoids and cytokines are implicated 
in a number of cases (Thompson and Palmer, 1998). Upregulation of the pathway 
occurs in most types of skeletal muscle damage/trauma, as damaged, mis-folded and 
abnormal proteins formed are targeted for degradation by the proteasome. For exam- 
ple, mechanical stimulation and contraction-induced damage induces ubiquitin pro- 
teasome pathway activation, which may be important during subsequent remodelling 
of cells, so as to degrade `old', redundant proteins (Stupka et al, 2001, Hasson et al, 
2002). 
Components of interest within skeletal muscle include the specific E2 (e. g. E214k, 
E2GI), E3 enzymes (e. g. Atrogin-1 and MuRF 1), specific proteasome subunits (e. g. 
C3, C7, C8 C9) and ubiquitin, as all are up-regulated during atrophic-catabolic con- 
ditions. 
2.10 THE CASPASE PROTEOLYTIC PATHWAY 
2.10.1 Structure of the Caspase Proteolytic Pathway 
The caspases are highly specific cysteine proteases (cysteine Martate proteases 
. 
Proteolysis by the caspases is restricted and limited. Peptide cleavage occurs only 
after recognising specific tetrapeptide motifs in target proteins, followed by cleavage 
of the peptide bond C-terminal to aspartic acid residues, producing disassembly of 
the protein (Grimm, 2003d). Therefore, they are not involved in gross proteolysis. 
They do not play a role in basal protein turnover within muscle, but instead are in- 
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volved in ordered proteolysis having highly specific roles in other cell processes, in 
particular apoptosis (Israels and Israels, 1999, Budihardjo et al, 1999, Slee et al, 
1999, Strasser et al, 2000). 
The caspases have many similarities to and inter-relationships with the calpain sys- 
tem. The similarities include specificity of cleavage reactions and similar interactions 
with protein kinases affecting cell function / regulation; whilst there is a relationship 
between calpain and caspase interactions during programmed cell death (apoptosis) 
(Grimm, 2003a, Krebs and Graves, 2000). 
The caspases are constitutively expressed zymogens (inactive precursors) present 
within the cytoplasm. At least 14 mammalian caspases have now been identified (10 
human) (Strasser et al, 2000, Grimm, 2003d). These proteases are thought to activate 
themselves and other members of the family in an apoptotic cascade. Caspases are 
able to activate other procaspases in a sequential cascade, but also are activtated by 
self-cleavage (Slee et al, 1999, Strasser et al, 2000, Grimm, 2003d). 
The caspase family can be divided into three groups depending on their structure and 
what is known about their regulation and function (Israels and Israels, 1999, Budi- 
hardjo et al, 1999, Slee et al, 1999, Grimm, 2003d). The first group, known as long 
prodomain `initiator' caspases (2,8,9 and 10) are thought to act at a proximal location 
in the caspase cascade. The second group, the short prodomain terminal `effectors' 
(includes 3,6 and 7) are activated by the initiators. A third group, (including 1,4,5, 
11,12,13, and 14) are believed to play a role in processing the pro-forms of cyto- 
kines prior to secretion. Long prodomain caspases contain either a death effector 
domain (DED), i. e. caspase-8 and 
-10; or a caspase recruitment domain (CARD) in 
their prodomain region, i. e. caspase-1, 
-2, -4, -5, -9, -11, -12 (see Figure 2.10.1-1). 
The DED and CARD domains mediate recruitment of procaspases to specific signal- 
ling complexes, with the aid of specific adaptor molecules. This results in autoactiva- 
tion/autolysis of the caspase. Short prodomain-effectors are thus unable to be acti- 
vated this way and rely on activated up-stream initiators. 
Regulation of caspase gene transcription is unknown at present (Grimm, 2003d). The 
caspase system has been suggested to constitutively produce mRNA and regulate ac- 
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tivation of these inactive zymogens at the level of autolytic cleavage. Recent studies 
suggest increases in mRNA levels for some caspases (e. g. caspase-3) may coincide 
with catabolic conditions (see Table 2.10.4-1). 
Figure 2.10.1-1. Structure of the caspases. DED, Death Effector Domain. CARD, 
Caspase Recruitment Domain. L 1-L4 loops that form the substrate binding site. 
A) Caspases with DEDs (e. g. Caspase-8 and 
-10) 
LI L2 L3 L4 
B) Caspases with CARD (Caspase-1, 
-2, -4, -5, -9, -11 and 
-12) 
C) Caspases with short prodomain (Caspase-3, 
-6 and 
-7) 
Prodomain Large Subunit ' Small Subunit 
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Caspase activity is thought to be increased predominately by caspase-mediated 
cleavage or autocleavage (Slee et al, 1999, Strasser et al, 2000, Grimm, 2003d). The 
calpains may participate in cleavage activation of specific caspases during specific 
conditions (Nakagawa and Yuan, 2000, Grimm, 2003a, Grimm, 2003c). Some stud- 
ies have suggested specific protein kinases may have the ability to directly phos- 
phorylate some caspases, inhibiting protease activity, autolytic cleavage and activa- 
tion (Krebs and Graves, 2000). 
2.10.2 Caspase Pathway Function 
The caspase proteolytic pathway is intimately involved in the process of controlled 
cell death, apoptosis (Israels and Israels, 1999, Budihardjo et al, 1999, Slee et al, 
1999, Strasser et al, 2000, Grimm, 2003d). Apoptosis is the major physiological 
mechanism of cell removal, where cells are `silently' but actively removed under 
normal conditions, when they reach the end of their life span, are damaged or super- 
fluous (Israels and Israels, 1999). This mechanism of cellular turnover is a general 
tissue phenomenon necessary for development and homeostasis (Strasser et al, 
2000). It allows the deletion of excess cells during embryonic development, tissue 
remodeling and/or regeneration in adult organisms (Sandri and Carraro, 1999, 
Strasser et al, 2000, Grimm, 2003e). Apoptosis keeps cell numbers regulated during 
excessive cell proliferation (Sandri and Carraro, 1999, Grimm, 2003e). This becomes 
an important issue during tumor growth (Strasser et al, 2000, Grimm, 2003e). There- 
fore, dysregulation of apoptosis has been implicated in a variety of diseases (Sandri 
and Carraro, 1999, Israels and Israels, 1999, Strasser et al, 2000, Gill et al, 2002). 
Apoptosis is viewed as a form of programmed cell death (PCD), where the cell even- 
tually after protease action, shrinkage and formation of apoptotic bodies, is rapidly 
ingested by adjacent macrophages, or other neighbouring phagocytes (Israels and 
Israels, 1999). As the apoptotic bodies induce no significant cytokine release from 
the phagocytic cell, there is no concomitant inflammatory response. This therefore, is 
unlike cell necrosis, in which the release of intracellular proteases and lysozymes in- 
duce an inflammatory response (and hence a greater propensity/possibility for wide 
spread damage) (Israels and Israels, 1999, Grimm, 2003c). 
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The process of apoptosis and activation of the caspase pathway may be set in motion 
by the following mechanisms: 
1) Genotoxic damage, from cell injury, chemotherapy, radiation etc., initiating acti- 
vation of the p53 protein (a regulator of DNA transcription), cell-cycle arrest, or 
apoptosis promotion (Israels and Israels, 1999, Budihardjo et al, 1999, Strasser et al, 
2000). p53 probably regulates ratios of apoptosis-inhibitory proteins (e. g. Bcl-2, and 
Bcl-XI) and promoters of apoptosis (e. g. Bax, Bad, Bid). A high expression of the 
Bax group will promote apoptosis by affecting mitochondrial permeability with con- 
comitant release of cytochrome c and apoptosis-inducing factor (AIF). AlF moves to 
the nucleus to promote nuclear fragmentation. Cytochrome c acts to activate the cy- 
toplasmic protein Apaf-1 (apoptotic protease activating factor), once cytochrome c is 
bound to Apaf-1, there is subsequent activation of procaspase 9 (i. e. initiator cas- 
pases). Caspase-9 activation then acts to activate downstream caspases, including 
procaspase-3 (effector). 
2) Death signals received at the cell surface membrane involves an alternative, non- 
secretory mechanism of apoptosis. I. e. "death receptors" are expressed on the cell 
membrane. Fas (CD 95), a cell-surface receptor and a member of the tumour necrosis 
factor family receptor (TNF-R) family, is a transducer of the apoptotic signal (Israels 
and Israels, 1999, Strasser et al, 2000, Grimm, 2003e). Therefore, the Fas ligand (a 
member of the TNF family), and TNF produce apoptosis in an analogous fashion- 
FasL through the Fas receptor protein, and TNF by binding to the TNF receptor 
(TNFR-1). Binding of ligands, causes "trimerisation" of receptors, activation of 
death domains (DD), interaction with cytoplasmic proteins, activation of these pro- 
tein DDs, with eventual recruitment and activation of the caspase cascade, through 
procaspase-8 activation. 
3) Apoptosis may also be stimulated by procaspase activation by granzyme B (the 
Granzyme system) (Israels and Israels, 1999, Grimm, 2003a). This system allows 
removal of pathogen infected cells and tumour cells. Perforins and granzymes are 
proteins contained within the cytoplasmic secretory granules of cytotoxic lympho- 
cytes (CTL's), and natural killer (NK) cells. Upon CTL receptor-mediated binding to 
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a target cell, perforins and granzyme B, are cosecreted, enter target cell and eventu- 
ally granzyme B activates caspase cascade. 
4) The endoplasmic reticulum (ER), or sarcoplasmic reticulum (SR) in muscle allows 
the correct folding and modificaton of proteins and acts as a primary Ca2+ ion store. 
Accumulation of misfolded proteins in the ER lumen leads to activation of the `un- 
folded protein response' and survival signals. Alterations in ER/SR calcium homeo- 
stasis induces SR/ER stress and leads to Ca2+ release. These stimuli lead to ER stress 
which can lead to activation of cell death pathways (Nakagawa and Yuan, 2000, Rao 
et al, 2001, Rao et al, 2002, Grimm, 2003c). It has been suggested that ER stress 
signals activate caspase 12 through a caspase-7-mediated pathway (Rao et al, 2001). 
m-Calpain is known to activate caspase 12, in response to an increase in cytosolic 
near-ER-membrane [Ca2+], due to raised ER Ca2+ release (from ER stress); and lead 
to aQtivation of effector caspases (Nakagawa and Yuan, 2000, Gill et al, 2002, 
Grimm, 2003b). In addition, m-calpain may activate pro- and inactivate anti- 
apoptotic proteins, Bid, and Bcl-xL, respectively. A novel, mitochondrial and Apaf- 
1-independent apoptotic pathway which may involve cytochrome c and Apaf-1 inde- 
pendent activation of caspase 9 has also been implicated (Rao, 2002). The mitochon- 
dria is the major site of oxidative phosphorylation and hence ATP and reactive oxy- 
gen species production. It also acts as a secondary store for Ca2+ ions and repository 
for pro- and anti-apoptotic molecules. During ER/SR stress, several other pathways 
may become activated promoting mitochondrial pro-apoptotic signals. High Ca2+ re- 
lease from the SR and subsequent uptake by the mitochondria (at ER-mitochondrial 
junctions) can lead to PTP (permeability transition pore) opening and release of 
apoptogenic factors, Ca2+ and cytochrome c. 
5) Increased mitochondrial ROS production or exposure to oxidants can lead to cyto- 
chrome c release and mitochondrial dysfunction, through a disruption in mitochon- 
drial membrane potential and uncoupling of oxidative phosphorylation, leading to a 
depletion in [ATP] (Neuss et al, 2001, Grimm, 2003b). These occurrences may 
stimulate caspase-dependent or 
-independent apoptosis/necrosis-like death pathways. 
The above activation mechanisms of apoptosis stimulate effector caspase activity 
(caspase-3, 
-6 and -7). This activity is responsible for: Cleavage of cytoskeletal pro- 
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teins, disruption of the nuclear membrane, disruption of cell-cell contacts and the 
freeing of the DNA nuclease (CAD, caspase-activated deoxyribonuclease) from its 
associated protein inhibitor (ICAD) (Strasser et al, 2000, Grimm, 2003d). The cas- 
pases may in addition act on mitochondrial membranes with further release of cyto- 
chrome c and intramitochondrial procaspases (i. e. possible feed forward mechanism) 
(Grimm, 2003d). 
Activation of caspase-mediated restricted proteolysis results not in cellular lysis, but 
in membrane-bound sealed apoptotic bodies (Israels and Israels, 1999, Strasser et al, 
2000). Many diverse pro- and anti-apoptotic signals from intra- and extra-cellular 
origins affect cell death/survival pathways and mediators (Budhardjo et al, 1999, 
Strasser et al, 2000, Gill et al, 2002, Grimm, 2003a, Grimm, 2003b, Grimm, 2003c). 
It is the overall balance of these signals that leads to a net effect of cell death pro- 
gression or survival (Krebs and Graves, 2000, Grimm, 2003e). 
It is thought that caspase targets fall into two groups; those that are inactivated upon 
proteolysis in order to hasten cell death and those that are activated and may contrib- 
ute to the induction or progression of apoptosis (Krebs and Graves, 2000, Strasser et 
al, 2000). Therefore, the caspases may act within skeletal muscle to aid in de- 
activation and/or inhibition of various intracellular signalling pathways, involved in 
cellular growth and proliferation, e. g. caspase-mediated processing of PKC isoforms 
and members of the MAPK kinase pathways (Smith et al, 2000, Krebs and Graves, 
2000). Caspase processing of atypical PKC-ý, activates it and targets it for degrada- 
tion, by the ubiquitin-proteasome system (Smith et al, 2000). Atypical PKC's also 
regulate the expression of genes that mediate inflammatory responses and cell sur- 
vival. This is accomplished through NF-kB activation (Smith et al, 2000, Grimm, 
2003e). Evidence suggests that activated caspases attempt to down-regulate the NF- 
KcB pathway in a number of ways, including the above example (Krebs and Graves, 
2000, Grimm, 2003e). Caspase 3 may have a direct effect on the NF-xB pathway, 
cleaving IKB, creating a truncated, suppressive form of IxB, resistant to degradation 
(Krebs and Graves, 2000). 
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2.10.3 Inhibitors of Apoptosis 
An important group of regulators of caspase activation and apoptosis is the caspase 
inhibitors. Termed IAPs (Inhibitors of Apoptosis Proteins), they are are known to 
directly interact with caspases, inhibit their activity and act as one of the many fail- 
safe mechanisms within the cell to prevent apoptosis (Budihardjo et al, 1999, Gill et 
al, 2002, Grimm, 2003e). Of interest, is the discovery of a skeletal and cardiac mus- 
cle specific inhibitor of apoptosis, reported by Koseki et al, 1998. ARC, (Apoptosis 
Repressor with Caspase recruitment domain), was found to selectively inhibit cas- 
pase-8 and hence inhibit the extrinsic pathway of death-receptor-induced activation 
of caspase-8 and subsequent effector activation. ARC was also found to protect heart 
myogenic cells from hypoxia-induced apoptosis and prevented cytochrome c release 
(Ekhterae et al, 1999). Neuss et al, 2001b, found that H202 exposure in a myogenic 
cell line lead to dissipation of mitochondrial membrane potential, ATP depletion, mi- 
tochondrial dysfunction and loss of plasma membrane integrity leading to cell death, 
including necrosis-like changes. This was associated with a downregulation of ARC 
protein levels. Increased expression of ARC prevented H202-induced cell death, by 
preservation of mitochondrial integrity. 
Figure 2.10.3-1 illustrates a proposed scheme of caspase activation and apoptosis 
pathways that may function within skeletal muscle. It includes the extracellular death 
receptor, intracellular mitochondrial and sarcoplasmic reticulum (SR) pathways. The 
IGF-1 pathway has an anti-apoptotic effect via PI (3) Kinase (PI3K) and Akt activa- 
tion, with subsequent inhibition of the pro-apoptotic factor Bax. It was important to 
include the IGF-1 anti-apoptotic pathway as the GH-IGF axis was discussed in great 
detail in Section 2.3.3. IGF-1 is one of the most important cell growth regulators af- 
fecting protein turnover and satellite cell proliferation and differentiation. ß- 
adrenergic stimulation may also activate PI (3) Kinase (PI3K) /Akt (Glass, 2003). 
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Figure 2.10.3-1. A proposed simplified schematic of caspase activation and 
apoptosis signalling pathways. Adapted from Gill et al, 2002. Arrows indicate 
pathway activation. The pro-apoptotic proteins Bax, Bad and Bid are indicated. Pos- 
sible points of interaction by IAPs (Inhibitors of Apoptosis) and ARC (Apoptosis Re- 
pressor with CARD) are in red. SR is sarcoplasmic reticulum. 
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2.10.4 Metabolic Role in Skeletal Muscle 
Apoptosis is known to take place in proliferating myoblasts, i. e. an alternative path- 
way to differentiation and fusion (Sandri and Carraro, 1999). Differentiated and 
fused myotubes are also known to undergo apoptosis. Excess myoblast and myotube 
apoptosis may occur during pathogenesis of states like muscular dystrophies, along 
with adult myofibers. During such catabolic states atrophy eventually takes place, 
leading to decreases in protein content, cell size and myonuclei. The myonuclei loss 
during atrophy has been attributed to apoptosis and apopotosis markers have been 
found (Sandri and Carraro, 1999, Belizärio et al, 2001, Sandri et al, 2001). Examples 
of states known to affect caspase activation and apoptosis can be found in Table 
2.10.4-1. 
Table 2.10.4-1. Summary of a number of relevant conditions and states known 
to affect caspase activation and apoptosis. 
Condition or state Effect on Caspase system and apoptotic markers. Reference 
Inflammatory myopath- Inflammatory lesions cause expression of cyto- Li and Dalakas, 
ies plasmic and surface molecules, like Fas, not de- 2000 
tected in normal muscle. Muscle fibers may un- 
dergo apoptosis via caspase activation. 
Denervation atrophy IL-1 expression in motor end-plates Authier et al, 
1997 
Age-related sarcopenia 50% greater presence of apoptosis markers, in- Dirks and Leeu- 
in rats. cluding higher cytochrome c and caspase-3. wenburgh, 2002 
LGMD type 2A adult j apoptotic myonuclei, perturbation in the NF-KB Baghdiguian et al, 
patients pathway, loss of functional calpain 3 activity and 2001 
cytochrome c leakage. 
Duchennne MD (DMD), Caspase 
-8, -3, -5, -2, and 
-7, and granzyme B Sandri et at, 2001 
and facio-scapulo- mRNA detected in DMD muscles but not in nor- 
humeral dystrophy mal muscles. FSHD muscles had low levels of 
(FSHD) adult patients caspase-6, -3 and granzyme B. Caspase 3 protein 
correlated with apoptotic nuclei. 
Cancer cachexia in mice j in Caspase-1, 
-3, -6, -8, and -9 proteolytic ac- Belizario et al, 
tivities. Cytochrome c was present, although no 2001 
apoptosis present, or DNA fragmentation. 
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The last example of a state to be discussed that involves apoptosis and caspase acti- 
vation is that of the effects of chronic heart failiure (CHF) on skeletal muscle. Gill, et 
al, 2002, and Neuss et al, 2001, presented reviews regarding the presence of cardio- 
myocellular apoptosis and the pathways involved. Many of these pathways are 
thought to be similar and active in skeletal muscle during CHF (Libera et al, 1999, 
Vescovo et al, 2000, Vescovo et al, 2002a, Vescovo et al, 2002b). The key apop- 
tosis-activating mediators are unknown, but suggested to be through the actions of 
increased systemic TNF-a and possibly angiotensin II (ANGII) (Libera et al, 2001). 
Studies have detected in rat and human skeletal muscle increased atrophy, fatigabil- 
ity, expression of fast-glycolytic proteins, apoptotic markers and apoptosis during 
CHF. In particular, elevated levels of caspase-3, and 
-9, TNF-a (and its second mes- 
senger sphingosine) have been detected (Libera et al, 1999, Vescovo et al, 2000, 
Vescovo et al, 2002a, Vescovo et al, 2002b) and Ang II (Libera et al, 2001). 
As can be observed from Table 2.10.4-1 and in studies related to CHF, caspase-3 is 
one of the most prominent altering factors in many of the conditions described. Cas- 
pase-3 may play a critical role as a key caspase effector protease in many catabolic- 
atrophic conditions. Other researchers have suggested that caspase-3 may play a role 
in skeletal muscle differentiation, cell development, regeneration and myofibrillar 
degradation (Fernando et al, 2002, Ruest et al, 2002, Du et al, 2004a). 
2.10.5 Summary 
The caspases are specific cysteine proteases involved in selectively cleaving other 
caspases, regulatory and cytoskeletal proteins. They are constitutively expressed as 
zymogens within the cell, divided into three groups depending on their structure, 
regulation and function; and are activated by self-cleavage or by other caspases. 
Their precise role within skeletal muscle is un-clear, other than there studied function 
in orchestrating caspase-dependent programmed cell death, apoptosis. Apoptosis has 
been found to be an important process during tissue development, remodelling, regu- 
lation of cell growth and implicated in the pathogenesis of a number of clinical dis- 
orders. The caspases themselves are thought to play specific roles in muscle cell de- 
velopment at different stages and induction of pro-apoptotic responses during atro- 
phic, immuno-inflammatory conditions. 
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The `initiator' caspases (2,8,9 and 10) are activated by diverse intracellular and ex- 
tracellular pro-apoptotic signals and initiate an intracellular apoptotic caspase cas- 
cade. The `initiator' caspases in turn can activate the down-stream ` effector' caspases 
(includes 3,6 and 7), which leads to the `effector' caspase driven proteolytic cleav- 
age of a number of important cytoskeletal and regulatory proteins. This ultimately 
leading to membrane blebbing, cell shrinkage, chromosome condensation and frag- 
mentation of DNA and eventual cell death. 
In particular caspase-3 has been implicated as the key functioning `effector' protease 
in a number of pathological and catabolic-atrophic states. Caspase-3 may have addi- 
tional roles in muscle cell development and myofibrillar integrity. The muscle- 
specific caspase inhibitor ARC may play a key functional role in balancing out the 
pro-apoptotic responses from a number of various stimuli. 
2.11 OVERALL SUMMARY OF PROTEOLYTIC SYSTEMS 
As described above it is thought that four principle intracellular proteolytic systems 
operate and function within skeletal muscle, involved in many diverse cellular func- 
tions that are just being elucidated. Other proteases may also interact and function 
within muscle but the work described in this literature review has focused on these 
four only as they have been reasonably well characterised and known to be under 
regulatory control. An example of other interacting systems includes the matrix met- 
alloproteases (MMP's), active during cellular catabolic states (Huet et al, 2001). The 
ADAMs, transmembrane zinc metalloproteases and disintegrins are found in skeletal 
muscle tissue (Seals and Courtneidge, 2003) and expression of ADAM 12 in skeletal 
muscle reduced pathology in mdx mice (Kronqvist et al, 2002). 
In summary, the lysosomal-cathepsin system may have a minor role in basal skeletal 
muscle myofibrillar turnover and probably degrades, bulk quantities of sarcoplasmic 
proteins in to amino acids. However, this system is activated under catabolic condi- 
tions, including fasting and those that involve proinflammatory cytokines (Tsujinaka, 
et al, 1996, Deval et al, 2001, Jagoe et al, 2002). In these conditions it may play a 
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greater role in myofibrillar degradation and selective proteolysis. Cathepsin L, a 
main responsive proteolytic enzyme is implicated as playing a key role an all condi- 
tions mentioned, along with a possible role in glucose-insulin homeostasis, insulin 
sensitivity/resistance and glucose oxidation (Huang et al, 2003). 
The bulk of skeletal muscle protein degradation may occur through a coordinated 
response by the calpain and ubiquitin-proteasome systems. The calpains, a highly 
selective specific cleaving system do not completely degrade proteins to amino acids. 
They cleave specific sarcoplasmic proteins and many of which are associated with 
the myofibrillar lattice, initiating Z-disk disintegration and myofilament release. The 
suggested model is that myofilaments are unable to be degraded by the ubiquitin- 
proteasome and lysosomal systems whilst in their native functional state within the 
myofibril. However calpain-mediated processes (other proteases including caspase 3 
may be involved) cleave proteins in the myofilaments which then move to the pe- 
riphery of the myofibril. These myofilaments will then come in to close contact with 
complete degrading systems. The ubiquitin-proteasome pathway is thought to play a 
major role in myofibrillar degradation under basal and induced-catabolic conditons 
and specifically degrades, damaged, denatured and abnormal cell proteins. 
Caspase activation does not play a major role in basal protein turnover or bulk prote- 
olysis. Instead it is activated under developmental, catabolic, pathological conditions 
and cell dysfunction/damage. The calpains and caspases have important functional 
interactions (through cleavage mediated activation/deactivation) with themselves, 
each other and other regulatory proteins, like protein kinases and phosphatases 
within skeletal muscle (Krebs and Graves, 2000). This may affect and alter cell sig- 
nalling pathways and ultimately regulate cell growth, proliferation, overall protein 
turnover, cell death and inflammatory responses. The components of greatest interest 
within muscle include caspase-3 and ARC, a caspase-inhibitor. Caspase-3 is the main 
effector protease altered during catabolic states and myocellular development; and 
ARC is a potent muscle tissue-specific caspase inhibitor. 
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2.12 HYPOTHESIS AND AIM OF WORK UNDERTAKEN 
The central hypothesis of this thesis is the assertion that there is a co-ordinated 
change in the gene expression of key components of intracellular proteolytic path- 
ways under the influence of various physiological and pharmacological stimuli, 
known to alter skeletal muscle protein turnover and growth. This thesis describes a 
series of studies designed with the aim of investigating the relationship between al- 
tered states of muscle growth and mRNA expression of key components of the pro- 
teolytic systems described in this review of the literature. 
An initial study involves examining the hypothesis that alterations in the plane of nu- 
tritional intake can influence the gene expression of components of the calpain- 
calpastatin system in rapidly growing cattle. The calpain system was a model system 
for attempting to assess the gene expression of multiple components using the tech- 
nique of Quantitative Real-Time RT-PCR. 
The thesis then describes the synthesis of cDNA probes for components of the four 
proteoltytic systems of interest so they could be used to quantitatively measure 
mRNA gene expression in northern hybridisation's studies, using porcine skeletal 
muscle RNA. 
Having demonstrated that specific probes could be used to detect and quantify north- 
ern blot band signals in porcine skeletal muscle, probes were used to investigate the 
hypothesis that beta-adrenergic agonist administration in pigs would alter mRNA 
gene expression of components of specific proteolytic systems. 
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CHAPTER 3 MATERIALS AND METHODS 
3.1 MATERIALS 
Skeletal muscle tissue samples used both throughout all trial analysis studies and the 
development of techniques, were obtained from various sources from within the Di- 
vision of Nutritional Biochemistry; many thanks to all those who made this work 
possible. Individual acknowledgements are within the appropriate sections. All skele- 
tal muscle samples taken were frozen in liquid nitrogen and stored at 
-70°C. 
All chemicals used were of analytical grade where available and purchased from 
Fisher Scientific (Leicestershire, UK) unless otherwise stated. Solutions were made 
in double-distilled deionised water. Molecular biology reagents purchased from 
Promega (Southampton, UK) were as follows: 
Taq Polymerase, lOX Reaction Buffer and 25mM Magnesium Chloride (MgC12). 
M-MLV Reverse Transcriptase and M-MLV Reverse Transcriptase 5X Buffer. 
rRNasin® Ribonuclease Inhibitor. 
Nucleotides (dNTPS) and random hexamer primers. 
Restriction-endonucleases, associated buffers and BSA (Bovine Serum Albumin). 
DNA and RNA markers, and DNA loading dye. 
Nuclease-free water. 
Nucleotides were purchased separately as stocks of 100mM dATP, dTTP, dGTP and 
dCTP then diluted to 10mM, using nuclease-free water. 10mM dNTP mix was sub- 
sequently used for RT (Reverse Transcriptase) and PCR procedures. 
Radioisotopes were purchased from Perkin Elmer (USA). 
Gel electrophoresis was performed using BioRad (California, USA) electrophoresis 
tanks and power packs. PCR thermocycler machine used for all PCR and RT reac- 
tions was Eppendorf Mastercycler Gradient (Helena Biosciences, Sunderland, UK). 
The centrifuges were Heraeus Christ Biofuge A, Beckman J2-21, MSE 18, and 
Sanyo MSE Hawk 15/05 refrigerated centrifuge. 
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3.2 GENERAL MOLECULAR BIOLOGY PROCEDURES 
All procedures were carried out using sterile pipette tips, autoclaved solutions and 
wearing latex gloves at all times to prevent nuclease contamination of the samples. 
Additional care was taken in cleaning and sterilisation procedures during total RNA 
extractions and Northern blotting to avoid RNAase contamination, and subsequent 
RNA degradation. All glassware and plasticware was soaked overnight in OA M So- 
dium Hydroxide and 1 mM Ethylene Diamine Tetra-acetic Acid (EDTA), to denature 
RNAase; then washed with Diethylpyrocarbonate (DEPC (Sigma-aldrich, Dorset, 
UK))-treated water. DEPC treated water was made by adding 0.5 ml DEPC /11 dou- 
ble distilled water, which inactivates RNAase, then left overnight and autoclaved for 
3 autoclave cycles. All working solutions and buffers were prepared with DEPC- 
treated water (except those containing amide groups). 
3.3 TOTAL RNA EXTRACTION 
Total RNA suitable for use in gene expression experimental procedures was ex- 
tracted from samples, using an acidified Phenol Guanidine Thiocyanate method 
adapted from Chomczynski and Sacchi (1987). The reagents required for the proce- 
dure can be found within Appendix J. 
3.3.1 Extraction Procedure 
The Denaturing solution (see Appendix J. ) acts as a protein denaturant, thereby in- 
hibiting RNAase activity. To 50 ml of denaturing solution, 0.36 ml ß- 
Mercaptoethanol (ß-ME) was added giving a final working concentration of 0.1 M 
(see Appendix J. ). As the solution is stable for 1 month at room temperature all ex- 
tractions were performed in batches within days after solutions were made-up. Fro- 
zen muscle tissue stored at -70°C was crushed in liquid nitrogen using a pestle and 
mortar. Samples were weighed out (1 g ±0.03) into 50 ml sterile screw capped centri- 
fuge tubes (Sarstedt, Numbrecht, Germany). To this was added 10 ml of denaturing 
solution+ß-ME and the sample homogenised (Polytron PT 3000, Kinematica Cincin- 
nati, Ohio, USA) at high speed for approximately 20-30 sec. Once homogenised, a 
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Phenol Chloroform extraction was performed. The following solutions were added in 
the order specified, with gentle mixing between each addition of a solution: 1 ml 2M 
Sodium Acetate pH4,; 10ml water saturated Phenol; 4 ml Chloroform-isoamyl alco- 
hol (49: 1). Finally the solution was mixed well by shaking vigorously for 10-20 sec- 
onds. Samples were cooled on ice for 15-30 min then centrifuged at 12,000 g (J2-21 
Beckmann centrifuge) for 20 min at 4°C. The aqueous phase was removed and trans- 
ferred to a Corex centrifuge tube. To this 10 ml Isopropanol was added, mixed and 
samples left to precipitate overnight at 
-20°C. Samples were centrifuged at 12,000 g 
(as above) for 20 min at 4°C. Supernatant was removed and discarded and pellet re- 
suspended in 3m1 of Denaturing solution+(3-ME, 3 ml Isopropanol added, gently 
mixed and left at 
-20°C for a minimum of 1 hour. The samples were then centrifuged 
at 12,000 g for 20 min at 4°C, pelleting the total RNA. Supernatant was removed, 
pellet washed with 4 ml 75% (v/v) Ethanol, vortexed and centrifuged (as described 
above). The supernatant had to be completely and carefully removed to avoid dis- 
turbing the pellet and redissolved in 2 ml of nuclease-free water. Further precipita- 
tion steps were required to remove excess glycogen from the RNA by adding 6 ml 
4M Sodium Acetate, mixing, then leaving samples overnight at 0°C. Samples were 
then centrifuged (as described above), the supernatant removed, then pellet partly air- 
dried and redissolved in -100-500 µl (depending on estimated concentration re- 
quired) nuclease-free water. Samples were stored at 
-70-80°C. 
Total RNA was quantifed using spectrophotometer analysis (Section 3.3.2) and in- 
tegrity assessed by non-denaturing gel electrophoresis (Section 3.6), using one pg of 
total RNA/sample. Completely intact and purified total RNA should exhibit two 
clean sharp bands, corresponding to 28S and 18S ribsomal units. Presence of `band 
smearing', particularly at the lower molecular weights, indicates degradation; com- 
plete degradation by high intensity low molecular weight banding. DNA contamina- 
tion was indicated by the presence of band smearing near wells and a large molecular 
weight band. 
3.3.2 Nucleic Acid Quantification and Quality Assessment 
RNA and DNA samples in nuclease-free water, had their concentrations measured, 
along with an estimation of relative impurities by spectrophotometric analysis. Ab- 
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sorbance at wavelengths, 260 nm (for nucleic acids), 280 nm (for proteins), and for 
some samples at 320 nm (for contaminants, e. g. guanidinium thiocyanate) were 
measured using a spectrophotometer (Genequant Pro, Amersham Pharmacia Biotech 
Buckinghamshire, UK), and ratios 260/280 and 260/320 calculated. 1 µl of stock 
sample was diluted down at least 50 fold in nuclease-free water, mixed and OD 
measured (this was repeated in triplicate). For RNA samples a ratio reading of 1.8- 
2.0 at 260/280 was accepted, for DNA, 1.6-1.8. The RNA concentration was quanti- 
fied as 40 µg/ml RNA has an absorbance of 1.00 at 260 nm in a1 cm light path. 
3.4 QUANTITATIVE REAL-TIME RT-PCR (REVERSE TRANSCRIPTASE- 
POLYMERASE CHAIN REACTION) ANALYSIS OF GENE 
TRANSCRIPTS 
3.4.1.1 Introduction 
Real-time RT-PCR is a means of quantitatively analysing the relative expression of 
specific mRNA transcripts (Bustin, 2000, Yin et al, 2001). The techniques aim is to 
quantify the relative gene expression of large numbers of samples (using 96-well re- 
action plate) using very small amounts of starting tissue material or mRNAs with low 
transcript levels. 
The basic methodological concept is that mRNAs within an extracted tissue total 
RNA pool can be synthesised into a first strand cDNA pool by Reverse Transcription 
(RT-step). This can then be used as a cDNA template to amplify by PCR specific 
gene transcripts of interest using specific PCR oligonucleotide primers (and probe) 
From PCR amplification data relative gene expression can be quantified. 
3.4.1.2 RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) 
The Reverse Transcription step (RT-step) involved annealing of short oligonucleo- 
tide primers to single stranded RNA. In the studies discussed within this thesis re- 
verse transcription of the entire total RNA pool using random hexamer primers was 
performed. Once primers were annealed to RNA strands the RNA-dependent DNA 
polymerase MMLV (Moloney Murine Leukemia Virus) Reverse Transcriptase en- 
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zyme reverse transcribed RNA strands in the 5' 
- 
3' direction using free nucleotides 
to extend primers (see Figure 3.4.2-1. ). The synthesis of a single-stranded (ss) cDNA 
pool was then used as a suitable template for amplification of specific targets by 
PCR. The first step involved synthesis of a single, double stranded sequence through 
forward primer annealing, Taq Polymerase binding and synthesising a complemen- 
tary strand. A specific template region was amplified using a cyclical process of high 
temperature (94-95°C) denaturation of ds DNA, annealing of oligonucleotide primers 
(at a temperature dependant on melting temperature (Tm) of oligonucleotides), and 
extension of primers in 5' 
- 
3' direction (see Figure 3.4.2-1), as Taq Polymerase ex- 
tends in a 5' 
- 
3' direction. A 5'- forward primer anneals to the antisense strand and 
the 3'- reverse primer anneals to the sense strand. The extension step is performed at 
a higher temperature (72°C) than the annealing step, as this is the optimum tempera- 
ture for Taq Polymerase activity (optimum activity is 
-60 nucleotides/second). The 
duration of the extension cycle depends ultimately on the size of the amplicon to be 
synthesised, such that the larger the amplicon the longer the extension step required. 
Once the reaction is complete and two ds cDNA strands have been synthesised, the 
cycle is repeated in the same fashion, yielding twice the number of strands. The 
number of cycles required depends on the initial level of expression within the sam- 
ple. Genes of low expression require a greater number of cycles, e. g 35-40 cycles of 
amplification, to produce a level of detectable PCR product. The maximum number 
of cycles is 40, as non-specific amplification and amplification errors become more 
common as the number of cycles increases. 
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Figure 3.4.1.2-1. Diagram outlining RT-PCR reaction steps, and direction of 
strand synthesis. 
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3.4.1.3 Real-time PCR 
Specific fluorescent molecules are incorporated into the PCR reaction mix via use of 
specific oligonucleotide dual-labelled Taqman® probes with end-terminal fluorescent 
molecules (FAM and TAMRA), or SYBR-Green I dye. 
Real-Time PCR differs from PCR performed in a standard thermocycler (as de- 
scribed above) as reactions are performed in a Quantitative Real-Time thermocycler 
(Perkin Elmer, ABI Applied Biosystems, 7700 thermocycler). This system contains a 
laser and optical fiber network, causing the excitation of fluorescent molecules and 
subsequent detection and analysis of light emissions. The continuous collection of 
DNA template amplification data (as fluorescence intensity data) from each cycle is 
made. 
A) Tagman® Dual Labelled Fluorescence Probe Analysis 
Tagmari Probes are 20-25 bp oligonucleotides that anneal to a sequence in the am- 
plicon generated by the forward and reverse primers. The Probe is dual-labelled at 
the 5' end with a `reporter dye' (e. g. FAM) and a `quencher dye' (e. g. TAMRA), at 
the 3' end. The 'Taqman chemistry' reaction involves fluorescence energy transfer 
(FRET) (Yin et al, 2001). The Probe remains in an `in-active' state when free and 
bound to DNA strands as the quencher dye prevents the reporter dye fluorescing. 
Primer extension by the Taq Polymerase (AmpliTaq Gold) allows the 5' to 3' exonu- 
clease activity of the Taq Polymerase to degrade the Probe, releasing the reporter dye 
and produce fluorescence emission (see Figure 3.4.3-1). 
Tagman® Probes provide specificity to the PCR reaction. Non-specific amplicon syn- 
thesis possible with primer only reactions, are not detected when performing reac- 
tions in coordination with a Taqman® Probe. Specificity is also provided as fluores- 
cent signals are only emitted once primer extension of a precise region takes place by 
Taq Polymerase and Probe subsequently degraded. 
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Figure 3.4.1.3-1. Quantitative Real-Time PCR using a Taqman® Probe. 
R= Reporter dye H= Quencher dye. 
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(A) After the ds DNA template is denatured by heating to 95°C, temperature 
dropped to allow annealing of both specific oligonucleotide primers and 
Taqman* Probe to amplicon region. Nucleotides are then extended 
along strands from primers in a 5' to 3' direction by Taq Polymerase. 
(B) Taq Polymerase degrades annealed Tagman" Probe using 5' to 3' nu- 
clease activity. Reporter and quencher dyes are released from strand, 
Reporter is free from inhibition and emits fluorescence. 
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Figure 3.4.1.3-2. Quantitative Real-Time PCR using SYBR-Green I. 
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(A) ds DNA has SYBR-Green I bound, emitting fluorescence. (B) The ds DNA 
template is denatured by heating to 95°C, temperature dropped to allow 
annealing of specific oligonucleotide primers to amplicon region. As 
strands are denatured and single-stranded, SYBR-Green I does not emit 
fluorescence. 
(B) Nucleotides are then extended along strands. from primers in a 5' to 3' di- 
rection by Taq Polymerase. SYBR-Green I binds to new ds DNA and emits 
fluorescence. 
89 
B) SYBR-Green I Method 
SYBR-Green I is a sensitive dye that emits fluorescence when bound to dsDNA (see 
figure 3.4.3-2). When using this method fluorescent emissions are detected when 
SYBR-Green I binds to any dsDNA present during subsequent DNA amplification 
cycles. Therefore, if dsDNA is of non-specific origin, non-specific fluorescent sig- 
nals will be detected. Thereby making this method potentially less specific with high 
noise signals. 
Both methods allow quantitative analysis of gene expression through analysis of 
fluorescence-emission intensity data. Fluorescence data for every step at every cycle 
is detected, analysed and graphically presented in a data output (Figure 3.4.3-3). As- 
suming complete PCR reaction efficiency, theoretically fluorescence intensity is di- 
rectly proportional to [ds DNA] during the linear phase of amplification. Therefore, 
fluorescence intensity increases exponentially with cycle number as DNA replication 
is two-fold/cycle. A plateau phase of amplification and fluorescence is reached lead- 
ing ultimately to reaction end-point. End-point product analysis is a semi-quantitative 
method which is not accurate, as everything tends towards the same end point quan- 
tity. 
Figure 3.4.1.3-3. Outline of graphical fluorescence data output of Real-time 
PCR reactions and relationship between phases of template amplification. 
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In Figure 3.4.1.3-3 the quantification threshold and background threshold level is 
indicated. The quantification threshold is the user selected level of intensity of re- 
porter dye emission that is above background emission/noise. This is taken approxi- 
mately from mid-point of the linear-exponential phase. The cycle number corre- 
sponding to the quantification threshold level of fluorescent intensity is known as the 
cycle threshold (Ct value), which is recorded and can be used to assess relative ex- 
pression of samples. The greater the initial amount of target template, the lower the 
cycle value it requires to reach a set level of quantification threshold fluorescence, 
i. e. lower Ct Value. For example, in Figure 3.4.1.3-3 the sample producing the fluo- 
rescence intensity graph in red has a lower Ct value than blue sample, and hence a 
greater amount of starting template/gene expression. 
In summary, the Ct Value data can be used to comparatively assess the original level 
of [cDNA] target of interest within the total cDNA pool, and hence [mRNA] species 
of interest within the total RNA pool. This is assuming first strand synthesis is 
equally efficient between samples. Specific details of method of quantification using 
Ct values, assessment of reaction efficiencies and examples can be found within Sec- 
tion 3.4.4 and 4.3. The relative gene expression of multiple targets may be quantified 
from single total RNA extractions, as only small quantities of RNA/cDNA are re- 
quired per reaction. 
3.4.2 Bioinformatics Methods 
3.4.2.1 Sequence Retrieval and Multiple Sequence Alignments 
For target sequences to be amplified by PCR and Real-Time PCR, specific primers 
had to be designed based on sequence information of expressed genes of interest. 
Therefore, relevant complete mRNA sequences for bovine, porcine and human (and 
other species if necessary) species, were searched for using relevant EBI-EMBL 
(European Bioinformatics Institute-EMBL)/NCBI (National Center for Biotechnol- 
ogy Information)/DDBJ (DNA DataBank of Japan) nucleotide sequence databases; 
that can be found within the Hgmp. mrc. ac. uk webpage. Retrieved sequences were 
saved in appropriate formats (e. g. Fasta) to allow subsequent input into various pro- 
grams. The mRNA/cDNA sequences were aligned using the CLUSTAL W-multiple 
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sequence alignment program (EMBL/DDBJ). Sequences in Fasta formats were in- 
putted, aligned with one another and sequence similarity/homology across species 
analysed. The CLUSTAL W program assigned star symbols (*) underneath align- 
ments at every base which is identical across sequences analysed. 
3.4.2.2 BLAST Searches 
BLAST searches were routinely used on the NCBI and DDBJ nucleotide databases, 
to either identify similar sequences in the database, or identify RT-PCR generated 
products, after DNA sequencing. The sequence of interest (saved in Fasta format) 
was inserted into the query window within the standard nucleotide BLAST search 
webpage. Parameters were set for database types to search through (e. g. human, EST, 
mammals etc. ), the number of alignments to be made and how many to be viewed. 
The BLAST output showed listed sequences aligned to sequence of interest in order 
of greatest homology, measured by a Score, E Value and % sequence identities (Full 
explanation of these terms and search examples can be found within Appendix A). 
3.4.2.3 Oligonucleotide Primer and Dual-Labelled Fluorescence Probe 
(Tagman*) Design 
Once areas of high sequence homology across species were found, these were used 
to design Dual-labelled Fluorescence Probes and PCR primers: 
Real-Time PCR: an mRNA sequence used in the alignment (preferably same spe- 
cies of interest in Trial sample analysis) was inputted into the Primer Express pro- 
gram (ABI Biosystems), in Fasta format and sequence analysed for optimum specific 
primer pairs and probes. Areas targetted were of high similarity across species. Using 
default program parameters an optimum amplicon size of 100 bp was searched for 
(of optimal 50-150 bp minimum and maximum program parameters), and a large se- 
lection of suitable primer pairs and Taqman probes (based on oligonucleotide length, 
GC base content, and melting temperature, Tin), were listed in an output. When 
Real-Time RT-PCR was carried out using SYBR-Green method rather than Taqman 
probes, the program was re-set so as to analyse sequence for optimum primer pairs 
only. Listed output of primer pairs and probes had to be further carefully manually 
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analysed to be certain the correct area was targeted for amplification. This was to 
firstly double-check that primers had been designed to correct parameters. Secondly, 
slight species variation in sequence data may mean certain primer pairs couldn't be 
used as they may not be to a very high level of sequence specificity etc. Primers and 
Taqman probes were manufactured by Sigma-Genosys (Pampisford, UK). Primers 
were resuspended to 100 pmol/gl then diluted to a working concentration of 10 
pmolI. d in nuclease-free water. 
Standard PCR: In general, for standard PCR, primers were designed by searching 
for areas of the highest homology across species. Suggested primer sequences were 
checked using a primer test program (within Primer Express) for secondary struc- 
tures etc. Examples of standard PCR primer sequences designed from multiple 
alignments can be found within Appendix A. 
3.4.3 Real-Time Reverse Transcriptase PCR Method 
3.4.3.1 Reverse Transcription (RT-Step) 
Extracted total RNA samples were quantified and checked for quality and purity, us- 
ing analysis by spectrophotometer and non-denaturing gel electrophoresis methods 
(see section 3.32 and 3.6 respectively). 
The reverse transcription of total RNA to first strand complimentary DNA involved a 
2-step method. The first step required annealing of oligonucleotide primers to the 
total RNA sample. Random hexamer primers were annealed to total RNA pool. The 
second step involved reverse transcribing the entire total RNA pool, producing a first 
strand complimentary DNA pool. The reaction, was set up in 200 µl reaction tubes 
(Perkin Elmer), in following order: 
Reaction Constituents Volume 
Total RNA (0.1 µg/µ1) 5.0 µ1 
Random hexamer primers (0.5 9g/0) 1.0 . t1 
Nuclease free water 9.0 µl 
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Reactions were mixed by pipetting and incubated at 70°C for 5 min to denature sec- 
ondary structure. Tubes were then immediately placed on ice to prevent secondary 
structure reforming, but allowing the oligonucleotides to anneal. 
The second RT reaction-step was set-up using the following constituents whilst reac- 
tion tubes were on ice after previous step: 
Reaction Constituent Volume Final Cone. 
MMLV Reverse Transcriptase 5X Reaction Buffer * 5.0 µl 
Nucleotides (dNTPs) 10mM 1.25 µl 0.5mM 
rRNasin Ribonuclease Inhibitor 0.5 µl 25U 
M-MLV Reverse Transcriptase* 1.0 µl 200U 
Nuclease-free water 8.0 µl 
*MMLV, Moloney Murine Leukemia Virus Reverse Transcriptase. 5X Reaction 
Buffer: 50 mM Tris-HC1 (pH 8.3 @ 25°C), 75 mM KCI, 3 mM MgCl2 and 10 mM 
DTT. 
The reactions were mixed by pipetting then incubated at room temperature for 10 
min to allow random primer extension, followed by 42°C for 60 min. 
Samples were diluted four-fold after RT-step with nuclease-free water and stored at 
-20°C. These samples acted as substrates for subsequent PCR. 
3.4.3.2 Real-Time PCR Protocol 
Samples were set-up and analysed in triplicate on a 96-well plate. PCR mastermix 
was prepared on ice in a sterile 1.5 ml microcentrifuge tube, in the following order 
(see over page) for Tagman® Probe reactions: 
The volumes were increased to allow for pipetting errors, i. e. increase mastermix 
volume by -! /3 /reaction; extra 24 µl, equivalent to one extra reaction for each 96 µl 
triplicate sample. 
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Reaction Constituents Volume * 
2X Tagmanmastermix 12.5 µl 
Forward primer (10 µM) 0.75 µ1 
Reverse primer (10 µM) 0.75 
.d 
Taqman® Probe (5µM) 0.625 µ1 
Nuclease-free water 9.375 µl 
Total Volume 24 µl 
* Volume for a single reaction (multiples of this were always made). 
t Reagent acquired from ABI Biosystems. Contains Ampitaq Gold Polymerase and 
UNG (Uracil Glycosylase). 
Mastermix was vortexed, spun down briefly in a centrifuge, and 96 µl taken and pi- 
petted into into tube containing 4 µl bovine 1st strand cDNA pool sample (total RNA 
equivalent: 4µl = approximately 0.020 µg), or NTC (Non Template Control of 4 µl 
nuclease-free water) giving a final volume of 25 µl / reaction, effectively 4 reactions 
for each sampleand an excess of one reaction. 
The SYBR-Green I method required a similar reaction set-up, in that 100 µ1 PCR 
mastermix + cDNA template reaction mixes were prepared, i. e. 4x 25 µl reactions (3 
+1 extra to account for errors). The difference between methods was that SYBR- 
Green I required a greater amount of template for reactions (5 µl), due to lower sensi- 
tivities, therefore as can be seen below the mastermix volume is 20 µl. 
Reaction Constituents Volume* 
2X Tagman mastermix 12.5 µl 
Forward primer (IOpmol/µl) 0.75 µl 
Reverse primer (IOpmol/µl) 0.75 µl 
SYBR Green It (1 in 50 dilution 0.25 µl 
from I O, 000X stock solution) 
Nuclease-free water 5.75 µl 
Total Volume 20 µl 
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* Volume for a single reaction (multiples of this were always made). 
Reagent acquired from ABI Biosystems. 
Reagent acquired from Sigma-Aldrich. 
Similar to previous Taqman Probe Reaction mix, samples were vortexed, briefly 
spun down in a centrifuge, placed on ice, and 4x reaction volume (80 Al using 
SYBR-Green I) pipetted into tube containing 20 µl bovine 1St strand cDNA pool 
sample (4 x reaction) or NTC (20 µ1 nuclease-free water). 
Sample tubes from both methods were vortexed, spun down briefly in centrifuge, and 
pipetted on to a 96-well reaction plate kept on ice. Lid on reaction plate was then 
sealed. 
For all experiments computer program was set-up, and well-loading pattern entered 
into the Sequence Detection Software program (ABI Biosystems) file. The 96-well 
reaction plate was taken off ice, loaded into machine and reaction begun using the 
following thermocycle conditions: 
Reaction Phase Temperature Time Cycles 
Uracil Glycosylase step 50°C 2 min 1 
Amplitaq-Gold Activation step 95°C 10 min 1 
Denature 95°C 15 sec 40 
Anneal/Extend 60°C 1min 
3.4.4 Data Collection and Analysis 
The first experimental procedure undertaken before assaying trial samples was to 
perform preliminary standard curve experiments for all expressed genes of interest. 
This was used to check that a linear pattern of expression exists. Known serial dilu- 
tions of stock cDNA template (with mastermix and primers) were prepared and 
loaded on reaction plate as described in procedure above. 
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Fluorescence emission signals were collected automatically from reaction plate dur- 
ing reaction cycles and plotted onto fluorescent intensity (ARS, value) amplification 
curves (as of figure 3.4.1.3-3). ROX dye contained within the Tagman® mastermix 
acted as an internal-control dye. Errors in pipetting and hence volume of Tagman® 
mastermix loaded (and ROX dye), adjusts the fluorescence value for each well. This 
allowed triplicate sample Ct Values to be validated, by ROX fluorescence quantifica- 
tion. 
The NTC triplicate samples containing nuclease-free water allowed for sample con- 
tamination and PCR artifacts contributing to a signal to be validated. NTC samples 
with fluorescent amplification signals present signified template/DNA contamina- 
tion, therefore indicating nonspecific amplification. 
Post-PCR, triplicate reactions were pooled together for each sample and run on a 
1.8% non-denaturing agarose gel (see Section 3.6) to check for a single PCR product 
of correct band size. This indicated specific amplification of the template. 
The relationship between Ct value and initial concentration of the template was de- 
termined from a graph of Ct value against log RNA equivalent (example in Appendix 
D. ). Theoretically, assuming reaction efficiencies are 100% there is a doubling in 
[DNA] per cycle. Therefore, 10-fold dilutions in [cDNA] template would produce a 
slope of 
-3.3 on a graph of Ct vs logio [cDNA]. 
Once experimental procedures were validated for individual expressed genes of in- 
terest using method above, trial samples were analysed using protocol described 
(Section 3.4.3.2). By examining NTC, ROX dye and post PCR products by gel elec- 
trophoresis anomalities could be spotted and data accepted or rejected. 
3.5.1 Standard PCR Protocols 
Standard PCR was performed to produce PCR products of interest to be used as 
cDNA probes in subsequent gene expression studies (see Section 5 and Appendix 
A. ). In general, AmpliTaq-Gold was used as the enzyme of first choice due to its 
high efficiency and ease of use (as no manual hot-start was required). Those reac- 
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tions producing negative results after repeated attempts yielded positive results when 
using either Taq (Promega) or the Expand Taq (Roche). Expand system is highly ef- 
ficient and possesses inherent 3'-5' exonuclease proof-reading activity increasing 
DNA synthesis fidelity. According to the manufacturer, for 200-300 bp fragments 
Taq has an error rate of 2.6 x 10-5, whereas Expand 8.5 x 10-6. Expand was therefore 
used in problematic reactions. 
First-strand cDNA pool was synthesised from 0.5 µg porcine Longissmus Dorsi 
Poly-A`-enriched RNA (T. Parr), using RT-step described. Post-RT-step, cDNA was 
diluted to 500 d. 2 to 5 µl dilute first-strand cDNA pool was used as a PCR template 
(-0.001 µg/µ1 RNA equivalent), using specific oligonucleotide primers. All reactions 
were performed in 200 µ! thin-walled, PCR reaction tubes (Perkin Elmer). Three dif- 
ferent Taq polymerase systems were used in attempts to generate a PCR product: 
A) Taq system (Promega): a 39.5 µ1 mastennix/sample was set up in the following 
order in a sterile 1.5 ml microcentrifuge tube: 
Reaction Constituent Volume* 
10mM Nucleotide mix (dNTPs) 1.041 
Forward primer (1 OpmoVpl) 1.25 µl 
Reverse primer (l Opmol/0) 1.25 µl 
lOX PCR Buffer' 5.0 pl 
MgC12 (25mM) 2.0 pl 
Nuclease-five water 28 µl 
Total Volume 40 µl 
" Volume for a single reaction (multiples of this were always made). 
tl OX PCR reaction buffer contains following constituents: 10mM Tris-HC1(pH 9.0 
at 25°C)550mM KCI, and 0.1% Tritonen X-100. 
Maslermix was vortexed, spun down briefly in a centrifuge, 39.5 µl taken out and 
added to each individual 200 gl PCR reaction tube (Perkin Elmer) containing 10 Al 
dilute template (2 to 5 µl dilute cDNA template, as above and 5 to 8 µl nuclease-free 
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water-as above). Samples were mixed by pipetting. 0.5 gl Taq enzyme (Promega) 
(5U<µl) was added to individual reactions after a `hot start'. Amplification starts at an 
elevated temperature to try to control mispriming events and increase reaction speci- 
Eicity and sensititvity. Reactions were then mixed by gently `swirling' with pipette. 
Reaction conditions were as follows: 
Reaction Phase Temperature Time Cycles 
Denature 94°C 3 min 1 
Hot Start 
- 
0.5 pl Taq Polymerase/sample addition 
Denature 94°C 30 sec 
Primer Annealing "°C 30 sec 35 
Primer Extension 72°C 60 sec 
Printer Exk'nciOPl/polishing 72°C 5 min 1 
" Variable temperature primer annealing step, dependent on primer base pair compo- 
sition. 
B) Amplitaq Gold® Taq System (ABI Biosystems): a similar master mix was pre- 
pared as above containing 0.25 µl Perkin Elmer heat-activated AmpliTaq Gold® (5U/ 
µl) Taq Polymerase, PCR buffer and 25mM MgC12 reagents (Applied Biosystems, 
Roche). Reagents were prepared in a 40 id mastermix (using same concentration of 
constituents as above). Mastermix was added to 10 µl dilute template (as above). 
Reaction conditions were similar as above except first step was 10 min long at 95°C 
to activate Amplitaq Goldo, as is a heat-activated enzyme. The last primer extension 
polishing step was 10 min long. 
C) Expand High Fidelity PCR System (Roche): Two separate mastermixes were 
set up. In one tube, 10mM nucleotides, 10 pmol/µl primers and nuclease-free water 
was added mid mixed. In the second tube, Expand PCR Buffer (+15mM MgC12), Ex- 
pand High Fidelity PCR System-enzyme mix (2.6U) (Roche Molecular Biochemi- 
cals, Mannheim, Germany) and nuclease-free water was added and mixed. Master- 
mix concentrations and volumes were similar as above; when mixed with dilute tem- 
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plate sample (as above), producing a final volume of 50 µl. Reaction conditions were 
the same as used for the Promega system (a hot start was not required). 
All PCR products were viewed by non-denaturing gel electrophoresis (using method 
described in 3.6) on a 1.8% agarose gel, as expected size of products were in the 
range of -200-300bp. 
3.5.2 Annealing Temperatures 
The primer annealing temperatures for PCR were selected based upon oligonucleo- 
tide primer melting temperatures (Tm). Tm`s of primer pairs were within 2°C of each 
other. In general, annealing temperatures were calculated by 5°C below oligonucleo- 
tide Tm. However, most PCR reactions were empirically optimised using annealing 
temperature gradient reactions (using same Eppendorf thermocycler), to assess the 
optimal temperature producing the highest specific yield of correct PCR product. 
3.6 NON-DENATURING GEL ELECTROPHERESIS 
Examination of DNA and RNA samples throughout experimental procedures was 
undertaken by separating samples by electrophoresis using a non-denaturing agarose 
gel. The percentage of agarose required depended on the size of fragments to be run: 
Size of Fragments (bp) I% Agarose (w/v) 
>l kb 11% 
1.5% <1kb 1 
350 bp 11.8-2.0% 
Agarose (Amersham Pharmacia Biotech, Buckinghamshire, UK) was made up to the 
appropriate % (w/v) with 1 xTAE (0.04M Tris, 0.01M glacial acetic acid, 0.7mM 
EDTA), heated to boiling point, stirred and left to cool down to hand hot tempera- 
ture. molten gel was then poured into appropriate gel former with corresponding 
gel comb and left to set at 4°C. Once the gel was set it was placed in gel tank elec- 
trophoresis apparatus which was filled with 1xTAE buffer. Samples were loaded into 
100 
wells with all samples having a final volume of 10 µl (unless stated otherwise), and 2 
µl loading dye (15% Ficoll® 400,0.03% bromophenol blue, 0.03% xylene cyanol FF, 
0.4% orange G, 10mM Tris-HCL (pH 7.5) and 50mM EDTA) was added giving a 
ratio of 10 dye :5 µl DNA. Types of markers to be loaded in to separate wells was 
dependent on the size of sample fragments to be analysed. 100 bp markers with a 
fragment range of 100-1,500 bp. I kb markers with a fragment range of 250-10,000 
bp and Lambda DNA/HindIII markers with a fragment range of 125-23,130 bp. 
Gels were run for 45-60 min at 100V or until the loading dye reached 2/3-3/4 length 
of gel. Gels were subsequently stained in aI µg/ml solution of Ethidium Bromide 
(Sigma-Aldrich, Dorset, UK) for 20-30 min, destained briefly in water and viewed 
using a UV transilluminator (BioRad, California, USA). Ethidium bromide binds to 
nucleic acid and fluoresces a red-orange colour under UV light; the greater the fluo- 
rescence intensity, the greater amount of DNA/RNA present. The gel image was cap- 
tured using the MultiAnalyst (BioRad, California, USA) computer software. 
3.7.1 GEL EXTRACTION AND PURIFICATION OF PCR PRODUCTS 
Generated PCR products subjected to non-denaturing gel electrophoresis were gel- 
purified. PCR products were pooled together and separated by non-denaturing aga- 
rose gel electrophoresis (Section 3.6), with SYBR-Green I (Sigma-Aldrich, Dorset, 
UK) mixed into samples with loading dye; which binds dsDNA and fluoresces when 
illuminated with UV. For this procedure 1 gl of SYBR-Green I: 9 µl of PCR product 
was added at a1 in 100 dilution (from 10,000X stock solution), standard DNA load- 
ing dye added (at appropriate 1 gl :5 µl DNA), and tube vortexed and spun down. 
Samples were subjected to non-denaturing electrophoresis. Gel was illuminated on a 
Dark Reader Transilluminator (Genetic Research Instrumentation Limited, Braintree, 
UK). Bands were cut out with a new sterile scalpel blade and gel slice weight deter- 
mined. DNA was extracted from gel slices using the QlAquick Gel Extraction Kit 
Protocol (Qiagen, Hilden, Germany). 
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3.7.2 PCR Product Purification 
The QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) was used, following 
the suggested protocol. The method is an affinity column based procedure similar to 
that described above and in the purification of plasmid from minipreps. PCR prod- 
ucts were added to a membrane on a spin column and subjected to a series of cen- 
trifugal spin-steps and addition of buffers and wash solutions. DNA was eluted in a 
volume of 50 µl nuclease-free water. 
3.8 LIGATION OF PCR PRODUCTS INTO PLASMID VECTOR 
A number of generated PCR products to be used as probes, were ligated into a 
pGEM®-T Easy Vector (Promega, Southampton, UK). The appropriate molar con- 
centration of DNA to be used for ligations was determined using the following 
calculation: 
ng of vector x kb size of insert 
kb size of vector 
x insert : vector molar ratio = ng of insert 
As all PCR products were -200-300 bp in size and 50 ng of 3.0 kb vector was used 
in a ratio of 3: 1 (insert: vector), the amount of insert was calculated to be 
-12.5 ng. 
The following reactions were set up in a sterile microcentrifuge tube as follows: 
Reagents Standard Background 
Reaction Control 
2X Rapid Ligation -Buffer t, T4 DNA Ligase 5µl 5µl 
pGEM*-T Easy Vector (50 ng) 1111 IgI 
PCR product 3g1* 
T4 DNA Ligase (3 Weiss units/µl) 1111 1µl 
Nuclease free water to a final volume of. I Oµ1 l0µ1 
' 2X Rapid Ligation Buffer, T4 DNA Ligase contains: 60mM Tris-HCI, pH 7.8, 
20mM MgCl2,10mM DTT, 2mM ATP 10% PEG. 
* 3µl volume of all PCR products at -4ng/ µl was used to make up 12.0 ng. 
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Rapid Ligation Buffer was well thawed and vortexed before use; complete reactions 
were mixed by pipetting, and incubated at room temperature for 2 hr. Background 
controls were used during all cloning experiments- to determine the ligation effi- 
ciency of the vector alone. 
3.9 TRANSFORMATIONS AND CLONING 
pGEM4-T Easy Vector-ligation reactions were the transfected into high efficiency 
competent JM 109 cells (Promega, Southampton, UK). Ligation reactions were vor- 
texed, centrifuged down briefly and 2 µl of each reaction (-2.4 ng DNA) added to a 
sterile microcentrifuge tube placed on ice to which 50 µd of JM109 cells previously 
slowly thawed on ice (stock cells stored at -70°C) were added. After a 20 min incu- 
bation on ice, cells were heat-shocked for 45-50 sec in a 42°C water bath and then 
put back on ice for 2 min. 950 µl of thawed SOC medium (see Appendix L) was 
added and tubes incubated at 37°C for 1.5 hr with shaking (Lab Therm, Kohmer, 
Switzerland). Tubes were centrifuged at 
-. 
9,000 g for 5-7 min, 700 µl supernatant 
removed and pellet resuspended in 200 gi of supernatant. Resuspended cells were 
pipetted onto duplicate LB-agar plates with 100 p. g/ml ampicillin (see Appendix L), 
i. e. 100 µl resuspended cells /plate; and spread evenly using a sterile glass rod. Plates 
were incubated overnight (--18 hr) at 37°C. 
Using sterile pipette tips single colonies were picked from plates and placed in to a 
30 ml universal sterilin tube containing -3 ml LB media plus ampicillin (100 µg/ml). 
Steril ins were incubated overnight for -18 hr at 3 7°C with shaking. 
The bacterial culture was subject to plasmid DNA purification procedure using Wiz- 
ard'o Plus SV Minipreps DNA Purification System (Promega, Southampton, UK). 
3.10 PLASMID DNA PURIFICATION 
The Promega Wizard miniprep kit supplied all necessary reagents and equipment 
(columns, barrels etc. ) and protocol was followed as suggested by the manufacturer. 
Appropriate solutions volumes, incubation and mixing conditions can be found 
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within protocol. For preparation of plasmid DNA 1-1.5 ml bacterial culture/cells was 
routinely used. 
3.11 RESTRICTION ENDONUCLEASE DIGEST OF DNA 
Purified plasmid+inserts were linearised and insert excised by performing a routine 
restriction enzyme (RE) digest procedure as suggested by manufacturer (Promega, 
Southampton, UK). 
In a sterile 1.5 ml microcentrifuge tube the following reaction was prepared in order: 
Constituent Volume 
Purified plasmid DNA 10 µl 
Buffer H*0 0X) 2 µl 
BSA (1 in 10 dilution of 10 mg/ml stock) 2 Al 
Nuclease-free water 5 Al 
EcoR I '(12 U/ µl) 1 µl 
Final Volume 20 µl 
0 Buffer H constituents: 900 mM Tris-HCI (pH 7.5), 500 mM NaCl and 100 mM 
MgC12. 
EcoR I was RE of choice for pGEM®-T Easy Vector. Same procedure using differ- 
ent RE was used for other inserts/vectors etc. 
Digest mix was set-up and incubated for I hr at 37°C. 5-10 µl of digest was checked 
by running on a non-denaturing 1.5% agarose in 1X TAE gel using procedure de- 
scribed. 
3.12. ETHANOL PRECIPITATIONS OF DNA 
Ethanol precipitations were carried out either to concentrate nucleic acid solutions, or 
remove contaminating enzymes or reagents. It was used as a routine procedure 
throughout studies for `cleaning-up' DNA and RNA samples (as described in RNA 
extraction procedure). 2.5 volumes of ice-cold 100% ethanol was pipetted into a 1.5 
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ml microcentrifuge tube containing sample and 0.1 volumes 3M sodium acetate pH 
5.5 added. Sample was mixed by vortexing, briefly centrifuged down and left over- 
night at 
-20°C. Samples were centrifuged at 13,000 g (Hawk 15/05 refrigerated cen- 
trifuge) for 20 min at 4°C, ethanol layer pipetted off carefully and 1 volume 75% 
ethanol (ice-cold) added. Sample was mixed by vortexing and centrifuged (as above). 
Ethanol layer was pipetted off carefully, precipitate air-dried for 5 min and redis- 
solved into a minimal volume of nuclease-free water (20-50 µl). 
3.13 DNA SEQUENCING 
Purified PCR products and purified plasmids with inserts were sequenced by MWG- 
Biotech (Germany) to positively confirm the identification of the sequences gener- 
ated by PCR, using quantities of DNA as directed by supplier. 
3.14 NORTHERN BLOTTING 
3.14.1 Introduction 
Northern Blotting involves the transfer of RNA sequences separated on a denaturing 
agarose gel to a solid membrane support. The RNA is fixed to the blot (using UV 
crosslinking) and probe hybridisation experiments may be performed to allow the 
assessment of the size of full mRNA sequences and quantification of relative expres- 
sion of transcripts. Hybridised radio-labelled cDNA probes produce quantifiable 
band signals that can be detected using phosphoimaging technique. 
3.14.2 Denaturing Gel Electrophoresis procedure 
Denaturing gels had a maximum of 25 µg RNA loaded per lane. Total RNA was 
checked for integrity and quality before being subjected to northern blotting, by non- 
dentauring gel electrophoresis. A full list of chemicals used in procedure can be 
found in Appendix K. 
The agarose gel was prepared using the following constituents: 
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Constituent Amount 
100mM Sodium Phosphate Buffer, pH6.5 25 ml 
Agarose 
H2O 
dependent on % required 
to 250 ml 
Molten gel was poured carefully into a large gel former (20 cm x 21 cm). 
RNA samples at appropriate concentration and RNA markers (see Appendix K) were 
denatured by adding the following in order, in sterile 1.5 ml microcentrifuge tubes: 
Constituent Volume Final Conc. 
Total RNA sample/RNA marker 10.0 µl 
Deioinised Glyoxal 8.0 µd IM 
80mM Sodium Phosphate Buffer pH6.5 6.0 µl 10mM 
DMSO (Dimethylsulphoxide) 24.0 µl 50% 
Samples were mixed, incubated at 50°C for 1 hr, placed on ice then 7.5 µ1 loading 
buffer added, which was mixed by pipetting. Gel was run at 120 V for 45 min to al- 
low RNA to run in to gel, then voltage set at 100 V. The running buffer (10 mm So- 
dium Phosphate, pH6.5) was continuously re-circulated using magnetic stirrers and a 
peristaltic pump, to prevent the pH of the buffer changing. Gel was run for 
-4 hr at 
100 V, or until blue bromophenol blue dye had run 2/3_3 /4 down gel. The markers 
were then cut off using a sterile scalpel blade and soaked in 0.1 M ammonium ace- 
tate for 30 min, then subsequently stained in ethidium bromide for 45 min and 
viewed on UV transilluminator alongside a ruler, to allow marker band measurement. 
3.14.3 Blotting Procedure 
The gel electrophoresis tank was briefly washed with double-distilled DEPC-treated 
autoclaved water and tank half-filled with 20X SSC transfer buffer. 2x 3MM blot 
paper wicks were wetted with 20X SSC, placed on top of gel in gel former allowing 
wick ends to dip into 20X SSC. The gel was placed on top of the wicks (see Figure 
3.14.3-1). 
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Figure. 3.14.3-1 Northern blotting apparatus and set-up. 
Weight 
(-750g) 
Glass plate 
Paper 
"TOwC'. I Nvi1C1 
Nylon membrane 
3x3MM 
2x 3MM wicks 
Gel 
ýnx ccr 
Hybond-N (Amersham Pharmacia Biotech, Buckinghamshire, UK) was placed on 
top of gel and air bubbles rolled out. 3x 3MM blot paper was wetted with 20X SSC 
and placed on top of gel, followed by a paper towel wad, then a -750 g weight 
placed on top. 
After blotting overnight Hybond N membrane blot was removed, dried between two 
pieces of 3MM blotting paper and RNA UV crosslinked (UV Stratalinker 1800, 
Stratagene, California, USA) to the membrane. After crosslinking, 200 ml boiling hot 
20mM Tris-HCI pH 8.0 was poured over membrane to remove Glyoxal. Blot was 
washed with 2x SSC and stored at 4°C in fresh 2x SSC. 
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Gel electrophoresis apparatus 
3.15 RADIOLABELLED PROBE HYBRIDISATION 
3.15.1.1 Strip-EZTM DNA Probe synthesis and Removal Kit 
The Strip-EZTm DNA Random Primed StripAbleTM DNA Probe Synthesis and Re- 
moval Kit (Ambion, Huntingdon, UK), was the kit of choice for radioactively prob- 
ing trial northern blots. The kit generates a high specific activity probe that is stable 
during hybridisation and washsteps, but could be cleaved during incubation of blot 
with Probe Degradation Buffer at 68°C. These ` Milder' probe-removal ('stripping') 
conditions equated to less blot damage and greater preservation of blot integrity. 
3.15.1.2 Protocol 
25 ng of linearised DNA template made up to a volume of 9 µl with nuclease-free 
water, was denatured by heating at 95-100°C for 3-5 min. The probe was then snap- 
frozen in liquid nitrogen, thawed, microfuged and stored on ice. The following reac- 
tion mix was assembled in order, on ice, and mixed by gently pipetting: 
Component Amount/volume 
Denatured DNA 9.0 µl 
I OX Decamer Solution* 2.5 µ1 
5X Buffer 
- 
dATP/-dCTP* 5.0 µl 
1OX dCTP* 2.5 µl 
[a-32P]dATP (3000 Ci/mmol, 10 mCi/ml) 5.0 µl 
Exonuclease-free Klenow* 1.0111 
Nuclease-free Water made up to 25 µl 
*Reagents supplied with kit. 
The Probe Reaction mix was subsequently incubated at 37°C for 10-30min, to allow 
for radiolabelled nucleotide incorporation, the reaction terminated by addition of 1 µl 
of 0.5M EDTA (supplied with kit). 
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Radiolabelled cDNA probe was purified using a NICKTM Column (Amersham 
Pharmacia Biotech, Buckinghamshire, UK), which are prepacked disposable G-50 
Sephadex columns. Procedure was as described by manufacturer. The probe was 
eluted in 600 pl equilibration buffer, whilst a further 400 µl equilibration buffer was 
added to column, to collect un-incorporated nucleotides. An approximate level of 
incorporation could be used by comparing the ratio of incorporated vs unincorpo- 
rated nucleotides using a handheld Geiger counter. Only probes which had incorpo- 
rated greater than 50% of the isotope into the generated cDNAs were used. 
Purified diluted probe was heated to 90°C for 10 min, to denature strands, then dilut- 
ede in pre-warmed hybridisation buffer and placed into a hybridisation bottle con- 
taming a prehybridised northern blot. 
3.15.2 Rediprime 
The Rediprime II probe-labelling kit (Amersham Pharmacia Biotech, Buckingham- 
shire, UK) was originally used in preliminary probe hybridisation experiments, in 
combination with Rapid-hyb buffer. Standard blotting procedures were followed and 
Rediprime protocol followed as described by manufacturer. A 54 µl reaction was 
prepared in a sterile 1.5 ml microcentrifuge tube, containing: 10-20 ng cDNA probe, 
5.4 µl IOX TE (100 mM Tris-HCI, pH 8, and 10mM EDTA) pH 8 and made up to 54 
µl with nuclease-free water. 45 µl of 54 µl mix was denatured by boiling at 100°C for 
5 min, snap cooled by placing tube on ice for 5 min and centrifuged down briefly. 45 
µl denatured DNA was added to a single Rediprime reaction tube, 5 µl [a_32P] dCTP 
(3000 Ci/mmol, 10 mCi/ml) was added and tube mixed carefully by pipetting. Reac- 
tion was incubated at 37°C for 10 min then purified using NICKTm column method 
to remove un-incorporated nucleotides. 
Purified diluted probe was heated at 100°C for 5 min to denature strands and treated 
the same as described above. 
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3.15.3 Probe Hybridisation 
3.15.3.1 Rapid-hyb Hybridisation Buffer 
Rapid-hyb buffer (Amersham Pharmacia Biotech, Buckinghamshire, UK) was the 
buffer of choice for all test and trial northern blots, due to its rapid rate of probe hy- 
bridisation to northern blots, and hence dramatically decreasing detection time. Most 
probe hybridisation's required 1-2 hr. 
For prehybridisation and hybridisation 0.125 ml/cm2 was used. Northern blots placed 
in rotating hybridisation bottles were prehybridised in the buffer at 65°C for 30 min. 
Labelled probe was diluted into pre-warmed hybridisation buffer, pre-hybridisation 
buffer poured away and hybridisation buffer plus probe added. Care had to be taken 
to not directly add buffer to blot, otherwise localised background developed. Hy- 
bridisation bottles were continuously rotated, and incubated at 65°C for 1-2 hr. The 
hybridisation temperature and time was varied to optimise signals depending on in- 
dividual probe specificity's and expression level of mRNA species. However, lower 
temperatures produced less specificity, with greater probability of non- 
specific/multiple band detection. Full optimisation conditions for individual probes 
used in specific trial analysis can be found in relevant sections in Section 6. 
Washsteps were undertaken (see Washstep section), and standard detection methods 
used (Detection section). 
3.15.3.2 ULTRAhybTM Hybridisation Buffer 
ULTRAhybTM Ultrasensitive Hybridisation Buffer (Ambion, Huntingdon, UK), is 
reported to drastically increase hybridisation signal, without increasing background, 
by maximising sensitivity of blot hybridisation. Therefore it is ideal for genes with 
low expression. Although the product is effective and can be used for short 2 hr pro- 
cedures, maximum signals are produced using overnight hybridisation's (14-24 hr). 
ULTRAhybT"' was therefore tested on low signal producing probes/low expressed 
mRNA species, including ARC, Caspase-3 and Calpain-10. The procedure was fol- 
lowed as described by manufacturer. 
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3.15.4 Wash Step Procedure 
Wash steps were critical for removing excess radiolabelled probe and non-specific 
hybridisation signals thereby decreasing background signals. 
Hybridisation buffer was discarded and the blot washed for 3x5 min in 2X SSC, 
0.1% SDS (w/v) at room temperature, then for 2x 10-15 min in 0.1X SSC, 0.1% 
SDS (w/v) at 60-65°C. Washstep conditions were optimised for individual probes, 
such that low intensity band signals/low expressed mRNA were washed at a lower 
temperature (60°C), for 2x 10 min max. Higher expressed mRNA species producing 
very high band intensity signals, were washed at 65°C for full 2x 15 min providing a 
higher stringency wash. Wash-step conditions optimised for individual probes during 
trial analysis can be found in relevant sections within Section 6. 
3.15.5 Stripping Procedure of Probed Membranes 
3.15.5.1 Strip-EZTM: After probe detection (subsequent section) blots were stripped 
of hybridised probe using the following freshly prepared Probe Degradation and 
Probe Reconstitution solutions: 
Probe Degradation Solution Component Volume Final Conc. 
200X Probe Degradation Buffer 50 Al ix 
I 00X Degradation Dilution Buffer 100 µl Ix 
Nuclease-free water 10 ml 
Probe Reconstitution Solution Component Volume Final Conc. 
I 00X Probe Reconstitution Buffer 100 µl ix 
20% SDS 50 µl 0.1% 
Nuclease-free water 10 ml 
N. b. All reagents, apart from nuclease-free water were part of Strip-EZTm kit. 
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The 10 ml volume of both buffers was sufficient for treating a 100 cm2 membrane. 
The blot was incubated with Probe Degradation Buffer at room temperature for 2 
min in a hybridisation bottle. Blot was transferred to a 68°C hybridisation oven, in- 
cubated for 10-30 min to degrade the labelled probes and then Probe Degradation 
Buffer discarded, Blot Reconstitution buffer was then added and incubated in oven 
for 10-30 min at 68°C. 30 min incubations were required for both steps to adequately 
strip very intense signals (for example, actin probes). An additional 10 min wash in 
0.1% (w/v) SDS at 68°C was used to remove residual signal, using 10 ml / 100 cm2 
blot. Membrane was checked before further use by monitoring blot using a Geiger- 
counter to ensure proper stripping. If probes were not adequately stripped, (Geiger 
counts of more than 5 cpm), stripping process was re-done and/or radioactive blot 
left to decay for an appropriate period. 
3.15.5.2 Rediprime: After probe detection, blots were stripped using harsher condi- 
tions. The membrane was placed into a bag, -200-250 ml boiling 0.1% (w/v) SDS 
poured into bag, the bag sealed and left to cool to room temperature. Procedure was 
repeated to ensure adequate membrane stripping and blot checked using Geiger- 
counter, or by exposing to an autoradiograph. 
3.16 DETECTION METHOD OF RADIOISOTOPES 
Probe-hybridised membranes wrapped in Clingfilm and kept wet (to prevent perma- 
nent probe-fixing), were placed in a phosphoscreen (Kodak, Rochester, NY, US) de- 
veloping cassette. Membranes were left for at least 24 hr before scanning the phos- 
phoscreen in a phosphoimager (BioRad, California, US). Scans were captured, visu- 
alised and then analysed using the Quantity One program (BioRad California, US). 
Detected bands were sized using stained RNA markers. 
3.17 BAND INTENSITY ANALYSIS 
Using the Quantity One program (BioRad) band signals of interest were quantified 
using the pixel analysis function of the program. The Quantity One software allows 
the analysis of band intensity whilst adjusting for background, using pixel volume 
values (see Figure 2.17-1). 
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Figure 3.17-1. An example of pixel analysis of detectable bands. 
11 II 
.. 
II I 
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An example of a Northern blot hybridised with radiolabelled probe, scanned, 
bands detected, picture captured and analysed using Quantity One pixel analysis. 
Equal sized rectangular boxes were drawn around bands and pixel volume meas- 
ured within boxes relative to local background signals. As can be seen there is an 
increasing band signal intensity level across samples, possibly suggesting an in- 
crease in expression, only proven once an internal standard is analysed. 
3.18 DATA AND STATISTICAL ANALYSIS 
For trial sample analysis, adjusted volume measurements were inputted into Micro- 
soft Excel and treatment group mean values, SD (Standard Deviation) and SEM 
(Standard Error of the Mean) calculated. Individual values for an expressed gene of 
interest were normalised to an internal standard (e. g. Actin), i. e. adjusted value di- 
vided through by internal standard adjusted value. Again, treatment group mean, SD 
and SEM values were calculated. Bar graphs of mean values + SEM for groups was 
presented (as seen in Results section). 
Statistical analysis of normalised values depended on the type of trial that was under- 
taken and number of groups to be analysed. For two treatment groups and one indi- 
vidual time point a student t-test analysis was performed. An F-test analysis of data 
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was performed to assess whether there was significant variance of values within 
treatment groups. A significance level of < 0.05 was used (*). Greater significance 
was at < 0.01 (**) and highly significant < 0.001 (***) value. 
Where three treatment groups and one time point was used, One-Way ANOVA (Mi- 
crosoft Excel) analysis of data was applied, using same significance levels as above. 
Those experiments that required greater evaluation of data between treatment groups 
were inputted into the SPSS statistical package. A One-Way ANOVA and Bon- 
ferroni post-hoc test to examine pair wise significance was applied and interactions 
between all groups analysed. Trials involving greater than 2 interactions, for example 
treatment and time, were analysed by Two-Way ANOVA analysis of data using 
GENSTAT computer program. GENSTAT allowed analysis of all time point and 
treatment interactions, and incorporated SED (Standard Error of the Difference) val- 
ues. A comparison of means was performed between individual group pairs within 
the whole trial groups. This was performed using least significant difference (LSD) 
values. Care had to be used when using these values as it is only an indication of a 
potential difference as is any post-hoc test. The LSD value uses the SED value plus a 
factor for the significance using t values. 
LSD = SED x the t value for the level of significance. 
The t value was obtained using a students t distribution table (Altman, 1991). The t 
value depends on the level of significance followed and the degrees of freedom. A 
5% level of significance was followed for all LSD value calculations. If the value for 
LSD is less than the difference between the two means being examined then the val- 
ues are potentially significantly different. 
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CHAPTER 4 THE EFFECT OF LEVEL OF NUTRITIONAL 
INTAKE ON THE CALPAIN SYSTEM 
4.1 BOVINE PLANE OF NUTRITION TRIAL 
4.1.1 Trial Outline 
Gene expression studies, investigating the effects of altered planes of nutritional in- 
take in cattle on components of the calpain system, was undertaken using recently 
acquired (at that time) Quantitative Real-Time RT-PCR technology. The aim of the 
investigation was to determine whether restricted nutritional intake and realimenta- 
tion (refeeding) would affect calpain system component gene expression in skeletal 
muscle. A secondary component of the study was to determine whether the Real- 
Time RT-PCR system was a sensitive, reproducible technique for the analysis of cal- 
pain system transcript expression; with a view to use this technique to examine the 
expression of multiple components of the proteolytic systems discussed previously 
within the literature review. 
Dramatic alterations in the level of nutritional intake (i. e. metabolisable energy, 
macro- and micro-nutrients), so called `plane of nutrition', in young rapidly-growing 
farm animals (including cattle), is likely to profoundly influence whole animal and 
tissue growth rates, and skeletal muscle protein accretion (Kristensen et al, 2002, 
Kristensen et a!, 2004). It is yet to be established the precise effects feeding and al- 
terations in level of nutritional intake has on skeletal muscle proteolytic system ex- 
pression, activation and regulation; and, in turn how this is related to muscle protein 
turnover. Components of the calpain system, as discussed within the review of the 
literature (Section 2.8.3), are thought to play a role in skeletal muscle growth (Goll et 
al, 1998, Goll ei al, 2003). There is however a lack of studies investigating the ef- 
fects of nutritional intake and the regulation of calpain-calpastatin system. Mc 
Donagh et al, 1999 observed a decrease in calpastatin activity in M biceps femoris in 
lambs after a feed restriction, with no effects on , u- and m- calpains. Whereas Kris- 
tensen et a/, 2002 found a positive correlation between growth rates and m-calpain 
activities, with no change in calpastatin, with different feeding level treatments (high, 
restricted-low and refed-after a restriction), in pigs. 
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Our hypothesis was that as components of the calpain system are involved in muscle 
growth and remodelling, dramatic alterations in nutritional intake in growing calves 
would affect the expression of components of the calpain system. This was supported 
by the fact that calpastatin and muscle-specific calpain-3 have been implicated in a 
number of conditions known to affect muscle protein turnover (Goll et al, 1998, 
Baghdiguian et al, 2001, Navegantes et al, 2002, Tidball and Spencer, 2002). 
4.1.2 Trial Details 
Bovine Plane of Nutrition trial was carried out by Dr G. Lee and Professor Buttery 
(Dr G. Lee, Doctorate Thesis: Nutrient control of the growth hormone and insulin- 
like growth factor axis in cattle). Many thanks to them for use of Longissmus Dorsi 
(LD) samples from this trial. 
Twenty four weaned Friesian castrated calves at 61 days old (± 9 days) were ob- 
tained and initially group housed on straw for the first five days. They were fed 0.5 
kg of calf post weaner concentrate (WQC Quality Calves) per animal twice a day, ad 
libitum hay and free access to water. All calves were weighed and randomly allo- 
cated to one of three dietary treatment groups (three groups of eight). Calves were 
individually housed on wood shavings, with free access to a water drinker in each 
pen. Pens were arranged such that there were six pairs on either side of the barn, with 
four treatment-animals each side. Each pen-pair had the same treatment group to re- 
duce animal disturbance (i. e. two pen-pairs/side of four animals of same treatment). 
There then followed a three week acclimitisation period, where calves were intro- 
duced to a high plane of nutrition to encourage rapid growth. The animals were fed at 
2.5 x the recommended ME for maintenance (based upon ME (joules per day) intake 
of 5.67 + 0.061 liveweight (kg)/ 0.72 (Ministry of Agriculture, Food and Fisheries 
(MAFF)/Agricultural Development and Advisory Service (ADAS), 1984)), consist- 
ing of 30 g of BOCM Pauls Beef Super Grade diet (see Appendix G) per kg of live 
weight (70% intake), and 30% hay, which satisfied their nutritional demand. 
Day I of the trial was was the first day after the three week acclimitisation period. 
All calves were continued to be fed on the same diet (as above) for a further 16 days. 
On day 17, the `LOW' and `REFED' dietary treatment groups were restricted to 90% 
116 
of the recommended ME for maintenance without any adaptation period. The diet 
constituents remained at 70% intake from concentrates and 30% from hay. The 
`HIGH' dietary treatment group remained on 30g of concentrate/ kg live weight, and 
30% hay for the remainder of the trial, meeting all dietary needs. 
On day 47, the HIGH group continued to receive the same diet, as did the LOW 
group. The REFED group however, was immediately fed to the same level and diet 
as the HIGH group. On day 49, four animals from each group were slaughtered. Two 
weeks later on day 62, the remainder of the animals were slaughtered 15 days post 
re-feeding. A time-line diagram of the feeding regime is shown in Figure 4.1.2-1. 
Samples of Longissmus Dorsi (LD) muscle were removed from the carcass immedi- 
ately after slaughter, weighed briefly and snap frozen in liquid nitrogen for subse- 
quent storage at 
- 
70°C. 
Figure 4.1.2-1 Schematic outline of bovine plane of nutrition trial. The HIGH 
plane of 'nutrition group F--) remained at a high level of dietary intake for the en- 
tire length of the trial. The LOW plane group E- ) began at a high level of dietary 
intake, then reduced drastically on day 17 for the remainder of the trial. The REFED 
group f-) began at high level of intake, was reduced on day 17 and then reali- 
mented back to a high level of dietary intake on day 47; remaining at that level to 
slaughter. There were eight animals per group (n=8), with four animals per group 
slaughtered on day 49 (SI) (n=12), and again at day 62 (S2) (n=12). 
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4.2 TOTAL RNA EXTRACTION AND ANALYSIS 
From Longissmus Dorsi (LD) samples total RNA was extracted procedures as de- 
scribed in Section 3.3. Sample numbers and their respective treatment groups can be 
found within Appendix H. Extracted total RNA was checked for integrity and quality 
by standard spectrophotometer analysis and gel electrophoresis techniques (described 
within Sections 3.3.2 and 3.6, respectively). Total RNA for all twenty three samples 
showed little signs of qualitative degradation indicated by the lack of ribosomal/low 
molecular weight smearing and lack of DNA contamination indicated by lack of 
smeared large molecular weight band near wells (see Figure 4.2-1. ) 
Figure 4.2-1. The effect of plane of nutrition on bovine LD total RNA quality 
and integrity. Non-denaturing gel electrophoresis of LD total RNA (lug loaded/ 
sample) on a I% agarose gel. H= HIGH, L= LOW and R= REFED. 1kb markers 
(M) were loaded with main fragments noted (bp). Ribosomal RNA (rRNA) is indi- 
cated. 
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Extractable total RNA yields were determined. A Two-Way ANOVA analysis of 
data across slaughter date time points was made to assess if treatment or slaughter 
date had an effect on total RNA yield (Table 4.2-1). There was no significant effect 
of treatment on yield of total RNA (Table 4.2-1). However, it is noticeable that there 
was a larger numerical yield value for the REFED group that nears towards signifi- 
cance at both slaughters dates. There was a signifcant effect of slaughter date on 
yields, the yield of total RNA was greater across all groups for the second slaughter 
date (P < 0.05). Note that samples were randomly extracted suggesting a true effect. 
Table 4.2-1. The effect of plane of nutrition on extractable total RNA from LD. 
Two-way ANOVA analysis of extractable RNA yields (, ug RNA/g tissue). Slaughter 
date (SL. ), number of animals (n) and group mean yield ± SEM (Standard Error of 
Mean) for each value is indicated Significant effect of treatment, time and treatment 
x time interaction is indicated, using SED (standard error of the difference) and P 
significance values. 
Treatment Groups Treatment Time Treatment 
SL. HIGH LOW REFED X Time 
Total RNA (µg /g tissue) SED P SED P SED P 
J" (n=4) (n=4) (n=4) 
151.8 129.8 283.5 
±19.3 ±48.7 ±37.7 92.3 0.144 75.4 < 0.05 130.5 0.913 
2" (n=4) (n=3) (n=4) 
296.0 330.7 504.0 
±68.0 ±127.2 ±173.6 
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4.3 QUANTITATIVE REAL-TIME RT-PCR ANALYSIS OF GENE 
TRANSCRIPTS 
4.3.1 Experimental Procedure 
A total first strand cDNA pool was synthesised for all total RNA samples using Re- 
verse Transcriptase (RT-step) and random hexamer primers (see Section 3.4.3.1). 
Real-time PCR analysis was subsequently performed on all bovine first strand cDNA 
pool samples (see Section 3.4.3.2). It must be appreciated that this was the first time 
Real-Time PCR analysis had been undertaken within the Division of Nutritional Sci- 
ences. Part of the work in this thesis was establishing methodologies for analysis by 
Quantitative Real-Time PCR. Several components of the calpain system and internal 
standards, actin and rRNA 18S were analysed. Actin and rRNA 18S were chosen as 
internal standards as they had been used successfully as internal controls for a num- 
ber of years by many research groups. It was believed that the mRNA levels of these 
two expressed genes would not significantly change because of treatment. Primers 
and probes were designed for sequences of interest using procedure described within 
materials and methods (Section 3.4.2.3). Primers and probes for the ubiquitously ex- 
pressed p- and m- calpains, muscle-specific calpain-3 and specific endogenous in- 
hibitor calpastatin were specifically designed using available bovine sequence data. 
Bovine sequence accession numbers as follows: p-calpain: AF 221129, m-calpain: 
U07850, calpain-3: AF 087569, calpastatin: L 14450. Oligonucleotide sequences and 
region of amplification within the various mRNA sequences is summarised within 
Appendix C. At the time, database sequence for bovine actin was not available, 
therefore primers for actin were selected from regions of high similarity across spe- 
cies, using a multiple alignment of alpha and beta isoform cDNA sequences. This 
was possible as alpha and beta isoforms sequences are highly similar (an example of 
an actin sequence alignment across species and isoforms can be viewed in Appendix 
A). Human alpha-actin was used as sequence to design primers as it was highly simi- 
lar to other isoforms / species, in area to be amplified (using BLAST search of am- 
plicon, human alpha-actin had 96% sequence identity to porcine alpha actin gene, 
94% to porcine beta-actin mRNA and 95% to rabbit alpha-actin mRNA). 18S was 
designed using human sequence which was highly similar to rat species (using 
BLAST search of amplicon, human 18S had 100% sequence identity to porcine 18S 
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gene and bovine mitochondrial RNA and 99% to rat sequence), thus suggesting the 
sequence is highly conserved across species. Real-Time PCR reactions were per- 
formed for ubiquitously expressed 
, 
u- and m- calpains, calpastatin and actin using the 
SYBR-green procedure (see Section 3.4.3.2). For muscle-specific calpain-3 and 18S 
Tagman Quantitative PCR was done using primers and a dual labelled fluorescence 
probe. Reaction conditions are described within Section 3.4.3.2. 
4.3.2 Results 
Using the ABI 7700 Prism Quantitative Real-Time thermocycler (ABI Biosystems) 
the fluorescence data for the PCR amplification of the target cDNAs was collected. 
This data was analysed using the SDS software package (ABI Biosystems). Graphi- 
cal representations of changes in fluorescence intensity (iRn) values at successive 
PCR cycles for every reaction in the 96-well plate throughout the time course of the 
incubation were produced (examples can be seen in Figure 4.3.2-1). 
Preliminary evaluation of reaction efficiencies and specificities was performed be- 
fore trial sample analysis using standard curve analysis (as recommended by ABI 
Biosystems) to determine linear and quantitative amplification of the target cDNA 
and post-PCR product gel electrophoresis analysis to determine the specificity of the 
PCR (as described within Section 3.4.4) 
Standard curves were prepared for u- and m- calpains, calpain-3, calpastatin, actin 
and 18S, using known serial dilutions of a pooled cDNA template. For every cycle of 
PCR it would be expected that there would be a doubling in the quantity of DNA 
present if the reaction was 100% efficient. Therefore, the relationship between the 
factorial change in the concentration of target amplicon DNA present (the dilution 
factor) from any one concentration to another, AD, and the difference between Ct 
values determined at each of these concentrations, OCt, is given by the equation: 
AD = 2-(occ) 
as long as the Ct values are determined in the exponential amplification phase of the 
PCR. Therefore it would be expected that a dilution factor of 10 would result in a 
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corresponding increase in Ct value of 3.322. In addition Ct data obtained from a 
known serial dilution of template plotted on a graph of logio [total RNA] (or total 
RNA equivalents) against Ct value would be expected to have a gradient of approxi- 
mately 
-3.3. Such a relationship between template concentration and Ct value would 
indicate that the reaction was 100% efficient. The standard curve data and graphs 
plotted for all expressed genes of interest are presented in Appendix D. 
Determination of p- and m- calpain expression using the SYBR Green method pro- 
duced standard curves with slopes of 
-0.1012 and 
-2.5887, respectively, suggesting 
it would take 0.1 and 2.6 cycles to amplify a target sequence so that there was a 10 
fold increase in DNA copy number. These results suggested a higher than theoretical 
amplification efficency. This was likely due to non-specific template amplification 
during each PCR cycle using SYBR green instead of Taqman probe. u-Calpain had a 
high level of contamination in the Non Template Control (NTC) reaction (NTC Ct 
value analysis), with NTC data curve very close to serial dilutions curves suggesting 
amplifcation of non-specific components. As the standard curve and amplification 
data did not fit the expected theoretical data, p- and m- calpains mRNA expression in 
bovine trial samples could not be analysed. Analysis of calpastatin template amplifi- 
cation using SYBR Green produced a standard curve slope of -3.1455 (see Appendix 
D), a level closer to the theoretical -3.3 value. This gave a theoretical reaction effi- 
ciency of 104%, a slope of 3.3 would be equivalent to a 100% efficiency, which was 
considered to be an acceptable level (opposed to 122% for m- calpain); suggesting a 
lower level of non-specific amplification and primer-dimer formation. Analysis of 
calpain-3 using a dual-labelled fluorescence (Taqman) probe produced a slope of 
- 
4.1955 (see Appendix D), suggesting a lowered amplification efficiency (85%). 
Likewise analysis of 18S, also using a dual labelled fluorescence (Taqman) probe, 
produced a slope of -3.4888 (see Appendix D). However, amplification of actin us- 
ing SYBR Green produced a slope of 
-2.8118 (see Appendix D). An interesting 
point to note was that samples with good efficiencies of PCR amplification produced 
single specific bands after gel electrophoresis analysis of post-PCR products. In gen- 
eral, a greater amount of primer-dimer formation was detected (low molecular 
weight smeared bands on the gel) on those that used SYBR Green as opposed to dual 
labelled fluorescence (Taqman) probes. This may account for reduced/abnormal effi- 
ciencies. 
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As the standard curve gradient values for calpastatin, calpain-3 and 18S were ac- 
cepted as being in a suitable range from the expected 
-3.3 slope value, therefore trial 
sample analysis could be performed. This was performed even though calpastatin did 
have a level of non-specific amplification and calpain-3 and 18S had lowered effi- 
ciencies. Importantly, 18S was a more suitable internal standard to actin as dual la- 
belled fluorescence (Taqman) probe conferred greater reaction specificity and slope 
value was closest to to 
-3.3. Amplification of actin templates gave a high level of 
non-specific primer-dimer amplification. Calpain-3 had lowered reaction efficiency 
in each round of PCR. Importantly, the primers and dual labelled fluorescence 
(Taqman) probe did not exhibit non-specific amplification as determined from gel 
electrophoresis analysis of the products. In addition, the relationships between Ct and 
loglo [template] was linear. Therefore, calpain-3 probe was used in further trial 
analysis. 
Trial sample Real-Time PCR reactions were performed and analysed for calpain-3, 
calpastatin and 18S. Template amplification data outputs can be viewed in Figure 
4.3.2-1 (A)-(C). 
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Figure 4.3.2-1. Real-Time RT-PCR template amplification fluorescence data 
outputs for trial samples. All bovine trial samples and NTC are shown, for (A) Cal- 
pain-3, (B) Calpastatin and (C) 18S (internal standard). ARn, fluorescence intensity 
and cycle number are shown. Background threshold and amplification threshold lev- 
els are indicated. 
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4.3.3 Fluorescence Data Analysis 
Average Ct values of trial triplicate samples were taken at a quantification threshold 
where the amplification curves of all samples were linear, parallel to one another 
during the exponential amplification phase. The average Ct values were converted 
into relative amounts of total RNA, using standard curves (log total RNA vs Ct) and 
antilog of log RNA (see Section 3.44). Values for calpastatin and calpain-3 were 
normalised to 18S, giving a ratio of gene of interest relative to this internal standard. 
Mean treatment group values were calculated (Data presented in Tables 4.3.3-1, 
4.3.3-2 and Figures 4.3.3-1,4.3.3-2). A Two-Way ANOVA analysis was performed 
on all treatment groups comparing time and treatment interactions across all groups. 
From Table 4.3.3-1 it can be seen that there was no significant effect overall of die- 
tary treatment on calpain-3 mRNA expression. The LOW group values were numeri- 
cally lower than the HIGH and REFED groups at the Ist slaughter date. The LSD 
value indicated that this was potentially significant at a 5% level. The REFED group 
expression values were also numerically higher than the LOW group at the 2nd 
slaughter date, but this was not significant. 
There was also a definate trend towards significance for the expression of calpain-3 
mRNA between the l and 2"d slaughter date groups (Time, P=0.073). The values 
for both the LOW and REFED groups increased from the I" to 2nd slaughter, whilst 
the HIGH group decreased slightly suggesting a differential effect of treatment and 
time. The LSD value indicated that this was potentially significant at a 5% level. 
From Table 4.3.3-2 it can be seen that dietary treatment had no significant effect 
overall on calpastatin mRNA expression. However, in the 1 s' slaughter group calpas- 
tatin mRNA increased in the LOW group compared to the HIGH and REFED 
groups, numerically in the opposite direction to calpain-3. There was however a 
trend towards significance overall across slaughter date time points (P = 0.085), with 
all groups having increased calpastatin mRNA values from 1 st to 2"d slaughter dates. 
There was a larger increase in the REFED group across slaughter dates than for other 
groups. The LSD value indicated that this was potentially significant at a 5% level. 
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Table 4.3.3-1. The effect of plane of nutrition on relative expression of calpain-3. 
Two-way ANOVA analysis of quantified calpain-3 mRNA values normalised to 18S. 
Slaughter date (SL. ), number of animals (n=) and group mean ± SEM (Standard Er- 
ror of Mean). for each value is indicated. Significant effect of treatment, time and 
treatment x time is included using SED (standard error of the difference) and P sig- 
niftcance values. 
Treatment Groups Effect of: 
SL. Treatment Time Treatment 
HIGH 1, OWW' REFED X Time 
SED P SED P SED P 
ist (I1=4) (I1=4) (n=4) 
1.441 1.009 1.423 
ß. 078 ±0.154 ±0.139 0.173 0.127 0.141 0.073 0.244 0.312 
2n (n=4) (i1=3) (n=4) 
1.399 1.474 1.807 
±0.227 ±0.199 ±0? 03 
Figure 4.3.3-1. The effect of plane of nutrition on relative expression of calpain- 
3 for 151 and 2 °d slaughter dates. Mean quantified values, normalised to 18S, + 
SE. t! are presented. 
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Table 4.3.3-2. The effect of plane of nutrition on relative expression of calpas- 
tatin. Two-way ANOVA analysis of quantified calpastatin mRNA values normalised 
to 18S. Slaughter date (SL. ), number of animals (n=) and group mean ± SEM (Stan- 
dard Error of Mean) for each value are indicated. Significant effect of treatment, 
time and treatment x time is included using SED (standard error of the difference) 
and P significance values. 
Treatment Groups Treatment Time Treatment 
SL. HIGH LOW REFED X Time 
SED P SED P SED P 
I`t (Il 4) (I1=4) (I1=4) 
0.0363 0.0455 0.0343 
±0.005 +0.007 +0.007 0.010 0.874 0.008 0.085 0.014 0.649 
2n (I1=4) (Il 3) (n 4) 
00.0503 0.0512 0.0584 
fO. O1 ±0.020 ±0.00 
Figure 4.3.3-2. The effect of plane of nutrition on relative expression of calpas- 
tatin for IS' and 2"d slaughters dates. Mean quantified values, normalised to 18S, 
+SE. t1 are /)r'c sentc'd. 
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4.4 SUMMARY 
A trial was performed in which 24 cattle were placed into different feeding treatment 
groups. These consisted of a LOW and HIGH plane of nutrition group, along with a 
REFED group that was realimented back to a HIGH plane from an initial LOW 
plane, 2 days prior to the ist slaughter date. Half the animals from each group were 
slaughtered on the the 1 S` slaughter date, and the rest of the calves 2 weeks later. 
Analysis of extractable total RNA yields from bovine LD showed that there was a 
significant effect of slaughter date on yields (P < 0.05), with second slaughter date 
groups having greater numerical values. There was no significant effect of treatment, 
although the REFED group had greater numerical values than the LOW and REFED 
groups at both time points. 
Real-time analysis of the calpain-system and internal standards revealed that the 
technique can be problematic and requires extensive optimisation and testing. For 
example, when using SYBR-Green there is a much greater chance of non-specific 
amplification and primer-dimer formation, potentially invalidating experiments (as 
was seen for A- and m- calpains and actin). Also, Taqman Probes may be a preferen- 
tial technique to SYBR-Green offering a higher level of reaction specificity, con- 
firmed by post-PCR product analysis by gel electrophoresis and standard curve 
analysis. 
Standard curves were generated for all expressed genes of interest. Calpastatin (using 
SYBR-Green), muscle-specific calpain-3 (using Taqman Probe) and 18S (using 
Taqman Probe) were the only valid reactions that could be used in trial analysis. 
When analysing bovine trial samples, Ct values were taken at a suitable quantifica- 
tion threshold level, for each replicate. Values were averaged and quantified into ng 
equivalent amounts of total RNA using standard curves. There was no significant 
effect or trend of treatment on 18S values across groups, making 18S a valid internal 
standard. Quantified data for calpain-3 and calpastatin was normalised to 18S. 
Analysis of normalised calpain-3 mRNA data suggested that although there was no 
overall significant effect of dietary treatment (P = 0.127), during the 1 S` slaughter 
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only, the LOW group had lower calpain-3 mRNA compared to both the HIGH and 
REFED (30% lower from HIGH and 29% lower from REFED) groups. The LSD 
value indicated that this was potentially significant at a 5% level. The REFED group 
expression values were also numerically higher than the LOW group at the 2"a 
slaughter date (23% higher), but not significant. 
There was a trend towards significance for the effect of slaughter date on calpain-3 
mRNA expression (P = 0.073). Both the LOW (46% increase) and REFED (27% in- 
crease) groups increased by the 2°d slaughter date. The LSD value indicated that this 
was potentially significant at a 5% level. 
There was no observed significant effect of dietary treatment on calpastatin (P = 
0.874), although in the ls` slaughter mRNA increased in the LOW group compared to 
the HIGH and REFED groups (25% increase relative to HIGH and 33% relative to 
REFED). 
Calpastatin mRNA expression also increased across all treatment groups from the I 't 
to the 2"d slaughter with a trend towards significance (P = 0.085), with the REFED 
group having a larger numerical increase across slaughter time. The LSD value indi- 
cated that this was potentially significant at a 5% level. 
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CHAPTER 5 cDNA PROBE DEVELOPMENT 
5.1.1 Outline 
The hypothesis that proteolytic system components are co-ordinately regulated 
simultaneously in skeletal muscle, during various stimuli, required a means of 
investigation. Therefore, the aim was to generate cDNA probe sequences 
-200-300 
bp in length, by PCR suitable for experimentation on predominantly porcine, but also 
bovine and possibly human muscle tissues. These were to be used to determine 
changes in mRNA levels, using northern blot probing, or macroarray experimental 
procedures. These system components have been reported to be expressed in skeletal 
muscle, and, up/down-regulated during different physiological and pharmacological 
conditions, which are known to alter muscle atrophy/hypertrophy state, were focused 
on. 
It became clear that there were many time, financial, and experimental constraints; 
therefore, the most appropriate strategy would be to aim to synthesise, four-to-five 
main components for each system, and three-to-four internal standards. The main 
limitation was the requirement for porcine specific cDNA sequences, when many 
proteolytic system components had no porcine sequence available in databases. The 
result, after many months, was the generation of twenty positively identified PCR 
products, many of which were cloned into a plasmid-vector. Four components each 
from the caspase, cathepsin and ubiquitin-proteasome systems; five from the calpain 
system, and three internal standards were selected based on the review of the 
literature. These included: Caspases- 3,6 and 7- (all `effector' caspases), and ARC 
(Apoptosis Repressor with CARD domain). Cathepsins B, D, L, and H; E2G 1- an 
E2-ubiquitin conjugating enzyme, highly expressed in skeletal muscle, C8- a 
proteasome subunit, ubiquitin, and atrogin-l- an E3-ubiquitin Ligase, previously 
mentioned. p- and m-calpains, calpain-3, calpastatin, and calpain-10. Internal 
standards- actin, alpha-Tubulin, and TFIID (Transcription Factor II D)/TATA box 
binding protein. 
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5.1.2 Scheme of Work 
The developmental sequence of events in generation of the twenty cDNA probes are 
described as follows: 
Related mRNA and cDNA sequences for components of interest, across multiple 
species, were searched for, using SRS (Sequence Retrieval System), and BLAST 
programs, found on the NCBI, DDBJ and HGMP homepages (as described in 
Section 3.4.2). Emphasis was placed on available porcine, bovine and human 
sequences. Retrieved sequences were aligned using the Clustal W sequence 
alignment program found within the above homepages (see Section 3.4.2). Areas of 
high sequence homology across species were searched for as a suitable PCR target 
and used to direct searches for PCR primer pairs. Specific PCR primers were then 
designed using personal preference based on primer and sequence analysis (including 
using programs such as Primer Express (ABI Biosystems). 
PCR testing and optimisation procedures were then undertaken to synthesise DNA 
sequences of the correct size and sequence. Porcine skeletal muscle Poly-A+ 
enriched RNA was used as a PCR template after an RT-step (see Section 3.4.3.1) to 
produce first strand cDNA. Basic PCR procedures were then used (see Section 
3.5.1). The number of cycles used in all reactions was 35; as it was believed that 
many of the genes of interest are expressed at low levels. 
All PCR reactions, including controls, e. g. NTC (Non Template Control), were tested 
by standard gel electrophoresis and staining techniques. Once positive results were 
obtained, i. e. detection of a single band of the correct size (see examples, Figure. D 
in Appendices A 1-20), with no band present in NTC; positive PCR reactions were 
pooled together, separated by gel electrophoresis, and gel purified using standard 
technique. Once purified, samples were separated by gel electrophoresis and stained, 
to check the size and quality of the DNA recovered. 
Many of the cDNA sequences (Appendices A 1-5,7-10, and 12), were suitable to be 
cloned into a pGem-T Easy Vector (see Section 3.8-3.9). This was an important step 
as many of the sequences are novel, were problematic to synthesise by PCR, and 
meant, if cloned successfully, large quantities of DNA could be synthesised. 
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Problematic PCR targets, with an inability to produce a single band of the correct 
size, after gel electrophoresis and staining, underwent rigorous investigatory steps 
including (in this progressive sequence): varying a) annealing temperatures, b) 
template concentration, c) Taq polymerase type, d) DMSO addition (to denature any 
secondary structure formation) and e) change in primer location/size-composition. 
Examples of problematic PCR reactions included Ubiquitin (Appendix A-11), which 
required a change in primer pair sequence, temperature gradient experiments and 
Expand Taq system (Roche Molecular Biochemicals, Mannheim, Germany) to 
achieve a PCR product of the correct size and sequence; it was also found impossible 
to clone after numerous attempts. Cathepsin B PCR product (Appendix A-5) was 
found after DNA sequencing to have a good sequence alignment, yet the cloned 
insert had a poor sequence alignment similarity to Cathepsin B. 
Cathepsin D (Appendix A-6) and Calpain-10 (Appendix A-17) proved to be 
impossible PCR targets; at present there is no porcine or bovine sequence data 
available for these two in all relevant databases. Calpain-10 has proved difficult to 
clone in farm species (unpublished observations). Therefore, human EST (Expressed 
Sequence Tag) "IMAGE" clones, with 100% sequence alignment to retrieved human 
sequences- PCR target regions, were ordered from the IMAGE (Integrated Molecular 
Analysis of Genomes and their Expression) Consortium (see Appendix E). Standard 
bacterial-plasmid growth and purification procedures were used, yielding purified 
plasmid DNA (see Section 3.9,3.10 and Appendix E). Plasmid DNA was linearised 
(as described in Appendix E, using protocol in Section 3.11) and used as a PCR 
template. Finally, original primers designed previously, were used to successfully 
synthesise a cDNA sequence of correct size and sequence. Note; calpain- 10 still 
required a long series of optimisation steps (change of primer pairs, temperature- 
gradient PCR and taq enzyme variation), to yield a positive result. 
The final step involved analysis of all twenty synthesised PCR products and cloned 
inserts, by DNA sequencing (see Section 3.13). Returned sequences were recorded as 
shown in relevant box (Figure E) in Appendices Al-20. 
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Sequence identification was validated by performing BLAST searches, using the 
relevant database homepages (e. g. NCBI) (see Section 3.4.2.2); all twenty cDNA 
sequences were positively confirmed to be closest matched to mRNA/cDNA 
sequence identities of interest. From the BLAST program sequence list output, the 
three sequences most similar, or those from species of interest (i. e. Porcine, bovine 
and human), have been recorded in in Appendices Al-20 (Figure F); if no species of 
interest sequence data is available, ovine, murine, rat and related species have been 
listed. A score (in bits), sequence identity (value and %), and E Value has been 
recorded for each sequence noted (an explanation of the Score and E value can be 
found in Appendix A); for purposes of easy-viewing and comparison, the sequence 
identity only, has been noted within two summary tables in this section. The 
sequence identity value relates to the exact number of nucleotide bases matched from 
the specific cDNA probe sequence, and the sequence it is aligned with. For example, 
Cathepsin-D, is a 204 bp long PCR product, of which 134 bp were successfully 
sequenced; exactly matching base-for-base with a 134 bp region of 2038 bp, 
M11233: human cathepsin-D. A 134/134 nucleotide identity value (100%), is 
therefore given. 
5.2 PCR PRODUCT/cDNA PROBE SUMMARY 
Figures 5.2-1 and 5.2-2 show agarose gel electrophoresis pictures of all twenty 
cDNA probes generated and purified. The first two pictures (Figure 5.2-1) show all 
PCR products, except Caspase-3 and Cathepsin-L as limited PCR products were left 
in stock and therefore omitted from gel picture. The gel picture in Figure 5.2-2 is of 
selected cloned cDNA plasmid inserts, excised and purified. These system 
components were problematic to PCR in sufficient quantities for experimentation. 
Therefore, large quantities of cDNA was generated for each cDNA probe by 
performing large culture experiments, midi-prep plasmid purification methods and 
scaled-up bulk RE digests (see Appendix F). 
Table 5.2-1 summarises all 20 probes generated, including amplicon probe sizes and 
sequence identity scores for closest porcine, bovine and human sequences of interest 
(after previous BLAST searches). 
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Figure 5.2-1 Nondenaturing 1.8% agarose gel electrophoresis of purified PCR 
products. PCR products at different concentrations, with 100 bp markers (M), either 
side of gel. Three main bands of 100 bp markers (in bp), are noted either side (see 
list bottom ofpage"for corresponding probe no. s and names). 
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Figure 5.2-2. Nondenaturing 1.8% agarose gel electrophoresis of purified cDNA 
plasmid inserts. Probes 3, . 1,7,8,12 and 9 are loaded, with 100 bp markers (M), 
either 
. 
side of gel. Three main bands of 100 bp markers (in bp), are noted either side. 
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Key for Figure 5.2-1 and 5.2-2: 1: Caspase-7,2: ARC, 3: Caspase-3,4: Caspase-6, 
5: Cathepsin-B, 6: Cathepsin-D, 7: Cathepsin-L, 8: Cathepsin-H, 9: E2G1,10: C8, 
11: Ubiquitin. 12: Atrogin-1,13: µ- Calpain, 14: m-Calpain, 15: Calpain-3,16: 
Calpastatin, 17: Calpain-10,18: Actin, 19: Alpha-tubulin, 20: TFIID 
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Table 5.2-1. Summary of generated cDNA probes. Table to summarise in order 1- 
20 (numbers correspond to those indicated in Figures 5.2-1 and 5.2-2), the number, 
name, and amplicon probe size in bp of individual cDNA probes, and their sequence 
identity scores (as %) for closest porcine, bovine and human species sequences. NSD 
= No Sequence Data available in nucleotide databases. The corresponding appendix 
section is noted for each probe. 
No Probe Name Size 
(bp) 
Sequence identity (%) of probe to 
closest species of interest sequence. 
Appendix 
Porcine Human Bovine 
1 Caspase-7 207 NSD 91% NSD A-1 
2 ARC 240 NSD 84% NSD A-2 
3 Caspase-3 209 99% 90% 89% A-3 
4 Caspase-6 242 NSD 91% NSD A-4 
5 Cathepsin-B 206 NSD 91% 91% A-5 
6 * Cathepsin-D 204 NSD 100% 85% A-6 
7 Cathepsin-L 220 99% 89% 88% A-7 
8 Cathepsin-H 213 99% 90% NSD A-8 
9 E2G1 213 NSD 93% NSD A-9 
10 C8 217 NSD 94% NSD A-10 
11 Ubiquitin 229 99% 91% 94% A-11 
12 Atrogin-1 247 NSD 93% NSD A-12 
13 p-Calpain 201 99% 88% 93% A-13 
14 m-Calpain 201 99% 88% 88% A-14 
15 Calpain-3 201 100% 90% 94% A-15 
16 Calpastatin 236 100% 87% 86% A-16 
17 * Calpain-10 333 NSD 100% NSD A-17 
18 
19 
Actin 
Alpha- 
Tubulin 
201 
218 
100% 
NSD 
97% 
96% 
95% 
97% 
A-18 
A-19 
20 TFIID 1 , 251 NSD 93% NSD A-20 
*Cathepsin-D and Calpain-lu were sequences amplified from human IMAGE 
clones, hence have high identity to human species. 
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5.3 NORTHERN BLOT RADIOACTIVE PROBE TESTING 
The next course of action was to determine if the cDNA probes could detect their 
complementary sequence by probing Northern blots of porcine skeletal muscle total 
and poly A+-enriched RNA with radioactively labelled cDNA probes. A selection of 
probes were chosen and tested based on: probable level of expression in skeletal 
muscle, probable change in mRNA level with treatments, sequence alignment score 
with porcine, bovine and human tissue specific mRNA sequences and possible novel 
role in skeletal muscle (i. e. Calpain-10 and ARC). Probes tested included: ARC, 
Caspase-3, Cathepsin-L, E2G1, Ubiquitin, Atrogin-1, Calpain-3, Calpain-10 and 
Actin. 
Probes were tested on Northern blots of porcine total RNA and Poly-A+-enriched 
RNA. This RNA was separated on a denaturing agarose gel, and blotted onto hybond 
N, using technique described in Section 3.14. 
Probe testing and evaluation was critical as many sequences like E2G1 and Atrogin- 
1, have no porcine sequence data available. PCR products were generated from 
porcine skeletal muscle, Poly-A+-enriched RNA template (after RT step), but PCR 
primers were designed from human sequence data. BLAST searches after DNA 
sequencing confirmed 93% identities to human sequence 
for both system 
components. Therefore, it was assumed that porcine skeletal muscle expresses near 
identical sequences for E2G1 and Atrogin-1 with identical functions, although 
further studies would need to unequivocally confirm this. 
A comparison of all available mRNA sequences held in databases (including those 
previously used in Clustal W multiple sequence alignments and BLAST searches 
(see Appendices 1-20) was made (see Table 5.3-1. ), to estimate the probable size of 
the Northern blot probe signal band. This was complicated, as many of the 
proteolytic system components of interest 
had little, or no porcine sequence data (as 
described) and species available may not have had complete sequences, or they were 
alternatively spliced, giving a range of sizes for their appropriate mRNA species. 
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Many of the sequences in the database may have the potential to be alternatively 
spliced, or the sequence within the databse may have been for the open-reading 
frame (ORF) only or part of the ORF. A full mRNA with associated untranslated 
regions may be much longer. 
An extended period of probe hybridisation testing and optimisation was undertaken 
(see Section 3.15) to attempt to produce detectable, specific quantifiable band signals 
for each probe as described within the Laboratory Methods. Radioactive probe- 
labelling protocols: [a- 32P] dCTP Rediprime system, and [a- 32P] dATP Strip-EZ 
system; and hybridisation buffers: Rapid-Hyb and Ultrahyb, were used for these 
procedures (Section 3.15.3.1 and 3.15.3.2, respectively). The Strip-EZ system 
combined with Rapid-Hyb buffer was preferred, and utilised for the remainder of all 
experiments; due to greater preservation of Northern blot membranes from damage, 
an ability to probe membranes a greater number of times, and speed of hybridisation. 
All data and pictures presented are Northern blots probed using this technique only, 
unless stated otherwise. Figure. 5.3-1 shows phosphoimages of all probes tested. 
The cDNA probes produced specific detectable and quantifiable bands on porcine 
Northern blots (see Figure 5.3-1); however, some probes produced slight 
discrepancies in size and/or multiple band signals. Unknown band signals may be 
due to transcript variants, similar sequence cross hybridisation, or unknown porcine 
sequences/variations. Therefore, attempts at ascertaining band signal sequence 
identities were made; using previously described BLAST searches of nucleotide 
databases, for high scoring (bit score), similar related-sequences aligned to cDNA 
probes used in Northern probing. A full summary table of related mRNA sequences 
for Caspase-3, E2G1, Ubiquitin, Atrogin-1 and Calpain-3, is presented in Appendix 
B. 
137 
Figure 5.3-1. Phosphoimages of porcine skeletal muscle RNA Northern test 
blots. Northern blots hybridised with [a- 32P] dATP-labelled cDNA probes; using 
Strip E-Z probe-labelling kit and Rapid Hyb hybridisation buffer, unless stated 
otherwise (in brackets). Main representatives of each proteolytic system and internal 
standards have been presented. PA= Poly A RNA, T= Total RNA, and numbers 
indicate amount of RNA in weight (jig), loaded on Northern blot. 
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Table 5.3-1. Comparison of sizes of available mRNA sequence of interest. 
Sequence accession number, species, and size is included (taken from Appendix A: 
Sequence retrieval/multiple sequence alignments, and BLAST search). A summary of 
detected Northern blot signal band sizes is included; taken from phosphoimages in 
Figure 5.3-1. 
cDNA Probe Sequence Size (bp) in N-Blot band 
Acc. No. and Species Database sizes (bp) 
(2) ARC AF043244 
- 
Human 900 
-1000 
AY459322 
- 
Murine 983 
(3) Caspase-3 AB029345 
- 
Porcine 834 
-2660 
(7) Cathepsin-L D37917 
- 
Porcine 1378 
-1390 
(9) E2G1 D78514 
- 
Human 617 
-3981, -1995, 
AF099093 
- 
Rat 931 
-1350 
AK013902 
- 
Murine 1543 
(11) Ubiquitin M26880 
- 
Human 2309 
-2900, -1060 
(12) Atrogin-1 AY059629 
- 
Human 1068 
-6310, -4170, 
AF441120 
- 
Murine 2064 
-2820, -1585 
AY059628 
- 
Rat 1053 
(15) Calpain-3 AF043295 - Porcine 2512 -3200 
(17) Calpain-10 AF089088 
- 
Human 2620 
-2600 
(18) Actin J00068 
- 
Human 1374 
-1490 
NM 174225 
- 
Bovine 1485 
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Northern testing showed that the probes for Cathepsin-L, and Actin were able to 
produce single, specific reproducible band signals at -1.39 and 
-1.49 kb, 
respectively; that corresponded to the correct complete mRNA sequence sizes (see 
Table 5.3-1). The Actin signal had a very strong band intensity, and `vertical-spread' 
across blot; corresponding to the very high expression level of actin within skeletal 
muscle, and a degree of cross-hybridisation with other similar-sized actin isoforms 
(other than alpha-actin), e. g. beta ((1.8-2.2 kb), and gamma (-1.9 kb). 
Calpain-3 and the long-Calpain 3 probe were able to produce a strong, reproducible, 
signal single specific band at -3.2 kb; although long-Calpain 3 was shown to be 
more specific than the shorter probe. The porcine sequence, AF043295, available 
within the database is 2512 bp long. This is for calpain-3 mRNA sequence but does 
not contain the untranslated regions, which if included gives a size of 
-3.2 kb. In 
addition, The three complete calpain-3 sequences from Bovine, Ovine and Human 
species, are 2955,3165 and 3243 bp respectively, which also indicates that the 
expected size of calpain-3 mRNA would be in this range (see Appendix B). 
ARC, Caspase-3, and Calpain-10 were difficult to detect. Band signals detected were 
from porcine Poly-A-enriched RNA samples, indicating low tissue expression 
levels. Single, specific bands detected are thought to be the correct size based on 
what evidence is available (comparing available sequences from Table 5.3-1 and 
Appendix B), however no porcine sequence data is available for ARC or Calpain- 10. 
Calpain-10 was generated from a human IMAGE clone; therefore, any specific band 
signal would represent a human cDNA probe cross-hybridising with a porcine 
mRNA sequence. Caspase-3 had a specific band signal size of -2.6 kb, which is 
believed to correspond to a porcine skeletal muscle transcript variant/isoform, 
Human caspase-3 transcript variant alpha is 2646 bp, and human isoform alpha, 2635 
(Appendix B). UltraHyb hybridisation buffer was used to produce a result for 
Caspase-3, as the buffer system allows greater sensitivity by detecting low 
expression levels. 
E2GI, Ubiquitin and Atrogin-1 produced multiple band signals with porcine Poly- 
A+-enriched and total RNA Northern blots, even with higher stringency hybridisation 
conditions. E2G1 probing produced three relatively strong, reproducible bands, at 
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-3.98, -2.0 and -1.35 kb. Noting the size of other sequences found (Appendix B), 
i. e. the human transcript variants, it is possible porcine E2G1 may be alternatively 
spliced. The 
-1.35 kb band is believed to be the correct band to focus attention on, as 
using the Rediprime probe-labelling protocol, produced a single specific band at that 
size. Ubiquitin probing produced two bands, 
-2.9 and 
-1.01 kb. From the available 
sequences for Ubiquitin B and C (found in Appendix B), it would seem likely that 
the 
-2.9 and -1.01 kb bands correspond to porcine Ubiquitin B and C, respectively; 
considering also that the probe sequence produced a 99% sequence identity match 
with what porcine sequence was available (Appendix A: 11, Figure. F [acc. no. 
M18159] ). Atrogin-1 probing produced four bands, 
-6.31, -4.17, 
-2.82 and 
-1.59 
kb. It is most probable the band to focus on is the 
-1.59 kb signal, based on what 
sequence evidence is available (Table 5.3-1. and Appendix B). As all bands from 
E2G1, Ubiquitin and Atrogin-1 probing were to be found within the Poly A+- 
enriched sample of Northern blots, ribosomal RNA signals can be discounted as 
ribosomal RNA should not be present within the Poly A+-enriched RNA. It is 
possible that multiple band signals are due to unknown porcine skeletal muscle 
transcript variants, or, non-specific hybridisation with other mRNA sequence targets; 
as PCR primers were based on human sequence, and no porcine sequence exists for 
E2G1 and Atrogin-1. 
Therefore, the following probes were selected for further experimentation based on 
there strength of signal, specificity, reproducibility, and interest: Cathepsin-L, long- 
Calpain-3, Actin, and possibly E2G1 and Atrogin-1. 
5.4 SUMMARY 
As has been presented within this section and in detail within Appendix A; twenty 
cDNA probes were generated by PCR, and confirmed by DNA sequencing and 
subsequent BLAST search analysis, to be closest matched with the mRNA sequence 
identities of interest. 
The selection of probes tested on Northern blots was based on their possible 
functional importance within skeletal muscle (based on current literature), in addition 
to insufficient time and resources to test and optimise all twenty. It was theorised that 
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many of the sequences of interest are expressed within porcine skeletal muscle, play 
a role in specific states affecting muscle protein turnover, and could be detected and 
quantified using Northern blot hybridisation experiments. After testing, the choice of 
probes that produced the most specific and reproducable signals on porcine RNA 
Northern blots, and were most likely of porcine origin (based on fact that PCR 
primers designed using porcine sequence and generated using porcine skeletal 
muscle) were Cathepsin-L, long-Calpain-3 and Actin. This was essential as further 
trial studies were to use pigs as treatment subjects. 
144 
CHAPTER 6 THE EFFECTS OF A BETA-ADRENERGIC 
AGONIST ON PROTEASE EXPRESSION IN PIGS 
6.1 INTRODUCTION 
Previous studies (as described previously in Section 2.3.4) have shown that chronic ad- 
ministration of the synthetic ß2-adrenoceptor agonist clenbuterol has a potent nutrient 
repartitioning effect in farm animals (Bell et al, 1998, Mersmann, 1998). Clenbuterol 
induced increases in skeletal muscle hypertrophy and protein accretion are thought to be 
through alterations in muscle protein turnover, specifically by decreasing protein break- 
down (Mersmann, 1998, Navegantes et al, 2002). A proteolytic system which is known 
to have alterations in activity and mRNA levels with ß-adrenoceptor agonist treatment, 
are components of the calpain system, specifically the endogenous inhibitor calpastatin 
(Parr et al, 1992, Bardsley et al, 1992, Speck et al, 1993, Sensky et al, 1996, Goll et al, 
1998, Mc Donagh et al, 1999, Navegantes et al, 2002). It is thought that these alterations 
in specific components are thought to induce, or be involved in the processes of cell re- 
modelling, hypertrophy and possibly fiber transformation (Goll et al, 1998, Navegantes 
et al, 2002, Goll et al, 2003). 
However, the precise effects of chronic and acute /J-adrenoceptor stimulation- through 
endogenous and exogenous , B-receptor agonists, such as adrenaline and clenbuterol re- 
spectively, on the expression of muscle proteolytic systems is unknown. 
Three separate studies had been performed within the Department of Nutritional Sci- 
ences. These studies investigated the effects of variable dose, chronic and acute Q- 
adrenergic agonist administration in pigs. Pig Longissmus Dorsi (LD) total RNA sam- 
ples from all three trials were available for gene expression analysis. Therefore, northern 
blots were run and hybridised with specific protease system component cDNA probes. It 
was hypothesised that ß-adrenoceptor agonist treatment through clenbuterol administra- 
tion and adrenaline infusion would alter the gene expression of components of the cal- 
pain-calpastatin system, and other protease system components. 
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6.2 THE EFFECT OF 24 HOUR AND 7 DAY CLENBUTEROL TREATMENT 
IN PIGS 
6.2.1 Trial Details 
Samples were obtained from a trial that had been carried out by Dr. Paul Sensky, the de- 
tails of which are briefly outlined below: 
Thirty six Large White pigs were individually penned, housed approximately 2 weeks 
prior to treatment and fed a standard finisher diet (see Appendix I), which satisfied the 
nutritional requirement, up to the day before slaughter. The pigs were trained to eat their 
diet within a 60-min period by offering them 2 kg feed and withdrawing it 1h later, as 
the clenbuterol was to be fed in the animals diet. Animals were randomly divided into 
three treatment groups of twelve animals: Group (A): controls, (B): 7 day treatment of a 
5 parts per million (ppm) dose of clenbuterol (Sigma)/day and (C): 24 h treatment of 5 
ppm daily dose of clenbuterol. The start of the treatment groups were staggered to allow 
for three consecutive slaughter dates; start dates were: day 19,20 and 21, and slaughter 
dates: day 26,27 and 28. Therefore, four animals from each group (i. e. 12 animals total) 
started treatments, and were slaughtered together on the same dates. The 24 h group (C) 
started clenbuterol treatment on day 25,26 and 27 of the trial. Figure 6.2.1-1 illustrates 
the plan for individual treatment groups over the time course of the trial. 
Animals were slaughtered by electrical stunning and severance of the carotid arteries. 
Samples of LD muscle were removed from the carcass immediately after slaughter and 
snap frozen in liquid nitrogen for subsequent storage at - 70°C. 
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Figure 6.2.1-1. Schematic outline of clenbuterol trial. Control group A(-), re- 
mained on the same diet. for the whole time of the trial. Group B f--) was treated with 
a dietary supplemental dose of 5 ppm clenbuterol daily for 7 days before slaughter. 
Group C (-) was treated with a dietary supplemental dose of 5 ppm clenbuterol. for 24 
h before slaughter. As can he observed above, treatment start-dates and slaughter-dates 
were stuggo-ecl. (n= 12)(n= 12)(n= 12) 
y St S2 $3 
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6.2.2 Total RNA Extraction and Analysis 
Due to constraints of total RNA northern blot analysis (i. e. number of wells on a gel) LD 
samples of eight animals from each group were analysed. LD samples were randomly 
selected, 0.1 g weighed out and subject to total RNA extraction, using the RNAgents'' 
Total RNA Isolation System kit (Promega, Southampton, UK). The procedure was fol- 
lowed as described by the manufacturer and uses a similar method described previously 
(Section 3.3.1). Total RNA was extracted and checked for integrity and quality by spec- 
trophotometer analysis (see Section 3.3.2) and gel electrophoresis (see Section 3.6). As 
can be seen in Figure 6.2.2-1 the gel pictures suggest that total RNA samples show some 
signs of degradation due to presence of low molecular weight banding and some `smear- 
ing' of the rRNA bands. However, the 18S band appeared intact and therefore total RNA 
was used for further analysis. Subsequent northern blot analysis showed that bands were 
indeed intact. There was no distinct DNA contamination present. 
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Figure 6.2.2-1. The effect of clenbuterol on porcine LD total RNA quality and in- 
tegrity. Non-denaturing gel electrophoresis of skeletal muscle (LD) total RNA samples 
(l, ug loaded/ sample) on a I% agarose gel. Samples were loaded in order of groups (A) 
Control, (B) 7-Day, to (C) 24-Hour, with eight samples/group. 1kb markers (M) were 
loaded on the left hand side of gel, and used to separate treatment groups, with main 
fragment lengths noted (hp). Ribosomal RNA (rRNA) is indicated. 
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Total RNA extraction yields were calculated and analysed to determine if group yields 
were affected by treatments. A One-way ANOVA was performed. As can be seen in Ta- 
ble 6.2.2-1 there was no significant effect of treatment on total RNA yields. 
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Table 6.2.2-1. The effect of clenbuterol on porcine LD total RNA extraction yield. 
Mean total RNA yields (pg RNA / 0.1 g tissue) ± SEMfor all treatment groups. Number 
of samples analysed (n) is indicated. P value for One-Way ANOVA analysis of data. 
Treatment Groups 
Total RNA µg / 0.1 g muscle 
A: Control C: 24-Hour Clenbuterol B: 7-Day Clenbuterol P 
(n=8) (n=8) (n=8) 
49.4 33.4 42.6 0.278 
±5.0 ±9.6 ±6.6 
6.2.3 Glycogen Assay 
A glycogen assay was performed on 30 LD samples (10 samples per group) to assess 
whether clenbuterol treatment affected muscle glycogen metabolism (many thanks to Ms 
G. Carter). As described in detail in Section 2.3.4, it would be expected that clenbuterol 
and beta-agonist treatment would mobilise and therefore deplete muscle glycogen stores. 
Glycogen levels were calculated as mg per g tissue. As can be seen from Table 6.2.3-1. 
there was a highly significant effect of treatment on muscle glycogen levels (P < 0.001), 
which indicates that clenbuterol treatment had depleted muscle glycogen stores. These 
results give a direct indication that the dose of clenbuterol administered had caused an 
effect in the animals. It is interesting to note that the effect on the animals treated for 24 
hours was more marked than that for those treated for 7 days. 
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Table 6.2.3-1. The effect of clenbuterol on porcine LD glycogen stores. Mean Glyco- 
gen (mg /g tissue) ± SEM for all treatment groups. Number of samples analysed (n) is 
indicated. P value from One- Way ANOVA analysis of data. 
Treatment Groups 
Glycogen mg /g 
P 
A: Control C: 24-Hour Clenbuterol B: 7-Day Clenbuterol 
(n=10) (n=10) (n=10) 
9.489 1.392 4.246 < 0.001 
±0.492 ±0.114 ±0.480 
6.2.4 Northern Blot Analysis 
Total RNA (25 µg) extracted from eight animals from each treatment group were loaded 
onto a denaturing agarose gel (those on gel in Figure 6.2.2-1), run by electrophoresis and 
blotted overnight onto a Hybond N membrane, described previously (see Section 3.14). 
The northern blot was subsequently probed with cDNAs for cathepsin-L, E2G1, long- 
calpain-3 and actin, in that order (cDNA probes are described in Chapter 5 and Appen- 
dix A). Probes were labelled with [a- 32P]dATP using the Strip-EZ procedure (see Sec- 
tion 3.15.1.1), hybridised using Rapid-Hyb buffer (see Section 3.15.3.1) and stripped 
from membrane using Strip-EZ (see Section 3.15.5.1). This combined procedure al- 
lowed blot integrity to be maintained during a number of probe-hybridisations, prevent- 
ing membrane damage and the resulting high background signals. 
Table 6.2.4-1 shows the probe-hybridisation conditions developed to optimise band sig- 
nals. 
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Table 6.2.4-1. Optimised probe hybridisation, northern blot washstep and signal 
detection conditions. Hybridisation temperature (Hyb. Temp), hybridisation time (Hyb. 
Time), final high stringency washstep conditions and time to develop signal (Dev. Time) 
are included. 
Probe Hyb. 
Temp. 
Hyb. 
Time 
High Stringency Wash step Dev. 
Time 
Cathepsin-L 58°C 2 hr 0.1 x SSC + 0.1% SDS for 30 3 day 
min/65°C 
E2GI 60°C 2 hr 0.5 x SSC + 0.1% SDS for 30 min 2 day 
/60°C 
Long-Calpain-3 65°C 2.25 hr 0.1 x SSC + 0.1% SDS, 20 min / 3 days 
65°C 
Actin 65°C 1 hr 0.1 x SSC + 0.1% SDS, 30 min / -18 hr 
65°C 
Detected band-signal sizes (kb) were determined to correctly identify band identities 
(see Section 5.3). Band signal intensities for each sample were analysed as described 
within Section 3.17. 
Cathespin-L, Tong-calpain-3 and actin probing produced single specific bands at correct 
sizes, i. e. 1.38,3.2 and 1.49 kb, respectively (see Figure 6.4.3-1). E2G1 produced four 
bands, 6.0,3.8,2.0 and 1.4 kb. The 1.4 kb band had previously been identified as the 
band of interest (as discussed in Section 5.3). 
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Figure 6.2.4-1. The effect of clenbuterol on the mRNA expression of proteolytic sys- 
tem components in porcine LD (1). Phosphoimages of northern blot (25 ug total RNA 
loaded onto gel/sample), probed as described previously using following probes: (A): 
Cathepsin-L, (B): E2GI, (C): long-Calpain-3 and (D): Actin. Control, 7 day and 24 
hour Clenbuterol treatments are indicated. 
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The gels were loaded with equal quantities of total RNA as determined by the method- 
ology described previously (Section 3.3.2). Assuming that total RNA loaded was the 
same across the gel, as can be seen in Table 6.2.4-2, clenbuterol treatment did not sig- 
nificantly affect actin mRNA expression. Band intensity values for actin were analysed 
across treatment groups to ensure treatment had not affected the mRNA expression of 
this internal standard (see Table 6.2.4-2). 
Therefore, detected band signal intensities for Cathepsin-L, E2G1 and Calpain-3 were 
normalised to Actin and treatment group mean ratio values and SEM calculated (Table 
6.2.4-3 and Figure 6.2.4-2). 
Table 6.2.4-2. The effect of clenbuterol on the mRNA expression of actin. Table to 
show comparison of group mean northern band intensity values in counts per mm2 
(CNT/mm2) for Actin +/- SEM. Number of samples analysed (n) is indicated. P value 
from One- Way ANOVA. 
Treatment groups 
Actin Band intensity CNT/mm2 
/ 25 µg total RNA P 
Control Group 24-hour Group 7-Day Group 
(n=8) (n=8) (n=8) 
194045.2 178695.1 168461.9 0.701 
±21124.7 ±12009.9 ±27992.9 
A One-way ANOVA of E2G1 and Calpain-3 ratio values showed no significant change 
with clenbuterol treatment, whereas Cathepsin-L showed a highly significant (P < 
0.001) result (see Table 6.2.4-3). 
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Table 6.2.4-3. The effect of clenbuterol on the mRNA expression of proteolytic sys- 
tem components in porcine LD. Table to show comparison of treatment group mean 
Northern blot band intensity ratio values normalised to Actin, +/- SEM for northern 
blots probed with Cathepsin-L (Cath. L), E2GJ and long-Calpain-3 (Calp. 3) cDNA's. 
Number of samples analysed (n) is indicated. Note that some band signals were unde- 
tectable. P value from One- Way ANO VA test. 
Treatment groups 
Probe Band intensity ratio to actin p 
n Control Group n 24-hour Group n 7-Day Group 
Cath. 
-L 8 0.000549 8 0.002408 5 0.000819 < 0.001 
±0.00012 ±0.00033 ±0.00017 
E2G1 8 0.002882 8 0.004533 6 0.003727 0.260 
±0.00046 ±0.00052 ±0.00122 
Calp. 3 8 0.031517 8 0.037879 8 0.041745 0.644 
±0.00516 ±0.00762 ±0.00967 
Bonferroni Post-Hoc test after One-way ANOVA for Calpain-3 and E2G1 showed there 
was no significant difference between group interactions. However, the minimal in- 
crease in Calpain-3 was 32% after 1 week of treatment, relative to controls (see Figure 
6.2.4-2 (C)). E2G I increased by 57% relative to controls after 24 hour of treatment, al- 
though not significant (P = 0.316) (see Figure 6.2.4-2 (B)). Cathepsin-L analysis indi- 
cated that the 24 hour treatment group was significantly greater than Control group (P < 
0.001), a 339% increase relative to controls (see Figure 6.2.4-2 (A)). The 7-Day group 
was numerically greater than the control group (49% increase, relative to controls), al- 
though not significant. The 24 hour group was found to be also significantly greater than 
7-Day group (P < 0.01), with a 194% increase. 
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Figure 6.2.4-2. The effect of clenbuterol treatment on mRNA expression of prote- 
olytic system components in porcine LD (2). Mean relative northern band intensity 
ratio values normalised to actin. + SEM are presented, for (A) Cathepsin-L, (B) E2G1 
and (C) Calpain-3. a =p <0.00/, b=b<0.01. 
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6.2.5 Summary 
A trial was performed in which chronic and acute doses of the specific ß2-adrenergic 
agonist clenbuterol was administered to pigs. 
LD total RNA extraction yield analysis for group samples showed that there was no sig- 
nificant effect of clenbuterol treatment on extractable total RNA yields (P = 0.278). 
Glycogen assay analysis of trial samples (10 samples per treatment group) revealed that 
treatment had a highly significant effect on glycogen levels (P < 0.001). 24-hour clen- 
buterol treatment decreased average glycogen levels (mg per g tissue) by 85%, relative 
to Controls. The 7-Day group glycogen levels rose back up, compared to 24-hour treat- 
ment group, with a 55% decrease relative to Controls. 
Northern blot probe-hybridisation studies revealed no significant difference between 
treatments for E2G 1 and muscle-specific calpain-3 expression, although both increased 
numerically. E2G1 had increased by 57% relative to Controls after 24 hour of treatment 
and calpain-3 increased by 32% relative to Controls after 1 week of treatment. Cathep- 
sin-L after 24 hour clenbuterol treatment increased by 339% relative to Controls. This 
value was highly significant (P < 0.001). Cathepsin-L was numerically greater in the 7- 
day group relative to Control group with a 49% increase. This was found not to be sig- 
nificant. The 24-hour treatment was also significantly greater (P < 0.01) to the 7-day 
treatment (a 194% increase). Therefore, cathepsin-L mRNA expression was observed to 
increase rapidly to a highly significant value, then decrease after 7-day of treatment. 
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6.3 THE EFFECT OF ACUTE BETA-ADRENERGIC AGONIST ADMINI- 
STRATION IN PIGS 
6.3.1 Introduction 
There is great interest as to at what time point after administration of a beta- 
adrenergic agonist does mRNA expression change for various proteases. This would 
help to indicate whether transcriptional activating pathways are having significant 
effects in certain time frames after stimulation. As was observed in the previously 
described study in Section 6.2, there was a highly significant change in cathepsin-L 
mRNA after 24-hour 5 ppm clenbuterol treatment. Calpain-3 and E2G1 showed no 
significant change with treatment. However the numerical change was: E2G1 in- 
creased by 57% for the 24-hour group and calpain-3 by 32% after 7-day treatment. 
Therefore, it was of interest to see whether an acute, 16-hour large dose (20 ppm) of 
clenbuterol would alter mRNA expression of cathepsin-L and calpain-3, as it is 
known that at this dose level there is a significant effect on the expression of ubiqui- 
tous calpains and calpastatin. 
6.3.2 Trial Details 
Trial was carried out by Dr Paul Sensky and is described in Parr et al 2001. Briefly 
the details of the trial were: 
Twelve Large White x Landrace gilts comprising six pairs of full siblings were indi- 
vidually penned 4 weeks prior to treatment and fed a standard finisher diet (similar to 
that described within Appendix I, : 52.3% wheat, 20.1% barley, 23.7% soya, 1.3% 
Betamix, 1.3% limestone, 1.1% phosphate, 0.2% salt, plus 575 mg/kg synthetic ly- 
sine) up to the day before slaughter. The pigs were trained to eat their diet within a1 
hr period by offering them 2 kg feed and withdrawing it 1 hr later as the diet would 
contain the oral dose of clenbuterol. All pigs were trained within 3 days. On the eve- 
ning prior to slaughter (16 hrs pre-slaughter) six pigs received the standard diet as 
normal (control group), while their respective siblings received the same diet sup- 
plemented with 20 ppm clenbuterol (Sigma-Aldrich). With the exception of one ani- 
mal in the clenbuterol group, all animals ate their diet within 1 h, and the animal that 
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did not eat its diet was excluded from further analysis. Sixteen hours after treatment 
the animals were slaughtered by electrical stunning and severance of the carotid ar- 
teries. Samples of LD muscle were removed from the carcass within 5 min of slaugh- 
ter and snap frozen in liquid nitrogen then stored at 
- 
70°C. 
6.3.3 Total RNA Extraction and Analysis 
Total RNA was extracted from trial LD muscle samples for six control animals and 
five clenbuterol-treated animals by Dr T. Parr, using the methodology as described in 
Section 3.3. Total RNA extraction yields were calculated for all samples as µg total 
RNA per g tissue (see Table 6.3.3-1). As can be seen in Table 6.3.3-1 there was no 
significant effect of treatment on yields of total RNA. 
Table 6.3.3. 
-1. Effect of clenbuterol on quantity of total RNA extracted in por- 
cine LD. Mean total RNA extraction yields (, ug RNA /g tissue) f SEM for both 
groups. Number of samples analysed (n) is indicated. P value from t-test analysis of 
data. 
Treatment Groups 
Total RNA (µg /g muscle) P 
Control Clenbuterol 
(n=6) (n=5) 
1124 1021.6 0.58 
±147.4 ±84.3 
6.3.4 Northern Blot Analysis 
A northern blot was run using method described previously (see Section 3.14), with 
20 µg total RNA loaded for each sample. The blot had been previously been probed 
twice. 
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The northern blot was probed with Cathepsin-L and long-Calpain-3 cDNA probes, in 
that order. As blot had been previously probed using different cDNA probes other 
than Cathepsin-L and long-Calpain-3, blot integrity and RNA quality was compro- 
mised. This was apparent as band signals were more difficult to detect and quantify 
(see Figure 6.3.4-1). Therefore due to its low expression, analysis of E2G I was not 
possible. Probes were labelled with [a- 32P]dATP using the Strip-EZ procedure (see 
Section 3.15.1.1), hybridised using Rapid-Hyb buffer (see Section 3.15.3.1) and 
stripped using Strip-EZ kit (see Section 3.15.5.1). This allowed reprobing of the 
membrane with less membrane damage. 
Band signals were optimised for all probe-hybridisations using the following condi- 
tions discussed in Table 6.3.4-1: 
Table 6.3.4-1. Optimised probe hybridisation, northern blot washstep and signal 
detection conditions. Hybridisation temperature (Hyb. Temp), hybridisation time 
(Hyb. Time), final high stringency washstep conditions and time to develop signal 
(Dev. Time) are included 
Probe Hyb. Hyb. High Stringency Wash step Dev. 
Temp. Time Time 
Cathepsin-L 60°C 2.5 hr 0.1X SSC + 0.1% SDS for 30 2 days 
min / 60°C 
Long-Calpain-3 65°C 2.25 hr 0.1X SSC + 0.1% SDS for 30 2 day 
min / 60°C 
Detected band-signal sizes (kb) were determined to correctly identify band identities 
(see Section 5.3). Band intensity analysis was performed as described in Section 
3.17. 
Cathespin-L and long-Calpain-3 probing produced single specific bands at correct 
sizes, i. e. 1.38 and 3.2 respectively (see Figure 6.3.4-1) Cathepsin-L produced a less 
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clear and sharp signal than Calpain-3 despite attempts at optimising signal (see Table 
6.3.4-1). Actin expression data had been determined from probing the membrane 
with a specific actin probe previously. Although phosphoimage is not shown, band 
intensity absorption data is included in Table 6.3.4-2. 
Figure 6.3.4-1. The effect of an acute clenbuterol dose on the mRNA expression 
of proteolytic enzymes in porcine LD. Phosphoimages of 'northern blot (20µg total 
RNA loaded on to gel/sample) probed as described above using. following probes: 
(A): Cathepsin-L, and (B): long-Calpain-3. Cont. = Control, Clen. = Clenbuterol. 
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Band intensity values for actin were analysed across treatment groups to ensure 
treatment had not affected the mRNA expression of this internal standard (see Table 
6.3.4-1). As can be seen in Table 6.3.4-2, clenbuterol treatment did not significantly 
affect actin mRNA expression, based on the assumption that equal quantities of total 
RNA were loaded on the blot. 
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Table 6.3.4-2. The effect of clenbuterol on the mRNA expression of actin. North- 
ern blot band intensity values (absorption units) ± SEM values. Number of samples 
analysed (n) is indicated. P value from t-test. 
Treatment groups 
Actin Band intensity (absorption units) / 20µg total RNA P 
Control Group Clenbuterol Group 
(n=6) (n=5) 
46.167 42.109 0.558 
±2.696 ±6.604 
Band signal intensities for cathepsin-L and calpain-3 were normalised to actin. 
Group means and SEM values were calculated (see Table 6.3.4-3 and Figure 6.3.4- 
2). T-test analysis of data was performed showing no significant change due to 
treatment for the expression of both cathepsin-L and calpain-3 mRNA (see Table 
6.3.4-3). Examination of the numerical values showed that the Cathepsin-L group 
mean ratio value increased by 53% after treatment, relative to actin. Calpain-3 de- 
creased by 9% with treatment. 
Table 6.3.4-3. The effect of an acute clenbuterol dose on the mRNA expression 
of proteolytic enzymes in porcine LD. Table to show comparison of group mean 
northern band intensity ratio values, normalised to Actin +/- SEM, using Cathepsin-L 
(Cath. L), and long-Calpain-3 (Calp. 3) probes. Number of samples analysed (n) is 
indicated. P value from t-test. 
Treatment groups 
Probe Band Intensit Ratio Values P 
n Control Group n Clenbuterol Group 
Cath. L 6 76.203 5 116.379 0.279 
±21.862 ±27.807 
Calp. 3 6 13.208 5 11.978 0.427 
±0.904 ±1.205 
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Fig 6.3.4-2. The effect of an acute clenbuterol dose on relative expression of pro- 
teolytic enzymes in porcine LD. Group mean relative northern blot band intensity 
ratio values normalised to actin + SEM are presented, for (A) Cathepsin-L and (B) 
Calpain-3. 
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6.3.5 Summary 
The trial involved administering an acute high dose (20 ppm) of clenbuterol to pigs 
for 16 hr, before slaughter. 
Analysis of LD total RNA extraction yields found that there was no significant effect 
of treatment on group total RNA yields. 
Northern blot probing using Cathepsin-L and long-Calpain-3 produced detectable 
band signals of the correct sizes, i. e. 1.38 and 3.2 kb. Detected band intensities were 
normalised to Actin generating normalised ratio values. Analysis of treatment group 
normalised band intensity ratio values showed there was no significant change in 
cathepsin-L and calpain-3 relative expression with clenbuterol treatment. However, 
cathepsin-L increased by 53% relative to Controls with treatment, which is in the 
same direction as observed previously in the trial described in Section 6.2. Calpain-3 
decreased by 9% relative to Controls with treatment, which is unlike the numerical 
change observed in trial in Section 6.2. However, this increase is small and probably 
reflects that there was no significant difference in calpain-3 expression between 
treatments. 
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6.4 THE EFFECTS OF CHRONIC ADMINISTRATION OF ADRENALINE 
ON PROTEASE mRNA EXPRESSION IN PIGS 
6.4.1 Introduction 
The trials discussed in Section 6.2. and 6.3 involved acute and chronic administration 
of the specific ß2-adrenergic agonist clenbuterol. Another study performed within the 
Division of Nutritional Sciences involved chronic adrenaline administration in pigs. 
It was an important study so as to analyse the effects of chronic administration of an 
endogenous ß-adrenergic agonist on the mRNA expression of specific proteases in 
skeletal muscle. 
It has been documented that the endogenous catecholamines adrenaline and nora- 
drenaline are known to have positive effects on skeletal muscle protein turnover, 
possibly increasing protein synthesis and decreasing protein degradation (Navegantes 
et al, 2002) (discussed in Section 2.3.4). Adrenaline is a non-specific Q-adrenergic 
agonist, known to have binding affinities for the ßl, ß2 and ß3 receptor subtypes. 
Therefore, the effects of adrenaline may be different compared to a selective ß2- 
adrenergic agonist, such as clenbuterol. Another point of the study is to assess the 
effects of chronic administration as this is an `unnatural' pattern of endogenous 
adrenaline release and stimulation of ß-adrenergic receptors . 
6.4.2 Trial Details 
Samples were obtained from a trial carried out previously (Sensky et al, 1996, Parr et 
al, 2000). Brief details are discussed below: 
Twenty female Landrace x Large White pigs consisting of ten pairs of full siblings 
were used in the trial in which an individual of each pair was intravenously infused 
with adrenaline (treated group) at a continuous rate of 0.15 ug/kg/min while the sib- 
ling received placebo (control group) at the same rate, using an osmotic minipump 
inserted into the cephalic vein. After the 7-day infusion period the pigs were slaugh- 
tered by electrical stunning and severance of the carotid arteries. Samples of LD 
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muscle were removed from the carcass within 5 min of slaughter and snap frozen in 
liquid nitrogen for subsequent storage at 
-70°C. Unfortunately, only six out of the 
ten adrenaline treated animals survived. Therefore, six adrenaline treated and ten pla- 
cebo animals were used in subsequent analysis. 
6.4.3 Total RNA Extraction and Analysis 
LD samples were subject to total RNA extraction procedures, using the methodology 
as described previously (Section 3.3.1), by Dr Mike Arnold. Total RNA was checked 
for integrity and quality by spectrophotometer analysis (see Section 3.3.2) and gel 
electrophoresis (see Section 3.6). Figure 6.4.3-1 shows total RNA ribsomal bands 
have similar intensities indicating that the determined RNA concentration was cor- 
rect and equal quantities of total RNA were loaded on the gel. Figure 6.4.3-1 also 
indicated that 18S and 28S rRNA were intact with little degradation, ideal for further 
northern blot analysis. 
Figure 6.4.3-1. The effects of adrenaline on quality and integrity of porcine LD 
total RNA. Non-denaturing gel electrophoresis of skeletal muscle (LD) total RNA 
(l pg loaded/ sample) on a I% agarose gel. Samples are loaded in P= Placebo and 
A= Adrenaline treatment pairing. l kb markers (M) are loaded with selected frag- 
ment lengths noted (bp). Ribosomal RNA (rRNA) is indicated. 
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Total RNA extraction yields were calculated for six sibling pair samples as µg RNA 
per g tissue (see Table 6.4.3-1). A t-test analysis of data was performed to assess 
whether treatment significantly affected extractable total RNA yields (see Table 
6.4.3-1). As can be seen in Table 6.4.3-1 there was no significant effect of treatment 
on yields, although the values for the adrenaline treated samples were numerically 
higher. 
Table 6.4.3-1. Effect of adrenaline treatment on quantity of total RNA extracted 
from porcine LD. Mean total RNA extraction yields (pg RNA /g tissue) f SEMfor 
both groups. P value fr om t-test analysis of data. 
Treatment Groups 
Total RNA (µg /g muscle) P 
Placebo Adrenaline 
(n=6) (n=6) 
795.3 1058.7 0.204 
±147.8 ±125.0 
6.4.4 Northern Blot Analysis 
Total RNA (15 µg) from all samples from each treatment group was loaded onto a 
denaturing agarose gel, following Placebo-Adrenaline sample pairing loading pattern 
(as used in gel in Figure 6.4.3-1). Samples were run by denaturing gel electrophore- 
sis and gel blotted overnight onto a Hybond N membrane using northern blotting 
procedures described previously (see Section 3.14). 
The northern blot was subsequently probed with Cathepsin-L, long-Calpain-3 and 
Actin cDNA probes, in that order. E2G1 did not produce a clear quantifiable signal 
as was probed last in experimental order. Probes were labelled with [a- 32P]dATP 
using the Strip-EZ procedure (see Section 3.15.1.1), hybridised using Rapid-Hyb 
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buffer (see Section 3.15.3.1) and stripped using Strip-EZ (see Section 3.15.5.1). This 
helped maintain membrane integrity and allow re-probing. 
Band signals were optimised for all probe-hybridisations using the conditions de- 
scribed in Table 6.4.4-1. 
Table 6.4.4-1. Optimised hybridisation conditions. Hybridisation temperature 
(Hyb. Temp. ), hybridisation time (Hyb. Time), final high stringency washstep condi- 
tions and time to develop signal (Dev. Time) are included 
Probe Hyb. 
Temp. 
Hyb. 
Time 
High Stringency Wash step Dev. 
Time 
Cathepsin-L 58°C 2.5 hr 2X SSC + 0.1% SDS for 30 min / 4 days 
60°C 
Long-Calpain-3 65°C 2 hr 0.1X SSC + 0.1% SDS for 20 min -18 hr 
/ 65°C 
Actin 65°C 1.25 0.1X SSC + 0.1% SDS for 30 min -18 hr 
hr / 65°C 
Detected band-signal sizes (kb) were determined to correctly identify band identities 
(see Section 5.3). Band intensity analysis was performed as described in Section 
3.17. 
Cathepsin-L, long-Calpain-3 and Actin probing produced single specific bands at 
correct sizes, i. e. 1.38,3.2 and 1.49 kb, respectively (see Figure 6.4.4-1). Cathepsin- 
L produced a less clear and sharp signal than Calpain-3 and Actin despite numerous 
attempts at optimising signal. 
Band intensity values for actin were analysed across treatment groups to ensure 
treatment had not affected the mRNA expression of this internal standard (see Table 
6.4.4-2). As can be seen in Table 6.4.4-2 adrenaline administration did not signifi- 
cantly affect actin mRNA expression. 
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Figure 6.4.4-1. The effects of chronic adrenaline administration on the mRNA 
expression of proteolytic enzymes in porcine LD. Phosphoimages of northern blot 
(IS pg total RNA loaded onto gel/sample), probed as described previously, using. fol- 
lowing probes: (A): Cathepsin-L, (B): long-Calpain-3 and (C): Actin. Cont. = Con- 
trol, Adren. = Adrenaline. 
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Table 6.4.4-2. The effect of adrenaline administration on the mRNA expression 
of actin. Northern blot band intensity values (CNT/mm2) ± SEM values. Number of 
samples analysed (n) is indicated. P value from t-test. 
Treatment groups 
Actin Band Intensity (CNT/mm') P 
Control/Placebo Group Adrenaline Group 
(n=10) (n=6) 
1241.839 1505.377 0.297 
± 158.526 ± 168.480 
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Band signal intensities for Cathepsin-L and Calpain-3 were normalised to Actin. 
Group means and SEM were calculated (see Table 6.4.4-3 and Figure 6.4.4-2). The 
numerical change was that Cathepsin-L decreased by 23.9%. Calpain-3 increased by 
39.9%. However, T-test analysis of data showed no significant change in values with 
treatment for either Cathepsin-L or Calpain-3 mRNA expression (see Table 6.4.4-3). 
Table 6.4.4-3 Effects of chronic adrenaline administration on mRNA expression 
of proteolytic enzymes in porcine LD. Table to show comparison of group mean 
northern band intensity ratio values normalised to Actin +/_ SEM, for Cathepsin-L 
(Cath. L) and Calpain-3 (Calp. 3). Number of samples analysed (n) is indicated P 
value from t-test. 
Probe n Placebo Group n Adrenaline Group P 
Cath-L 9 0.380 6 0.289 0.258 
±0.051 ±0.053 
Calp-3 9 1.028 5 1.438 0.159 
±0.173 ±0.205 
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Figure 6.4.4-2. The effects of chronic adrenaline administration on relative 
mRNA expression of proteolytic enzymes in porcine LD. Mean, relative northern 
band intensity ratio values normalised to Actin, + SEM are presented for (A) Ca- 
thepsin-L and (B) Calpain-3. 
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6.4.5 Summary 
The trial described above was performed where the endogenous ß-adrenergic agonist 
adrenaline was infused at a continuous rate for seven days in pigs. Four out of the 
ten adrenaline-treated pigs died or were unable to be used further in the trial. 
LD total RNA extraction yields were calculated for both placebo and adrenaline 
groups. T-test analysis of data showed no significant effect of treatment on extract- 
able yields, although adrenaline treated animals had a numerically higher value. 
RNA samples were analysed by northern blot probe-hybridisation. Cathepsin-L, 
long-Calpain-3 and Actin produced detectable band signals of the correct sizes, i. e. 
1.38,3.2 and 1.49 kb, respectively. Actin band intensities were not found to signifi- 
cantly alter with treatment. Band signal intensities for Cathepsin-L and Calpain-3 
were analysed and normalised to Actin, generating ratio values. T-test showed there 
was no significant change in mRNA expression with adrenaline treatment for both 
Cathepsin-L and Calpain-3. Numercially Cathepsin-L decreased by 24% and Cal- 
pain-3 increased by 40%. 
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CHAPTER 7 DISCUSSION 
7.1 BOVINE PLANE OF NUTRITION TRIAL 
7.1.1 Introduction 
This study investigated the effects of different planes of nutrition and refeeding after 
a feed restriction, on the mRNA expression of components of the calpain system 
within skeletal muscle of calves. During periods of rapid muscle tissue growth, 
which takes place in young fast growing calves, there is a relatively high level of hy- 
pertrophy and remodelling taking place within myofibers (Lee, 2001, Kristensen et 
al, 2002, Sazili, 2003, Kristensen et al, 2004) These processes and general muscle 
protein turnover are thought to be sensitive to the plane of nutrition (see Section 
2.3.5). Well fed young animals are thought to exhibit higher rates of protein turnover, 
protein accretion and growth (Kristensen et al, 2002, Kristensen et al, 2004). It has 
been suggested that during feed restriction there is a decrease in both growth rate and 
protein turnover rates. If the restriction becomes extended and severe to the extent 
that the animals are in negative nutritional balance, muscle atrophy will eventually 
manifest due to a rise in net proteolysis. 
It has been previously shown that during re-alimentation after a feed restriction there 
is a greater than normal rise in growth rates and protein turnover, leading to so called 
`compensatory growth' (Kristensen et al, 2002, Kristensen et al, 2004). The level of 
compensatory growth and associated change in protein turnover rate depends on the 
length and intensity/severity of the previous feed restriction, the length of the refeed- 
ing period and whether it is an unrestricted feed intake period or not. 
It has been proposed that the calpain protease system and endogenous inhibitor cal- 
pastatin plays a role in the processes of myofibrillar protein degradation and thereby 
the processes of myofiber hypertrophy/atrophy, remodelling and transformation 
(Goll et al, 1998, Thompson and Palmer, 1998, Goll et al, 2003). Only a small num- 
ber of studies have been performed measuring calpain system changes at mRNA and 
protein level in response to altered planes of nutrition in farm animals. Mc Donagh et 
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al, 1999, reported a significant decrease in calpastatin activity (P < 0.01) in M bi- 
ceps femoris of lambs during a restricted feed intake (low plane of nutrition-60% 
maintenance feed intake, 7 days prior to slaughter), after an initial two weeks fed at 
twice maintenance (200%), with no effect on u- and m- calpains. Du et al, 2004b, 
observed a significantly greater calpastatin content/immunoreactivity (P < 0.05) in 
Longissmus muscle from control group cows compared to nutrient-restricted cows, 
with no change in the activities of y- and m- calpains. 
In comparison to Mc Donagh et al, 1999, Kristensen et al, 2002 found that there was 
a positive correlation between growth rates and m-calpain activities in pigs fed dif- 
ferent planes of nutrition. Calpastatin activity was also found to be unchanged with 
dietary treatments. In re-fed pigs (after a 60% of ad libitum feed restriction) in- 
creased growth rate (compensatory growth) was followed by an increase in the p- 
calpain-calpastatin ratio. In a later study by Kristensen et al, 2004, it was found that 
there was no significant effect of plane of nutrition in pigs, on the activities of Y- 
calpain, m-calpain or calpastatin at slaughter. However, growth rates did correlate 
with increased m-calpain, cathepsins B and B+L activities. Therefore, in summary, a 
minimal number of studies have been performed with contradictory results, with re- 
gards to the effects of plane of nutrition on the calpain-calpastatin system. 
It is important to emphasise that many of the studies, including the bovine plane of 
nutrition discussed here, focus upon calpastatin mRNA, protein and activity meas- 
urements, as in vivo the calpain: calpastatin activity ratio is thought to be of greatest 
importance. This ratio gives an indication of the overall `proteolytic potential'. 
Within the present study 24 calves were initially fed a high plane of nutrition (2.5 x 
the ME for maintenance) and placed into different feeding treatment groups (see Sec- 
tion 4.1). 8 calves were placed on a low plane of nutrition (LOW group) and feed- 
restricted to 90% ME for maintenance, with the aim of inducing growth arrest, but 
not muscle atrophy. A group of 8 calves were re-alimented back up to a high plane of 
nutrition (REFED group) after a 90% ME feed restriction, with the aim of re- 
establishing growth and inducing compensatory growth. A third group of 8 calves 
were fed a high plane of nutrition (HIGH group) throughout the entire trial to en- 
courage rapid growth. Four animals from each group were slaughtered 2 days after 
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the REFED group began re-alimentation and the remaining animals 13 days later. 
Animal growth rates were initially 1.02±0.04 kg/day on the high plane of nutrition 
before dietary treatments began (Lee, 2001). In the LOW plane and REFED groups 
growth was successfully stopped by restricted feeding (growth rates: 
-0.01 ±0.02 
kg/d and 
-0.04±0.03 kg/day, respectively). Re-alimentation in the REFED group 
over 15 days significantly increased growth rates (P < 0.001) to 1.14±0.19 kg/day, 
which did not differ from that of the HIGH group. This suggested that as although 
growth was successfully re-initiated, compensatory growth was not induced. The 
HIGH group animals were significantly heavier (P < 0.05) at slaughter than the other 
two groups. 
Quantitative mRNA expression of calpain-3, calpastatin, and 18S was analysed from 
bovine Longissmus Dorsi (LD) samples by Quantitative Real-Time RT-PCR, using 
Taqman Probe and SYBR-Green methods. The ubiquitous 4u- and m- calpains were 
unable to be measured due to non-specific template amplification problems, de- 
scribed in Section 4.3. 
7.1.2 The Effect of Plane of Nutrition on Extractable Total RNA Yield from Bo- 
vine Longissmus Dorsi Samples 
In the present study the amount of total RNA extracted per g of bovine LD was 
found to significantly increase (P < 0.05) across all treatment groups from the 1St o 
2°a slaughter dates (13 days later) (see Table 4.2-1). As samples were randomly se- 
lected during the total RNA extraction procedure, this is unlikely to represent an arti- 
fact of sample selection. This increase in total RNA is coincident with the period 
where these young farm animals would be expected to undergo changes in muscle 
growth and remodelling (which was observed in this study) (G. Lee, 2001). There- 
fore, although total protein levels may not alter to an extent that can be accurately 
measured at a significant level in a short time period (13 days-associated with this 
trial), it would be expected that total mRNA is likely to increase to prepare the myo- 
fibers for further adaptations. There was no significant effect of dietary treatment on 
total RNA, although the REFED group yield was greater numerically than both the 
HIGH and LOW groups at both slaughter dates. This suggests that there may be a 
minor effect of refeeding and re-initiation/compensatory growth on total RNA levels. 
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7.1.3 The Effect of Plane of Nutrition on Relative Expression of Calpain-3 
Muscle-specific calpain-3 was an important component to analyse as no previous 
studies have investigated the effect of altered planes of nutrition and growth rates on 
calpain-3 gene expression. The precise function of calpain-3 within skeletal muscle 
is unknown and debatable. Calpain-3 may play a role in transcription factor, myofi- 
brillar structure and metabolic regulation (Baghdiguian et al, 2001, Walder et al, 
2002, Goll et al, 2003, Kramerova et al, 2004). Therefore calpain-3 is thought to act 
as a protease with specific regulatory functions and not participate in gross, non- 
specific proteolysis. Calpain-3 gene expression has been reported to decrease in 
skeletal muscle during atrophic states including hindlimb unloading in rats (Steven- 
son et al, 2003), denervation in mice (Stockholm et al, 2002), cachexia in rats 
(Busquets et al, 2000) and in IL-6 transgenic mice (Tsujinaka et al, 1996). A defi- 
ciency in calpain 3 leads to LGMD type 2A and myoapoptosis in humans (Ono et al, 
1999, Baghdiguian et al, 1999, Richard et al, 2000, Tidball et al, 2000, Chae et al, 
2001) (as discussed in detail in Section 2.8.4). In all of the states described above 
there is an associated characteristic protein-catabolic response, leading to an atrophic 
condition, that may involve the formation of apopotic nuclei. 
Within this study it was found that there was no statistically significant effect overall 
of plane of nutrition on calpain-3 mRNA expression (P = 0.127) in LD samples (see 
Table 4.3.3-1). The LOW plane group in 1St slaughter had lower levels of calpain-3 
mRNA compared to both HIGH plane and REFED groups (30% lower relative to 
HIGH and 29% lower relative to REFED). The LSD value indicated that this was 
potentially significant at a 5% level. The REFED group had higher calpain-3 values 
than the LOW plane group (23% higher) at the 2nd slaughter date. 
Considering the low numbers of animals per group used in this trial these trends in 
mRNA expression suggest that calpain-3 mRNA may decrease during restricted 
feeding. A significant reduction in calpain-3 mRNA has been observed after a2 day 
fast in mice (Jagoe et al, 2002), although fasting is obviously a far more severe level 
of nutrient restriction. The potential effects of restricted feeding on lowering calpain- 
3 gene expression fits in with the observations and hypothesis that calpain-3 mRNA 
is reduced during catabolic-atrophic states (Tsujinaka et al, 1996, Busquets et al, 
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2000, Baghdiguian et al, 2001, Stevenson et al, 2003). However as will be later dis- 
cussed, the level of feed restriction was believed not to be severe enough to initiate 
significant muscle proteolysis and atrophy. This was assumed based on the effects of 
the feed restriction on growth rates and low level of lean tissue loss. It is probable 
that if the dietary restriction was more severe leading to muscle atrophy, a greater 
decrease in calpain-3 gene expression may be observed. The results in this thesis also 
indicate that calpain-3 mRNA may also be sensitive to the effects of refeeding as 
mRNA values for the REFED group in 1st slaughter were up to the HIGH plane 
group value range within the 2 day refeeding period. 
There was a trend towards significance for the effect of slaughter date on calpain-3 
mRNA expression (P = 0.073) (see Table 4.3.3-1). There was an increase in calpain- 
3 mRNA in both the LOW (46% increase) and REFED (27% increase) groups from 
the 1 S` to 2"d slaughter dates. The LSD value indicated that this was potentially sig- 
nificant at a 5% level. The HIGH plane group effectively remained unchanged. As 
these mRNA expression values were corrected to 18S and do not merely reflect a 
change in total RNA levels, as reported in Section 7.1.2. 
Assuming changes in calpain-3 mRNA results in an increase in the levels of their 
respective protein the trend in increase in calpain-3 mRNA expression for the LOW 
and REFED groups (but not HIGH) between slaughter time points, may suggest pos- 
sible compensatory mechanisms taking place within the myofiber to either avoid at- 
rophy (in LOW plane group) and/or initiate `catch-up' growth (in REFED group). 
This is obviously assuming that calpain-3 has a role in the regulation of hypertro- 
phy/atrophy, metabolic and regulatory pathways, as has been suggested by research- 
ers; acting as a highly specific protease not participating in basal proteolysis. 
This model for calpain-3 action is supported to some degree by the following obser- 
vations: p94 protein is localised to titin along the N2 line and Z-disk, and has been 
been suggested to possibly play a role in the regulation of myofibrillar turnover (Ono 
et al, 1999, Goll et al, 2003) (see Section 2.8.2). In calpain-3 deficient (knockout) 
mice, abnormal sarcomere formation has been reported, suggesting a role of calpain- 
3 in myofibrillogenesis and sarcomere remodelling (Kramerova et al, 2004). Cal- 
pain-3 mRNA is expressed at levels -10 times greater than p- and m- calpains, but 
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p94 protein is rapidly autolysed when dis-associated from titin suggesting it may 
have an important cellular function (Ono et al, 1999, Goll et al, 2003). An absence in 
p94 leads to a dystrophic condition in the regions of the psoas, soleus and deltoid 
muscles (LGMD2A), associated with weakness, atrophy and apoptosis. This evi- 
dence alone suggests that the muscle-specific calpain-3 protease has important regu- 
latory roles and doesn't act as a `traditionally-viewed' protease involved in basal pro- 
tein turnover. Why a deficiency in a protease would lead to a dystrophic state was 
contrary to previous views on the actions of proteases, and contrary to the Duchenne 
dystrophic state characterised by raised p- and m- calpain activities. Another perplex- 
ing question is why only the muscles of the proximal limbs are affected, when all 
skeletal muscles are affected in other dystrophic states (e. g. Duchenne). The 
LGMD2A dystrophic state has found to correlate with a disturbance in the normal 
functioning of the IwBa/NF-uB pathway within affected skeletal muscle (Bagh- 
diguian et al, 1999, Tidball et al, 2000, Richard et al, 2000, Baghdiguian et al, 2001). 
As calpain-3 has a potential nuclear translocation signal region in its sequence, it has 
been suggested to potentially alter transcription factor pathways (Ono et al, 1999, 
Goll et al, 2003). It has been proposed that calpain-3 may potentially cleave the IicBa 
inhibitor allowing free NF-xB to increase transcription of a number of cell survival 
proteins, including anti-apoptotic proteins (Tidball and Spencer, 2000 and Bagh- 
diguian et al, 2001). Interestingly, a recent study by Combaret et al, 2003 showed 
that in calpain-3 deficient mice although protein turnover rates, ubiquitination and 
cathepsins B and B+L activities were not significantly different from controls, ca- 
thepsin-L, the 14-kDa ubiquitin-conjugating enzyme and the C2 subunit of the 20S 
proteasome significantly decreased in mRNA levels by -47% (P < 0.005) in gas- 
trocnemius muscle. This may suggest calpain-3 plays a role in the regulation of tran- 
scription of proteases. In addition, studies also suggest that a reduction in calpain-3 
may also be involved in the response to contraction-mediated cell damage in skeletal 
muscle (Sultan et al, 2001, Fasson et a! 2002). In the eccentric contraction induced 
damage study in humans (Feasson et al 2002) mRNA expression of calpain-3 was 
rapidly reduced after exercise whilst there was simultaneously an increase in m- 
calpain mRNA, cathepsins-B+L and proteasome activity. This may suggest that cal- 
pain-3 plays a role in the remodelling response to training/contraction-induced dam- 
age. 
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Although speculative it would be interesting to suggest that calpain-3 may have some 
functional inter-relationships with the caspase system, considering the relationship 
and similarity between the ubiquitous calpain and caspase system, and their in- 
volvement in cell death and the NF-KB pathway (Krebs and Graves, 2001). 
Another important observation is that reduced calpain-3 mRNA has shown to be cor- 
related with insulin resistance in humans (Walder et al, 2002). It would be interesting 
to suggest that if calpain-3 does have a potential correlative relationship and role in 
glucose metabolism and/or insulin function/resistance as suggested by Walder et al, 
2002, calpain-3 has a bifunctional role related to metabolism and signalling rather 
than a gross proteolytic role. 
The increase in calpain-3 gene expression associated with refeeding is rapid and 
dramatic in that levels rise to similar levels to that of the HIGH plane group within 2 
days of refeeding. Taking the above obsevations and theories in to account this is a 
potentially important observation that may suggest that calpain-3 mRNA is sensitive 
to nutritional intake and may be involved in triggering the compensatory growth re- 
sponse associated with refeeding. 
Therefore in summary, a reduction or loss in calpain-3 mRNA as observed during the 
conditions described (including fasting) may potentially aid in inducing or be associ- 
ated with a loss in myofibrillar integrity and/or an increased susceptibility for atro- 
phy and apoptosis. The rapid rise in calpain-3 mRNA with refeeding may potentially 
suggest calpain-3 has a signalling role that may aid in the induction of the compensa- 
tory growth response. 
7.1.4 The Effect of Plane of Nutrition on Relative Expression of Calpastatin 
The mRNA expression of the endogenous calpain inhibitor calpastatin did not sig- 
nificantly alter with plane of nutrition (P = 0.874) in bovine LD samples (see Table 
4.3.3-2). However, the LOW plane group in the 1" slaughter had higher levels nu- 
merically compared to the HIGH plane (25% greater relative to HIGH group) and 
REFED group (33% higher relative to REFED group). 
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Kristensen et al, 2002 hypothesised that during a feed restriction calpain-dependent 
proteolysis is down-regulated and net protein turnover rates are reduced. A potential 
mechanism by which this may occur is through a rise in calpain-inhibitory calpas- 
tatin activity. Stevenson et al, 2003 investigated the effects of hindlimb unloading in 
rat Soleus muscle for 1,4,7 and 14 days, on the expression of numerous genes using 
Affymetrix Gene Chip technology. Interestingly, calpastatin was significantly 
upregulated, calpain-2 did not change and calpain-3 significantly downregulated, 
along with a calpain activator (diazepam-binding inhibitor). This may suggest that in 
some atrophic-catabolic states calpastatin is differentially regulated and may be up- 
regulated initially to avoid excessive calpain-dependent proteolysis. Considering the 
low numbers of animals per group used in this trial, although not a significant 
change, the numerical difference in the LOW group fits with the hypothesis that an 
increase in calpastatin during a feed restriction may act as a compensatory mecha- 
nism to protect the muscle from excessive calpain proteolysis, subsequent myofibril- 
lar degradation and myofiber atrophy. 
However, observations within our laboratories showed that immunoreactivity 135 
kDa calpastatin estimated at 0 hr post-slaughter was not significantly affected (P > 
0.05) by feeding level in LD muscle from calves in this present trial (Sazili, 2003, 
Sazili et al, 2003). Immunoreactivity of p- calpain, m- calpain was also unchanged. 
There was also an increase in calpastatin mRNA expression for all dietary treatment 
groups with a trend towards significance (P = 0.085) from the 1st to the 2nd slaughter 
dates (see Table 4.3.3-2). The REFED group increased over the 13 day period be- 
tween slaughter dates and the LSD value indicated that this was potentially signifi- 
cant at a 5% level. These mRNA expression values were corrected to 18S and don't 
merely reflect a change in total RNA levels, as reported in Section 7.1.2 
Interestingly, the numerical values for 135 kDa calpastatin immunoreactivity at 0 hr 
post-mortem increased numerically in all dietary treatment groups across slaughter 
dates (Sazili, 2003, Sazili et al, 2003). 
The potential trend of an increase in calpastatin gene expression in a short time pe- 
riod of 13 days (between slaughter dates) may be part of the cellular growth program 
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within skeletal muscle, i. e. as an animal goes through rapid growth an increase in 
calpastatin would act as one mechanism of many to initiate skeletal muscle growth. 
As described within Section 2.8.3, increased calpastatin activities have been reported 
in the pelvic limbs and back muscles of callipyge lambs, which have 30-40% more 
muscle mass (Goll et al 1998). Mice with overexpression of a calpastatin transgene 
were observed to have greater muscle mass (Otani et al, 2004). Overexpression has 
also been shown to reduce hindlimb unloading atrophy by 30% (Tidball and Spencer, 
2002) and reduce calpain activity, necrosis and dystrophic pathology in mdx dys- 
trophic mice (Spencer et al 2002). Q-adrenergic stimulation increases lean mass 
deposition (Goll et al, 1998, Grant et al, 1998) thought to be due in part to an in- 
duced reduction in calpain proteolysis, through increased calpastatin inhibitory activ- 
ity (Parr et al, 1992, Speck et al, 1993, Sensky et al, 1996, McDonagh et al, 1999, 
Navegantes et al, 2002). Therefore, these overall observations may suggest that for a 
significant change in calpastatin to be induced, there needs to be a more drastic or 
`unnatural' stimulatory effect on hypertrophy/atrophy signalling pathways within 
skeletal muscle. 
7.1.5 Summary of Plane of Nutrition Discussion 
In summary, there was a significant increase (P <0.05) in total RNA extraction yield 
per g of bovine LD across all dietary treatment groups over the 13 day period be- 
tween slaughter dates. This suggests that in young, fast-growing calves, the total cel- 
lular RNA pool increases in LD over a short time period, irrespective of plane of nu- 
trition; possibly in preparation for further cell growth and remodelling events. Inter- 
estingly, according to data from G. Lee thesis (Lee, 2003) there was an increase in 
GH receptor mRNA in LD of calves from this trial from the Ist to the 2"d slaughter 
dates. It would be interesting to speculate whether a significant increase in GH recep- 
tor expression would lead to a greater amount of GH stimulatory effects on skeletal 
muscle and subsequent rise in protein synthesis (and total RNA pool). 
Although not significant the REFED group total RNA yield was numerically greater 
than both the HIGH and LOW groups (at both slaughter dates). This trend may fit 
with the hypothesis that refeeding after a feed restriction induces a compensatory 
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growth response. Therefore once the animal is re-fed, a further up-regulation in the 
cellular total RNA pool may take place. Although noting that heightened compensa- 
tory growth didn't take place in the REFED group within this trial (confirmed by 
growth rates). Kristensen et al, 2002, found that total RNA concentrations in Sem- 
itendinosus in pigs were significantly greater in highly fed and refed pigs and corre- 
lated with growth rates. Interestingly, the group also found that total RNA concentra- 
tions in LD significantly correlated with growth rates and m-calpain activities. 
The trend for calpain-3 and calpastatin gene expression to increase numerically in 
treatment groups across slaughter dates (as discussed in 7.1.3 and 7.1.4), may also be 
as the young calves (slaughtered at 5 month old) were still undergoing changes in 
muscle size (hypertrophy), metabolic and contractile properties (remodelling). This 
may be confirmed in part by the change in total RNA discussed above. An essential 
part of these processes during rapid growth and development would hence involve 
cytoskeletal remodelling and myofibrillar hypertrophy, which may constitutively re- 
quire an increase in calpastatin and specific functions of calpain-3. Note that Sazili, 
2003 found that calpastatin immunoreactivity at 0 hr post-slaughter was numerically 
higher in all treatment groups in the 2°d slaughter date, compared to I" slaughter 
date. 
It was important to take into account that a 90% of maintenance ME feed restriction 
(LOW group) was not severe enough to induce atrophy in young, fast-growing 
calves. At 90% of maintenance ME a reduction in growth rate to conserve nutrients, 
an increase in fat mobilisation and oxidation is the theoretical observation unless the 
animal develops an illness or infection. Atrophy only develops when the length and 
severity of the feed restriction is increased. According to data from G. Lee thesis, dur- 
ing the LOW plane feed restriction there was a group decrease in body weight, 
growth rates and increase in fat mobilisation, which was altered after re-alimentation, 
indicating a significant metabolic effect on the animals. 
G. Lee also found that LD GH receptor mRNA and IGF-1 mRNA did not signifi- 
cantly change with dietary treatment, suggesting that the feed restriction wasn't se- 
vere; even though hepatic IGF-1 mRNA was significantly reduced and insulin levels 
reduced. Therefore, the anti-proteolytic effects of local IGF-l may have been main- 
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tained. According to A. Sazili thesis (Sazili, 2003), calpain protein levels were not 
significantly raised during the feed restriction. This suggests that the LOW plane diet 
induced growth arrest, but not myofiber atrophy and probably didn't significantly 
increase calpain-dependent degradation; as there was no change in calpain or calpas- 
tatin protein at slaughter in either groups. However, activity was not measured. 
Potentially important observations seen with dietary treatment included lower cal- 
pain-3 levels in the LOW plane group and the rapid rise in calpain-3 in REFED 
group, within the 1st slaughter date groups. These potentially significant results indi- 
cate that calpain-3 gene expression may alter rapidly with change in nutritional in- 
take in a pattern which fits with current hypothetical functions for calpain-3. 
With regards to transcriptional control of calpain-3, little is known at present. As cal- 
pain-3 is reduced in so many diverse atrophic-catabolic states it is probable there is a 
common regulator/s of transcription that alters rapidly after the onset of various 
states. Hasson et al, 2002 found that calpain-3 mRNA was decreased immediately 
post-eccentric exercise, suggesting that transcription is rapidly regulated. Calpain-3 
mRNA has been found to be reduced during cachexia (Busquets et al, 2000) which 
may suggest involvement of immun-inflammatory mediators. IL-6 transgenic mice 
have been found to have lowered calpain-3 mRNA which was inhibited when an IL- 
6 receptor antibody was administered (Tsujinaka et al, 1996), suggesting proinflam- 
matory cytokines are involved. Other obvious targets would include endocrine me- 
diators including glucocorticoids, a reduction/resistance to insulin /IGF-1 and possi- 
bly GH. 
Binding sites have been found within the large and small calpain subunits for tran- 
scription factors AP-1 and CCAAT/enhancer binding protein (C/EBP) (Penner et al, 
2001, Hasselgren and Fischer, 2001), whereas analysis of the calpain-3 sequence has 
found binding sites for NF-kB in the promoter region of the gene, but not AP-1 or 
C/EBP (Sorimachi et al, 1996). AP-1, C/EBP and NF-kB are associated with im- 
muno-inflammatory responses and all have been found to be up-regulated during 
sepsis (Macdonald et al, 2003), and specifically within muscle during sepsis (Penner 
et al, 2001, Hasselgren and Fischer, 2001). AP-1, C/EBP and NF-kB have therefore 
been suggested to be involved in the induction of the proteolytic response in muscle, 
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providing the trigger for an increase in transcription of protease system components 
(Penner et al, 2001, Hasselgren and Fischer, 2001). It is possible calpain-3 and the 
ubiquitous calpains may be differentially regulated in some way by these transcrip- 
tional regulators. This is likely considering that during many of the catabolic- 
atrophic states mentioned there is an associated decrease in calpain-3, but increase in 
ubiquitous calpain mRNA/activity (see Section 2.8.3) and rise in other proteolytic 
system components, e. g. lysosomal-cathepsins and ubiquitin-proteasome components 
(see Sections 2.7.2 and 2.9.3). Considering also the potential relationship between 
p94 and the IiBa/NFiB pathway, it would be interesting to suggest that NFxB may 
in some way play a regulatory role in calpain-3 transcription. 
Calpastatin has been proposed to be regulated by the cAMP responsive element bind- 
ing protein (CREBP) activated through a ß2-adrenergic pathway involving PKA 
(Navegantes et al, 2002). It is known that during fasting and many stressful catabolic 
states endogenous catecholamine (noradrenaline and adrenaline) levels rise above 
normal baseline levels (Biolo et al, 1997, Ingenbleek and Bernstein, 1999). Obvi- 
ously the level depends on the intensity of the stressful stimuli (Ingenbleek and Bern- 
stein, 1999). Speculative questions of interest therefore include whether a repeated 
trial with a larger number of animals and a more severe feed restriction would initiate 
significant rises in plasma noradrenaline and adrenaline. Would these raised levels of 
endogenous catecholamines in turn significantly increase calpastatin mRNA, protein 
and activity levels. This would be interesting so as to understand whether calpastatin 
mRNA rises in certain catabolic-atrophic conditions, as has been observed in 
hindlimb un-loading by Stevenson et al, 2003, and the non-significant numerical in- 
crease in mRNA expression observed within this trial in the low plane group of the 
1st slaughter. 
Overall, feeding affects multiple signalling pathways in skeletal muscle, through the 
effects of nutrients and endocrine mediators. Therefore, in reality calpain-3 transcrip- 
tion may be regulated by the net effect of a number of different stimulatory and in- 
hibitory pathways. For example, the effects of feeding on the ubiquitous calpains and 
calpastatin has been found to be very variable across animal studies, leading to the 
development of opposing hypotheses of system regulation by researchers as de- 
scribed in 7.4.1. This suggests that as no true consensus has been found, feeding and 
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planes of nutrition alters a myriad of complex signalling pathways that may lead to 
variable effects. Therefore, transcriptional regulators may be speculated on but until 
extensive studies on gene transcription and promoter studies provide conclusive evi- 
dence, little can be known for definate. 
Another important point to note is that the bovine Longissmus Dorsi (LD) samples 
are predominantly fast-twitch fibers (Totland and Kryvi, 1991). Fast-twitch fibers, as 
described in Section 2.2.3 are thought to be have dynamic characteristics, greater 
plasticity for necessary metabolic and contractile adaptations and most susceptible to 
atrophy and hypertrophy (Pette and Staron, 2000, Maltin et al, 2001, Spangenburg 
and Booth, 2003). Expression levels of calpastatin is known to vary between fiber 
types, with predominantly slow twitch muscles having greater levels compared to 
predominantly fast twitch muscles (unpublished observations). One question of in- 
terest during the rapid growth and development phase in calves, is whether fiber type 
characteristics alter in LD, would this in turn affect/be dependent on calpain-3 and 
calpastatin and would feeding level have an additional effect. 
It is important to re-iterate that the low number of animals per treatment group may 
have contributed to many of the trends observed in the mRNA expression of calpain- 
3 and calpastatin being non-significant. As many of the trends are logical changes as 
the fact they did not reach significance may be down to a lack of treatment group 
numbers. For example, a future trial may involve up to 8-12 animals per treatment 
group to observe an improved statistical significance. 
In addition the studies carried out in this thesis using Real-Time PCR were some of 
the first carried out within the Division of Nutritional Sciences and therefore indi- 
cated some of the potential problems associated with this technique. 
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7.2 cDNA PROBE DEVELOPMENT 
7.2.1 Introduction 
As described within Section 5, twenty cDNA probes were successfully generated by 
RT-PCR for components of the four proteolytic systems discussed within this thesis. 
They were designed to be used in further probe-hybridisation experiments such as 
Northern blotting and possibly cDNA macroarray experimentation. The cDNA mac- 
roarray experimental methods considered were based on Clontech, custom self-made 
arrays (BD Biosciences Clontech, 2002). The approach being similar to microarray 
technology except a small select number (-20) of cDNA probes of -200-300 bp are 
required. Microarrays have been used previously (Nguyen et al, 1995, Lee et al, 
1999, Feng et al, 2000, Lockhart and Winzeler, 2000). The macroarray was consid- 
ered as a method of investigating `global' protease gene expression in a single 
experiment, whereas methods such as Quantitiative Real-Time PCR, Northern blot- 
ting and RPA's (Ribonuclease Protection Assays) are specific to a single expressed 
gene of interest at a time. Testing of the cDNAs before their application to an array 
indicated that not all the probes had sufficient specificity to be used to identify spe- 
cific mRNA species. Due to time constraints, Northern blotting was performed in- 
stead of the macroarray approach, using a specific selection of cDNA probes tested 
on porcine RNA. Those expressed genes of interest of components of proteolytic sys- 
tems that are known to have important regulatory functions and/or key roles during 
atrophy and hypertrophy were used. 
Only a small number of the PCR products/cDNA probes were generated first time 
experimentally. Many required a long testing and optimisation period, using different 
reaction conditions, PCR primers and Taq enzymes to attain a specific PCR product 
(as described in Section 5.1). 
7.2.2 Probe Development and Testing 
Of the caspase system, only caspase-3 had porcine sequence data available. Caspase- 
3 cDNA was successfully generated and found to have a 99% sequence identity 
match to the porcine caspase-3 sequence (after DNA sequencing). This made it an 
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ideal candidate probe for porcine RNA Northern blot probing; especially considering 
caspase-3 is an effector protease with a possible key role in myofiber development, 
cell death/survival and degradation of specific proteins during muscle hypertro- 
phy/atrophy (see Section 2.10.5). Caspase-3 is also used in other experiments by re- 
searchers to indicate a generic change in the caspase system. 
Caspase 
-6, -7 and ARC (Apoptosis Repressor with CARD domain) had no porcine 
sequence data available, therefore DNA sequenced PCR products were assumed to 
be the porcine expressed genes of interest (based on sequence similarity with other 
species sequences). ARC was also tested on porcine Northern blots as it was believed 
to play an important role in muscle-specific caspase inhibition. Specific band signals 
detected for both caspase-3 and ARC were determined as being the correct size based 
on database sequence analysis (Appendix B). However, data for ARC was unclear as 
there was only human sequence available in the database. Unfortunately caspase-3 
and ARC were unable to produce reproducable and quantifiable band signals on 
Northen blots. This probably reflects low tissue expression levels in normal, basal 
cell conditions. This was reflected in the difficulties in trying to RT-PCR these 
cDNAs which produced low levels of cDNA even after extended cycles. As de- 
scribed in Section 2.10, the caspases are constitutively expressed zymogens, which 
are activated on autolysis. As they are involved in apoptosis induction, it may be a 
dangerous cellular situation to have high levels of mRNA and protein of caspases in 
normal, functional cells. However, after specific stimuli, e. g. chronic cytokines 
(TNF) the cell may then require an up-regulation of caspase mRNA. Detecting these 
changes would probably require a more sensitive method like Quantitative Real- 
Time PCR. However, subsequent experiments in our laboratories have also indicated 
that caspase-3 is difficult to quantify using Real-Time PCR due to its low levels of 
expression and resulting high Ct values obtained close to the limits of sensitivity. 
Cathepsin L and H both had available porcine sequence data available and specific 
PCR products were generated, both with 99% sequence identity with the porcine da- 
tabase sequences. Cathepsins B and D had no porcine sequence data available and 
PCR was problematic, although a specific band of the correct size and identity was 
generated. The cathepsin D probe had to be generated from a human EST IMAGE 
clone and therefore the PCR product was human tissue specific. 
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Cathepsin L was used in subsequent porcine RNA Northern blot testing procedures 
as firstly; the PCR product of the correct identity was easily generated and porcine 
specific. Secondly, Cathepsin L is thought to play a major role in the response to 
catabolic stimuli within skeletal muscle (see Section 2.7.2). Cathepsin L produced a 
highly reproducable and quantifiable signal of the correct size with testing. (see Sec- 
tion 5.3). 
Ubiquitin was the only ubiquitin-proteasome system component to have porcine se- 
quence data available. Subsequent PCR produced a specific band of the correct size 
and sequence identity (99% identity to porcine database sequence). For E2G1, C8 
and atrogin-1, specific PCR products of the correct sizes were generated and from 
DNA sequencing their sequence identities were believed to be correct, by comparing 
them to those already present within the database. E2G1, atrogin-1 and ubiquitin 
were then tested on Northern blots as they may all play important roles in skeletal 
muscle protein degradation during atrophic-catabolic states (see Section 2.9.3). E2G1 
was chosen as very little information regarding this ubiquitin-conjugating enzyme is 
available, except that it is highly expressed in skeletal muscle and therefore may play 
a role in the degradation of muscle-specific proteins (e. g. myofibrillar proteins). It 
may play a similar role to E214K, ubiquitin-conjugating enzyme, known to be up- 
regulated during catabolic conditions (Wing and Banville, 1994, Solomon et al, 
1998). E2GI and ubiquitin produced reproducable and quantifiable bands with 
Northern blots. After extensive sequence database analysis (as described in Appendix 
B) it was found that E2G1 has transcript variants that may be expressed in porcine 
skeletal muscle (although based on deduction). Ubiquitin is known to produce two 
specific band signals on a Northern blot (Llovera et al, 1999, Busquets et al, 2000), 
although the band sizes depend on the species. Atrogin-1 produced multiple bands of 
unknown identity on Northern blots. Database analysis showed that Atrogin-1 may 
have transcript variants in human tissue (see Appendix B). However, as other bands 
were unidentifiable and no porcine sequence data is available, atrogin-1 was not used 
in further experiments. 
Although porcine sequence data for p- and m- calpains, calpain-3 and calpastatin was 
available and used in designing PCR primers, PCR was problematic. To produce a 
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specific PCR product of the correct identity, PCR was performed using porcine 
clones (previously made by colleagues within the department) as DNA template. 
Calpain- 10 was unable to be successfully generated from porcine tissue, using prim- 
ers based on human sequence, as no porcine sequence is available at present. Subse- 
quent studies have had difficulty isolating this cDNA. Therefore, a cDNA probe was 
successfully generated by PCR using a human calpain-l0 EST IMAGE clone as 
template. Calpain 
-3 and -10 were the only components of the Calpain system to be 
tested on porcine Northern blots. Calpain-3 produced a specific, reproducable and 
quantifiable signal at the correct size (based on evaluation of transcripts in Appendix 
B). Calpain-10 produced a single specific band signal which was believed to be the 
correct mRNA species (based on human sequence data). However, the non- 
reproducability of the signal may be due to low expression levels or simply that the 
porcine sequence differs somewhat in sequence identity to human calpain-10. 
Of the internal standard probes generated, actin and alpha-tubulin had porcine se- 
quence data available, where as TFIID had only human and murine available. How- 
ever, PCR products of the correct identity were produced and actin was later used for 
Northern blot testing as it has been used as a reliable and suitable internal standard in 
a number of settings. Actin probing produced a single reproducable and quantifiable 
band of the correct size. 
7.2.3 Summary 
Twenty cDNA probes were generated by PCR with varying difficulty with the aim of 
hybridising specifically to transcripts in porcine skeletal muscle tissue RNA samples. 
Northern blotting techniques were used to determine whether the cDNA probes 
would specifically hybridise to their corresponding expressed target gene of interest 
within porcine RNA samples. Therefore, if the technique would not work for specific 
probes then it would be unlikely to work on a macroarray, which essentially relies on 
the same experimental technology. As no pig nucleotide sequence was available for 
many of the expressed genes of interest, PCR and subsequent probe testing on por- 
cine RNA Northern blots became difficult and time consuming. Many of the band 
signals produced on Northern blots had to have their mRNA identities deduced based 
on literature and further database searches for transcript variants and species variabil- 
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ity. As non-specific cross-hybridisation with other similar mRNA species is possible 
this process had to be rigorous. Understanding that all cDNA probes were DNA se- 
quenced and their identities were thought to be closest matched to the expressed 
genes of interest obviously strengthened any questions on band identities. 
7.3 COMPARISON OF GENE EXPRESSION TECHNIQUES 
The use of cDNA probes in Northern blotting experiments has many benefits over 
other methods and has been considered to be a reliable and reproducable technique in 
quantifying gene expression. If enough experimental sample numbers, strict RNA 
extraction and quantification procedures are followed and probes optimised cor- 
rectly, Northern blotting may produce specific reproducable band signals of a meas- 
urable size in kb and intensity. One problem with Northern blotting however, is the 
physical inability to be able to run a large number of RNA samples (>30) by gel elec- 
trophoresis and blot them. This is due to obvious size limits of the gel former, of the 
number of samples which can be loaded onto a single gel. 
Quantitative Real-Time PCR has found to be a very sensitive method, allowing a 
large number of samples to be analysed with quick throughput. However, there are 
many problems associated with reaction optimisation and reproducability as con- 
tarnination issues, non-specific amplification and incorrect reaction efficiencies can 
easily invalidate results. As described within Section 4.3, it was not possible to suc- 
cessfully quantify p- and m- calpain due to problems with reduced reaction efficiency 
and non-specific template amplification, making subsequent experiments invalid. 
The use of a Taqman probe offers a higher level of specificity due to binding of 
probe instead of primers alone. However, the main problems associated with Taqman 
probes is the financial cost and time required to optimise the experimental conditions 
to ensure specific detection of mRNAs. Therefore, I was unable to repeat experi- 
ments for µ- and m- calpain using Tagman probes. 
Microrarrays have 1000s of cDNAs of expressed genes of interest dotted onto a solid 
support (usually glass). This allows an overview of the global picture of gene expres- 
sion in a particular tissue sample. The issues with this method include its great finan- 
cial expense, difficulty with sensitivity and significance of results. Macroarrays are 
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not as expensive as microarrays and can be custom made. However, little studies 
have been performed using custom made, non-commercial arrays. Specificity of 
probes is a major consideration with this technique as the probes have to be designed 
for optimised specificity. Macroarray development has never been attempted before 
in out department and therefore is a part of future work. Considering all 20 cDNA 
probes were successfully generated, it would be interesting to have them dotted onto 
a nylon support and used in array test experiments. 
Although not described in this thesis, ribonuclease protection assays (RPA's), can 
also be a very sensitive and accurate method of quantifying gene expression, once 
method has been optimised. This is another technique to be developed as part of fu- 
ture work. 
7.4 THE EFFECTS OF A BETA-ADRENERGIC AGONIST ON PROTEASE 
EXPRESSION IN PIGS 
7.4.1 Introduction 
The following studies to be discussed are concerned with the effects of beta- 
adrenergic stimulation on the mRNA expression of muscle-specific calpain-3, ca- 
thepsin-L and E2GI (a ubiquitin-conjugating enzyme), in pig Longissmus Dorsi 
(LD) skeletal muscle. 
Following the development studies described above, Northern blotting was used as 
the technique of choice as it has been used previously to successfully quantify the 
mRNA expression of multiple proteolytic system components during various cata- 
bolic-atrophic states (Mansoor et al, 1996, Ralliere et al, 1997, Mosoni et al, 1999, 
Deval et al, 2001, Farges et al, 2002). 
The selection of expressed genes analysed were chosen based on their functional 
roles within skeletal muscle, relevance to hypertrophy/atrophic states. In addition, the 
specificity, quantifiiability and reproducability of the cDNA probes previously gener- 
ated, with porcine RNA Northern blots was an important concern. 
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From studies examining proteolytic enzyme expression in atrophy studies cathepsin- 
L is thought to play a key role during the early stages of atrophic and catabolic states, 
with increases observed at mRNA and protein level (Deval et al, 2001). For example, 
cathepsin-L mRNA increased in mice Gastrocnemius within 24 hour of fasting, 
when 11 other lysosomal proteases did not change (Jagoe et al, 2002). Cathespins L 
mRNA expression increased two- to three fold in rat Gastrocnemius during fasting, 
cancer cachexia, uremic and diabetic states when other lysosomal proteases did not 
change (Lecker et al, 2004). 
E2G1 is a specific E2 ubiquitin-conjugating enzyme, found in abundance within 
skeletal muscle and therefore may play a role in the degradation of muscle-specific 
proteins by the ubiquitin-proteasome system within skeletal muscle. E2 enzymes 
have been previously observed to increase in mRNA expression in muscle during a 
number of atrophic-catabolic states (Wing and Banville, 1994, Solomon et al, 1998, 
Hasselgren and Fischer, 2001). 
Calpain-3 function has been discussed a number of times throughout this thesis. It is 
of great interest as it is thought not to act as a protease involved in gross protein 
turnover, but may have important regulatory roles within skeletal muscle. It has been 
hypothesised to play a role in myofibrillar integrity, glucose-fatty acid metabolism 
and cell survival (Ono et al, 1999, Tidball and Spencer, 2000, Baghdiguian et al, 
2001, Walder et al, 2002, Goll et al, 2003, Kramerova et al, 2004) and known to de- 
crease at mRNA level in response to catabolic states like cachexia (Busquets et al, 
2000) and denervation (Stockholm et al, 2002). It was important to focus attention 
towards calpain-3 as little is known about the effects of Q-adrenergic stimulation on 
calpain-3, where as there is a wealth of confirmed information and observations 
known with regards to the effects of, B-adrenergic stimulation on the ubiquitous cal- 
pains and calpastatin. 
The first two studies involved the effects of chronic and acute administration of the 
selective ßz-adrenergic agonist clenbuterol, a known nutrient-repartitioning agent. As 
previously described, clenbuterol is known to induce fat mobilisation and muscle hy- 
pertrophy in farm animals when chronically administered (Mersman, 1998, Bell et 
al, 1998). Clenbuterol and other selective ß2-adrenergic agonists are thought to in- 
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duce protein accretion and muscle hypertrophy through decreasing protein degrada- 
tion and possibly by increasing synthesis (Mersman, 1998, Bell et al, 1998, 
McDonagh et al, 1999). The calpain-calpastatin system is thought to be the principal 
protease system that is affected by ß2-adrenergic agonists (Bardsley et al, 1992, 
Mersman, 1998, Goll et al, 1998, Navegantes et al, 2002). A decrease in mRNA and 
activity of 
, 
u-calpain, along with increases in calpastatin mRNA and activity, with 
variable effects on m-calpain has been reported with 82-adrenergic agonist admini- 
stration (Parr et al, 1992, Bardsley et al, 1992, Speck et al, 1993, McDonagh et al, 
1999, Navegantes et al, 2002). Little is known regarding the effects of clenbuterol 
and ß-adrenergic agonists on calpain-3 gene expresson. An incomplete report by Ji et 
al, 1993 (abstract) found that administration of 20 ppm ractopamine (a /3-adrenergic 
agonist) for 24 days in pigs decreased calpain-3 gene expression by 30% (P < 0.02) 
in LD muscle. The effects of clenbuterol on other proteolytic system components 
remains largely unknown. 
The third study to be discussed involves the effects of chronic adrenaline administra- 
tion on calpain-3 and cathepsin-L mRNA expression. Adrenaline is an endogenous 
non-specific ß-adrenergic receptor. agonist known to have a catabolic effect on lipid 
and glucose metabolism, but a positive anabolic effect on protein metabolism in 
skeletal muscle (Rooyackers and Nair, 1997, Mersman, 1998, Navegantes et al, 
2002). Adrenaline has been reported to decrease proteolysis within skeletal muscle 
through aß2-adrenoceptor mediated pathway, however little is known about the pre- 
cise effects of adrenaline on proteolytic system regulation (Rooyackers and Nair, 
1997, Navegantes et al, 2001, Navegantes et al, 2002). Samples from this present 
study were previously analysed by colleagues from the department of Nutritional 
Sciences. It was found that adrenaline infusion had no effect on 4u- and m- calpain 
activities, but increased calpastatin mRNA and activity (P < 0.01) in porcine LD 
muscle, leading to a reduced calpain: calpastatin activity ratio (P < 0.01) (Sensky et 
al, 1996, Parr et al, 2000). 
The ß-adrenergic stimulation studies differ greatly from the plane of nutrition trial as 
previous studies suggest conclusively that the specific nutrient repartitioning agents, 
ß-adrenergic agonists, increase muscle protein accretion significantly, coinciding 
with consistently observed significant alterations in the ubiquitous calpain system 
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and calpastatin. The consistant observed alterations in activity and gene transcription 
of calpastatin and the ubiquitous calpains has been suggested to be linked to activa- 
tion of specific ß-adrenergic stimulatory pathways, leading to cAMP formation, PKA 
activation and phosphorylation of a number of target proteins (see Section 2.3.4.3) 
(Navegantes et al, 2002). Target proteins suggested include those involved in glyco- 
gen metabolism, cAMP response element binding protein (CREBP), calpains and 
calpastatin (as phosphorylation sites have been identified within sequences) (Frayn, 
1997d, Goll et al, 2003). It is believed CREBP may regulate the transcription of cal- 
pastatin as CREBP binding sites have been identified within the bovine calpastatin 
sequence (Cong et at, 1998). 
Therefore, specific ß-adrenergic stimulatory pathways have been confirmed to affect 
the ubiquitous calpains and calpastatin, however, this is in direct contrast to the 
highly variable effect feeding and plane of nutrition has on the ubiquitous calpains 
and calpastatin. As multiple signalling pathways are altered globally by the response 
to feeding due to alterations in nutrients and hormones, this may lead to unpredict- 
able effects on the calpain proteolytic system. Calpain-3 however, was shown from 
data in this thesis to be potentially responsive to plane of nutrition, but regulators of 
transcription are unknown. Calpain-3 as yet, has not been studied extensively in rela- 
tion to ß-adrenergic stimulation. 
Lastly, it was important to take in to account when analysing changes in data that 
pigs are not as responsive to, ß-adrenergic agonists as other farm animals, such as cat- 
tle and sheep (Mersmann, 1998). From numerous studies performed it has been 
found that on average there is a 4% increase in muscle mass with ß-adrenergic ago- 
nists in pigs, 10% in cattle and 25% in sheep. (Mersmann, 1998). 
7.4.2 The Effect of 24 Hour and 7 day Clenbuterol Treatment in Pigs 
The present study investigated the effects of an acute (24 hour) and chronic (7 day) 
5 ppm daily dose of clenbuterol on glycogen store depletion and the mRNA expres- 
sion of muscle-specific calpain-3, cathepsin-L and E2G1 within porcine LD samples, 
using Northern blot hybrisation experimental techniques. 
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To ascertain whether the 5ppm clenbuterol treatment dose was adequate, effective 
and produced the desired characteristic effects on metabolism, glycogen levels were 
measured in porcine LD samples. Glycogen assay experiments indicated there was a 
highly significant effect (P < 0.001) of clenbuterol on glycogen store depletion (see 
Table 6.2.3-1). Glycogen levels (mg /g tissue) were depleted by 85% (relative to 
controls) within 24 hours of treatment indicating that the expected effect on glycogen 
breakdown and depletion was observed. This finding is in agreement with the obser- 
vation that ß2-adrenergic stimulation has a catabolic effect within muscle and fat tis- 
sue with regards to carbohydrate and fat metabolism (Frayn, 1997d, Mersmann, 
1998). Within skeletal muscle these processes are believed to be activated through 
ß2-adrenergic pathways described within Section 2.3.4.3 (see Figure 2.3.4.3-1), in- 
volving cAMP formation and PKA activation (Frayn, 1997d, Mersmann, 1998). 
Therefore, results from this study confirmed that the intracellular ß2-adrenergic 
pathways believed to alter calpain-calpastatin system components are being activated 
at this lower dose of 82-adrenergic agonist (5 ppm). Of interest however was the ob- 
servation that levels began to rise back up after 7 days of treatment, i. e. a 55% de- 
crease, relative to controls. The subsequent rise in glycogen stores after 7 days of 
treatment may be attributed to the down-regulatory, de-sensitisation effect of chronic 
stimulation of ß2. adrenergic pathways within skeletal muscle (Mersmann, 1998). 
Total RNA was hence extracted from bovine LD muscle tissue. Analysis of extrac- 
tion yields per 0.1 g LD tissue showed there was no significant effect of clenbuterol 
treatment on total RNA yield (P = 0.278) (see Figure 6.2.2-1). 
A northern blot was prepared and hybridised with radio-labelled cDNA probes for 
the proteolytic system components and the internal standard actin (described in Sec- 
tion 6.2.4). Analysis of northern blot band signals for actin showed there was no sig- 
nificant effect of clenbuterol treatment on actin mRNA expression (P = 0.701) (see 
Table 6.2.4-2). Assuming equal amounts of total RNA was loaded onto the northern 
blot, the analysis above of total RNA yield and actin expression indicates that any 
measurable changes in gene expression for other proteolytic system components are 
not the result of experimental errors or artifacts. 
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Muscle-specific calpain-3 mRNA expression was found to not significantly change 
with clenbuterol treatment, although levels did increase numerically by 32%, relative 
to Control group, after 1 week of treatment. Previous observations had reported that 
calpain-3 mRNA significantly decreased by 30% with 20 ppm ractopamine treatment 
in pigs (Ji et al, 1993). 
There was no significant effect of clenbuterol on E2G1 mRNA expression, although 
values increased numerically by 57%, relative to Control group after 24 hour clen- 
buterol treatment. If this is a trend it may signify a rapid response to an acute dose of 
clenbuterol. At present however, there is no literature that has studied the effects of 
ß2_adrenergic agonists on the expression or regulation of E2 enzymes. 
The greatest effect in terms of mRNA expression was the change in cathepsin-L 
mRNA levels which increased by 339%, relative to Control group, after 24 hour 
clenbuterol treatment (P <0.001). In the 7 day clenbuterol group cathepsin-L mRNA 
was 49% greater, relative to Control group, therefore decreased to a level found to be 
significantly lower than the 24 hour group (P <0.01). The pattern of mRNA expres- 
sion suggests that there is a rapid, acute response to clenbuterol treatment, which de- 
creases in intensity over time, after 7 days of chronic stimulation. This is a similar 
pattern of response to the effects of clenbuterol on glycogen stores. Data is of a simi- 
lar relative magnitude but in the opposite direction, i. e. glycogen stores are depleted 
as cathepsin-L mRNA expression is increased. The trends of a decline in response 
over time may be due in part to the effects of chronic stimulation on the desenstisa- 
tion and downregulation of Q-adrenergic pathways. 
The response and pattern of expression of cathepsin-L mRNA has not been reported 
before and it may signify an acute response to ß-adrenergic stimulation. As has been 
described throughout this thesis the catecholamine and B-adrenergic agonist com- 
pounds are known as counterregulatory and catabolic hormones. Their positive ef- 
fects on hypertrophy and lean body mass deposition are only observed after the 
chronic moderate-high dose administration of selective ß2-adrenergic agonists 
(Mersmann, 1998). Therefore, it may be that the initial effects of these compounds 
are to signal an acute stress response, similar to that produced by endogenous cate- 
cholamines and activate specific degradatory systems differentially. If the non- 
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significant trend of E2G1 to increase within 24 hours of administration is a reflection 
of a general change in this proteolytic system then it strengthens the argument dis- 
cussed here. Interestingly, many studies have shown variable results with regards to 
the effects of stimulation on protein degradation. However, there is conclusive evi- 
dence that ß-adrenergic treatment lowers calcium-dependent, calpain-mediated pro- 
teolysis (Navegantes et al, 2002). 
Although highly speculative one explanation may be that sarcoplasmic proteins are 
differentially regulated to myofibrillar proteins. Clenbuterol treatment may decrease 
myofibrillar degradation (through calpain-calpastatin system alterations), yet simul- 
taneously increase sarcoplasmic protein degradation via specific lysosomal cathepsin 
activation. McDonagh et al, 1999 reported that 7 day treatment with clenbuterol in- 
creased protein synthesis (p < 0.01) but had no effect on degradation, even though u- 
calpain activity (P < 0.01) was reduced and calpastatin activity (P < 0.1) increased. 
He suggested also that the discrepancy may be due to a differential regulation of 
myofibrillar and sarcoplasmic protein degradation. E2G1 is involved in the degrada- 
tion of specific cellular proteins, including sarcoplasmic proteins, via ubiquitin tag- 
ging and subsequent targetting to the proteasome. 
Another speculative theory may be that the dramatic rise in cathepsin-L and numeri- 
cal increase in E2G1 may be part of a rapid response in a muscle remodelling-growth 
program, induced by ß2-adrenergic agonists. As has been suggested throughout this 
thesis, during periods of muscle remodelling and catch-up/compensatory muscle 
growth there is a tendency for protein degradation to increase, or for specific prote- 
olytic system components to be upregulated. As mentioned previously in bovine 
plane of nutrition discussion, Kristensen et al, 2002 found that growth rates corre- 
lated with m-calpain activities in pigs and an increase in the y-calpain-calpastatin ra- 
tio was observed in refed pigs (after a feed restriction). Kristensen et al, 2004 found 
growth rates correlated with increased m-calpain, cathepsins B and B+L activities in 
pigs fed different planes of nutrition. 
Interestingly, mRNA levels for the 14kDa-ubiquitin conjugating enzyme E2 were 
found to decrease in response to muscle reloading (18 hr post-reloading), after 
unloading-induced atrophy, in addition to other ubiquitin-proteasome system compo- 
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nents (ubiquitin and 20S proteasome subunits C8, C9) and m-calpain increasing in 
mRNA expression (Taillandier et al, 2003). It was suggested by the author that this 
response may play an important role in the potential remodelling response to reload- 
ing-induced `catch-up' growth and recovery. Feasson et al, 2002 found that the rapid 
response to eccentric exercise included an increase in m-calpain (1 day post-exercise) 
and eventually over time (7-14 day post-exercise) increases in cathespins B+L and 
proteasome activities. Along this line of thought ß-adrenergic agonist administration 
has been obseved to increase m-calpain activity in some studies (Parr et al, 1992, 
Bardsley et al, 1992). 
Further work is needed to clarify if the increase in cathepsin-L mRNA is a result of 
an increase in transcription due to stimulation of ß2-adrenergic pathways, cAMP 
formation and PKA activation. The logical steps to take would be to analyse the ca- 
thepsin-L sequence data and attempt to identify CREBP binding sites within the 
promoter region. Transcription run-off experiments could be performed to ascertain 
whether the increase in mRNA is a result of transcription or due to changes in 
mRNA turnover/stability. As described previously, the effects of clenbuterol on gly- 
cogen breakdown are of a similar pattern to cathepsin-L mRNA expression, suggest- 
ing the rise in expression may be due to activation of specific ß2-adrenergic stimula- 
tory pathways and not an unknown mechanism. Later experiments are then required 
to confirm if there is a subsequent up-regulation of cathespin-L protein levels and 
activity. 
7.4.3 The Effect of Acute Beta-Adrenergic Agonist Administration in Pigs 
The present study investigated the effects of administration of an acute 16 hour, 20 
ppm dose of clenbuterol on the mRNA expression of muscle-specific calpain-3 and 
cathepsin-L in porcine LD samples, using northern blot hybridisation experimental 
techniques. 
Total RNA was extracted from porcine LD samples and yields per g tissue analysed. 
There was no significant effect of treatment on extractable total RNA yields. (P = 
0.58) (see Table 6.3.3-1). This therefore indicated that any experimental changes ob- 
served were not due to extraction artifacts. 
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A northern blot was prepared from porcine LD total RNA and hybridised with radio- 
labelled cDNA probes for calpain-3, cathepsin-L and actin (internal standard). 
Analysis of actin band intensity data showed there was no significant effect of clen- 
buterol treatment on actin mRNA expression (P = 0.558) (Table 6.3.4-2). This meant 
band intensity data for calpain-3 and cathepsin-L could be normalised to actin, pro- 
ducing valid results. 
There was no significant effect of the acute dose of clenbuterol on calpain-3 and ca- 
thepsin-L mRNA relative expression. Calpain-3 decreased by 9% (P = 0.427) with 
treatment, which is unlike the result observed in the 5 ppm clenbuterol trial in dis- 
cussed in Section 7.4.2. Cathepsin-L increased by 53% with treatment (P = 0.279). 
The rise in cathepsin-L is the same direction observed previously in the 5 ppm clen- 
buterol trial described Section 7.4.2. However, cathepsin-L didn't produce the clear- 
est of band signals which may have contributed to lower rises in mRNA expression 
(see Figure 6.3.4-1). Unfortunately, the low number of samples involved in the acute 
dose trial (Control, n=6 and Clenbuterol, n= 5) may be a limiting factor with as- 
sessing true significant changes. 
The numerical increase in cathepsin-L mRNA after a 16 hour 20 ppm dose of clen- 
buterol mirrors the results from the previous study and further suggests that cathep- 
sin-L mRNA increases as a possible rapid stress response. Although the effect was 
not statistically significant as opposed to the highly significant effect observed previ- 
ously, this may be due to various reasons. Firsly, there were less sample numbers in 
this trial which may have had an impact on the level of statistical significance not 
being reached. Further studies would need to be performed with a larger number of 
animals to confirm whether the rise in cathepsin-L mRNA is consistantly. Secondly, 
the strength and quality of the northern blot band signals were relatively poor as can 
be viewed in Figure 6.3.4-1, which may have led to insignificant results. 
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7.4.4 The Effects of Chronic Administration of Adrenaline on Protease mRNA 
Expression in Pigs 
This study investigated the effects of chronic-7 day adrenaline administration on the 
mRNA expression of muscle-specific calpain-3 and cathepsin-L in porcine Longiss- 
mus Dorsi samples, using northern blot hybridisation techniques. 
Total RNA was extracted and analysed to see if adrenaline treatment affected ex- 
tractable yield. There was no significant effect of treatment on total RNA yield per g 
LD porcine muscle tissue (P = 0.204) (see Table 6.4.3-1). This indicated that any 
changes observed in gene expression studies were not the result of extraction arti- 
facts. 
A northern blot was prepared from porcine total RNA samples and hybridised with 
radiolabelled cDNA probes for calpain-3, cathepsin-L and actin. Adrenaline admini- 
stration did not significantly affect actin mRNA expression (P = 0.297) (see Table 
6.4.4-2). This indicated that actin could be used to adequately normalise band inten- 
sity values for calpain-3 and cathepsin-L. 
There was no significant change in calpain-3 mRNA expression values with 7-day 
adrenaline treatment (P = 0.159). Calpain-3 increased numerically by 40%, relative 
to controls, a similar trend to that seen in trial discussed in Section 7.4.2, after 1 
week of 5 ppm clenbuterol administration (i. e. a 33% increase). 
There was no significant effect of 7-day adrenaline treatment on cathepsin-L mRNA 
expression values (P = 0.258). Cathepsin-L decreased numerically by 24% which is a 
different response to the trials discussed in Section 7.4.2 and 7.4.3. 
The different trend in response of cathepsin-L mRNA expression may be as adrena- 
line is a non-selective ß-adrenergic agonist. Adrenaline is known to activate 81-, 82- 
and ß3- adrenoceptors, although Q2 is the predominant receptor in skeletal muscle 
(Mersmann, 1998). As described previously in Section 7.4.2, the response of cathep- 
sin-L mRNA to clenbuterol is thought to be due to stimulation of specific Q2- 
adrenergic pathways within skeletal muscle. Therefore, activation of multiple ß- 
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adrenergic signalling pathways by adrenaline administration may lead to an alterna- 
tive transcriptional response, or no change in cathepsin-L mRNA expression (as 
change was not statistically significant). Further studies would need to confirm 
whether theories are valid using a larger number of animals, adrenaline treatment at 
variable doses and time patterns. 
7.4.5 Beta-Adrenergic Stimulation Discussion 
In summary, a5 ppm dose of clenbuterol acted as predicted on glycogen stores in 
porcine LD by significantly depleting them within 24 hour of administration. This 
indicated that specific ß2-adrenergic signalling pathways were being activated within 
skeletal muscle leading to increased glycogen breakdown, presumably through in- 
creased cAMP formation and PKA activation. 
Cathespin-L mRNA was dramatically increased through an acute 5 ppm dose of 
clenbuterol, which decreased in intensity after 7 day chronic adminstration. E2G1 
mRNA values increased numerically with a similar trend to cathepsin-L, although 
not significant. This may indicate that the initial stages of, ß2-adrenergic stimulation 
(acute) may be seen as a stressor. Catecholamines are traditionally viewed as cata- 
bolic, counterregulatory stress hormones (described in Section 2.3.4). Another likely 
view may be that the coordinate rise may indicate an induction of a remodelling- 
growth response to ß2-adrenergic stimulation. This theory is consistant with the in- 
crease in m-calpain activity observed with 8-adrenergic treatment and other condi- 
Lions that involve compensatory/ `catch-up' growth and remodelling. 
After 1 week of chronic administration of 5 ppm clenbuterol glycogen stores began 
to rise, but were still lower than controls and cathepsin-L mRNA fell. This similar 
pattern of response may suggest the down-regulation and/or desensitisation of /12- 
adrenergic signalling pathways. Studies have suggested that chronic administration 
of specific ß2-adrenergic agonists causes down-regulation and/or desensitisation of 
ß2-adrenergic receptor pathways leading to a down-regulation of cellular ß2- 
adrenergic agonist responses within skeletal muscle (Mersmann, 1998, Kearns et al, 
2001, Depreux et al, 2002, Pellegrino et al, 2003, Ryall et al, 2003, Shumay et al, 
2003). 
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Whether the rapid rise in cathepsin-L and possibly E2G1 is coordinately up-regulated 
with other components of the lysosomal-cathepsin and ubiquitin-proteasome systems 
is unknown and requires further investigation. Analysis of the promoter region of 
sequences for components of the ubiquitin-proteasome system has found that there 
are binding sites for the transcription factors NF-KB, AP-1, CfEBP-ß and S (Hassel- 
gen and Fischer, 2001, Penner et al, 2002). As has been previously mentioned all 
these transcription factors are associated with immuno-inflammatory responses and 
may be regulated by cytokines, glucocorticoids and other endocrine mediators, in- 
cluding insulin (Thompson and Palmer, 1998, Bertrand et al, 1998, Bertrand et al, 
1999, Hasselgen and Fischer, 2001, Penner et al, 2002, Macdonald et al, 2003). 
Therefore, further studies are required to see whether other protease components are 
altered by clenbuterol treatment and whether the up-regulation involves CREBP or 
other regulators described above. 
During clenbuterol administration calpain-dependent proteolysis is known to be al- 
tered and reduced, which is associated with muscle hypertrophy during long term ß- 
adrenergic agonist treatment. Therefore, the results described in this thesis go some 
way to suggest that overall clenbuterol may differentially affect multiple proteolytic 
systems. Whether this in turn initiates a remodelling response or differentially affects 
intracellular protein pools (i. e. myofibrillar and sarcoplasmic) is unknown. 
Calpain-3 mRNA expression was not significantly altered by clenbuterol treatment, 
either acute at 5 ppm or 20 ppm, or chronic dose at 5 ppm. This was not in accor- 
dance with the only previous incomplete study performed investigating the effects of 
ß-adrenergic agonist administration on calpain-3 mRNA (Ji et al, 1993); which ob- 
served a decrease in calpain-3 mRNA with ractopamine administration. Chronic 
adrenaline administration also failed to produce a significant treatment effect. The 
lack of treatment effect may suggest that calpain-3 is not affected by ß2-adrenergic 
signalling pathways (PKA and CREBP) and doesn't play an extensive role in initiat- 
ing the changes in myofiber hypertrophy associated with ß-adrenergic stimulation. 
Taking in to account these observations, other studies and the effects of plane of nu- 
trition in calves, it is probable calpain-3 plays a more important regulatory role in 
muscle-specific signalling pathways (e. g. IxBa: NF-uB pathway) and metabolism. 
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In conclusion, it is of great importance to study the effects of clenbuterol and Q- 
adrenergic agonists on muscle protein metabolism, proteolytic system regulation and 
associated signalling pathways, as 8-adrenergic agonists have been extensively 
proven to increase muscle mass and protein accretion. It is this property of these 
agents that makes them potentially useful tools in livestock production and in clinical 
settings such as reducing muscle atrophy and weakness in muscular dystrophies, ca- 
chectic and sarcopenic states. 
7.6 CONCLUSIONS 
Proteolysis within skeletal muscle as described within the literature review is a com- 
plex co-ordinated process involving multiple protease systems and requires further 
investigation. 
In young fast growing calves, there was a significant increase in the cellular total 
RNA pool in fast twitch muscle fibers (LD), over a short time period of 13 days (be- 
tween slaughter dates). The group of animals refed back up to a high plane of nutri- 
tion after a feed restriction, were found to have higher numerical levels of total RNA 
compared to low and high plane groups, at both slaughter dates, although not signifi- 
Cant. 
Calpain-3 mRNA increased numerically between the two slaughter dates time period 
of two weeks, in the low plane of nutrition and refed animal groups, with a trend to- 
wards significance. Calpastatin gene expression also increased numerically across all 
treatment groups during the two slaughter date time period, with a trend towards sig- 
nificance. This suggested that in young fast growing calves, heightened levels of 
growth and remodelling takes place within fast twitch muscle fibers; which may in- 
volve alterations in components of the calpain-calpastatin system. 
Overall there was no signficant effect of plane of nutrition on calpain-3 gene expres- 
sion. However, calpain-3 was lower during the Ist slaughter date in the low plane of 
nutrition group, compared to the high plane and refed animal groups. The refed ani- 
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mats in the 15t slaughter date had levels similar to the high plane group suggesting 
calpain-3 gene expression is sensitive to nutritional intake. The data in this thesis 
suggests that calpain-3 gene transcription may be regulated by nutritional intake, 
possibly involving multiple signalling pathways. The pathways that affect calpain-3 
may be unlike those that affect ubiquitous calpain and calpastatin gene transcription, 
as the effects of feeding and nutritional intake on ubiquitous u- and m- calpain and 
calpastatin has been reported to be highly variable. 
Calpastatin gene expression did not significantly alter overall with plane of nutrition. 
Although not significant, higher levels numerically were found in the low plane 
group in the ls` slaughter, compared to both high plane and refed groups. 
Administration of the selective ß2-adrenergic agonist, clenbuterol (5 ppm) induced a 
rapid depletion of muscle glycogen stores, a classical catabolic response involving 
stimulation of ß2-adrenergic signalling pathways, which decreased in intensity with 
chronic 7 day administration. Acute 24 hour administration dramatically increased 
cathepsin-L mRNA, a response which also decreased with chronic administration, 
suggesting similar ß2-adrenergic signalling pathways may be utilised to alter cathep- 
sin-L transcription. The precise significance of this response on cathepsin-L is un- 
clear at this present time and requires further investigation. E2G 1 increased numeri- 
cally with the same pattern as cathepsin-L, although not significant. This suggested a 
rapid up-regulatory response by specific proteolytic systems to an acute clenbuterol 
dose. Chronic administration may however downregulate these /32-selective pathways 
within muscle, as glycogen levels and cathepsin-L began to move towards control 
levels with chronic clenbuterol administration. A 16 hour 20 ppm does of clenbuterol 
failed to increase cathepsin-L mRNA significantly, although there was a numerically 
increase. Chronic 7 day adrenaline infusion failed to increase cathepsin-L mRNA. It 
was hypothesised that this may be due to the non-specific effects of adrenaline, acti- 
vating other 8-adrenergic receptor pathways and/or not maximally stimulating ßz- 
adrenergic receptors. The effects of ß-adrenergic stimulation on calpain-3 is unclear 
at this present time and requires further work, as no significant trends were apparent 
in any of the ß-adrenergic stimulation studies. This may suggest that calpain-3 gene 
transcription is regulated by alternative regulators/signalling pathways, compared to 
the ubiquitous calpains and calpastatin. 
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7.5 FUTURE WORK 
7.5.1 Plane of Nutrition 
To clarify the effects of plane of nutrition on proteolytic systems, a future trial would 
firstly ensure a greater number of animals per treatment group would be used. As 
changes in expression are small, a larger number of animals is required to overcome 
experimental variation. Different feeding patterns and levels of feed restriction could 
also be set up. A feeding restriction that induces atrophy would be of great interest as 
many of the protease systems are known to be up-regulated during catabolic/atrophic 
states. Another interesting trial component would be to use an older animal group in 
comparison. It is possible that older animals lose some of the compensatory muscle- 
protective/growth mechanisms discussed within this thesis, that may be active during 
altered planes of nutrition in young, growing animals. As described within the Intro- 
duction, age-associated sarcopenia is associated with loss of muscle mass, through 
alterations in endogenous endocrine and neural pathways. 
In terms of laboratory work, it would be interesting to have protein turnover and pro- 
teolysis rate measurements. It is would be advantageous to be able to re do y- and m- 
calpain Quantitiative Real-Time PCR studies using a Taqman probe. It is important 
to have data for the entire calpain system, as the calpain: calpastatin ratio is thought to 
give an indication of the overall calpain proteolytic potential, over seperate calpain or 
calpastatin measurements. Key components from other proteolytic systems includ- 
ing: Cathepsin L, E2G1, atrogin-1 and caspase-3 could also be measured using Real- 
Time PCR, to have a view of coordinate changes within other systems. Any future 
work would ideally be validated by performing Northern blot experiments in coordi- 
nation. 
7.5.2 ß-Adrenergic Stimulation 
For the ß-adrenergic stimulation trials a greater number of animals per treatment 
group is also important in future trials for similar reasons, as described above. For 
example, the 5 ppm clenbuterol trial showed greater significant changes in measure- 
ments compared to the other ß-adrenergic trials, which had lower sample numbers. 
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Once optimised other cDNA probes may be tested on northern blots. Other compo- 
nents of the lysosomal, ubiquitin-proteasome and caspase systems would be interest- 
ing to evaluate. Other methods of detection could be incorporated including Quanti- 
tative Real-Time PCR, especially for those mRNA species with low expression lev- 
els (e. g. caspase-3). 
7.5.3 Detection Methods 
The main aim of future work would be to move towards developing and optimising a 
cDNA macroarray, with proteolytic system components specific to porcine tissue and 
human and bovine if possible. However, one issue with the array technique is the in- 
ability to detect relatively small changes consistantly and effectively. For example, 
with the plane of nutrition trial there were only small, subtle changes in mRNA ex- 
pression observed to be taking place, that may not be identified in array studies. In 
terms of cDNA probes, porcine nucleotide sequence for many of the expressed genes 
of interest should be available in the near future. This could then be used in hybridi- 
sation experiments for a number of animal trials and possibly human trials, to inves- 
tigate global cellular gene expression. 
Another aspect that could be investigated to strengthen the work with gene expres- 
sion studies, is performing protein level and protease activity studies. This obviously 
would aid in understanding the relationship between mRNA levels and subsequent 
changes in protein and activity levels. 
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APPENDIX A. cDNA PROBE DEVELOPMENT 
This section of the appendix contains information and data, previously summarised 
within the cDNA Probe Development section (Chapter 5). The following describes 
in `probe order' 1-20 (Appendix A 1-20), detailed figured and sectioned information 
regarding: 
Fig. A) cDNA/mRNA sequences available in nucleotide database for specified gene 
of interest. Each related sequence- to be used for a multiple sequence alignment (Fig. 
B), is numbered, followed by an accession number, and species identification, e. g. for 
Caspase-7 (appendix Al): 1)- U39613 
- 
Human. It is assumed that sequences are 
mRNA species unless stated otherwise in brackets, e. g. (cDNA EST clone etc. ) 
Fig. B) A cDNA/mRNA multiple sequence alignment across species using sequences 
in Fig. A. Sequences are aligned in a numbered order, as indicated in A). * symbol 
indicates that a base is conserved across all sequences analysed. The region illustrated 
includes the specific PCR target region of the sequences. Forward and reverse PCR 
primer locations are highlighted in red, and by directional arrows. 
Fig. Cl) PCR conditions: Indicated are the optimal conditions (arrived at experimen- 
tally) for yielding a positive PCR result: Primer length, and sequence; start and finish 
base numbers of one of the sequences indicated in Fig. A., and PCR amplicon size; 
optimum annealing temperature, number of thermocycles, and Taq polymerase used 
is indicated and PCR conditions were as indicated in materials and methods. 
Fig. C2) Problematic PCR reactions, that involved profound alterations in PCR con- 
ditions to yield a positive result, are described in an additional box directly below 
Figure. B. Alternative PCR template and primers are described. 
Fig. D) An example of a positive PCR result, viewed after gel electrophoresis and 
staining, next to a 100 bp marker. 
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Fig. E) Sequence of the PCR product/cloned cDNA plasmid insert generated is in- 
cluded; along with note of length in bp. 
Fig. F) A summary of a BLAST search on the sequenced PCR product. Three exam- 
ples are given of mRNA sequences (unless stated otherwise under description) with 
the closest homology, and if possible, closest human, porcine, bovine, or ovine tissue- 
specific alignments. The accession number, species and description is listed; along 
with a sequence `identities' value and % (previously described in results section), 
alignment score in `bits', and an E Value. 
Score and E Value: These are based on the statistical analysis of sequence compari- 
sons, described in detail on the NCBI homepage. The Score, in `bits', is a normalised 
raw data score, that takes in to account specific statistical parameters. A score value 
is given to sequence comparisons, such that the higher the bit score, the greater the 
similarity of sequences. Blast outputs are arranged in a listed manner in order of 
Score numbers. The E Value describes the number of sequence `hits' that can be "ex- 
pected", by chance, when searching a specific database, with a specific sequence of 
certain length. The lower the E Value, and closer to 0, the more significant the search 
alignment is, i. e. the lower the probability the sequence is found by pure chance. The 
E Value takes in to account the raw score value and sequence length, such that 
smaller sequences will obviously have a higher probability (or expect value) to be 
found by chance. 
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APPENDIX Al: CASPASE-7 
Figure A. Available Caspase-7 
sequences. 
No. Acc. No. Species 
1) U39613 Human 
2) U67321 Murine 
3) U47332 Hamster 
(Golden Hamster) 
N. B. No Porcine, Bovine or 
Ovine sequence data available. 
Figure C 1. PCR Conditions. 
Fwd. primer- 19 bp 
(TT, AJ. 
_ýrl_wý. CCc, =; JTCT 
) 
Start- 1107 of 2006 bp 
sequence (2). 
Rev. primer- 19 bp 
(TTGCACAAACCAGGAGCCT) 
Finish- 1313 of 2006 bp 
sequence (2). 
Amplicon size- 207 bp 
Annealing temp. 
- 
53°C 
Cycles- 35 
Promega taq polymerase 
Figure B. Multiple alignment of sequences 
for Caspase-7. PCR target region and primer 
locations are included. 
10 
1) AAAACCCTT ::. 
_ .. ___.. 
: TCTTCATT'AGG(P" 
2) AAAACCCTGIPA2AC 1:: C: CAAACTCTTCTTCATTCAGGCATGCCGAGG 
3) AAAACCCTGTTAGAGAAACCCAAACTCTTCTTCATCCAGGCATGCCGAGG 
1)GACCGAGCTTGATGATGCCATCCAGGCCGACTCGGGGCCCATCAATGACA 
2) GACGGAGCTCGACGATGGAATCCAGGCTGACTCGGGGCCCATCAACGACA 
3) CACGGAGCTCGATGACGGGGTCCAGGCCGACTCTGGGCCTATCAACGAAA 
1) CAGATGCTAATCCTCGATACAAGATCCCAGTGGAAGCTGACTTCCTCTTC 
2) TTGACGCTAATCCCCGCAACAAGATCCCGGTGGAAGCCGACTTCCTCTTT 
3) CTGACGCCAACCCCCGGTACAAGATCCCGGTGGAAGCCGACTTCCTCTTC 
xx xx <x xx xx . xxxx. xx. x xx.. x... xx.... x.... 
1) GCCTATTCCACGGTTCCAGGCTATTACTCGTGGAGGAGCCCAGGAAC;. 
2) GCTTACTCCACGGTTCCAGGTTATTACTCATGGAGGAACCCAGGGAA: 
3) GCTTACTCCACAGTTCCAGGCTATTACTCATGGAGGAACCCGGGAAA; 
.x xx xxxxx xxxxxxxx xxxxxxxx xxxxxxx xx. ..... 
1) CTCCTGGTTTGTGCAAGCCCTCTGCTCCATCCTGGAGGAGCACGGA;,;, A ; 
2) CT('CTGGTTTGTGCAGGCCCTCTGCTCCATCCTGAATGAGCATGGCAAGG 
3)C': ':: 'TGGTTTGTGCAGGCCCTCTGTTCCATCCTGGATGAGCATGGCAAAG 
Figure D. Caspase-7 PCR product 
run on a 1.5% agarose gel, along- 
side a 100bp marker. 
M ICaspase-7 
1,500 
1000 
, 
P- 
501 
- 
PCR 
product 
-207 bp 
Figure E. DNA sequencing of 
cloned cDNA insert. 
TI AGAGAAACC('AAACT('1TCTTCA'FTCAGGC'T'TG 
('('GGGGC'AC'GGAGCTCGATGA('GGGATCCAGGCA 
GAcrCGGGGCTTATCAATGACACAGATGCTAATCC 
('('GGTATAAGATCCCAGTTGAAGCCGA('TTTCTC T 
I ('G('CTATTCCACAGTTCCAGGCTATTACTC'ATGGA 
GG: \G('('('GGGGAGAGGCTCCTGGTTGGG('AA 
(206 bp sequenced) 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score (bits) 
U67206 Human Caspase-7 182/200 (91%) 254 
U47332 Golden 
Hamster 
Y13088 Murine 
Caspase-7 178/200 (89%) 222 
E value 
6e-65 
2e-55 
Caspase-7 174/200 (87%) 190 7e-46 
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APPENDIX A2: ARC (Apoptosis repressor with CARD domain) 
Figure A. Available ARC sequences. 
Acc. No. Species Description 
AF043244 Human ARC mRNA, 900 bp's, complete cds 
N. B. No Porcine, Bovine, Ovine, sequence data available. 
Figure C 1. 
PCR Conditions. 
Fwd. primer- 20 
bp 
(AAACGCCTGGTCGAGAC3CT) 
Start- 168 bp. 
Rev. primer- 19 
bp 
(CACGTGCTGCCAGTCCCAA) 
Finish- 407 bp. 
Amplicon size- 
240 bp 
Annealing temp. 
- 
58=C 
Cycles- 35 
Promega taq 
polymerase 
Figure B. Human ARC mRNA sequence. PCR target 
region and primer locations are included. 
aGCCTGAGG. AGGAGACAGGACAGAGCGTCTGGAGAGGCAGGAGGACACCGAGTTCCCCGTGTTGGCCTCý: 
AGGTCCTGTGCTTGCGGAGCCGTCCGGCGGCTGGGATCGAGCCCCGACAATGGGCAACGCGCAGGAGCGG 
CCGTCAGAGACTATCGACCGCGAGCGGAAACGý': ': GCAGGCGGACTCGGGACTGCTGT 
GGACGCGCTGCTGGCGCGGGGCGTGCTCACCGGGCCAGAGTACGAGGCATTGGATGCACTGCCTGATGC 
CGAGCGCAGGGTGCGCCGCCTACTGCTGCTGGTGCAGGGCAAGGGCGAGGCCGCCTGCCAGGAGCTGCTA 
CGCTGTGCCCAGCGTACCGCGGGCGCGCCGGACCCCGCTTGGGACTGGCAGCACGTGGGTCCGGCCTACC 
GGGACCGCAGCTATGACCCTCCATGCCCAGGCCACTGGACGCCGGAGGCACCCGGCTCGGGGACCACATG 
CCCCGGGTTGCCCAGAGCTTCAGACCCTGACGAGGCCGGGGGCCCTGAGGGCTCCGAGGCGGTGCAATCC 
GGGACCCCGGAGGAGCCAGAGCCAGAGCTGGAAGCTGAGGCCTCTAAAGAGGCTGAACCGGAGCCGGAGC 
CAGAGCCAGAGCTGGAACCCGAGGCTGAAGCAGAACCAGAGCCGGAACTGGAGCCAGAACCGGACCCAGA 
GCCCGAGCCCGACTTCGAGGAAAGGGACGAGTCCGAAGATTCCTGAAGGCCAGAGCTCTTGACAGGCGGT 
GCCCCGCCCATGCTGGATAGGACCTGGGATGCTGCTGGAGCTGAATCGGATGCCACCAAGGCTCGGTCCA 
GCCCAGTACCGCTGGAAGTGAATAAACTCCGGAGGGTCGGACGGGACCTGGGCTCTCTCC 
Figure D. ARC PCR product run on 
a 1.5% agarose gel, alongside a 
100bp marker. 
Figure E. DNA sequencing of 
cloned cDNA insert. 
AA MO(( I((C((. AGA('(( I A('AGGCAGA(' I('AGGGC 
FCiCI-000GC: A I (; ('(i(' I CC'I CiGC'AC'GGG(i('GIGCTCAGC 
(CGGACTAGA('CACGATGCGiTGGAC'C. ('AC' I'GC'CTGATG 
('CGAGCGCAGGGTACGTCGC(' FG('TGCTG('TGGTG('. AA 
AGCAAGGGCGAGGCCGCCTG('(G IG: AA(' 1 GTI GAAC'TG 
('GCC'('AGCGAACCGTGCACG(A(('(GA('('C('G(' I-I GG(i 
AC'TGGCAGCACGTG 
(241 bp sequenced) 
1,500 
1000 
5(111 
PCR 
product 
-240 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
AF043244 Human ARC 204/241 (84%) 176 le-41 
AY459322 Murine ARC 127/152 (83%) 95.6 4e-17 
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APPENDIX A3: CASPASE-3 
Figure A. Available Caspase-3 
sequences. 
No. Acc. No. Species 
1) U19522 Murine 
2) U84410 Rat 
3) U27463 Hamster 
(Chinese Hamster) 
4) U13737 Human 
5) AB029345 Porcine 
6) AF068837 Ovine 
Figure Cl. PCR Conditions. 
Fwd. primer- 21 bp 
( 
. 
ATAGCAAAAGGAGCAGTT'I: ) 
Start- 322 of 834 bp 
sequence (5). 
Rev. primer- 21 bp 
(CCACTGTCCGTCTCAATCCCA) 
Finish- 530 of 834 bp 
sequence (5). 
Amplicon size- 209 bp 
Annealing temp. 
- 
59°C 
Cycles- 35 
Promega taq polymerase 
Figure E. DNA sequencing of 
cloned cDNA insert. 
('ATALC. A: A. A: A(iG: AG(-AGTI'TTAI('rGC(; TG(TT('TA 
AG('CATGGTGAAGAAGGAAAAA I-ITTTGGAA('AAA 
TGGACCTGTTGATCTG AAAAAATTAACAAGTTTCTT 
C'AGAGGGGACTGTTGTAGAACTCTAACTGGCAAA(' 
('CAAA('TITTCATAATTCAGGCCTGCCGAGG('ACAG 
AA ITGGACT(; TGGGATTGAGACGGACAGTGG 
(209 bp sequenced) 
Figure B. Multiple alignment of sequences 
for Caspase-3. PCR target region and 
primer locations are included. 
1) GAAGAT, 
..:.:, ..... .. 
; TGTG T,. 
.I.: ,.. ý, .: '.; 
...... .. 2) GAAGATC:. ýý1ýýA A. iý. ýr. GCAC; 'P1':: GTGTGTGTGATTCTlU\(-; 'P(: AFGG 
2) GAAGATCACAGCAAAAGGAGCAGTTTCGTTTGTGTGATTCTAAGCCATGG 
4) GAAGATCACAGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGCCATGG 
5) GAAGACCATAGCAAAAGGAGCAGTTTTATTTGCGTGCTTCTAAGCCATGG 
6)GAAGACCATAGCAAAAGGAGCAGTTTTATTTGCGTGCTTCTAAGCCATGG 
1) TGATGAAGGGGTCATTTATGGGACAAATGGGCCTGTTGAACTGAAAAAGTs 
2) AGATGAAGGAGTAATTTTTGGAACGAACGGACCTGTGGACCTGAAAAAAC 
2) TGATGAAGGAGTAATTTTTGGAACAGATGGGCCTATTGACCTGAAAAAAC 
4) TGAAGAAGGAATAATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAA 
5) TGAAGAAGGAAAAATTTTTGGAACAAATGGACCTGTTGATCTGAAAAAAT 
6) TGAAGAAGGAATCATTTTTGGAACCAATGGACCCGTCGATCTGAAAAAAT 
1) TGACTAGCTTCTTCAGAGGCGACTACTGCCGGAGTCTGACTGGAAAGCCG 
2) TAACTAGTTTCTTCAGAGGCGACTACTGCCGGAGTCTGACTGGAAAGCCG 
2) TAACTAGTTACTTCAGAGGGGACTATTGCCGAAGTCTAATTGGAAAGCCC 
4) TAACAAACTTTTTCAGAGGGGATCGTTGTAGAAGTCTAACTGGAAAACCC 
5) TAACAAGTTTCTTCAGAGGGGACTGCTGTAGAACTCTAACTGGCAAACCC 
6) TAGCAAGTTTCTTCAGAGGGGACTGTTGCAGAAGTCTGACTGGAAAACCC 
xxxxx. xxxxxx xx xx xx . x. x . rx 
.x .r 
1) AAACTCTTCATCATTCAGGCCTGCCGGGGTACGGAGCTGGACTGTGGCAT 
2) AAACTCTTCATCATTCAGGCCTGCCGAGGTACAGAGCTGGACTGCGGTAT 
2) AAACTCTTCATCATTCAGGCCTGCCGTGGTACGGAGCTGGACTGTGGCAT 
4) AAACTTTTCATTATTCAGGCCTGCCGTGGTACAGAACTGGACTGTGGCAT 
5) AAACTTTTCATAATTCAGGCCTGCCGAGGCACAGAATTCGACTGTGGGAT 
6) AA ACTTTTCATTATTCAGGCCTGCCGAGGCACAGAACTGGAý'T: 
1) Cs; 
"..;:: _: '.;?. 'F5_. >. _GACTGATGAGGAGATGC; C^T ; Cý 
2) :, >.. 
.. 
ý; i6.; AACTGACGATGATATGGCATGCC 
2)PGAGACAGACAGTGGAACCGAAGATGACATGACATGCC 
4) TGAGACAGACAGTGGTGTTGATGATGACATGGCGTGTC 
5)": '-'. 'GACTGAAGATGACATGGCGTGTC 
5)'_,; TTCTCAGGACGACATGGCCTGTC 
Figure D. Caspase-3 PCR product run 
on a 1.5% agarose gel, alongside a 
100bp marker. 
1,5011 - 
1000 
500 = PCR 
product 
209 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
AB029345 Porcine Caspase-3 207/209 (99%) 398 e-108 
AY575000 Bovine Caspase-3 188/209 (89%) 252 2e-64 
U13737 Human Caspase-3 186/206 (90%) 250 9e-64 
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APPENDIX A4: CASPASE-6 
Figure A. Available Caspase-6 
sequences. 
No. Acc. No. Species 
1) U20536 Human 
2) Y13087 Murine 
N. B. No Porcine, Bovine 
or Ovine sequence data 
available. 
Figure B. Multiple alignment of sequences for 
Caspase-6. PCR target region and primer locations 
are included. 
11 ,. 'I'. SC,. 
....... ..,..... ... : 
". TTTGr. AGTCAA:, T"ý 
..... 
nT";.; 
.-....,. ý., . 
., 
'_ l 
. 
-'TGACT- - Ad. ý :TT I'CF,,;,, TC -rA-;,; i TTTGAAGTGAAATGCTTTAACGACCTCAGAGCA 
1) CAAGAACTACTGCTCAAAATTCATGAGGTGTCAACTGTTAGCCACGCAGATGCCGATTGC 
? )ý;, lAGAACTCCTGCTCAAAATTCACGAGGTGTCGACTTCAAGCCACATAGATGCCGATTGC 
11 TTTGTGTGTGTCTTCCTGAGCCATGGCGAAGGCAATCACATTTATGCATATGATGCTAAA 
2) TTCATCTGTGTCTTCCTGAGCCATGGGGAAGGCAACCACGTTTACGCATACGACGCCAAA 
*+ r +xrr+++r++x+xx+r+rr+ x+++++xx ++x rr++ ++x: + .x.. +. + 
Figure C 1. PC R Conditions. 1) ATCGAAATTCAGACATTAACTGGCTTGTTCAAAGGAGACAAGTGTCACAGCCTGGTTGGA 2) ATTGAAATTCAGACGTTGACTGGCTTGTTCAAAGGAGACAAGTGTCAGAGCCTGGTTGGA 
xx xxxxxxxxxxx xx xxxxxx+xxxxxxxxx.... xxxx. xx .............. 
Start- 303 of 1545 bp 
sequence (1). 
Rev. primer- 20 bp 
(TTGGCTTTTCCAACCAGGC-) 
Finish- 544 of 1545 
bp sequence (1). 
Amplicon size- 242 bp 
Annealing temp. - 62°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold polymerase/ Pro- 
mega taq polymerase 
Figure E. DNA sequencing of 
cloned cDNA insert. 
Figure D. Caspase-6 PCR product run 
on a 1.5% agarose gel, alongside a 
100bp marker. 
1,500 
1000 
Caspase-6 
500 
rr(i(i(i Ii rrcc : \: \c r: \GC (FC' rcAC . (t I (, I (TcCT Ii GAAC \: \G((Mi I C: \61-6 r('rGAATrrc'AA III r((('A TCA 1 ATGC 
(i I: \GATGTGATrGCCTTC'GCCGTGACT('AG(iAAAACACA('A 
AAAAGCAGTCGGCATCTA('ATGGCTAGCAGTTGATGC(' I (': \ 
TG A A-FMG AGC AG TAA TTC TTC AGC TCT. AAG ATC ATTA A: \ 
GCATTTCACTTC: \: \ATC('T: \G: \ rc GAA 
(234 bp sequenced of antisense 
strand) 
PCR 
product 
'-242 bp 
Figure F. Significant sequences from BLAST search of sequence in Fiji. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
U20536 Human Caspase-6 214/234 (91%) 305 2e-80 
AF025670 Rat Caspase-6 206/233 (88%) 248 4e-63 
Y13087 Murine Caspase-6 205/234 (87%) 234 7e-59 
; ATATTTATCATCCAGGCATGTCGGGGAAACCAGCACGATGTGCCAGTCATT 
;. aTATTTATCATCCAGGCCTGTCGGGGTAGCCAGCATGACGTACCCGTGGTT 
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APPENDIX A5: CATHEPSIN-B 
Figure A. Available Cath- 
epsin-B sequences. 
No. Acc. No. Species 
1) X82396 Rat 
2) M14222 Murine 
3) L16510 Human 
4) L06075 Bovine 
Figure. Multiple alignment of sequences for 
Cathepsin-B. PCR target region and primer locations 
are included. 
1) ACAGCGAATCT ; CAAA ý.. 2)ACAGTG 
3) ATAGCGAGAAGGACATCATGGCCGAGATCTACAAAAACGGCCCCGTGGAGGGAGCTTTCT 
4) ACAACGAGAAGGAGATCATGGCAGAGATCTACAAAAATGGCCCAGTCGAGGGGGCCTTCT 
11 CTGTGTTTTCTGACTTCTTGACTTACAAATCAGGCGTATACAAGCATGAAGCCGGTGATG 
2) CTGTGTTTTCTGACTTCTTGACTTACAAATCAGGAGTATACAAGCATGAAGCCGGTGATA 
3) CTGTGTATTCGGACTTCCTGCTCTACAAGTCAGGAGTGTACCAACACGTCACCGGAGAGA 
4) CTGTGTACTCGGACTTCCTGCTATACAAGTCTGGGGTGTACCAGCACGTCTCTGGAGAGA 
. xxxr. r. xxxxxx xx x+.. x xx rx xx xrr xx r 
.... 
N. B. No Porcine se- 1)TGATGGGAGGCCATGCCATCCGCATTCTGGGCTGGGGAATAGAGAATGGAGTACCCTACT 
qu encc d aCd avdi labte 2) TGATGGGTGGCCACGCCATCCGCATCCTGGTCTGGGGAGTAGAGAATGGAGTTCCCTACT 
3) TGATGGGTGGCCATGCCATCCGCATCCTGGGCTGGGGAGTGGAGAATGGCACACCCTACT 
4) TTATGGGAGGCCACGCCATCCGCATCCTAGGCTGGGGAGTGGAGAACGGCACCCCCTACT 
Figure C1. PCR Conditions. * _""*_ ..... *". ý "; t "} "ý ýý".. " ..... *< ....... 
Fwd. primer- 20 bp 
( ý; A3AAGGACATCAT000CCA ) 
Start- 883 of 1996 
bp sequence (3). 
Rev. primer- 21 bp 
(CAGTCAGTG TCCAGGAGTTG) 
Finish- 1088 of 1996 
bp sequence (3). 
Amplicon size- 206 bp 
Annealing temp. 
- 
57°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold polymerase/ Pro- 
mega taq polymerase 
Figure E. DNA sequencing of 
PCK product. 
(iG( (( (i(. I( (. v( (. (. (xGC( Fi(. -v( IGCTGIACTCGG 
\( fl(( I(i(. \(. I: \f, \. \( I( 1(i(i, uiFGTACCAGCAC (i I('A('AGG; \GA('TTGA I'(i(; (, AGC; (CATG('CATCC'G 
('A fCCT(i(i(iC fG(iGGA(iTGGA(; AATGGCACC('CCT 
V( 1I ('GGCAAC1( (' fGGAI G: A 
M Cathepsin-B 
1,500 
---- 
1000 
500 
PC R 
*soft product 
_Wniý Im 171 bo sequenced) 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value (bits) 
L06075 Bovine Cathepsin-B 156/171 (91%) 212 2e-52 
L16510 Human Cathepsin-B 132/145 (91%) 184 4e-44 
X82396 Rat Cathepsin-B 73/83 (87%) 86 3e-14 
1) GGCTGGTAGCAAACTCCTGGAACGTTGACTGGGGTG 
2)GGCTGGCAGCCAACTCTTGGAACCTTGACTGGGGTG 
3) GGCTGGT'^: C ý. 
_. _, 
C, AC. ACT, A=; GGGTG 
4) GGCTGGTC ý; G 'TG ; AACAc 7\;. a^. T ; GGGTG 
Figure C2. 
Target amplification problematic; Accom- 
plished using primers above on a long 
(--581 bp) Cathepsin-B PCR product made 
using above Rev. primer, and another 20 
bp Fwd. primer (TrcýccýcrcTCCriccoA start- 
508 bp sequence (3). 
Figure D. Cathepsin-B PCR product 
run on a 1.5% agarose gel, alongside a 
100bp marker. 
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APPENDIX A6: CATHEPSIN-D 
Figure A. Available Cath- 
epsin-D sequences. 
No. Acc. No. Species 
1) M11233 Human 
2) BM471202 Human 
3) AF164143 Ovine 
4) X53337 Murine 
5) X54467 Rat 
N. B. No Porcine se- 
quence data available 
Figure Cl. PCR Conditions. 
Fwd. primer- 21 bp 
Start- 667 of 2038 bp 
sequence (1). 
Rev. primer- 20 bp 
( 
-TGGACCTGCCAGTAGGCC. ) 
Finish- 870 of 2038 
bp sequence (1). 
Amplicon size- 204 bp 
Annealing temp. 
- 
57°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold polymerase 
Figure B. Multiple alignment of sequences for 
Cathepsin-D. PCR target region and primer loca- 
tions are included. 
1) CTGGGCATGGCCTACCCCCGCAT. ' 
2) CTGGGCATGGCCTACCCCCGCAPC'PCCGTCAA(- :, F, ýt; 7 ; 000GT(: TT 
3) CTGGGCATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCTGTCTT 
4) TTGGGCATGGGCTACCCTCATATCTCTGTTAACAACGTGCTTCCGGTCTT 
5) TTGGGCATGGGCTACCCTTTTATCTCTGTTAACAAGGTGCTCCCGGTCTT 
1) CGACAACCTGATGCAGCAGAAGCTGGTGGACCAGAACATCTTCTCCTTCT 
2) CGACAACCTGATGCAGCAGAAGCTGGTGGACCAGAACATCTTCTCCTTCT 
3) CGACAACCTGATGCGGCAGAAGCTGGTGGACAAGAACGTCTTCTCCTTCT 
4)TGACAACCTGATGCAACAGAAGCTGGTGGACAAGAACATCTTCTCCTTCT 
5) CGACAACCTGATGAAACAGAAGCTGGTGGAAAAGAACATCTTCTCCTTCT 
=xx+x++x+xx+ +++++xx+xx+xx+ xxxx+ xxxx+xxxx+: + 
1) ACCTGAGCAGGGACCCAGATGCGCAGCCTGGGGGTGAGCTGATGCTGGGT 
2) ACCTGAGCAGGGACCCAGATGCGCAGCCTGGGGGTGAGCTGATGCTGGGT 
3) TCCTGAACAGGGACCCGAAAGCCCAGCCCGGGGAAGAGCTGATGCTGGGC 
4) ACCTGAACAGGGACCCAGAAGGGCAACCCGGAGGAGAACTAATGCTTGGT 
5) ACCTGAACAGGGACCCAACCGGGCAACCTGGAGGAGAACTAATGCTTGGC 
xxxxx xxxxxxxrr x xx rx xx x xx rx xrxxx xr 
1) GGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCCTACCTGAATGTCAC 
2) GGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCCTACCTGAATGTCAC 
3) GGGACCGACTCCAAGTACTACAGAGGCAGCCTGACCTACCACAACGTCAC 
4) GGCACTGACTCCAAGTACTACCACGGGGAGCTGTCCTACCTGAACGTCAC 
5) GGCACTGACTCCAGATACTACCACGGGGAGCTGTCCTACCTGAACGTCAC 
1) CCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCCAGCG 
2) CCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCCAGCG 
3) CCGCCAGGCCTACTGGCAGATCCACATGGACCAGCTGGACGTGGGCAGCA 
4)TCGAA. GGCCTACTGGCAGCTCCACATGGACCAGTTGGAGGTGGGCAATG 
5) CCGAA:,..;.;,: 
-'TaC: GGCMG:; "JCa, 'ATGGACCAGCTGGAGGTGGGCAGCG 
Figure C2. 
PCR from porcine template problematic; 
Human Image Clone: 
-5563106, acc. no: - 
BM471202, (983 bp), used as template; tar- 
get region 100% alignment to (1). 
Figure. Cathepsin-D PCR product run on a 
1.5% agarose gel, alongside a 100bp marker. 
Figure E. DNA sequencing of ivi Cathepsin-D 
t t-LK roauct. 1,500 
rcI I( I(( [ILIM( It vOv(; ((vccc 1000 
vG: vJ (((; c: v(((I GGGG(; I GA(i( I GAT 
(; (T000TGGCA('AGAC'T('C AAGTA II\ 
(: \AGGGTT('T('TGICCTA('CT(iAATG f(' 
A( ' CCGCAAGG('C'TAC'TGGCAGGTC 500 
(134 bp sequenced) 
Figure F. Significant sequences from 
BLAST search of sequence in Fig. E. 
........... 
PCR 
-product 
-204 bp 
Significant sequence alignment to: 
Acc. NO. Species Description Identities Score E value 
(bits) 
M11233 Human Cathepsin-D 134/134 (100%) 266 le-68 
X53337 Murine Cathepsin-D 112/133 (84%) 98 5e-18 
AB055312 Bovine Cathepsin-D 72/84 (85%) 72 3e-10 
238 
APPENDIX A7: CATHEPSIN-L 
Figure A. Available Cath- 
epsin-L sequences. 
No. Acc. No. Species 
1) X91755 Bovine 
2) D37917 Porcine 
3) X06086 Murine 
Figure Cl. PCR Conditions. 
Fwd. primer- 21 bp 
(TGACATGACCAATGAAGAATT ) 
Start- 333 of 1388 bp 
sequence (1). 
Rev. primer- 21 bp 
( :: -_... : TCCTTC ) 
Finish- 552 of 1388 
bp sequence (1). 
Amplicon size- 220 bp 
Annealing temp. - 59°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold polymerase/ Pro- 
mega taq polymerase 
Figure E. DNA sequencing of 
cloned cDNA insert. 
1) AACTGTTTCATGAACCTCTCCTTGTTGACGTCCCCAAATCTGTGGATTGG 
2) AAGTGTTCCACGAATCTCTGGTTCTTGAGGTCCCCAAATCGGTAGATTGG 
3)GGCTTTTTCAGGAACCGCTGATGCTTAAGATCCCCAAGTCTGTGGACTGG 
« x« x« «xx x xx « «« x . x.. x.. x: x. .. x.. 
1) ACTAAGAAAGGCTATGTAACTCCTGTGAAGAATCAGGGTCAGTGTGGTTC 
2) AGAGAAAAAGGCTATGTCACTGCCGTGAAGAATCAGGGTCAGTGTGGTTC 
3) AGAGAAAAGGGTTGTGTGACTCCTGTGAAGAACCAGGGCCAGTGCGGGTC 
#+ t+ k# # +tt t+t t #t##tk+t tttYt f!! f! ft f" 
1) TTGTTGGGCGTTTAGTGCCACTGGTGCTCTTGAAGGACAGATG TCCG(', A 
2) TTGTTGGGCTTTTAGTGCCACCGGCGCCCTC ; AA; ; ArA(: A-'-" 
3)TTGTTGGGCGTTTAGCGCATCGGGTTGCCTA:: " 
... ..., 
++xxxxxxx xxxxx xx x .x.. 
................ 
1) AAACTGGCAAACTTGTTTCACTGAGTGAGCAAAAC(: T(' GTGGA':; '; 
... 2) AAACCGGCAAGCTTGTTTCACTGAGTGAGCAGAACCTCOT'] A ; T1 
3)AGACCGGCAAACTGATCTCACTGAGTGAACAGAACCTTGTGGACT'; TT: 'T 
Figure D. Cathepsin-L purified PCR 
product run on a 1.5% agarose gel, 
alongside a 100bp marker. 
I GACATGACCAA I'GAAGAA I'T('AGG('AGGTGATG 
. 
ATGGC1TrCAAAA('CAGAAG('ACAAGAAGGGGA 
\AGTGTTCC ACGAATCTCTGGTT('TTGAG GTCC'C'C 
AGATCGGTAGATTGGAGAGAAAAAGGCTATGTCA 
('TGCCGTGAAGAATCAGGGTCAGTGTGGTTC'iTGT 
TGGGCTTTIAGTGCCACCGGCGCCCTTGAAGGACA 
GATGTTCCGGAAA 
( 220 bp sequenced) 
1,500 
1000 
M Cathepsin-L 
500 PC R 
-220 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value (bits) 
D37917 Porcine Cathepsin-L 218/220 (99%) 420 e-115 
NM_001912 Human Cathepsin-L 197/219 (89%) 260 le-66 
X91755 Bovine Cathepsin-L 194/220 (88%) 230 9e-58 
Figure B. Multiple alignment of sequences for 
Cathepsin-L. PCR target region and primer loca- 
tions are included. 
1) CATGCGTTCCGCATGGCAATGAATGCCTTTGG:. 
2) CATGGCTTCAGCATGGCCATGAATGCCTTTGGTG:,,: A:.; Aý 
3) CACGGCTTTTCCATGGAGATGAACGCCTTTGGTGACATGACCAATGAGGA 
xx x xx xxxxx xxxxx xxxx«xxx. x.. x.......... 
.. 
1) ATTTAGGCAGGTGATGAATGGTTTTCAAAATCAGAAGCATAAGAAGGGGA 
2) ATTCAGGCAGGTGATGAATGGCTTTCAAAACCAGAAGCACAAGAAGGGGA 
3) ATTCAGGCAGGTGGTGAATGGCTATCGCCACCAGAAGCACAAGAAGGGGA 
. xx xx«. xxxxx xxxxxxx x «. x ««x. xxx: x......... 
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APPENDIX A8: CATHEPSIN-H 
Figure A. Available Cath- 
epsin-H sequences. 
No. Acc. No. Species 
1) U06119 Murine 
2) Y00708 Rat 
3) X07549 Human 
4) AF001169 Porcine 
Figure Cl. PCR Conditions. 
Fwd. primer- 21 bp 
(. ACn. =. ý CCTGTGAGCTTCGCC ) 
Start- 762 of 1149 bp 
sequence (4). 
Rev. primer- 21 bp 
(J:: GATGAGGAAGTACCCATT) 
Finish- 974 of 1149 bp 
sequence (4). 
Amplicon size- 213 bp 
Annealing temp. 
- 
59°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold Polymerase/ Pro- 
meaa 
Figure E. DNA sequencing of 
cloned cDNA insert. 
TGAGGAA(, TA('('CATT(. \ 1 1(((('\CT(i(i(iGA('C(' 
('ATGAG ITITTCACAAT('(': \ATATGG FA ICCCATTT 
TCTTCTC('GTACCCAACAGCCAGTACTGCGI'GG1'T 
GA('TTTATCTGGAGTTTTATGGCAGGAGGTACTGG 
AGTAGATGCCCTTTCTGT. ACATGAGAAAGTCATTA 
GTCACCTCGAAGGCGAAG(' FC\('; \((GTTGT; \ 
(208 bp of antisense strand 
sequenced) 
M Cathepsin-H 
1,500 
1000 
500 PC R 
product 
ýý213 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
AF001169 Porcine Cathepsin-H 207/208 (99%) 404 e-110 
X07549 Human Cathepsin-H 188/208 (90%) 254 6e-65 
U06119 Murine Cathepsin H 175/208 (84%) 151 7e-34 
Figure B. Multiple alignment of sequences for 
Cathepsin-H. PCR target region and primer loca- 
tions are included. 
1) ACGAGGCTGCAATGGTTGAGGCTGTGGCTCTA:,.. 
_:.:. 
2) ATCAGGCTGCAATGGTAGAGGCT(, TGGCCCTA: 'AC:,. A 
__..,..,,, 3)ACGAGGAAGCGATGGTGGAGGCTGTGGCCCTCTACAACCCTGTGAGCTTT 
4)ACGAGGAGGCGATGGTGGAGGCGGTGGCCCTGTACAACCCTG7'GAGCTTT 
-- x+ +++x+ xxxx+ xxxxx xx xxxxx xxxxx.. xxxx 
10 
1) GCCTTTGAGGTGACTGAAGATTTTTTGATGTATAAAAGTGGCGTCTACTC 
2)GCCTTTGAGGTGACTGAAGATTTTATGATGTATAAAAGTGGTGTCTACTC 
3)GCCTTTGAGGTGACTCAGGACTTCATGATGTATAGAACGGGCATCTACTC 
4) GCCTTCGAGGTGACTAATGACTTTCTCATGTACAGAAAGGGCATCTACTC 
. +x++ xxxx++++x + ++ ++ x x+xx+ x +« .x +x..... 
1)CAGTAAATCCTGTCATAAAACTCCAGATAAAGTAAACCATGCAGTCCTGG 
2) CAGTAACTCCTGTCATAAAACTCCAGATAAAGTAAACCATGCAGTCCTGG 
3)CAGTACTTCCTGCCATAAAACTCCAGATAAAGTAAACCATGCAGTACTGG 
4) CAGTACCTCCTGCCATAAAACTCCAGATAAAGTCAACCACGCAGTACTGG 
+x. x. . x. xx xxxxxxx: xxxxr.. x. xxr xxx.. ".. ". x... 
1) CGGTTGGCTATGGAGAACAGAATGGATTACTCTACTGGATTGTGAAAAAC 
2) CTGTTGGCTATGGAGAACAGAATGGATTACTCTACTGGATTGTGAAAAAC 
3) CTGTTGGGTATGGAGAAAAAAATGGGATCCCTTACTGGATCGTGAAAAAC 
4) CTGTTGGGTACGGAGAAGAAAATGGGATACCATATTGGATTGTGAAAAAC 
1)TCTTGGGGCTCCCAGTGGGGGGAGAATGGGTACTTCCTCATTGAACGTGG 
2) TCTTGGGGCTCCAACTGGGGGAACAAT'::: * '--- 
- : 'TGG 
3)TCTTGGGGTCCCCAGTGGCGAATGAA 
SGG 4) TCATGGGGTCCCCAGTGGGGAATGAA.: 
Figure D. Cathepsin-H purified PCR 
product run on a 1.5% agarose gel, 
alongside a 100bp marker. 
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APPENDIX A9: E2GI (Ubiquitin Conjugating Enzyme) 
Figure A. Available E2G1 
sequences. 
No. Acc. NO. Species 
1) AK013902 Murine 
2) D78514 Human 
3) AF099093 Rat 
N. B. No Porcine sequence 
data available. 
Figure Cl. PCR Conditions. 
F:. d. primer- 21 bp 
(;,, ý:.; TGG? ; 
-',: hTCATG. ) 
Start- 364 of 617 bp 
sequence (2). 
Rev. primer- 21 bp 
(= TGGAGACCCTGAAATAAGTG ) 
Finish- 576 of 617 bp 
sequence (2). 
Amplicon size- 213 bp 
Annealing temp. 
- 
56°C 
Cycles- 35 
Perkin Elmer Amplitaq 
Gold polymerase% Promega 
taq polymerase 
Figure B. Multiple alignment of sequences for 
E2G1. PCR target region and primer locations 
are included. 
1)AGAGGAACGCTGGTTACCTATCCAT:. 
2) AGAGGAACGCTGGCTCCCTATCCACl,. '7.; 
3) AGAGGAACGCTGGCTGCCTATCCATACTGTGGAAACCATCATGATTAGTG 
xxrxrxxrxxxxx x xxxxxxxr ". x. ""x. ««". "". x.. xxx"xx" 
1) TCATTTCTATGCTGGCAGATCCTAATGGAGACTCACCTGCAAATGTAGAT 
2)TCATTTCTATGCTGGCAGACCCTAATGGAGACTCACCTGCTAATGTTGAT 
3) TCATTTCTATGCTGGCAGATCCTAATGGAGACTCACCTGCAAATGTAGAT 
. x. xxxxxxxxxx+xxx. x rx. rxxxxxxxx.. xx... x r. x.. 
... 
1)GCTGCGAAAGAATGGAGGGAAGACAGAAACGGAGAATTTAAAAGGAAAGT 
2)GCTGCGAAAGAATGGAGGGAAGATAGAAATGGAGAA7TTAAAAGAAAAGT 
3)GCTGCGAAAGAATGGAGGGAAGACAGAAATGGAGAATTTAAAAGGAAAGT 
.. rrxxxxxxxxxrrxxxxxxxx rxxxr xxrrxxx. x. x.. « . x... 
1)TGCCCGCTGTGTAAGAAAAAGCCAAGAAACTGCTTTTGAGTGATGTATAT 
2) TGCCCGCTGTGTAAGAAAAAGCCAAGAGACTGCTTTTGAGTGACATTTAT 
3) TGCCCGCTGTGTAAGAAAAAGCCAAGAAACTGCTTTTGAGTGATGTTTAT 
. xxxxxxxxxxxxxxxxxrxxxxrrrx xxxxxxx"xxrxx.. 
. x«. 
1) TCAATAGTTAGTAACTTCACTTATTTCAGGGTCTCCAATTGAGAA-CATG 
2) TTAGCAGCTAGTAACTTCACTTATTTCAGGGTCTC(-AATTGAGAAACATG 
3) TC. AATAGCTAGTAACTT'... -- -- "TGAGAAACATC; 
4 
Figure D. E2GI purified PCR product 
run on a 1.5% agarose gel, alongside a 
100bp marker. 
Figure E. DNA sequencing of 
cloned cDNA insert. 
A(1G IY, G: \: \ \('( \ f(': \i'G: \ I I, vi IGI TT('-i'AT 
G(((iG(': \G: \('C(' f: \: \CGGCGA( I ('GCCTGC FAAT 
GTGGAC'GCTG('GA: \AGAAT(; GAG. AGAAGACAGAA 
ATGGAGAATTCAAAAGGAAAGTCGCC('GCTGTGTA 
AGAAAAAGCCAAGAGA('TGCTTITGAG f(;. \('A FIT 
A rrCAAC'AGCTGTAACTTCA('TTA'TTTCAG(ic CI C 
CAA 
(212 bp of sequenced) 
1,500 
M k2G1 
10uß 
51ý PCR 
JOE-' roduct 
-213 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
D78514 Human E2G1 200/213 (93%) 311 3e-82 
AF099093 Rat E2G1 198/213 (92%) 295 2e-77 
AK013902 Murine E2G1 192/213 (91%) 272 3e-70 
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APPENDIX A10: C8 (Proteasomal Subunit) 
Figure A. Available C8 
sequences. 
No. Acc. No. Species 
1) AF055983 Murine 
2) X55985 Rat 
3) D00762 Human 
N. B. No Porcine sequence 
data available. 
Figure C 1. PCR Conditions. 
Fwd. primer- 21 bp 
Start- 577 of 938 bp se- 
quence (1). 
Rev. primer- 21 bp 
( ;: TCATC ITC=CrrCA ) 
Finish- 793 of 938 bp 
sequence (1). 
Amplicon size- 217 bp 
Annealing temp. 
- 
523C 
Cycles- 35 
Perkin Elmer : imp ji Laq 
Gold polymerase/ Promega 
taq polymerase 
Figure B. Multiple alignment of sequences for C8. 
PCR target region and primer locations are in- 
cluded. 
1) GGCAGGCTGCAAAGACAGAGATAGAA 
2) GGCAAGCTGCAAAGACAGAAATAGAt, 
_. 
_ .... 
_, 3) GGCAAGCTGCAAAGACGGAAATAGAGAAGC'PTCAGATGAAAGAAi. TGACC 
. xxx xxxxxxxxxxx xx xxxxx xxr". r. "...... 
...... ". 
1) TGCCGTGATGTAGTTAAAGAAGTTGCAAAAATAATTTACATAGTACACCA 
2) TGCCGTGATGTAGTTAAAGAAGTTGCAAAAATAATTTACATAGTACATGA 
3) TGCCGTGATATCGTTAAAGAAGTTGCAAAAATAATTTACATAGTACATCA 
1)TGAAGTTAAAGATAAAGCTTTTGAACTGGAGCTCAGCTGGGTTGGTGAAT 
2) TGAAGTTAAGGATAAAGCTTTTGAACTAGAGCTCAGCTGGGTTGGTGAAT 
3)CGAAGTTAAGGATAAAGCTTTTGAACTAGAACTCAGCTGGG7TGGTGAAT 
xxxxxxx. .. x.. xxxxxxxxx.. x .... x....... x........ 
1) TAACTAAAGGAAGACATGAAATTGTTCCCAAAGACATAAGAGAGGAAGCA 
2) TAACTAAAGGAAGACATGAAATTGTTCCCAAAGACGTAAGAGAGGAAGCA 
3) TAACTAATGGAAGACATGAAATTGTTCCAAAAGATATAAGAGAAGAAGCA 
1)GAGAAATATGCCAAGGAATC7TTGAAGGAAGAAGATGAATCAGATGATGA 
2) GAGAAATATGCCAAGGAATCTTT(7AAGGAAG; q,.,: AT, 7AA': ': ATGACGA 
3) OAGAAATATGCTAAGGAATCTC: 
. 
--; ATGA 
........... ......... 
......................... .. 
Figure D. C8 purified PCR product 
run on a 1.5% agarose gel, alongside a 
100bp marker. 
M C8 
1,50 u 
10111 
50( PCR 
product 
-217 bp Figure E. DNA sequencing of 
cloned cDNA insert. 
('FGA rrc: \ rc ITCTTCCTrc: \: AGATTCC r rAGCG 
r: \TTACTCIGC(-TC TCCCrTATArcFrrTGGAAC 
. 
\AT7TCATGTcrrcc TTGTTAmCACCAACCC 
\ GC TG AGC TCTAGTTC AAA AGC TTTA T('CTTAA(' 
TTCATCATGTACTATGTAAA TTATrTTPGCAACTT 
CTITAACAACATCACGGCAGGTCAm(mC: \7 
CTGAAGCTT 
(217 bp of antisense strand 
sequenced) 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
D00762 Human C8 205/217 (94%) 335 2e-89 
X55985 Rat C8 204/217 (94%) 327 5e-87 
AF055983 Murine C8 201/217 (92%) 303 8e-80 
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APPENDIX Al 1: UBIQUITIN 
Figure A. Available 
Ubiquitin mRNA sequences, 
No. Acc. No. Species 
1) M18159 Porcine 
2) M62428 Bovine 
3) M26880 Human 
Figure B. Multiple alignment of sequences for 
Ubiquitin. PCR target region and primer loca- 
tions are included. 
1) GAGTCCACCCTGCACCTGGTCCTCCGCCT: 
=, ;.. 
,.:. 
21 GACTCCACTCTGCACCTGGTCCTCCGCCT 4:, ß_I, 
_,..... 3) GAGTCTACCCTGCACCTGGTGCTCCGTCTCAGAGGTGGGATG,:.; AIC: 
-TCGTGAAGACC 
1) TTGACTGGTAAGACCATCACCCTGGAAGTGGAGCCCAGCGACACCATCGAGAACGTCAAG 
2) TTGACCGGCAAGACCATCACCCTGGAGGTGGAGCCCAGTGACACCATCGAGAACGTCAAG 
3)CTGACTGGTAAGACCATTACCCTCGAGGTGGAGCCCAGTGACACCATCGAGAATGTCAAG 
1) GCGAAGATCCAGGACAAGGAAGGCATCCCCCCAGACCAGCAGAGGCTGATCTTTGCCGGG Figure C I. PCR Conditions. 2ý CýCCAAGATCCAAGACAAAGAGGGCATCCCCCCAGACCAGCAGAGGCTGATCTTTGCCGGG 
i1:. ^aa a_a mrrnar_n ma Anna annrnm. r. 
Fwd. primer- 21 bp 
Start- 524 of 832 bp 
sequence (1). 
Rev. primer- 20 bp 
(. A GCGCAGGACCAAGTGC-. ) 
Finish- 752 of 832 bp 
sequence (1). 
Amplicon size- 229 bp 
Annealing temp. 
- 
61FC 
Cycles- 35 
Expand high fidelity 
system 
. --... .. "ý........ ýý...,., vv, -.., v. +.. ý.,...,.. a.,... ývýiý. aýv n WAL, 11" 1I, L1 
.. xxe««xx. t rx r. rr wx+rr+r< rr rx rr r. trr r, rx r......... 
... 
1) AA1CAGCTGGAAGATGGGCGCACCCTGTCTGACTACAACATCCAGAAGGAGTCCACC 
2)AAACAGCTGGAAGATGGCCGCACCCTGTCTGACTACAACATCCAGAAAGAGTCCAC'^':. 
3) AAACAGCTGGAAGATGGACGCACCCTGTCTGACTACAACATCCAGAAAGAGTCC'A('" 
x. x. xxxxxxxx. xxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxx x..... 
. ýý 
1)C: ICTTGGTCCTGCGCTTGAGGGGAGGT-TTCTAAGTTCTCCCTTTTAAGCTTT(: AA-'AAA 
2). '. ai'TTCCTCCTGCGCTTAAGGGGAGGTGTTTTAAGTTCTCCCTTTTAAGCTTTCGATAAG 
31 
. 
:.:: :........; CT'TGAGGGGGGGT-GTCTAAGTTTCCCCTTTTAAGGTTTCAACAAA 
Figure D. Ubiquitin purified PCR 
product run on a 1.5% agarose gel, 
alongside a 100bp marker. 
Figure E. DNA sequencing of 
PCR product. 
GTGG: v((((ýGC(, v(\((: ý rcG: ýG: ý. arcrc. a. acG 
C('AG('AGAGGCTGAT('1"I-TG('('GGGAA(i('AG('TGG 
AGATG(GGCGCACCCTGTCTGA('TACAA('\ IY'('AG 
\ «; GA(; I( ('ACC('rG('ACTr(; (iG CTG( (i( 
(169 bo seauenced) 
M t'hiquitin 
1,500 
1000 
. __,. 
500 PCR 
product 
-229 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
M18159 Porcine Ubiquitin 155/156 (99%) 301 2e-79 
M62428 Bovine Ubiquitin 160/169 (94%) 256 le-65 
M26880 Human Ubiquitin 155/169 (91%) 216 le-53 
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APPENDIX A12: ATROGIN-1 (specific E3, Ubiquitin Ligase) 
Figure A. Available Atrogin- 
I sequences. 
No. Acc. No. Species 
1) AY059628 Rat 
2) AY059629 Human 
N. B. No Porcine sequence 
data a ailab'_a 
Figure B. Multiple alignment of sequences for 
Atrogin-1. PCR target region and primer loca- 
tions are included. 
11. AAAGTAGTACTGAAAGTT 
-. 
--- -- 
- 
2 AAAGTGGTACTGAAAGTC I 
..,.,. ,. -. ....  
TA , TAJ ;. c 
#wxxx #kk##x++x#+ xwtxx#xx#srx#xxwwx: x ##xxx fxr e 
1)3 GAACTTCTCCAGACCCTCTACACATCCTTATGCACGCTGGTCCAGAGAG 
2)CGAACTACTCCAGACCCTCTACACATCCTTATGTACACTGGTCCAAAGAG 
+.. xxx xxxxxxxrxxxxrxxxxxxxx. xrxx xx xx... x.. ... x 
Figure C 1. PCR Conditions. 
Fwd. primer- 20 bp 
Start- 469 o`- 1068 bp 
sequence to!. 
Rev. primer- " bp 
Finish- 715 0: 1068 bp 
sequence (2). 
Amplicon size- 247 bp 
Annealing temp. - 54CC 
Cycles- 3: 3 
Perkin Einer Amplitaq 
Gold ? o_}nerase 
Figure E. DNA sequencing of 
cloned cDNA insert. 
( 1-I(iA: 1GA('CA(i(. \\\1l: \ I'(': \GA('T(iATAAC, (i(i 
AACTC'cTCCAG: \('(( IUFA('A('GC(i'('TGTGC'A('A 
('TGGTCCAGACi: 1(i I ((G((AAGTCCG I GCTGGTCGG 
GAACATTAACATG I GGGTGTATCGGA I GGAGAC'GA 
ITC'TA('ACTGGCAGCAUCAG('TGAAC'AAC'A T('('AG 
A [CACCAGG('C TGC('TT(' \\ wo( ('I(: \('( 1_I (': \(' 
.\ \l .\ 
fl :1I Gl' (GA('cTGC'c T('TGTGTT T: \( V 16 
AGA 
(247 bp sequenced) 
1) TCGGCAAGTCCGTGCTGGTGGGCAACATCAACATGTGGGTGTATCGAATG 
2) TCGGCAAGTCTGTGCTGGTCGGGAACATTAACATGTGGGTGTATCGGATG 
xr+x+xxr+r ++rrxrrx ++ . rrrr +xxr+x. r+xrr+a... 
... 
1) GAGACCACTCTACACTGGCAACAGCAGCTGAACAGCATCCAGATCAGCAG 
2) GAGACGATTCTCCACTGGCAGCAGCAGCTGAACAACATTCAGATCACCAG 
xxxxx x xxx xxxxxx. x . xxxxxx. xxx, x xxx x..,... x. x 
1) GCCGGCCTTCAAAGGTCTCACGATCACCGACCTGCCTGTGT: 
2) GCCTGCCTTCAAAGGCCTCACCTTCACTGACCTGCCTTTGT 
r+x x+x, +xx, x+, +++++ xrrx xxrx+++, r +,... 
. 
GGCTGAGCGATGGGCGGGACCTGGTC.,,; :... 
', GGCTGAGCGACGGGCGGGACCTGGTCAG,:,: 'F 
. =xx+x++x++ x+xx+xxrx+xx............ 
Figure D. Atrogin-1 purified PCR 
product run on a 1.5% agarose gel, 
alongside a 100bp marker. 
1,501 
101)1 
5O 
1 
NCR 
product 
'47 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value (bits) 
AY059629 Human Atrogin-1 232/247 (93%) 371 e-100 
AF441120 Murine Atrogin-1 227/247 (91%) 331 4e-88 
AY059628 Rat Atrogin-1 224/247 (90%) 307 6e-81 
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APPENDIX A13: N-CALPAIN 
Figure A. Available 
u-Calpain sequences. 
N(D 
. 
Species 
1) AF263610 Porcine 
(Isoform-A) 
2) AF263609 Porcine 
(Isoform-B) 
3) AF221129 Bovine 
4) X04366 Human 
Figure C I. PCR Conditions. 
Fwd. primer- 20 bp 
(:.: 
._,;..; 000AA- ) 
Start- 1633 of 2994 
bp sequence (1). 
Rev. primer- 20 bp 
(CCCTGACGCTGATCTCC':.. 
Finish- 1833 2994 
bp sequence (: ). 
Amplicon size- 201 bp 
Annealing 'e: np. 
- 
557C 
Cycles- 33 
Perkin E17, o: Arrpiitaq 
Gold Pol)^merase 
Figure D. p-Calpain-1 purified PCR product 
run on a 1.5% agarose gel, alongside a 100bp 
marker. 
Figure E. DNA sequencing of 
PCR product. 1,500 
100 
FFGT6CIGC(, 111(IIC I(: \( : \(: \(( \: \: AC((((1. A("CCAAGA(i( lCi<i: AC(iA('('AG(iTCCAGGC(''A11'('I' S(ýO ( (YY'GACGA(i(AAGTGcTCTCGGAAGAGGA(i: \TI 
(; ATG AGAA('TTC. A AAGC(iCTCTTCAGACAGCT(iC i(' 
A(ic(; c. A(i(; A( \ R; (i: AGAr( : \(i('GT(". A000: \('1"1 
(172 bp sequenced) 
Pc 1( 
product 
-201 bp 
Figure F. Significant sequences frone BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value (bits) 
AF263610 Porcine p-Calpain 168/169 (99%) 327 4e-87 
/09 
AF221129 Bovine p-Calpain 154/165 (93%) 240 7e-61 
X04366 Human N-Calpain 143/161 (88%) 176 9e-42 
Figure B. Multiple alignment of sequences for y- 
Calpain. PCR target region and primer locations 
are included. 
33TCAGTl:: CCwCT=-CCCTGCCGCCCGGC, 3A6TAC"TG31'CGr_; C 
3)G. GTCAGCACCCGCT'TCCGCCTGCCGCCTGGGGAGTACGTGGTGGTGCCCT 
4) GcTCAGCACCCGCTTCCGCCTGCCACCCGGGGAGTATGTGGTGGTGCCCT 
01 
: )ACAAGGAGGGCGACTTTGTGCTGCGTTTCTTCTCA 
2)CCAC2': TCAGCCC.. ACAAGGAGGGCGACTTTGTGCTGCGTTTCTTCTCA 
3) CCACCTTCGAGCCCAACAAGGAAGGTGACTTTGTGCTGCGTTTCTTCTCA 
4) CCACCTTCGAGCCCAACAAGGAGGGCGACTTCGTGCTGCGCTTCTTCTCA 
1) GAGAAGAAAGCCGGGACCCAAGAGCTGGACCACCAGGTCCAGGCCATTCT 
2) GAGAAGAAAGCCGGGACCCAAGAGCTGGACGACCAGGTCCAGGCCATTCT 
3) GAGAAGAGCGCAGGGACCCAAGAGCTGGATGACCAGGTCCAGGCCAATCT 
4) GAGAAGAGTGCTGGGACTGTGGAGCTGGATGACCAGATCCAGGCCAATCT 
.. xx... .xx. x.. .. xxx... xxxxxx x.. xx... x ... 
1) CCCCGACGAGCAAGTGCTCTCGGAAGAGGAGATTGATGAGAACTTCAAAG 
2) CCCCGACGAGCAAGTGCTCTCGGAAGAGGAGATTGATGAGAACTTCAAAG 
3) CCCCGACGAGCAAGTGCTCTCAGAAGAGGAGATTGATGAGAACTTCAAGT 
4) CCCCGATGAGCAAGTGCTCTCAGAAGAGGAGATTGACGAGAACTTCAAGG 
. xxa. x +xxrrr. r.. xx.. .... rrrrxx.... . exrr... r.. 
1) CGCTCTTCAGACAGCTGGCAGGGGAGGACATGGAGATCAGCGTCAGGGAG 
2) CGCTCTTCAGACAGCTGGCAGGGGAGGACATGGAGATCAGCGTCAGGGAG 
3) CCCTCTTCAGACAACTGGCAGGGGAGGACATGGAGATCAGCGTCAAGGAG 
4) CCCTCTTCAGGCAGCTGGCAGGGGAGGACATC A' AT,, A^r'^T ".; - ;; AG 
Figure C2. 
PCR problematic; long 883bp p-Calpain 
probe[990-1872bp region of sequence (1)] 
used as template; target region 100% 
alignment to (1). 
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APPENDIX A14: m-CALPAIN 
Figure B. Multiple alignment of sequences for in- 
Figure A. Available Calpain. PCR target region and primer locations 
in-Calpain sequences. 
Species 
_.: e 
2) '. '2 
3 ': 07850 B :,. e 
4) NM 009794 ^'": 
_ 
5 3. '. 65306 Rat 
Figure C f. PCR Conditions. 
Fwd. primer- 20 bp 
Start- 1438 of 3213 
bp se_7 ') 
. 
Rev. 
. 
'0 hp 
Finish- : 63ý 3213 
bp sequence (2). 
Amplicon size- 201 bp 
Annealing temp. 
- 
62'C 
Cycles- 3": > 
Perkin E17ýo_ A. p=irýq 
Gold ? o:,, -erase 
are included. 
GAGGACATGCACACCATCGCCTTTGGCATCTATGAGGT I 
3) GAGGACATGCACACCATTGGCTTCGGCATCTATGAGGTTCCAGAGGAGTT 
4) CAGGACATGCACACCATTGGCTTCGGCATCTATGAGGTTCCAGAGGAGCT 
+ 
.., 
TGCACACCATTGGCTTCG(3CATCTATGAGGTCCCAGAGGAGCT 
......... xx. xxxx. . x+xx xrxxxx+x .. xrx xx x. .. x . 
- 
AGACCAACATCCACCTCAGCAAGAACTTCTTCCTGACGCACA 
AGACCAACATCCACCTCAGCAAAAACTTCTTCCTGACGAATC 
. ",.:;. CAGACCAACATCCACCTCAGCAAAAAATTCTTCCTGACAACCA 
4). 
, ACAGGGCAGACCAACATCCACCTCGGCAAAAACTTTTTCCTCACAACCC 
5) AACAGGGCAGACCAACATCCACCTCAGCAAAAACTTTTTCCTGACAACCC 
" ........ xr... xxxx.. r rxr. x. .r rrr. x rr 
1) GAGCGAGGGAGCGATCGGACACCTTCATCAACCTGCGGGAAGTGCTGAAC 
2) GCGCCAGGGAGCGCTCAGACACCTTCATCAACCTCCGGGAGGTGCTCAAC 
3)OAGCGCGGGA-CGTC--GACACCTTCATCAACCTGCGG-AGGTGCTCAAC 
4) GAGCCAGGGAGCGGTCAGATACCTTCATTAACCTCCGCGAGGTCCTCAAC 
5) GAGCCAGGGAGCGGTCAGATACCTTCATCAACCTCCGGGAGGTCCTCAAC 
_) CGCTTCAAGCTGCCGCCGGGCGAGTACATCCTGGTGCCCTCCACCTTCGA 
21 CGCTTCAAGCTGCCGCCAGGAGAGTACATTCTCGTGCCTTCCACCTTCGA 
3) CGCTTCAAGCTGCCCCCCG--GAGTACATCGTGGTGCCCTCCACCTTCGA 
4) CGCTTCAAGCTGCCCCCGGGAGAGTATGTCCTCGTTCCCTCCACCTTCGA 
5) CGCTTCAAGCTGCCCCCGGGAGAATATGTCCTTGTTCCTTCCACCTTCGA 
1) GCCCAACAAGGACGGGGACTTCTGCATCCGCGTCTTTTCCGAAAAGAAGG 
2) ACCCAACAAGGATGGGGATPTCTGCATCCGGGTCTTTTCTGAAAAGAAAG 
3) GCCCAACAAGGACGGCGACTTCTGCATCCGGGTCTTTTCCGAGAAGAAAG 
4) ACCCCACAAGGATGGCCATTTCTTCATCCGAGTCTTCTCGGAGAAGAAGG 
il. ; CCCCACAAGAATGGCGAT: :...,.. ;A,. 
... 
_`. 'A,; AGAAGAAGG 
IF*giire C7 
PCR problematic; long 732bp m-Calpain 
probe[1016-1747bp region of sequence(2)] 
used as template; target region 100% 
alignment to (1). 
Figure D. in-Calpain purified PCR product 
run on a 1.5% agarose gel, alongside a 100bp 
marker. \I Iin-Calpain 
Figure F. I)N. sequencin 1,500 
of PCR product. 1000 
I( (. I( Il(. l lt tt(I\ \k a 1\Rit 500 - 
A((\((iAlt, Iu PCR GAA(. ('GGI J(A(; ( At UR (c(x'AGart(; 
TGAAG(: TGT('('(, A('(ZH'T('('( It'(( It It; product TG('GT('AG(: AAGAAGTT('Tl(. ( It. ü ý. lt; 
... 
GATGTTGGF(-TGTCCG6T 
--201 bp ( 163 bp sequenced) 
Figure F. Sii nifcant sequences from BLAST search of sequence in Fig. E. 
Significa :: _ 11ig11mont to: 
Acc. No. Species Description Identities Score E value (bits) 
U01181 Porcine m-Calpain 158/159 (99%) 307 4e-81 
U07850 Bovine m-Calpain 138/156 (88%) 204 4e-50 
M23254 Human m-Calpain 136/153 (88%) 168 2e-39 
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APPS NI)IX A15: ('ALPAIN-3 
Figure A. Available 
Calpain-3 sequences. 
.. 
o 
. 
Acc..... ;, _ ý5 
1) APO -- 55) 3ý". "i: e 
2) 
, 
F04329--) -- 'ý:; 
_.: t? 
Human 
Figure B. Multiple alignment of sequences for 
Calpain-3. PCR target region and primer loca- 
tions are included. 
No 
"_ýTGGCý. 
...,.,.,,, 
CCACGCCTATTCGGTTACTGGGCTGGAGGAGGCCCTGT 
TGGCC I.;,: wLL GTCAGAGGTCACGCCTACTCTGTCACGGGGCTGGATGAGGTCCCGT 
1) ACAAGGGTGAGAAAGTGAAGCTGGTGCGGCTGCGGAACCCCTGGGGCCAGGTGGAGTGGA 
2 TCAAGGGTGAAAAGGTGAAGCTTGTGCGGCTGCGGAACCCCTGGGGCCAGGTGGAGTGGA 
. 
:; AAGGTGAGAAAGTGAAGCTGGTGCGGCTGCGGAATCCGTGGGGCCAGGTGGAGTGGA 
. 
,.:: CTCCTGGAGTGACAGCTGGAAGGACTGGAGCTATGTGGACAAGGACGAGAAGGCCC 
Figure C 1. PCR Conditions. '" CTCCTGGAGTGACAGTTGGAAGGACTGGAGCTTTGTGGACAAAGATGAGAAGGCCC ACGG1"PC7! 'GGAGTGATAGATGGAAGGACTGGAGCTTTGTGGACAAAGATGAGAAGGCCC 
Fwd. primer- -9 bp 
(1 
Start- 1020 of 2 )1. 
bp sequence (2). 
Rev. nr 
. 
er- 20 n 
bp sequence <2, 
Amplicon size- 20_ ibP 
Annealing temp. 
- 
62 C 
Cycles- 35 
Perkin Elmer Amplitaq 
Go: ci PoLy r, 1Se 
Figure E. DNA sequencing 
311'TGCAGCACCAGGTCACTGACGATGGAGAGTTCTGGATGTCCTACGATGATTTTATCT 
: GATGGAGAGTTCTGGATGTCTTATGATGATTTCATCT 
'- -++.. +.. ". 
.. 
: ýATGGAGAGTTCTGGATGTCCTATGAGGATTTCATCT 
.. " .............. ýx:. xrxxrxrxxrrxrrr rr rx rrr.. ... s 
Figure C2. 
PCR problematic; long 1122 bp Calpain-3 
probe[869-1990bp region of sequence(2)] 
used as template; target region 100% 
i: ignment to (2). 
Figure D. Calpain-3 purified PCR product 
run on a 1.5% agarose gel, alongside a 100bp 
marker. 
of PCR product. 
r(((( I(. t \(. ((1(, II( %\('6616A 
l(, a Uý (I I(, r(x (, (x I(, (ý, ( : ýA( c( 
(, A(, I (, A( A(. 1' I (i(iAA(i(3A(TCXiA(X' Il-1( i 
(X; AC'AAA(6A T(iA(iAA(iCXYYYiT(T(i( 
146 bp seq"=. -^ced) 
1,500 
11 (Calpain-3 
1000 
500 
- PCR 
product 
-201 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value (bits) 
AF043295 P cint Calpain-3 146/146 (100%) 289 7e-76 
AF087569 Calpain-3 134/142 (94%) 218 2e-54 
X, 85030 Hu:::. tn C, ilpain-3 131/145 (90%) 176 8e-42 
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APPENDIX A16: C: \LPASTATIN 
Figure 
. 
\. A. ailable Figure B. Multiple alignment of sequences for 
('alpastatin sequences. Calpastatin. PCR target region and primer 
Specie:. 
A'-'5 55: 95 Porci:. e 
M20: 60 Porcine 
iHear_ 
3, D: 62: ' 
... 
ý. a:: 
v .. 
_. 
": ' 13 i". 
_.: e 
locations are included. 
.. 
_'. 
'TCAGCTCCAACCA000ACTCT 
.. 
': TCAGCTCCAACCA000ACTCT 
i1: GCS A :.:. 
.... 
u, 
_, . ""....... ..,. 
- 
; CCCCAGCTTCAACGACCCAAGCT 
4) CTGTCGTCTCTGAAGTGG'PT"ICCCAAACCCCAGCTCCAACCACCCAGGCA 
... . ....................... ..... .... ..... . 
1) GCAGGTCCACCCCCT(; ACACTGTGAGTGATGACAAAAAACTPGACGATGC 
2) GCAGGTCCACCCCCTGACACTGTGAGTGATGACAAAAAACTTGACGATGC 
l) GGAGCCCCACCCCGTGATACCTCGCAGAGTGACAAAGACCTCGATGATGC 
=CGGTCCACCCCCAGACTGCGCACGTGACAACAAAGAACTTGACGATGC 
" ....... ....... . .... ..... 
il, '; 'TGGATCAGCTTTCTGACAGTCTGGGGCAAAGACAGCCTGACCCAGATG 
.: l "TGGATCAGCTTTCTGACAGTCTGGGGCAAAGACAGCCTGACCCAGATG 
+': 'TGGATAAACTCTCTGACAGTCTAGGACAAAGGCAGCCTGACCCAGATG 
4 '. 'TGGATCAACTTTCTGACACTCTCGGGCAAAGACAGCCTGATCCAGATG 
. ..... . ......... ... ....... ........ ....... 
Figure C 1. PCR Conditions. 
Primer- 21 bp 
Start- 174:: 4 38 bp 
sequence (-' 
Rev. prime: 
- 
Finish- 1976 o: 4038 bp 
sequence (2). 
Amp: icon size- 236 bp 
A:: nea:. ng temp. - 55'C 
35 
(; old Po. ymerase 
: '. ý: IACAAGCCCATAGAGGATAAAGTCAAGGAAAAAGCTGAAGCTGAACAT 
. 
1:.: AACAAGCCCATAGAGGATAAAGTCAAGGAAAAAGCTGAAGCTGAACAT 
+) AGAACAAACCAATGGGAGATAAAGTAAAGGAAAAAGCTAAAGCTGAACAT 
4) AGAATAAACCCGTAGAGGATAAAGTCAAGGAAAAAGCCAAAGCTGAACAC 
: )A.; AGACAAGCTGGGAGAAAGAGATGACACTATCCCGCCTGAATATAGACA 
'iA:; AGACAAGCTGGGAGAAAGAGATGACACTATCCCGCCTGAATATAGACA 
3). A GAGACAAGCrfGGAGAA-, ý7,,... 
.. - 
AT^T; AATACAGACA 
4i A7 AGACAAGCTGGGA,; A+.. 
...,. _.,. ... 
": ý.. ATACCAACA 
........... 
................. ..... ... .... ... 14 
Figure C2. 
PCR problematic; long 808 bp Calpas- 
tatin probe[1409-2216 bp region of 
sequence(2)] used as template; tar- 
get region 100% alignment to (2). 
Figure D. Calpastatin purified PCR product 
run on a 1.5% agarose gel, alongside a 100bp 
marker. 
\1 I 
Figure E. D`: 1 sequencing 
of P('R product. 
( rn k(. ( rrivit('rr(. %( III %I( ( I('r: AI(i(i(. ( 
ITU iT(-T( AruT(iti(; T( V. l. l R I( 111(i ((('A 
(-%( T(iT('AGAAA(i('T(i \ I(( \(, (, (, (. 
-\T('GTCAA 
(. I I rrrl(iT('ATCACT('A('A(i rliT('A(i(i(i(i(JTGG 
%( (T(X AGA(iTG(XiTG(iTT(i(iAG(T(iA(i(irrr(i 
.4" kA 
1 '4 bp sequenced) 
1O( 
51, PCR 
product 
-236 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score E value 
(bits) 
AY555195 Porcine Calpastatin 174/174 (100%) 345 2e-92 
/M20160 
L14450 Bovine Calpastatin 147/169 (86%) 161 6e-37 
D50827 Human Calpastatin 81/93 (87%) 90 2e-15 
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. 
\PPENI)IX A17: ('. LP: AIN-10 
Figure A. Available 
(alpain-10 sequences. 
No. Acc. No. ý: cie s 
i SQ057475 ; 
(Image c1o:.,, 
Figure B. Multiple alignment of sequences 
for Calpain-10. PCR target region and 
primer locations are included. 
-_ 
--"..... 
..,.. 
... .... 
-.. 
. 
-, 
; 'AA000CAAATTCTGGCTGCG 
. 
';:;...., 
`_. 
.................. ..... 
:,.; CAA000CAAATTCTGGCTGCG 
.......................................... 
0X9088 
calpain-10aß 
N. B. No Porcine. Bovine or 
:: ne sequence data available. 
-it and Murine sequences vari- 
, n. ý:: e target reg. 
Figure CL PCR Conditions. 
ti'art- 1243 
sequence (2 
Rev. primer- bp 
Finish- .55 of 2620 bp 
sequer. 
_-, 
Ampl is:. 333 'p 
Annealing temp. 
- -57 
Cycles- 35 
Perkin Elmer Amp: itaq mold 
- 
; GTCTCAGAACCGAGTGAGGTGTACATTGCCGTCCTGCAGAGATCCAGGC 
GTCTCAGAACCGAGTGAGGTGTACATTGCCGTCCTGCAGAGATCCAGGC 
...... ................................. r... rr... r 
: )TGCACGCGGCGGACTGGGCAGGCCGGGCCCGGGCACTGGTGGGTGACAGT 
TGCACGCGGCGGACTGGGCAGGCCGGGCCCGGGCACTGGTGGGTGACAGT 
............................... r........ r.....:... 
1) CATACTTCGTGGAGCCCAGCGAGCATCCCGGGCAAGCACTACCAGGCTGT 
2) CATACTTCGTGGAGCCCAGCGAGCATCCCGGGCAAGCACTACCAGGCTGT 
: I; GGTCTGCACCTCTGGAAGGTAGAGAAGCGGCGGGTCAATCTGCCTAGGG 
'); GGTCTGCACCTCTGGAAGGTAGAGAAGCGGCGGGTCAATCTGCCTAGGG 
:i PCCTGTCCATGCCCCCCGTGGCTGGCACCGCGTGCCATGCATACGACCGG 
'i: 'CCTGTCCATGCCCCCCGTGGCTGGCACCGCGTGCCATGCATACGACCGG 
i ; AGGTCCAQ' :': '-. ........ ......,.. 7A. 'CTGGCT 
; AGGTCCAC ': ': ', ---: ': ; 
". 
CTGGCT 
.......... 
................ ..............:..., 
04 
Figure C2. 
PCR from porcine template problem- 
atic; Human Image Clone: 
-5813098, 
acc. no: 
-BQ057475, (1048 bp), used as 
template; target region 100% align- 
ment to (2). 
Figure D. Calpain-10 PCR product run 
on a 1.5% agarose gel, alongside a 100bp 
marker. 
M Calpain-10 
1,500 
1000 
5111 
..... 
PCR 
product 
-333 bp 
Figure F. DNA sequencing 
of P('R product. 
\I Il IIA A 1(1C(: (i(. 1( It \(i\A( C(i: \(i Il. \(, l, I1, 
%i 11"T(: (('GTC('T(A'AGA(i \I(( %(i(iC I ci('A('(: ( 
. 
4, ( (i(:. ACT(: (: (i('A(: (XY'(: (: (i((( (i(i(: ('ACT(: (: T(: 
i. I(, ACAGTCATA(TT(Y: T(: (: A(: ('('('A(: ('GA(i('AI 
(i(AA AA(i('ACTA(Y'A(i(: ('T(iT(: (: (: T('T(i('A('(' 
( I(d: AA(i(iTA(: A(: AA(i('(: (i('(: (: (: T('AAI('r(: CCT 
t i(i(Y'AT(7(' AT A('(iA('CG(: (iA(i(i TY('AC('T(: CG TT 
(288 bo sec: ".:, -:: ced) 
OEM 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
ignmont to: 
ACc. No. Species Description Identities Score E value 
(bits) 
AF089088 Human Calpain-10a 288/288 (100%) 571 e-160 
AF089089 Hurine Calpain-10 115/138 (83%) 92 8e-16 
AF22'909 Rat Calpain-10 115/138 (83%) 92 8e-16 
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: APPH: NDI\ A18:: ACTIN 
Figure A. Available Figure B. Multiple alignment of sequences for 
2) J00068 Human 
(alpha-actin) 
3) M12866 -: e 
(alpha-actin 
"; ) U39357 ovine 
(beta-actin) 
5ý AF035774 Equine 
Actin. PCR target region and primer locations 
are included. 
: GGCCGGCCGCG 
_'--GGCGGGCCGCG 
3) CCATCTATGAGGGCTATGCCCTGCCACACGCCATCATGCGTCTGGACCTGGCCGGTCGCG 
4) CCATCTACGAGGGGTACGCCCTCCCCCACGCCATCCTGCGTCTGGACCTGGCTGGCCGGG 
5) CCATCTACGAGGGGTACGCCCTCCCCCACGCCATCCTGCGTCTGGACCTGGCTGGCCGGG 
. 
xx. +. 
. r. +r +r .... +. . +.. xxxxx xx.. xxxxx+++. +x xx ++ r 
1) ATCTCACCGACTACCTGATGAAGATCCTCACCGAGCGTGGCTACTCCTTCGTGACCACAG 
2) ATCTTACCGACTACCTGATGAAGATCCTCACTGAGCGTGGCTACTCCTTCGTGACCACAG 
3) ACCTCACTGACTACCTGATGAAAATCCTCACTGAGCGTGGCTATTCCTTCGTGACCACAG 
4) ACCTGACGGACTACCTCATGAAGATCCTCACGGAGCGTGGCTACAGCTTCACCACCACGG 
5) ACCTGACGGACTACCTCATGAAGATCCTCACGGAGCGTGGCTACAGCTTCACCACCACGG 
1) CTGAGCGCGAGATCGTGCGCGACATCAAGGAGAAGCTATGCTACGTGGCCCTGGACTTCG 
2) CTGAGCGCGAGATCGTGCGCGACATCAAGGAGAAGCTGTGCTACGTGGCCCTGGACTTCG 
3) CTGAACGTGAGATTGTGCGCGACATCAAAGAGAAGCTGTGCTATGTGGCCCTGGACTTCG 
4) CCCAGCGGGAAATCGTCCGTGACATCAAGGAGAAGCTCTGCTACGTGGCCCTGGACTTCG 
5) CCGAGAGGGAAATCGTGCGTGACATCAAGGAGAAGCTCTGCTATGTCGCCCTGGACTTCG 
1) AGAACGAGATGGCCACCGCCGCCTCCTCCTCCTCCCTGGAGAAGAGCTACGAGCTGCCAG 
2) AGAACGAGATGGCGACGGCCGCCTCCTCCTCCTCCCTGGAAAAGAGCTACGAGCTGCCAG 
Figure C I. PC R Conditions. 
3) AGAATGAGATGGCCACCGCTGCCTCTTCCTCCTCCCTGGAGAAGAGCTATGAGCTGCCCG 
4)AGCAGGAGATGGCCACCGCGGCCTCCAGCý 
. .. 
',;, AGCTACGAGCTGCCGG 
ýI ACCAGGAGATCGCCACCGCGGCCTCCAGC. 
.., 
GAGCTACGAGCTGCCCG 
wd. 19 bp 
Ä^: n. vvACCT ) 
Rev. primer- 22 bp 
(C C;: A aC"IC--. CTCCAGGGA,, ) 
Finish- 830 of : 374 bp 
X01 bp 
62 C 
' : es- 35 
Perkin Elmer Amplitaq 
ri'. 
-. 
nerase 
Figure D. Actin PCR product run on a 1.5% 
agarose gel, alongside a 100bp marker. 
1,50 
100, 
50 = 
PCR 
product 
-201 bp 
Figure E. DNA sequencing of PCR product. 
i. \( º: \( (I( \I(.. \. ( \UU( I(. \((( ; (crGCC r: ýcý((lrcG 
I(, Ac(A(: ux ra: ux c. cc; A(iAI((, 1 6((\(. \ºc : \AGGAG: \
. 
VA IA IGc rAcrrc; <. cccrcc \( i rr(, \. \((\(. I((((. 
(148 bo sequenced) 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
sequence alignment to: 
Acc. NO. Species Description Identities Score E value 
(bits) 
J00068 Human a-Actin 144/148 (97%) 262 2e-67 
NM_174225 Bovine a-Actin 142/148 (95%) 246 le-62 
U16368 Porcine a-Actin gene 99/99 (100%) 196 9e-48 
250 
AI'I'F: 1l)IX AI9: ALPII: k-'I'UBt'I, IN 
Figure A. Available Alpha- 
tubulin sequences. 
f5 es 
1) AU059326 Porci:: o 
(clone, EST 
2) AF251146 Ovine 
Figure CI. PCR Conditions. 
Start- 26 _ . 43 bp 
sequence i:, 
" 
Rev. primer- 20 
(A".. AAO CACAATC J1-: 
Finish- 243 of 243 hp 
sequence (1). 
Amp; icon size- 218 bp. 
Figure E. I)N. sequencing of 
P('R product. 
ýnnný\i-. III Ii. t. (, II((( 1(t It. t 
\l I. I( It Il T(i t((. %I I \It. ln 
+Vºl. +ºU. II It +ºA(. ( I(i(iA(, TT(1t ( 
. 
11'1 I% 
"A ACAA'((iä'A(i(irM ('A('A(iCT(iTA(i 
T7(iA(i(Yä'T A(' AACTC('A TCCTCAC('A('( 
CACA(Y'ý( (Y'T(i(. A(. CA('T(T 
on. PdI 
1 000 
PC R 
product 
-218 bp 
Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
Significant sequence alignment to: 
Acc. No. Species Description Identities Score 
(bits) 
AF251146 Ovine a-Tubulin 155/159 (97%) 276 
AF081484 Human a-Tubulin 154/158 (96%) 268 
AB099045 Bovine a-Tubulin 134/138 (97%) 226 
(partial cds clone) 
E value 
le-71 
3e-69 
le-56 
Figure B. Multiple alignment of sequences for 
Alpha-tubulin. PCR target region and primer 
locations are included. 
3) GTGCACCGGTCTTCAGGGCTTCTTGGTTTTCCACAGCTTTGGTGGGGGAA 
4) GTGCACCCGTCTTCAGGGCTTCTTGGTTTTCCACAGCTTTGGTGGGGGAA 
..... 
....... .......................... .... x+. 
1) CGGGTICTGGGTrCACCTCCCTGCTGATGGAACGTCTCTCTGTCGATTAT 
2) CTGGTTCTGGGTTCACCTCCCTGCTGATGGAACGCCTCTCTGTCGATTAT 
-"-, CTTICTGGG'M'CACCTCCCTGCTCATGGAACGTCTCTCAGTTGATTAT 
41 , v'TTCTGGGTTCACCTCCCTGCTCATGGAACGCCTGTCAGTTGATTAT 
:, 'AAGAAGTCCAAGCTGGAGTTCTCCATTTACCCAGCCCCCCAGGTTTC 
-; GCAAGAAGTCCAAGCTGGAGTTCTCCATTTACCCAGCCCCCCAGGTTTC 
GCAAGAAGTCCAAGCTGGAGTTCTCCATTTACCCAGCACCCCAGGTTTC 
4' GGCAAGAAATCCAAGCTGGAGTTCTCCATTTACCCGGCACCCCAGGTTTC 
" ....... 
.............. - x...... x. "x ." rxxxx: xxx"x 
1) CACAGCTGTAGTTGAGCCCTACAACTCCATCCTCACCACCCACACCACCC 
2) CACAGCTGTCGTTGAGCCCTACAACTCTATCCTCACCACCCACACCACCC 
3) CACAGCTGTAGTTGAGCCCTACAACTCCATCCTCACCACCCACACCACCC 
4) CACAGCTGTAGTTGAGCCCTACAACTCCATCCTCACCACCCACACCACCC 
"""...... "....... ". "... xx" .... ".. rx. xxxx:. xxxxxx 
TGGAGCACTCTGATTGTGCCTTCATG------------------------ 
TGGAGCACTCTGATTGTGCCTTCATGGTAGACAATGAGGCCATCTATGAC 
i'CCAGCACTCTGATTGTGCCTTCATGGTAGACAATGAGGCCATCTATGAC 
. 
... 
ý... 
.,.. ,.. 
G'TGC: °"... ', T TAGACAATGAGGCCATCTATGAC 
.......................... 
Q 
Figure D. Gel purified a-Tubulin 
PCR product run on a 1.5% aga- 
rose gel, alongside a 100bp marker. 
MI a-Tubulin 
251 
. 
%PPFNDIX A20: "1'FIID (Transcription Factor II D) 
Figure A. Available 
TH ID sequences. 
tý f\. tit tý týti 
1) D01034 Murir. t' 
2) M55654 Humar. 
Figure B. Multiple alignment of sequences for 
TFIID. PCR target region and primer locations are 
included. 
tiAAACGCCGAATATAATCCCAAGCGGTTTGCTGCGGT 
..................... .... .................. ....... .. 
. ATCAIGAGAATAAGAGAGCCACGGACAACTGCGTTGATTTTCAGTTCTGGAAAAATGGT 
1A7'CATGAGGATAAGAGAGCCACGAACCACGGCACTGATTTTCAGTTCTGGGAAAATGGT 
........ .............. .... .................. :....... 
:;.: TGCACAGGAGCCAAGAGTGAAGAACAATCCAGACTAGCAGCAAGAAAATATGCTAGAGT 
3T CACAGGAGCCAAGAGTGAAGAACAGTCCAGACTGGCAGCAAGAAAATATGCTAGAGT 
........................... ..... r.. 
......:............... r 
1)TCI(; CAGAAGI74GGGCTTCCCAGCTAAGTTCTTAGACTTCAAGATCCAGAACATGGTGGG 
2) TCTACAGAAGTIGGGT'M"rcCAGCTAAGTTCTTGGACTTCAAGATTCAGAACATGGTGGG 
Figure C 1. PC R Conditions 
. 
....................................................... f-- 
9 bp 
start- 782 of 
bp sequence(2). 
Rev. primer- 20 
(ACAxAaºae ccccxCA 
Fi^: sh- 1032 : 
, 'romega Taq Po. v- 
rcý:. ise 
, '? }'T'. ATM: TGAAGTTCCCCATAAGGCTGGAAGGCCTTGTGCTGACCCACCAGCAGTT 
.,.. ... .. _.,: I 
:.. C,:, _-'T'*'ý T(; CTCACCý. AC; - AACAATT 
...... ........ . ............ ........ ..., 
Figure. Gel Purified TFIID PCR product, 
run on a 1.5% agarose gel, alongside a 
IOObp marker. 
RI ITFIID 
1,500 
1000 
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Figure E. DNA sequencing of PCR product. 
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Figure F. Significant sequences from BLAST search of sequence in Fig. E. 
In. . I:: reL, 'o: 
Acc. No. Species Description Identities Score E value 
(bits) 
M55654 Human TFIID 178/191 (93%) 276 2e-71 
)0; 034 Murine TFIID 171/191 (89%) 220 8e-55 
XM_21"-R5 Rat TFIID 168,1191 (87%) 196 le-47 
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APPENDIX B. CLOSE-MATCHED RELATED SEQUENCES 
Sequence information listed in Appendix B links directly to 5.3 Northern Blot 
Radioactive Probe Testing section within Chapter 5, cDNA Probe Development. 
As explained within the cDNA Probe Development section, no porcine data exists 
for many sequences, and multiple band signals/ unexpected band sizes on Northern 
test-blots (using porcine RNA) was observed. Therefore, additional closely-related 
mRNA sequences of interest were searched for, by performing BLAST searches, on 
those specific cDNA probe sequences generated, and used in Northern blot probing. 
mRNA sequences of similar sizes to Northern band signals, - with high bit scores, E 
Values and sequence similarity values; that may explain band identities were 
searched for, and listed in figure. A: Probe number and name (abbreviated); related 
sequence accession number, species, description, size and sequence identity value is 
included. 
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Figure A-B-1. Close-matched mRNA sequences (related to cDNA- 
probe/expressed gene). Similar-sized to band signals produced in porcine RNA 
Northern test-blots (see 5.3 Northern Blot Radioactive Probe Testing), are presented 
below. Abbreviations = Casp-3 (Caspase-3), Ubiq (Ubiquitin), At-1 (Atrogin-1) and 
Calp-3 (Calpain-3). Seq. Id. (Sequence Identities), in bp and %. 
cDNA Related sequences Description of related Size Seq. 
Probe of interest: sequences (mRNA). (Bp) Id. 
Acc. No. 
- 
Species 
(3) NM 032991 
- 
Human Caspase-3 transcript 2479 186/206 
Casp- variant beta. (90%) 
3 
NM 004346 
- 
Human Caspase-3 transcript 2646 186/206 
variant alpha. (90%) 
U13737 
- 
Human Caspase-3 isoform alpha. 2635 186/206 
(90%) 
(9) NM 003342 
- 
Human E2G1 transcript variant 2626 200/213 
E2G1 1. (93%) 
(11) AF038129 
- 
Ovine Polyubiquitin, UbB. 1102 141/156 
Ubiq (90%) 
AF506969 
- 
Equine Ubiquitin. 1157 144/156 
(92%) 
NM 018955 
- 
Human Ubiquitin B. 971 153/169 
(90%) 
AB009010 
- 
Human Polyubiquitin, UbC. 2192 143/153 
(93%) 
D17296 
- 
Rat Polubiquitin, UbC. 2545 152/166 
(91%) 
NM 019639 
- 
Murine Ubiquitin C. 2661 141/153 
(92%) 
(12) NM 058229 
- 
Human F-box protein 32 1530 232/247 
At-1 transcript variant 1. (93%) 
AJ420108 
- 
Human F-box protein 32. 1391 232/247 
(93%) 
(15) AF087569 
- 
Bovine Skeletal muscle-specific 2955 134/142 
Calp- calpain. (94%) 
3 
AF087570 
- 
Ovine Skeletal muscle-specific 3165 134/142 
calpain. (94%) 
NM 212465 
- 
Human Calpain-3 transcript 3243 131/145 
variant 7. (90%) 
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APPENDIX C. OLIGONUCLEOTIDE PROBES AND PRIMERS 
FOR REAL-TIME PCR 
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Using the Primer Express package (ABI Biosystems), oligonucleotide primers and 
dual labelled fluorescent probes were designed specifically for those expressed genes 
of interest:. u- and m- calpains, calpain 
-3, calpastatin, actin and 18 S. The computer 
package searched for optimal sequence and amplicons, with the optimal amplicon 
size set at 100 bp. Indicated are the cDNA sequences that were used for designing 
primers and probes, the region of amplification and primer and probe sequences. 
Note: for ubiquitous 1u- and m- calpains non-bovine sequences were inputted into 
primer express as primer region was identical to bovine sequence. 
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APPENDIX D. REAL-TIME PCR STANDARD CURVE DATA 
As described within Chapters 3 and 4, a standard curve was generated by Real-Time 
PCR for the ubiquitously expressed u- and m- calpains, muscle-specific calpain-3, 
calpastatin, actin and 18S. The results are summarised within Chapter 4 and the raw 
data and curves is as follows for each expressed gene: 
Figure A-D-1. Graph to show standard curves for (A) p-Calpain, (B) m-Calpain, 
(C) Calpain-3, (D) Calpastatin and (E) Actin and (F) 18S. Table shows amount of 
total RNA equivalents used to generate I' strand cDNA using random primers (ng), 
log total RNA and average Ct value. Identified is the slope of the bestfit line for the 
points plotted. 
(A) 
25 
20 
is 
10 
5 
Log RNA 
(B) 
25 
20 
13 
,o 
5 
Total log Avg. 
RNA RNA Ct 
(ng) 
150 2.20 20.78 
100 2.00 19.76 
50 1.70 19.71 
25 1.40 19.76 
12.5 1.10 20.78 
Slope 
= 
-0.102 
R2 
= 
0.0061 
Total log Avg. 
RNA RNA Ct 
150 2.18 19.77 
100 2.00 20.11 
50 1.70 20.79 
25 1.40 22.12 
12.5 1.10 22.33 
Slope 
= 
-2. 5887 
2.3 R2 = 0.9601 
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(E) 
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20- 
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01- 
0.9 
Total 
RNA 
(ng) 
log 
RNA 
Avg. 
Ct 
200 2.30 20.74 
100 2.00 21.71 
50 1.70 22.91 
25 1.40 24.44 
10 1.00 26.08 
Slope = -4.1955 
R2 = 0.995 
Total 
RNA 
(ng) 
log 
RNA 
Avg. 
Ct 
150 2.17 20.60 
100 2.00 21.00 
50 1.70 21.96 
25 1.40 23.10 
12.5 1.10 23.91 
Slope = 
-3.1455 
R2 
= 
0.9954 
Total 
RNA 
(ng) 
log 
RNA 
Avg. 
Ct 
150 2.20 16.20 
100 2.00 17.00 
50 1.70 17.60 
25 1.40 18.70 
12.5 1.10 19.20 
Slope 
= 
-2.8118 
R2 
= 
0.9832 
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Log RNA 
Total 
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(ng) 
log 
RNA 
Avg. 
Ct 
200 2.30 13.70 
100 2.00 14.80 
50 1.70 15.70 
25 1.40 16.80 
10 1.00 18.30 
Slope = 
-3.4888 
R2 = 0.9988 
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APPENDIX E. IMAGE CLONES 
EST clone match to human Cathepsin-D: Accession No. BM471202, IMAGE Clone 
No. 5563106, Clone name- 11567-d21.983 bp insert within 4396 bp pCMV- 
SPORT6 Ampicillin-resistant vector. EST clone match to human Calpain-10: Acces- 
sion No. BQ057475, IMAGE Clone No. 5813098, Clone name- CM2064 j 11.1048 
bp insert within 1815 bp pOTB7, Chloramphenicol resistant vector. A full vector 
map for both can be found at http: //www. hgmp. mrc. ac. uk/geneservice/rea... / prod- 
ucts/datasheets/MGC/plate_info. shtml). Both clones were Purchased as a `stab agar' 
sample, i. e. clones had been streaked onto LB agar containing 50 µg/ml ampicil- 
lin/12.5 µg/m1 Chloramphenicol. Clones were stored at 4°C and re-streaked onto du- 
plicate LB-agar plates containing ampicillin (100 µg/ml)/Chloramphenicol (12.5 
µg/ml). Cathepsin-D clone was incubated overnight at 37°C, Calpain-10 for 24 hr at 
33°C. 
Single colonies grown on LB-agar plates were picked using sterile pipette and grown 
in 3 mis LB media containing ampicillin (100 µg/ml) for the Cathepsin-D IMAGE 
clone and Chloramphenicol (12.5 gg/ml) for Calpain-10 IMAGE clone. 
Both IMAGE clones were grown up as described previously (Section 3.9) incubating 
sterilins overnight at 37°C with shaking and plasmid DNA purified using Promega 
miniprep method described previously. 
IMAGE Clone Digest Procedure 
IMAGE clones were linearised using similar RE digest procedure described in Sec- 
tion 3.11. For Cathepsin-D IMAGE Clone, a single Nco I RE digest was performed. 
The Calpain-10 IMAGE Clone was linearised using EcoR I. Both digested IMAGE 
Clones were separated by non-denaturing gel electrophoresis (Section 3.6) using a 
1.5% agarose in 1X TAE gel and checked for linearisation (see Figure A-E-1). 
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Figure A-E-1. An example of linearised IMAGE Clones. Figure below shows ex- 
amples of un-cut and linearised IMAGE Clones. The samples loaded were IMAGE 
Clones digested with EcoR I, including Calpain-10, with lambda/hind III DNA mark- 
ers at either end of gel. 
Calpain-10 IMAGE Clones 
b "0 
1I 
Un-cut 
Plasmid 
- -; 
``" 
.. '. 
(2 band WW» y 
, 
ice! ` 0. °1, w,,,,, arm ON . O" "_ 
super-coiling) 
Linearised 
plasmid 
(single-band 
-2900 bp) 
Image clones were subsequently `cleaned-up' using a routine ethanol precipitation 
procedure (see Section 3.12) 
261 
APPENDIX F. MIDI-PREP PURIFIED PLASMIDS 
Large quantities of Caspase-3, 
-6, Cathepsin-L, -H, E2G1 and Atrogin-1 cDNA 
probe sequences were grown up from glycerol stocks and purified using plasmid 
midi-prep procedure. These probes are described in Section 5.2. 
cDNA inserts were excised from pGEMý-T Easy Vectors using an EcoR I RE digest 
(as above). As can be seen from figure all inserts were 200-300 bp, however analysis 
of the E2G I sequence suggested it had an internal EcoR 1 cut site, as it was a small 
size following digest. Another digest was performed using Not 1 (10 U/ µl) RE and 
Buffer D and samples run by electrophoresis (Figure A-F-1). 
Figure A-F-I. Non-denaturing gel electrophoresis of Midi-Prep purified plas- 
mids +inserts. cDNA inserts excised from pGEMe-T Easy Vectors by RE digest (as 
above), for E2G1, using Not I digest. 100 bp markers are run alongside. 
n C 
ýý 
°U 
ß 
U 
v ý CSC N 
UUW 
L ý,, d 
O 
° 
Cut 
! ._*, am saw am 
Plasmid . 
500 bp 
- -ý.... r. 
300 bp º ýý 
.l 
üll 
Wu_. ý. 
size 200 bp 
l2Gl 
100 bp 
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APPENDIX G. CALF DIET 
(Calf diet used for the trial outlined in Chapter 4) 
BOCM Pauls Beef Super Grade Diet 
This diet contains: Wheat, palm kernal explant, low glucosinolate rape seed extract, 
soya bean hulls, shea nut extract, molasses, calcium carbonate, cocoa hulls, bakery 
by-product, as declaired by BOCM Pauls. 
g/kg dry matter 
Dry Matter (DM) 862 
ME 9.05 MJ/kg 
Oil 38.8 
Protein 129.3 
Fibre 103.4 
Ash 77.6 
Vitamin A 7000 iu/kg 
Vitamin D 2000 iu/kg 
Vitamin E 25 iu/kg 
Sodium Selenite 0.0003 mg/g 
Copper Sulphate 0.0350 mg/g 
Hay 
Measured in the University of Nottingham Laboratory 
g/kg dry matter 
Dry Matter (DM) 940.7 g/kg 
Gross Energy 16.22 MJ/kg 
Nitrogen 9.76 g/kg 
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APPENDIX H. CALF LD MUSCLE SAMPLES 
RNA samples randomly selected were allocated a number (1-24), with 1-12 
corresponding to slaughter date 1, and 13-24: slaughter date 2; which was used 
throughout trial analysis, i. e. for gel loading patterns etc. Note: sample 00534 (21 in 
table) was missing from sample stocks at the time analysis was performed. 
Table A-H-1. Randomly selected LD samples allocated number 1-24. Table 
shows corresponding eartag number, treatment group and slaughter date (S): 1/ 2= 
1 sr12"d slaughter. Sample 21 in italics as not present during time of sample analysis. 
No. Eartag No. Group S No. Eartag. No. Group S 
1 400149 HIGH 1 13 300141 HIGH 2 
2 700039 REFED 1 14 700042 LOW 2 
3 02497 HIGH 1 15 600001 REFED 2 
4 300007 LOW 1 16 400005 LOW 2 
5 400012 LOW 1 17 100031 HIGH 2 
6 300004 REFED 1 18 700044 REFED 2 
7 300163 REFED 1 19 100161 REFED 2 
8 200140 HIGH 1 20 600034 HIGH 2 
9 700037 LOW 1 21 00534 LOW 2 
10 600003 HIGH 1 22 700004 HIGH 2 
11 500002 LOW 1 23 500042 REFED 2 
12 300045 REFED 1 24 200091 LOW 2 
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APPENDIX I. PIG DIET 
Pig diet used for the trial outlined in Chapter 5 
STANDARD FINISHER DIET 
Constituent Kg/tonne 
Barley 300 
Wheat 393 
Hi Pro Soya 275 
DCP 9 
Mineral 314 12.5 
Vitamin E 50 1 
Salt 2.7 
Limestone 6.8 
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APPENDIX J. RNA EXTRACTION REAGENTS 
Table A-J-1. Chemical reagents used for RNA extraction procedure 
Reagent Composition Final 
Conc. 
Denaturing 250 g Guanidinium Thiocyanate 4M 
Solution 293 ml Water 
17.6 ml 0.75M Sodium Citrate, pH 7 25 mM 
26.4 ml 10% Sarcosyl 0.5% 
ß-mercaptoethanol 0.36 ml / 50ml Denaturing 0.1M 
Solution 
Sodium Acetate, 2M 
pH 4 
Sodium Acetate, 4M 
Ph 7 
Phenol Phenol liquefied 80 w/w in water 
(water saturated) 
Chloroform Isoamyl Chloroform and Isoamyl 
alcohol alcohol in ratio of 49: 1 
Isopropanol 
(Propan-2-ol) 
Ethanol 100% 
and 
75% 
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APPENDIX K. NORTHERN BLOTTING REAGENTS 
Table A-K-1. Northern Blotting procedure reagent list 
Reagent Composition Final 
Conc. 
Sodium Phosphate, 15.6g in 1L double-distilled H20. 100mM 
pH6.5 DEPC-treated (0.05% w/v), autoclaved 
X3. 
Sodium Phosphate, made up from 100mM stock with 10mM 
pH6.5 double-distilled, DEPC-treated, auto- 
claved(X3) water. 
Sodium Phosphate, made up from 100mM stock with 80mM 
pH6.5 double-distilled, DEPC-treated, auto- 
claved(X3) water. 
RNA Markers A ladder of nine RNA transcripts. 
Sizes: 281,623,955,1383,1908, 
2604,3638,4981 and 6583. 
Glyoxal 40% solution deioinised as described 
below. 
DMSO 
Loading Buffer 50% glycerol 
10mM Sodium Phosphate, pH 6.5 
Bromophenol Blue 
SSC 175.3 g 3M NaCl 20X 
88.2 g 0.3M NaCitrate 
made to 1L with double-distilled, 
DEPC-treated, autoclaved(X3) water. 
Ammonium Acetate 7.7 g dissolved in 1L double- 0.1M 
distilled de-ionised water 
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Glyoxal-40%: Solution was de-ionised by adding 20 ml to a 50 ml sterile screw 
capped centrifuge tube (Sarstedt, Numbrecht, Germany), adding 20 g AG501 ion ex- 
change beads (Biorad) and mixed at room temperature by gentle shaking. Beads were 
centrifuged down for 5 min at 3,000 g, supernatant was removed and added to an- 
other 50 ml sterile screw capped centrifuge tube containing 4g beads. Beads were 
shaken gently for 30 min at room temperature and same process repeated until beads 
turned from blue to gold (i. e. beads exhausted). 
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APPENDIX L. BACTERIAL GROWTH MEDIA 
LB MEDIUM (per 100 ml) 
1. Og Bacto-tryptone (Oxoid, Basingstoke, UK) 
0.5g Yeast extract (Oxoid, Basingstoke, UK) 
1. Og NaCl 
Bacto-tryptone, yeast extract and NaCl are mixed in a clean container, with double 
distilled water added. Whilst solution is stirred continuously, pH is made up to 7.0, 
by addition of NaOH. Solution is autoclaved and allowed to cool to room 
temperature. 
LB AGAR PLATES WITH AMPICILLIN (200 ml/-7-8 plates) 
2. Og Bacto-tryptone (Oxoid, Basingstoke, UK) 
1.0g Yeast extract (Oxoid, Basingstoke, UK) 
2. Og NaCl 
3. Og Agar (Oxoid, Basingstoke, UK) 
200pi Ampicillin (100 jig/ml) 
Bacto-tryptone, yeast extract, NaCI and Agar are mixed up in a sterile container with 
double-distilled water (made up to 200 ml final volume), autoclaved, left to cool to 
room temperature, 100 µg/ml ampicillin added (i. e. 200 µl), mixed and poured 
equally into 7-8 petri dishes. 
SOC MEDIUM (100 ml) 
2. Og Bacto-tryptone (Oxoid, Basingstoke, UK) 
0.5g Yeast extract (Oxoid, Basingstoke, UK) 
lml 1M NaCl 
0.25m1 1M KC1 
lml 2M Mg 2+ stock, filter-sterilised 
lml 2M glucose, filter-sterilised 
Bactotryptone, yeast extract, NaCI and KCl are added to 97 ml double-distilled 
water, stirred, autoclaved, and left to cool to room temperature. 2M Mg2+ stock 
(20.33 g MgC12.6H20 and 24.65 g MgSO4.7H20, made up to 100 ml with double- 
distilled water) and 2M glucose are added, final volume made up to 100 ml with 
double-distilled water; filtered through a 0.2 µm filter, and checked final pH is 7.0. 
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